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Abstract 
 
We have demonstrated the usefulness of tert-butylsulfonyl (N-Bus) 
protecting group in amino acid and peptide chemistry. It is formed in a 2-step 
procedure involving reaction of an amine with tert-butylsulfinyl chloride, 
followed by oxidation with m-CPBA to obtain the corresponding tert-butyl- 
sulfonamides in excellent yields. The N-Bus group can be cleaved to regenerate 
the corresponding amino salt in 0.1 N TfOH/DCM/anisole at 0 oC for 10 h.  
A variety of N-Bus protected amino acids and other common amino acids 
can be used to form dipeptides and tripeptides. With the exception of the 
N-Fmoc group, the conditions required for the N-Bus group cleavage also 
cleaved the N-Boc, N-Cbz and O-Bn groups. Selective and orthogonal 
deprotection of N-Boc, N-Cbz, N-Fmoc and O-Bn groups could be achieved in 
the presence of the N-Bus protecting group. 
The new unnatural amino acids (3R, 2R) 3–methyl-D-leucine (β-Me-Leu) 
and its 2-methyl regioisomer were synthesized by ring opening of an N-Ts 
aziridine intermediate with excess LiMe2Cu. The 1:1.2 mixture of regioisomers 
were each converted to the corresponding methyl leucines, then coupled to 
D-phenyllactic acid, followed by coupling with 2-carboxyperhydroindole 
4-amidino-benzamide core in the presence of DEPBT. Further elaboration led to 
linear peptidic unnatural analogues of known aeruginosins such as 
chlorodysinosin A. The two analogues were also evaluated in enzymatic assays 
for their inhibitory activity against thrombin and trypsin. 
The presumed 3-sulfated aeruginosin 205B and its β–anomer were 
successfully synthesized from 5 subunits: 3-chloroleucine, D-phenyllactic acid, 
D-xylose, 2-carboxy-6-hydroxyoctahydroindole, and agmatine. Comparison of 
ix 
 
1H and 13C NMR reported data with that of synthetic aeruginosin 205B revealed 
a disturbing discrepancy with regard to the position of the presumed 3'-sulfate 
on the D-xylopyranosyl unit. We synthesized methyl α-D-xylopyranosides with 
sulfates at each of the hydroxyl groups and conclusively demonstrated the the 
presence of a C-4'-sulfate by comparison of the 1H and 13C NMR spectroscopic 
data. Thus, the structure of aeruginosin 205B should be revised. 
One of the key steps in the synthesis is glycoside formation of the axially 
oriented C-6 hydroxyl group in the Choi subunit. The 2-thiopyridyl carbonate 
was a suitable method for anomeric activation, followed by treatment with 
AgOTf and tetramethylurea in ether-DCM solution to give the desired α-anomer, 
which was easily separable from the β-anomer by column chromatography. 
 
 
 
 
 
 
 
 
Keywords:  tert-butylsulfonyl (N-Bus) group, amino acid protection, 
β–methyl-D-leucinyl aeruginosin, (3R, 2R) 3–methyl-D-leucine (β-Me-Leu), 
aeruginosin 205B, axially oriented glycoside synthesis  
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Résumé 
 
Nous avons démontré l’utilité du groupement protecteur tert-butylsulfonyle 
(N-Bus) pour la chimie des acides aminés et des peptides. Celui-ci est préparé 
en deux étapes, impliquant la réaction d’une amine avec le chlorure de 
tert-butylsulfinyle, suivie par l’oxydation par du m-CPBA, pour obtenir les 
tert-butylsulfonamides correspondants avec d’excellents rendements. Le 
groupement N-Bus peut être clivé par traitement avec 0.1 N TfOH/DCM/anisole 
à 0oC en 10h pour régénérer le sel d’ammonium.  
Une variété d’acides aminés N-Bus protégés ainsi que d’autres aminoacides 
peuvent alors être utilisés pour préparer divers dipeptides et tripeptides. A 
l’exception du groupe N-Fmoc, les conditions de déprotection du groupe N-Bus 
clivent également les groupements N-Boc, N-Cbz et O-Bn. Une déprotection 
sélective et orthogonale des groupes N-Boc, N-Cbz, N-Fmoc et O-Bn est 
également possible en présence du groupe protecteur N-Bus. 
Le nouvel acide aminé non-naturel (3R, 2R) 3–méthyl-D-leucine (β-Me-Leu) 
et son régioisomère 2-méthyle ont été synthétisés par ouverture d’une N-Ts 
aziridine en présence d’un excès de LiMe2Cu. Chacun des régioisomères du 
mélange (1:1,2) a été converti en la méthylleucine correspondante, puis couplé 
à l’acide D-phényllactique puis au motif 2-carboxyperhydroindole 
4-amidinobenzamide en présence de DEPBT. Des élaborations ultérieures ont 
conduit à des analogues peptidiques non-naturels d’aeruginosines telles que la 
chlorodysinosine A. Les deux analogues ont ensuite été évalués pour leur 
activité inhibitrice de la thrombine et la trypsine.  
La présumée aeruginosine 3-sulfate 205B et son anomère β ont été 
synthétisés avec succès à partir de 5 sous-unités : la 3-chloroleucine, l’acide 
xi 
 
D-phényllactique, le D-xylose, le 2-carboxy-6-hydroxyoctahydroindole et 
l’agmatine. La comparaison des données RMN 1H et 13C reportées avec celles 
obtenues avec l’aeruginosine synthétique 205B révèle une différence majeure 
pour la position du groupe présumé 3'-sulfate sur l’unité D-xylopyranosyle. 
Nous avons alors synthétisés les dérivés méthyl-α-D-xylopyranosides avec un 
groupement sulfate à chacune des positions hydroxyles, afin de démontrer 
sans ambiguïté la présence du sulfate en position C-4' par comparaison des 
données spectroscopiques RMN 1H et 13C. La structure de l’aeruginosine 205B a 
alors été révisée. 
Une des étapes-clés de cette synthèse consiste en la formation du glycoside 
avec le groupe hydroxyle en C-6 orienté en axial sur la sous-unité Choi. Le 
2-thiopyridylcarbonate s’est avéré une méthode efficace pour l’activation 
anomérique. Le traitement par AgOTf et la tétraméthylurée en solution dans un 
mélange éther-DCM permet d’obtenir l’anomère α désiré, qui peut alors être 
aisément séparé de l’anomère β par chromatographie 
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Chapter One 
Tert-Butylsulfonyl (Bus), a New Protecting 
Group for Amino Acids and Peptides 
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1-1 Introduction 
1-1-1 Common amino acid protecting groups: Cbz, Boc, Fmoc… 
N-Protecting groups are of primary importance in the utilization of amino 
acids and nitrogen containing organic molecules in synthesis.[1-3] Among the 
more popular N-protecting groups that can also benefit from an orthogonal 
deprotection strategy are the N-Boc, N-Cbz and N-Fmoc groups (Figure 1).[4,5] 
 
 
Figure 1. Structures of the N-Boc, N-Cbz and N-Fmoc groups. 
 
1-1-1-1 N-Boc group  
The Boc group is used extensively in peptide synthesis for amine 
protection,[6] due to its stability under basic conditions and its inertness to 
many other nucleophilic reagents.  
One of the more common methods for Boc introduction is to treat the amine 
with Boc anhydride (Boc2O) in aqueous sodium hydroxide. It has the advantage 
that the product is easily isolated.[7] For sterically hindered amino acids, a 
superior method is to utilize Boc2O with tetramethylammonium hydroxide 
pentahydrate (Me4NOH.5H2O) in acetonitrile.[8] Both of these procedures afford 
excellent yields. 
The N-Boc group is sensitive to acidic conditions, such as 3 M HCl in ethyl 
acetate, [9] acetyl chloride (AcCl) in methanol,[10] 10% H2SO4 in dioxane and 50% 
trifluoroacetic acid (TFA) in dichloromethane.[11] The N-Boc group can also be 
deprotected by a catalytic amount of cerium(IV) ammonium nitrate (CAN) in 
3 
 
acetonitrile.[12]  
 
1-1-1-2 N-Cbz group 
The N-Cbz group is similar to the N-Boc group in its stability under basic 
conditions, however unlike N-Boc group, is also stable under mild acidic 
conditions. 
The reagent dibenzyl dicarbonate (PhCH2OCO)2O with sodium hydroxide or 
triethylamine (Et3N) as base in dioxane-water mixture[13,14], has been used to 
prepare N-Cbz compounds. Better yields were reported than with benzyl 
chloroformate (PhCH2OCOCl)[15]. 
The most common method to cleave the N-Cbz group is to use Pd over 
activated carbon (Pd-C) as a catalyst under hydrogen gas atmosphere.[15] The 
N-Cbz group is also readily cleaved under strongly acidic conditions such as 
hydrogen bromide (HBr) in acetic acid (AcOH),[16] 50% trifluoroacetic acid (TFA) 
solution,[17] or trifluoromethanesulfonic acid (CF3SO3H).[18] This group is also 
unstable under strongly basic condition such as 40% potassium hydroxide in 
the methanol-water solution[19] and with sodium (Na)-ammonia (NH3) in a 
dissolving metal reduction. [20] 
 
1-1-1-3 N-Fmoc group 
A major advantage of the Fmoc protecting group is that it has excellent 
acid stability, under which N-Boc and N-Cbz groups can be removed. It can be 
readily cleaved by simple amines to liberate the amine as its free base.[21]  
The most common method of introducing Fmoc is using 9-fluorenyl- 
methoxycarbonyl chloride (Fmoc-Cl) with sodium bicarbonate (NaHCO3) as a 
base in dioxane.[22] Diisopropylethylamine is reported to suppress dipeptide 
formation during Fmoc introduction with Fmoc-Cl.[23] Another reagent that also 
could be used is 9-fluorenylmethyl succinimidyl carbonate (Fmoc-OSu) in 
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acetonitrile-water solution.[24,25] The advantage of Fmoc-OSu is that little or no 
oligopeptides are formed when amino acid derivatives are prepared.[26] 
The N-Fmoc group is cleaved under mild conditions with an amine base, 
such as 20% piperidine in DMF, to afford dibenzofulvene and free amine.[26] 
N-Fmoc is generally considered to be stable to hydrogenation, but it has been 
shown that under certain conditions it can be hydrogenated by Pd-C as a 
catalyst under hydrogen gas in the presence of acetic acid in methanol.[27] 
 
1-1-2 Tert-Butylsulfonyl (Bus), as a new protecting group for 
amines  
Sulfonyl groups have had a long history in the protection of amines and 
other nitrogeneous functionalities.[28] Their stability within a wide array of 
reaction conditions is one of the most attractive features of sulfonamides. 
Unfortunately due to the harsh conditions, which are required for their removal, 
N-sulfonyl groups are not as versatile in highly functionalized or sensitive 
substrates. 
In recent years, N-sulfonyl protecting groups have been improved by 
addition of new aryl varieties, including the heteroarene-2-sulfonyl chlorides 
such as BtsCl and ThsCl groups (Figure 2) introduced by Vedejs[29]; and the 
N-o-nitrophenylsulfonyl chlorides such as DNsCl and NsCl groups (Figure 2), 
which were introduced by Fukuyama[30]. Those are stable in acidic conditions 
and amenable to mild removal, such as N-Bts or N-Ths groups were removed by 
treatment with zinc (Zn) in acetic acid-ethanol mixture or aluminum-mercury 
(Al-Hg) in ether-water solution at room temperature,[29] deprotection of N-DNs 
group was performed by treatment with thioglycolic acid (HSCH2CO2H) and 
triethylamine in dichloromethane,[30] and N-Ns group was deprotected with 
thiophenol (PhSH) and cesium carbonate (Cs2CO3) in acetonitrile.[30] 
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Figure 2. Structures of the BtsCl, ThsCl, DNsCl, NsCl and N-Bus groups. 
 
In 1997 Sun and Weinreb reported the use of the N-tert-butylsulfonyl group 
(Figure 2) as a new protecting group for amines.[31] tert-Butylsulfonyl chloride 
is quite unstable and does not normally undergo nucleophilic displacement at 
sulfur with amines.[32] The preparation of N-tert-butylsulfonamides consists of 
a 2-step procedure, which involves: 1) reaction of an amine with the 
commercially available tert-butylsulfinyl chloride; 2) oxidation of resulting 
tert-sulfinamide with a variety of oxidants, including KMnO4,[33]  m-CPBA,[31]  
RuCl3/NaIO4,[31]  H2O2/LiOH[34] and NaOCl/PTC;[35] to afford the corresponding 
product in excellent overall yield. Sun and Weinreb showed that the N-Bus 
group is stable to a variety of organolithium and Grignard reagents and also 
exhibited stability toward strong bases. The N-Bus group can be cleaved with 
TFA/anisole at room temperature to regenerate the amine salt in good yields. 
 
1-1-3 Tert-butylsulfonamide as a new functional group 
Only limited use has been made of this versatile functionality since its initial 
report in 1997 by Sun and Weinreb.[31]  
 
1-1-3-1 As an effective nitrogen source of aziridine 
Sharpless and coworkers have shown that tert-butylsulfonamide is an 
effective nitrogen source for catalytic aziridination of olefins (Scheme 1).[36]  
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R1
R2
NBus
R1
R2
NHBus
X
R1
R2 a b c R1
R2
NH2
X
Scheme 1: Reagents and conditions: a) 1.2 eq. Bus-NClNa, PTAB (phenyltrimethylammonium
tribromide) 10 mol%, MeCN, r.t.,10 h; b) nucleophilic reagent; c) 20 eq. anisole,
TfOH, DCM, r.t.;
1.1 1.2 1.3 1.4
 
 
With simple unfunctionalized olefins 1.1, aziridines 1.2 which often are the 
only reaction products, are generally obtained in high yields. Product isolation 
is simple, and purification does not require chromatography. The aziridination 
of the olefins is stereospecific. For example, cis- and trans-β-methylstyrene 
afford exclusively the cis- and trans-aziridines, respectively. Substantial 
amounts of the rearranged allylic sulfonamide were obtained in the case of 
exocyclic olefins, such as methylenecyclohexane. Nucleoplilic attack led to 
tert-butylsulfonamides 1.3. The corresponding amines 1.4 were formed under 
reasonably mild acidic conditions, after cleavage of the Bus-group. 
 
1-1-3-2 As a protecting group in regioseletive opening of aziridines 
During the total synthesis of chlorodysinosin A, the regioselective opening 
of an aziridine intermediate 1.5 with CeCl3 (Scheme 2),[37] was only possible 
with the N-Bus protecting group on the aziridine. 
 
 
 
 The ratio of the products 1.6 and 1.7 was more than 10 to 1. A steric clash 
between the isopropyl group and the tert-butyl group on the N-Bus group could 
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be the reason for the high regioselectivity of CeCl3-mediated opening of the 
Bus-protected, and thus providing an open path for SN2 attack at C3. The less 
sterically demanding N-Ts and N-trifluoromethylsulfonyl groups led to a 
competitive reaction at C2. This hypothesis is supported by the fact that 
cleavage of the aziridine with the smallest N-sulfonyl group (SO2CF3), showed 
the lowest regioselectivity at C3. The corresponding 3-chlorosulfonamide was 
obtained with the same region- selectivity and yield by CeCl3-mediated opening 
of hydroxymethyl aziridine, suggesting that the steric bulk of the TBS group 
was not responsible for the selectivity. 
Lithiation and electrophile trapping of terminal N-Bus aziridine 1.8,[38] led 
to an α-lithiated aziridine 1.9, which underwent rapid dimerization to afford 
2-ene-1,4-diamine 1.10 (Scheme 3).  
 
 
 
The aziridine 1.8 was transformed to the α-lithiated aziridine 1.9, which 
could occur via a 1,2-metallated shift. In the process, a nucleophilic attack can 
occur on 1.8. Subsequent syn-elimination, driven by the steric demand of the 
aziridine substituents and the N-Bus groups, leads to the formation of the 
E-alkene isomer 1.10 in highly selectivity. Compared to the analogous epoxide 
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dimerization reactions, the improved E/Z selectivity is attributed to the extra 
steric demand of the Bus groups. If a pendant alkene is present, as in 
compound 1.11, the N-Bus-α-lithiated unsaturated aziridine 1.11a affords a 
2-aminobicyclo-[3.1.0]hexane 1.12. 
 
1-1-3-3 As a functional group on imines 
There are also applications involving addition reactions on N-Bus imines, as 
exemplified by the asymmetric synthesis of fused bicyclic amino acids (Scheme 
4).[39] 
 The N-tert-butylsulfonyl imino ester 1.14 was used in one of the key steps 
of the synthesis. Firstly, starting material 1.13 was transformed to 
enantiomerically a pure bis(allylsulfoximine)titanium complex, which reacted 
with imino ester 1.14, through a highly selective allylation to give the enantio- 
and diastereo- merically pure product 1.15. 
 
 
 
Another example is the asymmetric synthesis of fused bicyclic proline 
1.22.[40] The key steps of this synthesis are: 1) a highly regio- and diastereo- 
selective amino alkylation of the cyclic bis(allylsulfoximine) titanium complex 
1.19 with the tert-butylsulfonyl imino ester 1.14; 2) a novel migratory 
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cyclization of the α-amino alkenyl sulfoxonium salt 1.21 (Scheme 5).  
 
 
 
1-2 Results and Discussion 
1-2-1 Tert-Butylsulfonyl (Bus), as a new protecting group for 
amino acids 
To date, there are no reports of the use of N-Bus protecting group in amino 
acid and peptide chemistry.[1-5] In this chapter, we report our efforts in the 
preparation of a variety of N-Bus derivatives of common amino acids and 
peptides. We further show the combination of N-Bus and other common 
N-protecting groups, and also show the prospects of performing orthogonal 
deprotections. 
 
1-2-2 N-Bus formation and cleavage 
1-2-2-1 Formation of the N-Bus group of amino acid esters 
tert-Butylsulfonyl chloride is quite unstable and cannot be used directly in 
the sulfonation of amines. Therefore, the straightforward and well-documented 
2-step procedure was chosen. [31] The amine 1.23 was reacted with the tert- 
butylsulfinyl chloride 1.28 to afford the corresponding tert-butylsulfonamides 
1.24. The reagents and conditions are shown in Scheme 6.[31]  
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a b
Scheme 6: Reagents and conditions: a) tert-butylsulfinyl chloride 1.28, Et3N, DCM, 0 oC, 1 h;
b) m-CPBA, DCM, r.t., 1 h;
1.23 1.24 1.25
 
 
Due to the low purity of commercially available tert-butylsulfinyl chloride 
1.28, it was prepared by a 2-step procedure.[37] The Grignard reagent from 
tert-butylmagnesium chloride 1.26, was reacted with the excess SO2 gas, 
followed by the acylation of the resulting sulfinic acid 1.27 with thionyl chloride 
to afford tert-butylsulfinyl chloride 1.28 as a light yellow oil (Scheme 7).  
 
a
Scheme 7: Reagents and conditions: a) SO2, THF, 0 oC, 3 h; b) thionyl chloride, THF, r.t., 4 h;
Mg
Cl S
O
OH S
O
Cl
b
1.26 1.27 1.28
 
 
Neat tert-butylsulfinyl chloride 1.28 decomposes readily. However, a 
solution of 1.28 in dry DCM can be stored in a freezer for prolonged periods 
(more than 6 months without decomposing). 
The resulting sulfinamide 1.24 can be oxidized with a variety of oxidants. 
For our purposes, m-CPBA was proved to be a much milder and efficient oxidant. 
Since the thiohydryl group of cysteine is also oxidized by m-CPBA under these 
conditions, the Bus group cannot be used as a protecting group for cysteine. 
The results of the N-Bus group formation for a series of amino acid esters 
are shown in Table 1. 
 
1-2-2-2 Cleavage of the N-Bus group of amino acid esters 
A catalytic amount of CAN was found to act as an efficient catalyst for 
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removal of the N-Boc group from an amino, hydroxyl, or mercapto functionality 
in organic compounds, under the mild and neutral reaction conditions.[12] In 
contrast, the N-Bus group was completely unreactive when refluxed with 1 eq. 
CAN for 24 h. 
Various methods for the Bus cleavage were attempted, however the best 
way to cleave and to regenerate the corresponding amine salt was found to be 
with 0.1 N TfOH/DCM/anisole at 0 oC for 10 h (Scheme 8).  
 
 
 
During the workup either a strong base resin, such as DOWEX Monosphere 
550A a hydroxide form anion exchange resin, or saturated aqueous NaHCO3 
was used to neutralize the excess trifluoromethanesulfonic acid (TfOH) and to 
remove anisole from the reaction mixture. However, since some free amino 
acids are volatile, the amino acid esters were isolated as HCl salts. 
The results of the N-Bus group cleavage for a series of amino acid esters 
are shown in Table 1. 
 
Table 1 Bus-group formation and cleavage for amino acid esters 
Entry Compound 
N-Bus Formationb  N-Bus cleavage 
Compound Yield%a Compound Yield%a
1 
 
1.25a  84 1.23a 89 
2 
 
1.25b 82 1.23b 90 
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3 
 
1.25c 82 1.23c 79 
4 
 
1.25d 77 1.23d 85 
5 
 
1.25e 88 1.23e 85 
6 
 
1.25f 77 1.23f 85 
7 
 
1.25g 72 1.23g 84 
a) yields of isolated pure product; b) the total yields over two steps   
 
The results show that the 2-step formation of N-Bus derivatives of the 
amino acids some common and N-Bus cleavage with TfOH/anisole could be 
achieved in excellent overall yields.  
 
1-2-2-3 Retention of the stereochemistry during the protection and 
deprotection 
It is very important to retain the stereochemistry of the amino acid during 
the protection and deprotection steps. The stereochemistry of the amino acid 
esters, obtained after the Bus-group protection and deprotection, was analyzed 
by transforming them to the corresponding Mosher amides and NMR analysis. 
The 1H NMR and 19F NMR spectrum showed that the chirality of the amino acids 
was unaffected. 
HPLC was used for the further verification. The de % of the alanine Mosher 
amide and phenylalanine Mosher amide were >99.9%.  
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In conclusion, the process of Bus-groups formation and cleavage does not 
affect the stereochemistry of the amino acids. 
 
1-2-3 Forming dipeptides and tripeptides with the Bus 
protecting group 
1-2-3-1 Formation of amino acid esters dipeptides 
The formation of peptides using the N-Bus protected amino acids was 
studied next.  
N-Bus-O-benzyl-L-serine methyl ester 1.30a and N-Bus-O-benzyl- 
L-tyrosine methyl ester 1.30b were formed as previously described, then 
hydrolyzed using aqueous lithium hydroxide to afford carboxylic acids 1.31a 
and 1.31b, respectively. These were coupled with the primary amine of N6-Boc- 
L-lysine methyl ester 1.34 by using EDC, 2,6-lutidine and HOBt as coupling 
reagents to afford dipeptides 1.32a and 1.32b in 85% and 93% yield 
respectively (Scheme 9).  
 
BusHN
R
O
N
CO2Me
Scheme 9: Reagents and conditions: a) i) tert-butylsulfinyl chloride, Et3N, DCM, 0 oC, 1 h;
ii) m-CPBA, DCM, r.t., 1h; b) LiOH.H2O, MeOH/H2O, 4 oC, 10 h; c) EDC, HOBt,
2,6-lutidine, N6-tert-butyloxycarbonyl-L-lysine methyl ester 1.34, DMF/DCM 1:4, r.t.,
4 h; d) L-proline methyl ester 1.23b, EDC, HOBt, 2,6-lutidine, DMF/DCM 1:4, r.t., 4 h;
1.33a. R=OBn, 86%
1.33b. R=p-C6h4OBn, 89%
1.31a. R=OBn, 86%
1.31b. R=p-C6h4OBn, 88%
BusHN CO2Me
R
a b
1.30a. R=OBn, 78%
1.30b. R=p-C6h4OBn, 80%
BusHN CO2H
R
BusHN R
CO2Me
NHBoc
N
H
O
1.32a. R=OBn, 85%
1.32b. R=p-C6h4OBn, 93%
c
ClHH2N CO2Me
R
d
1.29a. R=OBn
1.29b. R=p-C6h4OBn
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The carboxylic acids 1.31a and 1.31b were also coupled under the same 
conditions with L-proline methyl ester 1.23b to form corresponding dipeptides 
1.33a and 1.33b in high yields (Scheme 9).  
Next N-Bus-L-alanine methyl ester 1.25d and N-Bus-L-phenylalanine 
methyl ester 1.25e were also hydrolyzed to the free acids 1.36a and 1.36b 
respectively, then coupled with N6-Boc-L-lysine methyl ester 1.34 and N6-Cbz- 
L-lysine methyl ester 1.35 to form dipeptides 1.37a-d in excellent yields 
(Scheme 10). 
 
BusHN CO2H
R
BusHN R
CO2Me
NHR1
N
H
O
Scheme 10: Reagents and conditions: a) LiOH.H2O, MeOH/H2O, 4 oC, 10 h; b) EDC,
HOBt, 2.6-lutidine, N6-tert-butyloxycarbonyl-L-lysine methyl ester 1.34 or
N6-benzyloxycarbonyl-L-lysine methyl ester 1.35, DMF/DCM 1:4, r.t., 4 h;
1.36a. R=Me, 88%
1.36b. R=CH2Ph, 90%
1.37a. R=Me, R1=Boc, 90%
1.37b. R=CH2Ph, R1=Boc, 94%
1.37c. R=Me, R1=Cbz, 90%
1.37d. R=CH2Ph, R1=Cbz, 93%
BusHN CO2Me
R
1.25d. R=Me
1.25e. R=CH2Ph
a
BusHN CO2H
R
BusHN R
CO2Me
NHR1
N
H
O
1.38a. R=Me
1.38b. R=CH2Ph
1.39a. R=Me, R1=Boc, 92%
1.39b. R=CH2Ph, R1=Boc, 93%
1.39c. R=Me, R1=Cbz, 92%
1.39d. R=CH2Ph, R1=Cbz, 92%
b
b
 
 
D-Amino acids were also utilized in preparation of N-Bus-D-alanine 1.38a 
and N-Bus-D-phenylalanine 1.38b. Following the same procedure, the 
carboxylic acids 1.38a and 1.38b were also coupled with N6-Boc-L-lysine 
methyl esters 1.34 and N6-Cbz-L-lysine methyl esters 1.35 to form dipeptides 
1.39a-d in excellent yields (Scheme 10). 
In order to study an N-Bus protected secondary amine, N-Bus-prolines 
1.40a and 1.40b were used. These were obtained from corresponding proline 
methyl esters using the standard method. Following the same procedure, the 
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N-Bus carboxylic acids 1.40a and 1.40b were coupled with N6-Cbz-L-lysine 
methyl esters 1.35 to form a pair of diastereomeric dipeptides 1.41a and 
1.41b in 91% and 92% yield, respectively (Scheme 11). 
 
 
 
1-2-3-2 Retention of the stereochemistry during the formation of 
the dipeptide 
HPLC was utilized to check the de% of dipeptides 1.37 and 1.39. The 
corresponding peptides, 1.37a and 1.39a differing in one chiral center, were 
used as tests. The 4 pairs were utilized to validate that the stereochemistry was 
retained during dipeptide formation as shown in Table 2. 
 
Table 2 HPLC results and methods of the peptides 
Entry Compound De % Compound De % HPLC method 
1 1.37a >99.9% 1.39a >99.9% a 
2 1.37b >99.9% 1.39b 99.86% b 
3 1.37c 95.66% 1.39c 96.24% c 
4 1.37d 95.50% 1.39d 92.22% d 
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a) AS-RH 150*4.6 mm, 25% MeCN in H2O (0.1%TFA), 0.5 mL/min; 
b) AS-RH 150*4.6 mm, 35% MeCN in H2O (0.1%TFA), 0.5 mL/min; 
c) OJ-R 150*4.6 mm, 30% MeCN in H2O (0.05%TFA), 0.5 mL/min; 
d) C-18 250*4.6 mm, 60% MeCN in H2O (0.1%TFA), 0.5 mL/min. 
 
In conclusion, little or no erosion of stereochemistry was observed during 
peptide formation using the N-Bus protected amino acids. 
 
1-2-3-3 Formation of amino acid ester tripeptides 
To form a tripeptide, N6-tert-butyloxycarbonyl-L-lysine methyl ester 1.34 
and tert-butylsulfonyl-L-proline-N6-benzyloxycarbonyl-L-lysine methyl ester 
1.41a were used as examples. First, proline-lysine peptide methyl ester 1.41a 
was hydrolyzed using LiOH×H2O to free acid 1.42. Then, N6-Boc-L-lysine 
methyl ester 1.34 was used to couple with proline-lysine acid 1.42 using 
2.6-lutidine, EDC and HOBt as coupling reagents to form tripeptide 1.43 in 
excellent yield (Scheme 12). 
 
 
  
1-2-4 Retaining the Bus group, and use in the orthogonal 
deprotection 
The deprotection of the N-Bus derivatives to regenerate the corresponding 
amino salt was realized by using 0.1 N TfOH/DCM/anisole at 0 oC for 10 h. 
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Unfortunately these conditions also cleaved N-Boc, N-Cbz and benzyl ether 
groups. However selective deprotection of N-Boc, N-Cbz, N-Fmoc and benzyl 
ether groups could be achieved in the presence of the N-Bus protecting group. 
The formation of N-Bus derivatives of N-protected amino acids and 
orthogonal deprotection in presence of N-Bus group was also studied (Table 3). 
 
Table 3 Protection and orthogonal deprotection of N-Bus derivatives 
 
BusHN CO2Me
R
ClH.H2N CO2Me
R
BusHN CO2Me
R'
R=N-protected amino acid, R'=N-unprotected amino acid
Bus protection orthogonal
deprotection
 
 
Entry Compound 
Bus-Formation Orthogonal Cleavage 
Compound 
Yield
%a
Compound 
Yield
%a 
1 
 
78
 
97b 
2 80 97b
3 
 
80 
 
97c 
4 
 
76 
 
97b
18 
 
5 
 
81 
 
92d
89e
6 
 
76 
 
95b
a) yields of isolated pure product;  b) 20% wt.% Pd(OH)2, H2, MeOH, r.t., 2 or 3 h;  
c) 5 eq. TFA, DCM, r.t., 8 h;  d) 5% piperidine, DMF, r.t., 8 h;  e) CF3SO3H, DCM, 
anisole, 4 oC, 6 h. 
 
In conclusion, the N-Bus formation of the N-Boc, N-Cbz, N-Fmoc and benzyl 
ether protected functionalized amino acids was achieved in good overall yields. 
Selective deprotection of other N-protecting groups in the presence of the 
N-Bus group was also realized in excellent yields. 
The N-Fmoc is stable during the deprotection of the N-Bus derivatives to 
regenerate the corresponding amino salt. As an example, the compound 1.44a 
N6-Bus-N-Fmoc-L-Lys-OMe was used to afford free amine N-Fmoc-L-Lys-OMe 
compound 1.44c, by using 0.1 N TfOH/DCM/anisole at 4 oC for 6 h with an 
excellent yield. 
The selective and orthogonal deprotection of the N-protecting groups on 
the dipeptides in the presence of N-Bus group was also studied. The results are 
shown in Table 4. 
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Table 4 Orthogonal deprotection of N-Bus group peptides 
Entry 
Start 
Material  
cleavage  
Product  Method Yield%a
1 1.37b BusHN Bn
CO2Me
NH2TFA
N
H
O
1.46a
 
10% TFA, DCM, 
r.t., 2 h, 
94 
2 1.39d 
 
20 wt.% 
Pd(OH)2, H2, 
r.t., 2 h,  
MeOH, 
95 
3 1.33a 
 
20 wt.% 
Pd(OH)2, H2, 
r.t., 3 h, MeOH, 
89 
4 1.33b 
 
20 wt.% 
Pd(OH)2, H2, 
r.t., 3 h, MeOH, 
89 
5 1.37c 
 
20 wt.% 
Pd(OH)2, H2, 
r.t., 2 h, MeOH, 
89 
6 1.39a 
 
10% TFA, DCM, 
r.t., 2 h, 
90 
20 
 
7 1.32a 
 
20 wt.% 
Pd(OH)2, H2, 
r.t., 1 h, MeOH, 
86 
8 1.32a 
 
10% TFA, DCM, 
r.t., 2 h 
92 
9 1.32b 
20 wt.% 
Pd(OH)2, H2, 
r.t., 1 h, MeOH, 
87 
10 1.32b 
10% TFA, DCM, 
r.t., 2 h 
94 
a) yields of isolated pure product 
 
Thus, selective and orthogonal deprotections of N-Boc, N-Cbz, and benzyl 
ether groups in the presence of the N-Bus dipeptides were also achieved in 
excellent yields. 
The results of orthogonal deprotection the N-protecting groups on the 
triipeptide are shown in Scheme 13. Using different methods, the selective and 
orthogonal deprotection steps of N-Boc, N-Cbz and N-Bus of N-Bus tripeptides 
could be realized in excellent yields. 
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1-2-5 O-Bus as a leaving group: 
When 1.0 equivalent serine methyl ester hydrochloride 1.48 was treated 
with 2.5 equivalents tert-butylsulfinyl chloride 1.28 and 3.0 equivalents 
m-CPBA, N-Bus-O-Bus-L-serine methyl ester 1.50 was isolated (Scheme 14). 
The O-Bus group underwent facile elimination to form a double bond even in 
the mild and neutral reaction conditions of tetrabutylammonium azide. With the 
O-Bus group of compound 1.50 being a good leaving group and an acidic 
proton present, the elimination occurs faster than the SN2 substitution. 
 
ClH.H2N CO2Me
HO
t-Bu
S
O
N
H
CO2Me
O
S
t-BuO
BusHN CO2Me
OBus
BusHN CO2Me
a b c
Scheme 14: Reagents and conditions: a) 2.5 eq. compound 1.28, 5 eq. Et3N, DCM, 0 oC, 1 h;
b) 3 eq. m-CPBA, DCM, r.t., 1 h; 60% over 2 steps; c) THF, 2.4 eq. Bu4N+ N3-,
r.t., 2 h. 62%
1.48
1.49
1.50 1.51
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1-2-6 Conclusion: 
The N-Bus protecting group in amino acid and peptide chemistry is formed 
in a 2-step procedure involving reaction of an amine with the commercially 
available tert-butylsulfinyl chloride, followed by oxidation of the resulting 
sulfinamide with a variety of oxidants to afford the corresponding tert-butyl- 
sulfonamides in excellent overall yields. The N-Bus group can be cleaved to 
regenerate the corresponding amino salt in 0.1 N TfOH/DCM/anisole at 0 oC for 
10 h.  
A variety of N-Bus protected amino acids and other common amino acids 
can be used to form dipeptide and tripeptides.  
Our studies showed that the conditions required for the N-Bus group 
cleavage, also cleaved the N-Boc, N-Cbz and O-Bn groups. The N-Fmoc is 
stable during the deprotection of the N-Bus derivatives to regenerate the 
corresponding amine salt with an excellent yield. However, selective and 
orthogonal deprotection of N-Boc, N-Cbz, N-Fmoc and O-Bn groups could be 
achieved in the presence of the N-Bus protecting group. 
 
1-3 Experimental 
General: Solvents were distilled under positive pressure of dry argon before 
use and dried by standard methods. THF, ether, DCM and toluene were dried by 
the SDS (Solvent Delivery System). All commercially available reagents were 
used without further purification. All reactions were performed under argon 
atmosphere and monitored by thin-layer chromatography. Visualization was 
performed by ultraviolet light and/or by staining with ceric ammonium 
molybdate, ninhydrine or potassium permanganate. IR, Perkin-Elmer FTIR 
Paragon 1000. Low- and high- resolution mass spectra were recorded using 
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fast atom bombardement (FAB) or electrospray techniques. Optical rotations 
were recorded in a 1 dm cell at 20 oC (PerkinElmer 343). Flash column 
chromatography was performed using (40-60 μm) silica gel at increased 
pressure. NMR (1H, 13C, 19F) spectra were recorded on Bruker AV-300 and 
AV-400 spectrometers. When necessary, assignments were aided by DEPT, 
COSY, NOESY, and HMBC and HMQC correlation experiments.  
 
 
Tert-butylsulfinic acid (1.27): Excess sulfur dioxide was bubbled quickly 
through a solution of tert-butylmagnesium chloride 1.26 (1.0 M in THF, 100 mL) 
at 0 oC in a fume hood allowing for adequate venting of excess gas. When the 
solution became saturated with SO2, (then excess SO2 was sent out from the 
solution and the pH of the bubble was <6), the SO2 bubble was stopped. After 
stirring at 0 oC under the argon atmosphere for 3 h, the reaction mixture was 
cautiously diluted with ice-cold 5% aqueous HCl (100 mL). After effervescence 
subsided, the aqueous layer was extracted with 100 mL×3 of DCM. The organic 
extracts were combined, dried over MgSO4, and concentrated under reduced 
pressure to afford tert-butylsulfinic acid 1.27 (11.37 g, 93%) as a colorless 
solid. The material was used without further purification: 1H NMR, (400M Hz, 
CDCl3) δ 1.20 (s, 9H).  
 
 
Tert-butylsulfinyl chloride (1.28): To a solution of tert-butylsulfinic acid 
1.27 (11.0 g, 90 mmol) in THF (50 mL), thionyl chloride (7.88 mL, 108 mmol) 
in THF (10 mL) was added dropwise at R.T.. After 4 h, the solvent was removed 
under reduced pressure and excess thionyl chloride was evaporated under 
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reduced pressure at 40 oC. The residue was then distilled at 61-62 oC at 
aspirator pressure to give tert-butylsulfinyl chloride 1.28 (9.97 g, 79%) as a 
light yellow oil: 1H NMR, (400 MHz, CDCl3) δ 1.40 (s, 9H). 
 
General Procedure for Formation of tert-Butylsulfonamides. 
 
 
N-Bus-L-Phe-OEt (1.25a): A solution of L-phenylanine ethyl ester 
hydrochloride 1.23a (58 mg, 0.25 mmol) in 3 mL of DCM was cooled to 0 oC and 
treated with Et3N (0.35 mL, 2.5 mmol), followed by dropwise addition of 
tert-butylsulfinyl chloride 1.28 (62 μL, 0.5 mmol) in 1 mL of DCM. The reaction 
mixture was stirred at 0 oC until TLC showed consumption of the starting 
material (1 h). Upon completion, 5 mL of saturated aqueous NaHCO3 were 
added, and the layers separated (note: acidic washes should be avoided as 
tert-butylsulfinamides 1.24a are known to be unstable at low pH). The organic 
layer was then dried over Na2SO4, and concentrated under reduced pressure. 
Flash column chromatography (EtOAc/hexane 3:2) gave pure sulfinamide 
1.24a which was directly taken up in 5 mL of DCM, and treated with m-CPBA 
(58 mg, 0.34 mmol) at 0 oC to R.T.. After the oxidation was complete by TLC (at 
R.T. for 1 h), the mixture was diluted with a mixture of saturated aqueous 
NaHCO3 (5 mL) and saturated aqueous Na2SO3 (5 mL). The aqueous layer was 
extracted with DCM (2×10 mL). The organic extracts were combined, dried 
over Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (EtOAc/hexane 1:1) to afford 
tert-butylsulfonyl-L-phenylalanine ethyl ester 1.25a (66 mg, 84% over 2 
steps), as a colorless solid, m.p. 71-73 oC: 1H NMR, (400 MHz, CDCl3) δ 
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7.31-7.20 (m, 5H), 4.80 (d, 1H, J=10.3 Hz), 4.21-4.16 (m, 3H), 3.10-3.04 (m, 
2H), 1.25-1.21 (m, 12H); 13C NMR, (100 MHz, CDCl3) δ 172.2, 135.8, 129.8, 
128.7, 127.4, 61.8, 60.2, 58.9, 39.7, 24.0, 14.2; [α]D +6.7 (c 1.0, CHCl3); 
HRMS for C15H23NO4S calculated (M+H+) 314.14206, found 314.14119. 
 
 
N-Bus-L-Pro-OMe (1.25b): The general procedure was followed using 
L-proline methyl ester hydrochloride 1.23b (166 mg, 1.0 mmol), Et3N (1.39 mL, 
10.0 mmol), tert-butylsulfinyl chloride 1.28 (0.25 mL, 2.0 mmol) in 5 mL of 
DCM and DCM (5 mL). The crude product was purified by flash column 
chromatography (EtOAc/hexane 4:1), which was oxidized with m-CPBA (233 
mg, 1.35 mmol) and DCM (10 mL). The residue was purified by flash column 
chromatography (EtOAc/hexane 1:3) to afford tert-butylsulfonyl-L-proline 
methyl ester 1.25b (203 mg, 82% over 2 steps), as a colorless oil: 1H NMR, 
(400 MHz, CDCl3) δ 4.45 (d, 1H, J=6.6 Hz), 3.58-3.55 (m, 4H), 3.38-3.36 (m, 
1H), 2.10-2.07 (m, 1H), 1.88-1.80 (m, 3H), 1.24 (s, 9H); 13C NMR, (100 MHz, 
CDCl3) δ 173.0, 61.0, 60.9, 51.8, 49.9, 30.5, 24.7, 23.9; [α]D -66.9 (c 1.0, 
CHCl3); HRMS for C11H23NO4S calculated (M+H+) 250.11076, found 250.11106. 
 
 
N-Bus-L-Leu-OMe (1.25c): The general procedure was followed using 
L-leucine methyl ester hydrochloride 1.23c (182 mg, 1.0 mmol), Et3N (1.39 mL, 
10.0 mmol), tert-butylsulfinyl chloride 1.28 (0.25 mL, 2.0 mmol) in 5 mL of 
DCM and DCM (5 mL). The crude product was purified by flash column 
chromatography (EtOAc/hexane 3:2), which was oxidized with m-CPBA (233 
26 
 
mg, 1.35 mmol) and DCM (10 mL). The residue was purified by flash column 
chromatography (EtOAc/hexane 1:3) to afford tert-butylsulfonyl-L-leucine 
methyl ester 1.25c (219 mg, 82% over 2 steps), as a colorless solid, m.p. 
56-57 oC: 1H NMR, (400 MHz, CDCl3) δ 5.21 (d, 1H, J=9.9 Hz), 3.88-3.82 (m, 
1H), 3.53 (s, 3H), 1.60-1.54 (m, 1H), 1.38-1.21 (m, 1H), 1.15 (s, 9H), 
0.75-0.72 (m, 6H); 13C NMR, (100 MHz, CDCl3) δ 173.5, 59.5, 55.4, 51.9, 42.6, 
24.0, 23.7, 22.4, 21.4; [α]D -16.0 (c 1.0, CHCl3); HRMS for C11H23NO4S 
calculated (M+H+) 266.14206, found 266.14225. 
 
 
N-Bus-L-Ala-OMe (1.25d): The general procedure was followed using 
L-alanine methyl ester hydrochloride 1.23d (209 mg, 1.5 mmol), Et3N (2.09 
mL, 15.0 mmol), tert-butylsulfinyl chloride 1.28 (0.37 mL, 3.0 mmol) in 8 mL 
of DCM and DCM (8 mL). The crude product was purified by flash column 
chromatography (EtOAc/hexane 4:1), which was oxidized with m-CPBA (350 
mg, 2.025 mmol) and DCM (20 mL). The residue was purified by flash column 
chromatography (EtOAc/hexane 2:3) to afford tert-butylsulfonyl-L-alanine 
methyl ester 1.25d (257 mg, 77% over 2 steps), as a colorless solid, m.p. 
69-70 oC: 1H NMR, (400 MHz, CDCl3) δ 5.07 (d, 1H, J=9.5 Hz), 4.08-4.04 (m, 
1H), 3.68 (s, 3H), 1.38 (d, 3H, J=7.2 Hz), 1.30 (s, 9H); 13C NMR, (100 MHz, 
CDCl3) δ 173.7, 59.9, 52.8, 52.6, 24.0, 20.2; [α]D -12.4 (c 1.0, CHCl3); HRMS 
for C8H14NO4S calculated (M+H+) 224.09511, found 224.09507. 
 
 
N-Bus-L-Phe-OMe (1.25e): The general procedure was followed using 
L-phenylalanine methyl ester hydrochloride 1.23e (86 mg, 0.4 mmol), Et3N 
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(0.14 mL, 1.0 mmol), tert-butylsulfinyl chloride 1.28 (55 uL, 0.44 mmol) in 0.5 
mL of DCM and DCM (4 mL). The crude product was purified by flash column 
chromatography (EtOAc/hexane 3:2), which was oxidized with m-CPBA (93 mg, 
0.54 mmol) and DCM (3 mL). The crude residue was purified by flash column 
chromatography (EtOAc/hexane 13:7) to afford tert-butylsulfonyl-L-phenyl- 
alanine methyl ester 1.25e (105 mg, 88% over 2 steps), as a colorless solid, 
m.p. 101-103 oC: 1H NMR, (400 MHz, CDCl3) δ 7.34-7.27 (m, 3H), 7.19-7.17 (m, 
2H), 4.49 (d, 1H, J=10.3 Hz), 4.34-4.28 (m, 1H), 3.76 (s, 3H), 3.15-3.03 (m, 
2H), 1.20 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 172.7, 135.8, 129.7, 128.8, 
127.5, 60.3, 58.8, 52.7, 39.9, 24.0; [α]D +12.1 (c 1.0, CHCl3); HRMS for 
C14H21NO4S calculated (M+H+) 300.12641, found 300.12591. 
 
 
N-Bus-L-Val-OMe (1.25f): The general procedure was followed using 
L-valine methyl ester hydrochloride 1.23f (1.26 g, 7.5 mmol), Et3N (2.61 mL, 
18.75 mmol), tert-butylsulfinyl chloride 1.28 (1.02 mL, 8.25 mmol) in 25 mL of 
DCM and DCM (25 mL). The crude product was purified by flash column 
chromatography (EtOAc/hexane 4:1), which was oxidized with m-CPBA (1.75 g, 
10.125 mmol) and DCM (30 mL). The residue was purified by flash column 
chromatography (EtOAc/hexane 13:7) to afford tert-butylsulfonyl-L-valine 
methyl ester 1.25f (1.46 g, 77% over 2 steps), as a colorless solid, m.p. 70-72 
oC: 1H NMR, (400 MHz, CDCl3) δ 5.14 (d, 1H, J=10.2 Hz), 3.71-3.67 (m, 1H), 
3.53 (s, 3H), 1.90-1.85 (m, 1H), 1.14 (s, 9H), 0.78 (d, 3H, J=6.8 Hz), 0.73 (d, 
3H, J=7.3 Hz); 13C NMR, (100 MHz, CDCl3) δ 172.5, 62.3, 59.7, 51.9, 31.7, 
23.8, 18.8, 17.6; [α]D -8.9 (c 1.0, CHCl3); HRMS for C10H21NO4S calculated 
(M+H+) 252.12641, found 252.12660. 
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N-Bus-L-Asp-diOMe (1.25g): The general procedure was followed using 
L-aspartic dimethyl ester hydrochloride 1.23g (198 mg, 1 mmol), Et3N (0.35 
mL, 2.5 mmol), tert-butylsulfinyl chloride 1.28 (0.14 mL, 1.1 mmol) in 2 mL of 
DCM and DCM (15 mL). The crude product was purified by flash column 
chromatography (EtOAc/hexane 9:1), which was oxidized with m-CPBA (233 
mg, 1.35 mmol) and DCM (10 mL). The residue was purified by flash column 
chromatography (EtOAc/hexane 2:3) to afford tert-butylsulfonyl-L-aspartic 
dimethyl ester 1.25g (201 mg, 72% over 2 steps), as a colorless solid, m.p. 
77-78 oC: 1H NMR, (400 MHz, CDCl3) δ 5.14 (d, 1H, J=9.6 Hz), 4.34-4.32 (m, 
1H), 3.75 (s, 3H), 3.67 (s, 3H), 3.02 (dd, 1H, J=4.6 Hz, J=17.2 Hz), 2.85 (dd, 
1H, J=4.7 Hz, J=17.2 Hz), 1.36 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 171.3, 
171.2, 60.5, 53.5, 53.1, 52.3, 38.6, 24.1; [α]D +21.3 (c 1.0, CHCl3); HRMS for 
C10H19NO6S calculated (M+H+) 282.10058, found 282.10097. 
 
 
N-Bus-O-Bn-L-Ser-OMe (1.30a): The general procedure was followed 
using O-benzyl-L-serine methyl ester hydrochloride 1.29a (1.13 g, 4 mmol), 
Et3N (1.39 mL, 10.0 mmol), tert-butylsulfinyl chloride 1.28 (0.55 mL, 4.4 
mmol) in 5 mL of DCM and DCM (40 mL). The crude product was purified by 
flash column chromatography (EtOAc/hexane 4:1), which was oxidized with 
m-CPBA (932 mg, 5.4 mmol) and DCM (30 mL). The residue was purified by 
flash column chromatography (EtOAc/hexane 2:3) to afford tert-butylsulfonyl- 
O-benzyl-L-serine methyl ester 1.30a (1.02 g, 78% over 2 steps), as a 
colorless solid, m.p. 88-89 oC: 1H NMR, (400 MHz, CDCl3) δ 7.35-7.25 (m, 5H), 
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4.98 (d, 1H, J=9.8 Hz), 4.52 (dd, 2H, J=12.2 Hz, J=25.3 Hz), 4.28-4.24 (m, 
2H), 3.87 (dd, 1H, J=3.2 Hz, J=9.4 Hz), 3.75 (s, 3H), 3.70 (dd, 1H, J=3.5 Hz, 
J=9.4 Hz), 1.37 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 170.9, 137.4, 128.4, 
127.9, 127.6, 73.2, 71.1, 60.1, 57.3, 52.7, 24.0; [α]D +2.4 (c 1.0, CHCl3); 
HRMS for C15H23NO5S calculated (M+H+) 330.13697, found 330.13723. 
 
 
N-Bus-O-Bn-L-Tyr-OMe (1.30b): The general procedure was followed 
using O-benzyl-L-tyrosine methyl ester hydrochloride 1.29b (1.13 g, 3.5 
mmol), Et3N (1.22 mL, 8.75 mmol), tert-butylsulfinyl chloride 1.28 (0.48 mL, 
3.85 mmol) in 4 mL of DCM and DCM (40 mL). The crude product was purified 
by flash column chromatography (EtOAc/hexane 3:2), which was oxidized with 
m-CPBA (699 mg, 4.05 mmol) and DCM (50 mL). The residue was purified by 
flash column chromatography (EtOAc/hexane 1:1) to afford tert-butylsulfonyl- 
O-benzyl-L-tyrosine methyl ester 1.30b (1.14 g, 80% over 2 steps), as a 
colorless solid, m.p. 107-108 oC: 1H NMR, (400 MHz, CDCl3) δ 7.44-7.32 (m, 
5H), 7.16 (d, 2H, J=8.5 Hz), 6.94 (d, 2H, J=8.6 Hz), 5.08 (d, 1H, J=10.3 Hz), 
5.04 (s,2H), 4.32-4.26 (m, 1H), 3.74 (s, 3H), 3.08-3.02 (m, 2H), 1.21 (s, 9H); 
13C NMR, (100 MHz, CDCl3) δ 172.8, 157.9, 136.9, 130.6, 129.5, 128.1, 127.9, 
127.4, 115.0, 69.8, 60.0, 59.0, 52.4, 38.6, 23.7; [α]D +11.8 (c 1.0, CHCl3); 
HRMS for C21H27NO5S calculated (M+H+) 406.16827, found 406.16843. 
 
 
N-Bus-N6-Cbz-L-Lys-OMe (1.35a): The general procedure was followed 
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using N6-benzyloxycarbonyl-L-lysine methyl ester hydrochloride 1.35 (1.46 g, 
4.4 mmol), Et3N (1.53 mL, 11.0 mmol), tert-butylsulfinyl chloride 1.28 (0.60 
mL, 4.84 mmol) in 5 mL of DCM and DCM (40 mL). The crude product was 
purified by flash column chromatography (EtOAc/hexane 4:1), which was 
oxidized with m-CPBA (812 mg, 5.94 mmol) and DCM (30 mL). The residue was 
purified by flash column chromatography (EtOAc/hexane 2:3) to afford 
tert-butylsulfonyl-N6-benzyloxycarbonyl-L-lysine methyl ester 1.35a (1.02 g, 
76% over 2 steps), as a colorless solid, m.p. 82-83 oC: 1H NMR, (400 MHz, 
CDCl3) δ 7.25-7.21 (m, 5H), 5.38 (d, 2H, J=9.5 Hz), 5.00 (s, 2H), 3.98-3.94 (m, 
1H), 3.64 (s, 3H), 3.08 (d, 2H, J=6.2 Hz), 1.72-1.62 (m, 2H), 1.44-1.38 (m, 
4H), 1.27 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 173.2, 156.5, 136.6, 128.3, 
127.83, 127.81, 66.2, 59.8, 56.9, 52.3, 40.2, 33.0, 29.0, 23.9, 22.2; [α]D +2.4 
(c 1.0, CHCl3); HRMS for C19H30N2O6S calculated (M+H+) 415.18973, found 
415.19077. 
 
Et3N, DCM
m-CPBA
DCM
1.28
ClH.H2N CO2Me BusHN CO2Me
NHBoc NHBoc
1.34 1.34a
 
N-Bus-N6-Boc-L-Lys-OMe (1.34a): The general procedure was followed 
using N6-tert-butyloxycarbonyl-L-lysine methyl ester hydrochloride 1.34 (950 
mg, 3.2 mmol), Et3N (1.12 mL, 8.0 mmol), tert-butylsulfinyl chloride 1.28 
(0.44 mL, 3.52 mmol) in 5 mL of DCM and DCM (30 mL). The crude product was 
purified by flash column chromatography (EtOAc/hexane 4:1), which was 
oxidized with m-CPBA (746 mg, 4.32 mmol) and DCM (30 mL). The residue was 
purified by flash column chromatography (EtOAc/hexane 7:13) to afford 
tert-butylsulfonyl-N6-tert-butyloxycarbonyl-L-lysine methyl ester 1.34a (978 
mg, 80% over 2 steps), as a colorless solid, m.p. 84-85 oC: 1H NMR, (400 MHz, 
31 
 
CDCl3) δ 5.00 (d, 1H, J=9.8 Hz), 4.73 (s, 1H), 4.04-3.98 (m, 1H), 3.71 (s, 3H), 
3.05 (s, 2H), 1.75-1.66 (m, 2H), 1.46-1.39 (m, 2H), 1.37 (s, 9H), 1.31 (s, 9H); 
13C NMR, (100 MHz, CDCl3) δ 173.1, 155.8, 78.4, 59.6, 56.9, 52.1, 39.7, 33.0, 
29.1, 28.1, 23.8, 22.3; [α]D +1.4 (c 1.0, CHCl3); HRMS for C16H32N2O6S 
calculated (M+Na+) 403.18733, found 403.18793. 
 
 
N-Bus-O-Bus-L-Ser-OMe (1.50): The general procedure was followed 
using L-serine methyl ester hydrochloride 1.48 (934 mg, 6 mmol), Et3N (4.18 
mL, 30 mmol), tert-butylsulfinyl chloride 1.28 (1.86 mL, 15 mmol) in 15 mL of 
DCM and DCM (40 mL). The crude product was purified by flash column 
chromatography (EtOAc/hexane 3:2), which was oxidized with m-CPBA (3.11 g, 
18 mmol), DCM (25 mL). The residue was purified by flash column 
chromatography (EtOAc/hexane 1:4) to afford tert-butylsulfonyl-O-tert-butyl- 
sulfonyl-L-serine methyl ester 1.50 (1.30 g, 60% over 2 steps), as a colorless 
solid, m.p. 61-62 oC: 1H NMR, (400 MHz, CDCl3) δ 5.15 (d, 1H, J=9.7 Hz), 4.54 
(dd, 1H, J=5.4 Hz, J=10.8 Hz), 4.45-4.39 (m, 2H), 3.79 (s, 3H), 1.40 (s, 9H), 
1.36 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 169.4, 69.4, 60.5, 60.0, 56.5, 53.4, 
24.4, 24.1; [α]D +14.5 (c 1.0, CHCl3); HRMS for C12H25NO7S2 calculated (M+H+) 
360.11452, found 360.11443. 
 
 
N-Bus-Nδ,Nω-di-Cbz-L-Arg-OMe (1.45a): The general procedure was 
followed using Nδ,Nω-dibenzyloxycarbonyl-L-arginine methyl ester 1.45 (319 
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mg, 0.7 mmol), Et3N (0.13 mL, 0.91 mmol), tert-butylsulfinyl chloride 1.28 (95 
μL, 0.77 mmol) in 1 mL of DCM and DCM (15 mL). The crude product was 
purified by flash column chromatography (EtOAc/hexane 1:1), which was 
oxidized with m-CPBA (163 mg, 0.95 mmol) and DCM (10 mL). The residue was 
purified by flash column chromatography (EtOAc/hexane 1:3) to afford 
tert-butylsulfonyl-Nδ,Nω-dibenzyloxycarbonyl-L-arginine methyl ester 1.45a 
(307 mg, 76% over 2 steps), as a mucous soft solid: 1H NMR, (400 MHz, CDCl3) 
δ 9.45 (s, 1H), 9.26 (s, 1H), 7.39-7.26 (m, 10H), 5.22 (s, 2H), 5.14 (d, 1H, 
J=10.0Hz), 5.12 (s, 2H), 4.16-4.14 (m, 1H), 4.05-4.00 (m, 1H), 3.62 (s, 3H), 
1.78-1.66 (m, 4H), 1.30 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 173.0, 163.7, 
160.6, 155.7, 136.9, 134.6, 128.8, 128.33, 128.28, 128.0, 127.8, 68.9, 66.9, 
59.9, 56.8, 52.4, 44.9, 30.4, 24.6, 24.0; [α]D +6.4 (c 1.0, CHCl3); HRMS for 
C27H36N4O8S calculated (M+H+) 577.23266, found 577.23372. 
 
Et3N, DCM
m-CPBA
DCM
1.28
FmocHN CO2Me FmocHN CO2Me
NH2TFA NHBus
1.44a1.44
 
N6-Bus-N-Fmoc-L-Lys-OMe (1.44a): The general procedure was followed 
using tert-butylsulfinyl chloride 1.28 (68 μL, 0.55 mmol) in 0.5 mL of DCM, 
N-9-fluorenylmethoxycarbonyl-L-lysine methyl ester hydrochloride 1.44 (248 
mg, 0.5 mmol), Et3N (0.17 mL, 1.25 mmol) and DCM (12 mL). The crude 
product was purified by flash column chromatography (EtOAc/hexane 1:1), 
which was oxidized with m-CPBA (117 mg, 0.675 mmol) and DCM (10 mL). The 
residue was purified by flash column chromatography (EtOAc/hexane 2:3) to 
afford N6-tert-butylsulfonyl-N-9-fluorenylmethoxy-carbonyl-L-lysine methyl 
ester 1.44a (204 mg, 81% over 2 steps), as a colorless solid, m.p. 49-51 oC: 1H 
NMR, (400 MHz, CDCl3) δ 7.75 (d, 2H, J=7.5 Hz), 7.63-7.60 (m, 2H), 7.40-7.37 
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(m, 2H), 7.32-7.28 (m, 2H), 5.65 (d, 2H, J=8.2 Hz), 4.64-4.61 (m, 1H), 
4.38-4.33 (m, 3H), 4.23-4.19 (m, 1H), 3.73 (s, 3H), 1.86-1.78 (m, 1H), 
1.73-1.65 (m, 1H), 1.61-1.51 (m, 2H), 1.47-1.40 (m, 2H), 1.37 (s, 9H); 13C 
NMR, (100 MHz, CDCl3) δ 173.1, 156.2, 144.0, 143.9, 141.3, 127.8, 127.2, 
125.3, 120.0, 67.1, 59.9, 53.8, 52.5, 47.2, 44.4, 32.0, 30.6, 24.4, 22.2; [α]D 
+6.5 (c 1.0, CHCl3); HRMS for C26H34N2O6S calculated (M+H+) 503.22103, 
found 503.22105. 
 
General Procedure for Cleavage of tert-Butylsulfonamides. A. 
 
 
Cleavage of N-Bus-L-Phe-OEt (1.23a): To a solution of anisole (0.65 mL, 
6.0 mmol) and tert-butylsulfonyl-L-phenylalanine ethyl ester 1.25a (90 mg, 
0.3 mmol) in DCM (9 mL) was slowly added trifluoromethanesulfonic acid (0.2 
N in DCM, 9 mL) at 0 oC. The solution was stirred at 0 oC for 2 h, then warmed 
to 4 oC for 10 h (TLC monitoring, EtOAc/hexane 1:1), 15 mL H2O was added. 
The aqueous layer was neutralized with saturated aqueous NaHCO3 at 0 oC until 
pH=7.5, then extracted with DCM (2×10 mL). The organic extracts were 
combined and acidified with 1 M HCl aqueous (10 mL). The aqueous layer was 
frozen and lyophilized to give L-phenylalanine ethyl ester hydrochloride salt 
1.23a (61 mg, 89%), as a colorless oil. 
 
CF3SO3H
anisole, DCMBusHN CO2Me
Ph
ClHH2N CO2Me
Ph
1.25e 1.23e
 
Cleavage of N-Bus-L-Phe-OMe (1.23e): The general procedure was 
followed using tert-butylsulfonyl-L-phenylalanine methyl ester 1.25e (60 mg, 
0.2 mmol), trifluoromethanesulfonic acid (0.2 N in DCM, 6 mL), anisole (0.43 
34 
 
mL, 4.0 mmol), and DCM (6 mL). The aqueous layer was frozen and lyophilized 
to afford L-phenylalanine methyl ester hydrochloride salt 1.23e (37 mg, 85%), 
as a colorless oil. 
 
 
Cleavage of N-Bus-L-Leu-OMe (1.23c): The general procedure was 
followed using tert-butylsulfonyl-L-leucine methyl ester 1.25c (80 mg, 0.3 
mmol), trifluoromethanesulfonic acid (0.2 N in DCM, 9 mL), anisole (0.65 mL, 
6 mmol), and DCM (9 mL). The aqueous layer was frozen and lyophilized to 
afford L-leucine methyl ester hydrochloride salt 1.23c (43 mg, 79%), as a 
colorless oil.  
 
General Procedure for Cleavage of tert-Butylsulfonamides. B. 
 
 
Cleavage of N-Bus-L-Ala-OMe (1.23d): To a solution of anisole (0.22 mL, 
2.0 mmol) and tert-butylsulfonyl-L-alanine methyl ester 1.25d (45 mg, 0.2 
mmol) in DCM (3 mL) was slowly added trifluoromethanesulfonic acid (0.2 N in 
DCM, 3 mL) at 0 oC. The solution was stirred at 0 oC for 2 h, then warmed to 4 
oC for 10 h (TLC monitoring, EtOAc/hexane 2:3), and 6 mL H2O was added. The 
aqueous layer was neutralized with DOWEX Monosphere 550A hydroxide form 
anion exchange resin at 0 oC until pH=8.5, then 6 mL MeOH was added and the 
resin was filtered. The filtrate was combined and acidified with 1 M HCl aqueous 
(3 mL). The aqueous layer was frozen and lyophilized to afford L-alanine methyl 
ester hydrochloride salt 1.23d (24 mg, 85%), as a colorless oil. 
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Cleavage of N-Bus-L-Pro-OMe (1.23b): The general procedure was 
followed using tert-butylsulfonyl-L-proline methyl ester 1.25b (50 mg, 0.2 
mmol), trifluoromethanesulfonic acid (0.2 N in DCM, 3 mL), anisole (0.22 mL, 
2 mmol), and DCM (3 mL). The aqueous layer was frozen and lyophilized to 
afford L-proline methyl ester hydrochloride salt 1.23b (30 mg, 90%), as a 
colorless oil. 
 
 
Cleavage of N-Bus-L-Val-OMe (1.23f): The general procedure was 
followed using tert-butylsulfonyl-L-valine methyl ester 1.25f (50 mg, 0.2 
mmol), trifluoromethanesulfonic acid (0.2 N in DCM, 3 mL), anisole (0.22 mL, 
2.0 mmol), and DCM (3 mL). The aqueous layer was frozen and lyophilized to 
afford L-valine methyl ester hydrochloride salt 1.23f (28 mg, 85%), as a 
colorless oil.  
 
 
Cleavage of N-Bus-L-Asp-diOMe (1.23g): The general procedure was 
followed using tert-butylsulfonyl-L-aspartic dimethyl ester 1.25g (56 mg, 0.2 
mmol), trifluoromethanesulfonic acid (0.2 N in DCM, 3 mL), anisole (0.22 mL, 
2.0 mmol), and DCM (3 mL). The acid aqueous layer was frozen and lyophilized 
to afford L-aspartic dimethyl ester hydrochloride salt 1.23g (33 mg, 84%), as 
a colorless oil.  
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Cleavage Bn of N-Bus-O-Bn-L-Ser-OMe (1.30c): To a solution of tert- 
butylsulfonyl-O-benzyl-L-serine methyl ester 1.30a (99 mg, 0.3 mmol) in 
MeOH (5 mL), 20 wt.% Pd(OH)2 over activated carbon (5 mg, cat.) was added 
and hydrogenated at 1 atm at R.T. for 2 h (TLC monitoring, EtOAc/ hexane 3:7). 
The reaction mixture was filtered over celite, and filtrate was concentrated 
under reduced pressure to afford tert-butylsulfonyl-L-serine methyl ester 
1.30c (70 mg, 97%), as a colorless solid, m.p. 77-79 oC: 1H NMR, (400 MHz, 
CDCl3) δ 5.66 (d, 1H, J=9.5 Hz), 4.18-4.16 (m, 1H), 3.96 (d, 1H, J=11.2 Hz), 
3.86 (d, 1H, J=11.2 Hz), 3.77 (s, 3H), 3.23 (s, 1H), 1.35 (s, 9H); 13C NMR, (100 
MHz, CDCl3) δ 171.4, 64.5, 60.5, 59.2, 53.0, 24.2; [α]D +0.99 (c 1.0, CHCl3); 
ESI/MS for C8H17NO5S calculated (M+H+) 240, found 240. 
 
 
Cleavage Bn of N-Bus-O-Bn-L-Tyr-OMe (1.30d): To a solution of tert- 
butylsulfonyl-O-benzyl-L-tyrosine methyl ester 1.30b (122 mg, 0.3 mmol) in 
MeOH (5 mL), 20 wt.% Pd(OH)2 over activated carbon (5 mg, cat.) was added 
and hydrogenated at 1 atm at R.T. for 3 h (TLC monitoring, EtOAc/hexane 1:1). 
The reaction mixture was filtered over celite, and filtrate was concentrated 
under reduced pressure to afford tert-butylsulfonyl-L-tyrosine methyl ester 
1.30d (92 mg, 97%), as a colorless solid, m.p. 141-143 oC: 1H NMR, (400 MHz, 
CD3OD) δ 7.08 (d, 2H, J=8.5 Hz), 6.74 (d, 2H, J=8.5 Hz), 4.60 (s, 1H), 
4.02-3.99 (m, 1H), 3.72 (s, 3H), 3.03-2.98 (m, 1H), 2.80-2.74 (m, 1H), 1.34 
(d, 1H, J=7.1 Hz), 1.09 (s, 9H); 13C NMR, (100 MHz, CD3OD) δ 174.9, 157.6, 
131.9, 129.0, 116.4, 61.3, 61.0, 53.0, 39.2, 24.2; [α]D -23.8 (c 1.0, MeOH); 
ESI/MS for C14H21NO5S calculated (M+H+) 316, found 316.  
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Cleavage Cbz of N-Bus-N6-Cbz-L-Lys-OMe (1.35b): To a solution of tert- 
butylsulfonyl-N6-benzyloxycarbonyl-L-lysine methyl ester 1.35a (125 mg, 0.3 
mmol) in MeOH (5 mL), 20 wt.% Pd(OH)2 over activated carbon (5 mg, cat.) 
was added and hydrogenated at 1 atm at R.T. for 2 h (TLC monitoring, EtOAc/ 
hexane 1:1). The reaction mixture was filtered over celite and acidified with 1 
M HCl aqueous (10 mL). The aqueous layer was frozen and lyophilized to afford 
tert-butylsulfonyl-L-lysine methyl ester hydrochloride salt 1.35b (92 mg, 97%), 
as a colorless oil: 1H NMR, (400 MHz, CD3OD) δ 4.02-4.00 (m, 1H), 3.75 (s, 3H), 
2.98-2.94 (m, 2H), 1.84-1.77 (m, 1H), 1.76-1.69 (m, 3H), 1.64-1.53 (m, 2H), 
1.35 (s, 9H); 13C NMR, (100 MHz, CD3OD) δ 174.7, 61.0, 58.3, 53.1, 40.6, 34.0, 
28.0, 24.5, 23.8; [α]D -15.0 (c 1.0, MeOH); ESI/MS for C11H25ClN2O4S 
calculated (M+H+-HCl) 281, found 281. 
 
 
Cleavage Cbz of N-Bus-Nδ,Nω-di-Cbz-L-Arg-OMe (1.45b): To a solution 
of tert-butylsulfonyl-Nδ,Nω-dibenzyloxycarbonyl-L-arginine methyl ester 1.45a 
(58 mg, 0.1mmol) in MeOH (5 mL), 20 wt.% Pd(OH)2 over activated carbon (3 
mg, cat.) was added and hydrogenated at 1 atm at R.T. for 2 h (TLC monitoring, 
EtOAc/hexane 1:1). The reaction mixture was filtered over celite and acidified 
with 1 M HCl aqueous (10 mL). The aqueous layer was frozen and lyophilized to 
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afford tert-butylsulfonyl-L-arginine methyl ester hydrochloride salt 1.45b (29 
mg, 95%), as a colorless oil: 1H NMR, (400 MHz, CD3OD) δ 4.07-3.98 (m, 1H), 
3.76 (s, 3H), 3.26-3.22 (m, 2H), 1.86-1.79 (m, 1H), 1.77-1.72 (m, 3H), 1.36 
(s, 9H); 13C NMR, (100 MHz, CD3OD) δ 174.4, 158.7, 61.1, 58.1, 53.1, 41.9, 
31.9, 26.4, 24.5; [α]D -9.6 (c 1.0, MeOH); ESI/MS for C11H25ClN4O4S calculated 
(M+H+-HCl) 309, found 309. 
 
 
Cleavage Boc of N-Bus-N6-Boc-L-Lys-OMe (1.34b): To a solution of tert- 
butylsulfonyl-N6-tert-butyloxycarbonyl-L-lysine methyl ester 1.34a (95 mg, 
0.25 mmol) in DCM (5 mL), trifluoroacetic acid (56 μL, 0.75 mmol) was added 
dropwise and stirred at R.T. for 8 h (TLC monitoring, EtOAc/hexane 1:1). 
Solvent was evaporated, then 15 mL H2O was added and neutralized with 
saturated aqueous NaHCO3 at 0 oC until pH=7.5, then extracted with DCM 
(2×10 mL). The organic extracts were combined and acidified with 1 M HCl 
aqueous (10 mL). The aqueous layer was frozen and lyophilized to afford tert- 
butylsulfonyl-L-lysine methyl ester hydrochloride salt 1.34b (77 mg, 97%), as 
a colorless oil: 1H NMR, (400 MHz, CD3OD) δ 4.02-4.00 (m, 1H), 3.75 (s, 3H), 
2.98- 2.94 (m, 2H), 1.84-1.77 (m, 1H), 1.76-1.69 (m, 3H), 1.64-1.53 (m, 2H), 
1.35 (s, 9H); 13C NMR, (100 MHz, CD3OD) δ 174.7, 61.0, 58.3, 53.1, 40.6, 34.0, 
28.0, 24.5, 23.8; [α]D -15.0 (c 1.0, MeOH); ESI/MS for C11H25ClN2O4S 
calculated (M+H+-HCl) 281, found 281.  
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Cleavage Fmoc of N6-Bus-N-Fmoc-L-Lys-OMe (1.44b): To a solution of 
5% piperidine in DMF (1 mL) was added N6-tert-butylsulfonyl-N-9-fluorenyl- 
methoxycarbonyl-L-lysine methyl ester 1.44a (50 mg, 0.1 mmol) at R.T.. The 
reaction mixture was stirred at R.T. for 8 h (TLC monitoring, EtOAc/hexane 2:3), 
after which time it was diluted with 50 mL of EtOAc. The reaction mixture was 
washed with 2×50 mL of saturated aqueous Na2CO3 and 50mL of brine. The 
organic layer was dried over Na2SO4, and solvent was evaporated. The crude 
product was purified by flash column chromatography (EtOAc/hexane 2:3). The 
organic extracts were combined and acidified with 1 M HCl aqueous (10 mL). 
The aqueous layer was frozen and lyophilized to afford N6-tert-butylsulfonyl- 
L-lysine methyl ester hydrochloride salt 1.44b (26 mg, 92%), as a colorless oil: 
1H NMR, (400 MHz, CD3OD) δ 4.07-4.04 (m, 1H), 3.85 (s, 3H), 3.18- 3.15 (m, 
2H), 1.99-1.92 (m, 2H), 1.61-1.49 (m, 4H), 1.36 (s, 9H); 13C NMR, (100 MHz, 
CD3OD) δ 171.1, 60.8, 54.1, 53.8, 45.0, 31.9, 31.2, 24.8, 22.9; [α]D +13.3 (c 
1.0, MeOH); ESI/MS for C11H25ClN2O4S calculated (M+H+-HCl) 281, found 281. 
 
 
Cleavage Bus of N6-Bus-N-Fmoc-L-Lys-OMe (1.44c): To a solution of 
N6-tert-butylsulfonyl-N-9-fluorenylmethoxycarbonyl-L-lysine methyl ester 
1.44a (25 mg, 0.05 mmol) and anisole (0.11 mL, 1.0 mmol) in DCM (1.5 mL) 
was slowly added trifluoromethanesulfonic acid (0.2 N in DCM, 1.5 mL) at 0 oC. 
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The solution was stirred at 4 oC for 6 h (TLC monitoring, EtOAc/hexane 2:3), the 
reaction was finished. Solvents were evaporated. The residue was taken up in 
the 20 mL H2O and washed with 3×20 mL Et2O. The water layer was frozen and 
lyophilized to afford N-9-fluorenylmethoxycarbonyl-L-lysine methyl ester 
trifluoromethanesulfonic acid salt 1.44c (24 mg, 89%), as a colorless oil: 1H 
NMR, (400 MHz, CD3OD) δ 7.80 (d, 2H, J=7.5 Hz), 7.67 (t, 2H, J=6.7 Hz), 
7.40(t, 2H, J=7.3 Hz), 7.32(t, 2H, J=7.5 Hz), 4.42-4.32 (m, 2H), 4.24-4.16 (m, 
2H), 3.72 (s, 3H), 2.92 (t, 2H, J=7.2 Hz), 1.92–1.82 (m, 1H), 1.78–1.65 (m, 
3H), 1.52–1.42 (m, 2H); 13C NMR, (100 MHz, CD3OD) δ 174.5, 158.8, 145.3, 
145.2, 142,7, 128.9, 128.3, 126.34, 126.32, 121.0, 120.3, 68.0, 55.2, 52.9, 
48.5, 40.6, 32.0, 28.0, 23.9; [α]D –9.5(c 1.0, MeOH); ESI/MS for 
C23H27F3N2O6S calculated (M+H+-CF3SO3H) 383, found 383. 
 
General Procedure for Hydrolysis of tert-Butylsulfon amides. 
 
 
Hydrolysis of N-Bus-L-Ala-OMe (1.36a): To a solution of tert-butyl- 
sulfonyl-L-alanine methyl ester 1.25d (669 mg, 3.0 mmol) in MeOH (21 mL) 
and H2O (7 mL) was slowly added LiOH×H2O (627 mg, 15 mmol) at 0 oC. The 
solution was stirred at 4 oC for 10 h (TLC monitoring, EtOAc/hexane 3:2), and 
solvents were evaporated. Then the residue was taken up in the 30 mL H2O and 
acidified with 1 M HCl aqueous to pH=1, the aqueous layer was extracted with 
EtOAc (4×50 mL). The organic extracts were combined, dried over Na2SO4, and 
concentrated under reduced pressure to give tert-butylsulfonyl-L-alanine 
1.36a (552 mg, 88%), as a colorless solid, m.p. 161-162 oC: 1H NMR, (400 MHz, 
CD3OD) δ 4.03 (dd, 1H, J=7.3 Hz, J=14.6 Hz), 1.43 (d, 3H, J=7.3 Hz), 1.35 (s, 
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9H); 13C NMR, (100 MHz, CD3OD) δ 176.4, 60.8, 54.1, 24.5, 20.4; [α]D -19.9 (c 
1.0, MeOH); HRMS for C7H15NO4S calculated (M+Na+) 232.06140, found 
232.06111.  
 
 
Hydrolysis of N-Bus-L-Phe-OMe (1.36b): The general procedure was 
followed using tert-butylsulfonyl-L-phenylalanine methyl ester 1.25e (500 mg, 
1.67 mmol), LiOH×H2O (351 mg, 8.36 mmol), MeOH (21 mL) and H2O (7 mL). 
The organic extracts were combined, dried over Na2SO4 and concentrated 
under reduced pressure to afford tert-butylsulfonyl-L-phenylalanine 1.36b 
(425 mg, 90%), as a colorless solid, m.p. 203-205 oC: 1H NMR, (400 MHz, 
CD3OD) δ 7.30-7.22 (m, 5H), 4.04 (dd, 1H, J=4.5 Hz, J=10.0 Hz), 3.15 (dd, 1H, 
J=4.5 Hz, J=13.5 Hz), 2.87 (dd, 1H, J=10.0 Hz, J=13.5 Hz), 1.07 (s, 9H); 13C 
NMR, (100 MHz, CD3OD) δ 175.8, 138.6, 130.9, 129.6, 128.1, 61.0, 60.9, 40.2, 
24.2; [α]D -21.5 (c 1.0, MeOH); HRMS for C13H19NO4S calculated (M+Na+) 
308.09270, found 308.09191. 
 
 
Hydrolysis of N-Bus-L-Pro-OMe (1.40a): The general procedure was 
followed using tert-butylsulfonyl-L-proline methyl ester 1.25b (250 mg, 1.0 
mmol), LiOH×H2O (210 mg, 5.0 mmol), MeOH (15 mL) and H2O (5 mL). The 
organic extracts were combined, dried over Na2SO4, and concentrated under 
reduced pressure to afford tert-butylsulfonyl-L-proline 1.40a (214 mg, 90%), 
as a colorless solid, m.p. 135-137 oC: 1H NMR, (400 MHz, CDCl3) δ 9.85 (s, 1H), 
4.55 (d, 1H, J=6.3 Hz), 3.67-3.65 (m, 1H), 3.46-3.45 (m, 1H), 2.27-2.21 (m, 
1H), 2.07-1.93 (m, 3H), 1.36 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 178.5, 61.6, 
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61.5, 50.3, 31.0, 25.1, 24.4; [α]D -67.3 (c 1.0, CHCl3); HRMS for C9H17NO4S 
calculated (M+H+) 236.09511, found 236.09521.  
 
 
Hydrolysis of N-Bus-L-Val-OMe (1.52): The general procedure was 
followed using tert-butylsulfonyl-L-valine methyl ester 1.25f (25 mg, 0.1 
mmol), LiOH×H2O (21 mg, 0.5 mmol), MeOH (3 mL) and H2O (1 mL). The 
organic extracts were combined, dried over Na2SO4, and concentrated under 
reduced pressure to afford tert-butylsulfonyl-L-valine 1.52 (21 mg, 89%), as a 
colorless solid, m.p. 101-104 oC: 1H NMR, (400 MHz, CDCl3) δ 9.01 (s, 1H), 5.01 
(d, 1H, J=10.2 Hz), 3.95 (dd, 1H, J=4.8 Hz, J=10.3 Hz), 2.20-2.16 (m, 1H), 
1.36 (s, 9H), 1.04 (d, 3H, J=6.8 Hz), 0.94 (d, 3H, J=6.9 Hz); 13C NMR, (100 
MHz, CDCl3) δ 177.2, 62.5, 60.7, 32.1, 24.3, 19.5, 17.6; [α]D -3.2 (c 1.0, 
CHCl3); HRMS for C9H19NO4S calculated (M+Na+) 260.0927, found 260.09235. 
 
 
Hydrolysis of N-Bus-O-Bn-L-Ser-OMe (1.31a): The general procedure 
was followed using tert-butylsulfonyl-O-benzyl-L-serine methyl ester 1.30a 
(495 mg, 1.5 mmol), LiOH×H2O (315 mg, 7.5 mmol), MeOH (15 mL) and H2O 
(5 mL). The organic extracts were combined, dried over Na2SO4, and 
concentrated under reduced pressure to afford tert-butylsulfonyl-O-benzyl- 
L-serine 1.31a (408 mg, 86%), as a colorless solid, m.p. 58-60 oC: 1H NMR, 
(400 MHz, CDCl3) δ 7.33-7.28 (m, 5H), 6.95 (s, 1H), 5.22 (d, 1H, J=9.3 Hz), 
4.55 (s, 2H), 4.30-4.27 (m, 1H), 3.93 (dd, 1H, J=3.4 Hz, J=9.5 Hz), 3.73 (dd, 
1H, J=3.6 Hz, J=9.5 Hz), 1.37 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 174.6, 
137.3, 128.7, 128.2, 127.9, 73.6, 71.1, 60.5, 58.3, 24.2; [α]D -4.7 (c 1.0, 
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CHCl3);HRMS for C14H21NO5S calculated (M+H+) 316.12132, found 316.12180. 
  
 
Hydrolysis of N-Bus-O-Bn-L-Tyr-OMe (1.31b): The general procedure 
was followed using tert-butylsulfonyl-O-benzyl-L-tyrosine methyl ester 1.30b 
(609 mg, 1.5 mmol), LiOH×H2O (315 mg, 7.5 mmol), MeOH (15 mL) and H2O 
(5 mL). The organic extracts were combined, dried over Na2SO4, concentrated 
under reduced pressure to give tert-butylsulfonyl-O-benzyl-L-tyrosine 1.31b 
(518 mg, 88%), as a colorless solid, m.p. 148-149 oC: 1H NMR, (400 MHz, CDCl3) 
δ 7.96 (s, 1H), 7.43-7.30 (m, 5H), 7.17 (d, 2H, J=8.4 Hz), 6.93 (d, 2H, J=8.4 
Hz), 5.04 (s, 2H), 5.02 (d, 1H, J=13.0 Hz), 4.25 (s, 1H), 3.14 (dd, 1H, J=4.7 Hz, 
J=13.9 Hz), 2.98 (dd, 1H, J=7.7 Hz, J=13.8 Hz), 1.20 (s, 9H); 13C NMR, (100 
MHz, CDCl3) δ 176.7, 158.2, 137.0, 130.9, 128.7, 128.1, 128.0, 127.6, 115.2, 
70.1, 60.5, 58.9, 38.6, 23.9; [α]D +3.7 (c 1.0, CHCl3); HRMS for C20H25NO5S 
calculated (M+H+) 392.15262, found 392.15377.  
 
General Procedure for Peptide Coupling:  
 
 
 N-Bus-L-Phe-N6-Boc-L-Lys-OMe (1.37b): A solution of tert-butyl- 
sulfonyl-L-phenylalanine 1.36b (143 mg, 0.5 mmol) in 8mL of DCM and 2 mL of 
DMF was cooled to 0 oC, then EDC (144 mg, 0.75 mmol), HOBt (101 mg, 0.75 
mmol), N6-tert-butyloxycarbonyl-L-lysine methyl ester hydrochloride 1.34 
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(148 mg, 0.5 mmol) and 2,6-lutidine (0.17 mL, 1.5 mmol) were added. The 
reaction mixture was stirred at 0 oC for 1 h, then at R.T. until MS showed 
consumption of the starting material (4 h). Upon completion, 20 mL of DCM was 
added and washed successively with the saturated aqueous NaHCO3 (2×30 mL), 
1 M HCl aqueous (2×30 mL) and brine (30 mL). The organic layer was dried 
over Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (EtOAc/hexane 1:1) to afford tert- 
butylsulfonyl-L-phenylalanine-N6-tert-butyloxycarbonyl-L-lysine methyl ester 
1.37b (247 mg, 93%), as a colorless solid, m.p. 131-132 oC: 1H NMR, (400 MHz, 
CDCl3) δ 7.26-7.16 (m, 5H), 6.95 (d, 1H, J=7.5 Hz), 5.51 (d, 1H, J=9.9 Hz), 
4.91 (s, 1H), 4.56-4.54 (m, 1H), 4.09-4.07 (m, 1H), 3.66 (s, 3H), 3.11-3.02 
(m, 4H), 1.82-1.71 (m, 1H), 1.66-1.60 (m, 1H), 1.45-1.38 (m, 11H), 
1.28-1.21 (m, 2H), 1.12 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 172.5, 172.4, 
156.1, 136.5, 129.9, 128.6, 127.1, 78.9, 60.1, 59.8, 52.4, 52.1, 40.1, 39.1, 
31.7, 29.2, 28.5, 23.8, 22.2; [α]D -15.9 (c 1.0, CHCl3); HRMS for C25H41N3O7S 
calculated (M+H+) 528.27380, found 528.27291. 
  
 
  Cleavage Boc of N-Bus-L-Phe-N6-Boc-L-Lys-OMe (1.46a): To a solution 
of tert-butylsulfonyl-L-phenylalanine-N6-tert-butyloxycarbonyl-L-lysine methyl 
ester 1.37b (53 mg, 0.1 mmol) in DCM (5 mL), trifluoroacetic acid (0.5 mL, 6.7 
mmol) was added dropwise and stirred at 0 oC (TLC monitoring, EtOAc/hexane 
1:1). Solvent was evaporated to afford tert-butylsulfonyl-L-phenylalanine- 
L-lysine methyl ester trifluoroacetic acid salt 1.46a (51 mg, 94%), as a 
colorless oil: 1H NMR, (400 MHz, MeOH-d4) δ 7.38-7.30 (m, 4H), 7.27-7.24 (m, 
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1H), 4.56-4.53 (m, 1H), 4.11-4.07 (m, 1H), 3.73 (s, 3H), 3.09 (dd, 1H, J=4.4 
Hz, J=13.7 Hz)， 2.96-2.92 (t, 2H, J=7.5 Hz), 2.82 (dd, 1H, J=10.6 Hz, J=13.5 
Hz), 2.02-1.91 (m, 1H), 1.83-1.60 (m, 3H), 1.58-1.49 (m, 2H), 1.06 (s, 9H); 
13C NMR, (100 MHz, MeOH-d4) δ 175.4, 175.3, 173.8, 138.8, 131.1, 129.6, 
128.1, 61.7, 60.9, 53.0, 52.9, 40.7, 40.0, 32.2, 27.8, 24.1, 23.5; [α]D -20.9 (c 
1.0, MeOH); ESI/MS for C22H34F3N3O7S calculated (M+H+) 428, found 428.  
 
 
N-Bus-D-Phe-N6-Boc-L-Lys-OMe (1.39b): The general procedure was 
followed using tert-butylsulfonyl-D-phenylalanine 1.38b (14 mg, 0.05 mmol),  
N6-tert-butyloxycarbonyl-L-lysine methyl ester hydrochloride 1.34 (15 mg, 
0.05 mmol), EDC (14 mg, 0.08 mmol), HOBt (10 mg, 0.08 mmol), 2,6-lutidine 
(17 μL, 0.15 mmol), DCM (0.8 mL) and DMF (0.2 mL). The product (33 mg) was 
checked directly by HPLC and purified by flash column chromatography (EtOAc/ 
hexane 1:1) to afford tert-butylsulfonyl-D-phenylalanine-N6-tert-butyloxy 
carbonyl-L-lysine methyl ester 1.39b (24 mg, 92%), as a colorless soft powder: 
1H NMR, (400 MHz, CDCl3) δ 7.35-7.25 (m, 5H), 6.68 (d, 1H, J=7.4 Hz), 4.96 (d, 
1H, J=9.0 Hz), 4.72 (tr, s, 1H), 4.56 (dd, 1H, J=7.6 Hz, J=12.4 Hz), 4.16(dd, 
1H, J=7.2 Hz, J=16.1 Hz), 3.73 (s, 3H), 3.19-2.98 (m, 4H), 1.81-1.71 (m, 1H), 
1.69-1.59 (m, 1H), 1.45-1.41 (m, 11H), 1.31-1.17 (m, 11H); 13C NMR, (100 
MHz, CDCl3) δ 172.5, 171.2, 156.2, 136.4, 129.8, 129.0, 127.5, 79.3, 60.5, 
60.0, 52.7, 52.3, 40.2, 40.0, 31.8, 29.5, 28.6, 24.1, 22.3; [α]D +17.3 (c 1.0, 
CHCl3); ESI/MS for C25H41N3O7S calculated (M+H+) 528, found 528. 
 
46 
 
 
  N-Bus-D-Phe-N6-Cbz-L-Lys-OMe (1.39d): The general procedure was 
followed using tert-butylsulfonyl-D-phenylalanine 1.38b (143 mg, 0.5 mmol) 
N6-benzyloxycarbonyl-L-lysine methyl ester hydrochloride 1.35 (166 mg, 0.5 
mmol), EDC (144 mg, 0.75 mmol), HOBt (101 mg, 0.75 mmol), 2,6-lutidine 
(0.17 mL, 1.5 mmol), DCM (8 mL) and DMF (2 mL). The crude product was 
purified by flash column chromatography (EtOAc/hexane 2:3) to afford tert- 
butylsulfonyl-D-phenylalanine-N6-benzyloxycarbonyl-L-lysine methyl ester 
1.39d (257 mg, 92%), as a colorless solid, m.p. 57-59 oC: 1H NMR, (400 MHz, 
CDCl3) δ 7.31-7.21 (m, 5H), 7.02 (d, 1H, J=7.9 Hz), 5.58 (d, 1H, J=9.3 Hz), 
5.32-5.29 (m, 1H), 5.14-5.03 (m, 2H), 4.59-4.54 (m, 1H), 4.18-4.12 (m, 1H), 
3.66 (s, 3H), 3.19-3.10 (m, 3H), 3.03-2.98 (m, 1H), 1.77-1.73 (m, 1H), 
1.63-1.60 (m, 1H), 1.43-1.29 (m, 2H), 1.25-1.22 (m, 2H), 1.10 (s, 9H); 13C 
NMR, (100 MHz, CDCl3) δ 172.5, 171.6, 156.7, 136.7, 136.6, 129.7, 128.7, 
128.4, 128.0, 127.9, 127.2, 66.5, 60.3, 60.2, 52.4, 52.0, 40.4, 39.5, 31.4, 
29.1, 23.8, 22.0; [α]D +21.1 (c 1.0, CHCl3); ESI/MS for C28H39N3O7S calculated 
(M+H+) 562, found 562.  
 
 
Cleavage Cbz of N-Bus-D-Phe-N6-Cbz-L-Lys-OMe (1.46b): To a solution 
of tert-butylsulfonyl-D-phenylalanine-N6-benzyloxycarbonyl-L-lysine methyl 
ester 1.39d (56 mg, 0.1 mmol) in MeOH (5 mL), 20 wt.% Pd(OH)2 over 
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activated carbon (5 mg, cat.) was added and hydrogenated at 1 atm at R.T. for 
2 h (TLC monitoring, EtOAc/hexane 1:1). The reaction mixture was filtered over 
celite and acidified with 1 M HCl aqueous (10 mL). The aqueous layer was 
frozen and lyophilized to afford tert-butylsulfonyl-D-phenylalaninel-L-lysine 
methyl ester hydrochloride salt 1.46b (44 mg, 95%), as a colorless oil: 1H NMR, 
(400 MHz, MeOH-d4) δ 7.34-7.32 (m, 4H), 7.28-7.26 (m, 1H), 4.40 (dd, 1H, 
J=4.6 Hz, J=8.8 Hz), 4.14-4.09 (m, 1H), 3.74 (s, 3H), 3.11 (dd, 1H, J=5.6 Hz, 
J=11.5 Hz)， 2.93-2.86 (m, 3H), 1.94-1.82 (m, 1H), 1.79-1.64 (m, 3H), 
1.40-1.33 (m, 2H), 1.13 (s, 9H); 13C NMR, (100 MHz, MeOH-d4) δ 174.8, 174.7, 
138.6, 131.0, 129.7, 128.2, 62.0, 61.0, 53.4, 53.0, 40.8, 40.6, 32.2, 28.0, 
24.3, 23.5; [α]D +27.8 (c 1.0, MeOH); ESI/MS for C20H34ClN3O5S calculated 
(M-HCl+H+) 428, found 428. 
 
 
  N-Bus-L-Phe-N6-Cbz-L-Lys-OMe (1.37d): The general procedure was 
followed using tert-butylsulfonyl-L-phenylalanine 1.36b (14 mg, 0.05 mmol), 
EDC (14 mg, 0.08 mmol), HOBt (10 mg, 0.08 mmol), 2,6-lutidine (0.017 mL, 
0.15 mmol), N6-benzyloxycarbonyl-L-lysine methyl ester hydrochloride 1.35 
(16 mg, 0.05 mmol), DCM (0.8 mL) and DMF (0.2 mL). The crude product (34 
mg) was checked directly by HPLC, then purified by flash column 
chromatography (EtOAc/hexane 2:3) to afford tert-butylsulfonyl-L-phenyl- 
alanine-N6-benzyloxy-carbonyl-L-lysine methyl ester 1.37d (26 mg, 93%), as 
a colorless solid, m.p. 136-138 oC: 1H NMR, (400 MHz, CDCl3) δ 7.37-7.22 (m, 
5H), 6.77 (d, 1H, J=7.8 Hz), 5.23 (d, 2H, J=7.0 Hz), 5.24-5.04 (m, 2H), 
4.63-4.60 (m, 1H), 4.13-4.07 (m, 1H), 3.73 (s, 3H), 3.20-3.08 (m, 4H), 
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1.93-1.85 (m, 1H), 1.73-1.62 (m, 1H), 1.57-1.43 (m, 2H), 1.32-1.26 (m, 2H), 
1.16 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 172.5, 171.3, 156.9, 136.8, 136.4, 
130.0, 128.8, 128.7, 128.3, 128.2, 127.4, 127.1, 66.8, 60.4, 59.9, 52.6, 52.1, 
40.5, 39.3, 31.7, 29.2, 23.9, 22.1; [α]D -13.8 (c 1.0, CHCl3); HRMS for 
C28H39N3O7S calculated (M+H+) 562.25815, found 562.25834. 
 
 
 N-Bus-L-Ala-N6-Cbz-L-Lys-OMe (1.37c): The general procedure was 
followed using tert-butylsulfonyl-L-alanine 1.36a (209 mg, 1.0 mmol), EDC 
(288 mg, 1.5 mmol), HOBt (202 mg, 1.5 mmol), 2,6-lutidine (0.35 mL, 3.0 
mmol), N6-benzyloxycarbonyl-L-lysine methyl ester hydrochloride 1.35 (331 
mg, 1.0 mmol), DCM (16 mL) and DMF (4 mL). The crude product was purified 
by flash column chromatography (EtOAc/hexane 2:3) to afford tert- 
butylsulfonyl-L-alanine-N6-benzyloxycarbonyl-L-lysine methyl ester 1.37c 
(437 mg, 90%), as a thick colorless liquid. 1H NMR, (400 MHz, CDCl3) δ 
7.33-7.28 (m, 5H), 7.10 (d, 1H, J=7.8 Hz), 5.53 (d, 1H, J=9.4 Hz), 5.43-5.40 
(m, 1H), 5.12-5.03 (m, 2H), 4.58-4.53 (m, 1H), 4.09-4.02 (m, 1H), 3.70 (s, 
3H), 3.20-3.08 (m, 2H), 1.90-1.82 (m, 1H), 1.74-1.65 (m, 1H), 1.56-1.45 (m, 
2H), 1.41-1.37 (m, 5H), 1.33 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 172.60, 
172.57, 156.9, 136.7, 128.5, 128.09, 128.07, 66.6, 60.0, 53.6, 52.5, 52.1, 
40.4, 31.5, 29.2, 24.1, 22.2, 19.8; [α]D -17.5 (c 1.0, CHCl3); HRMS for 
C22H35N3O7S calculated (M+H+) 486.22685, found 486.22712. 
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Cleavage Cbz of N-Bus-L-Ala-N6-Cbz-L-Lys-OMe (1.46c): To a solution 
of tert-butylsulfonyl-L-alanine-N6-benzyloxycarbonyl-L-lysine methyl ester 
1.37c (49 mg, 0.1 mmol) in MeOH (5 mL), 20 wt.% Pd(OH)2 over activated 
carbon (5 mg, cat.) was added and hydrogenated at 1 atm at R.T. for 2 h (TLC 
monitoring, EtOAc/hexane 1:1). The reaction mixture was filtered over celite 
and acidified with 1 M HCl aqueous (10 mL). The aqueous layer was frozen and 
lyophilized to afford tert-butylsulfonyl-L-alanine-L-lysine methyl ester 
hydrochloride salt 1.46c (35 mg, 90%), as a thick colorless oil. 1H NMR, (400 
MHz, MeOH-d4) δ 4.48 (dd, 1H, J=6.8 Hz, J=9.8 Hz), 4.11-4.04 (m, 1H), 3.73 
(s, 3H), 2.96-2.92 (t, 2H, J=7.5 Hz), 2.00-1.89 (m, 1H), 1.81-1.63 (m, 3H), 
1.56-1.47 (m, 2H), 1.40 (d, 3H, J=7.2 Hz), 1.37 (s, 9H); 13C NMR, (100 MHz, 
MeOH-d4) δ 175.9, 173.8, 60.9, 54.9, 53.1, 53.0, 40.7, 32.1, 27.9, 24.6, 23.6, 
19.9; [α]D -50.6 (c 1.0, MeOH); ESI/MS for C14H30ClN3O5S calculated (M-HCl 
+H+) 352, found 352. 
 
 
  N-Bus-D-Ala-N6-Cbz-L-Lys-OMe (1.39c): The general procedure was 
followed using N6-benzyloxycarbonyl-L-lysine methyl ester hydrochloride 1.35 
(33 mg, 0.1 mmol), tert-butylsulfonyl-D-alanine 1.38a (21 mg, 0.1 mmol),  
EDC (29 mg, 0.15 mmol), HOBt (20 mg, 0.15 mmol), 2,6-lutidine (0.035 mL, 
0.3 mmol), DCM (1.6 mL) and DMF (0.4 mL). The product (61 mg) was checked 
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directly by HPLC and purified by flash column chromatography (EtOAc/hexane 
2:3) to afford tert-butylsulfonyl-D-alanine-N6-benzyloxycarbonyl-L-lysine 
methyl ester 1.39c (45 mg, 92%), as a thick colorless liquid. 1H NMR, (400 MHz, 
CDCl3) δ 7.36-7.28 (m, 5H), 7.09 (d, 1H, J=7.9 Hz), 5.37 (d, 1H, J=8.9Hz), 
5.19 (tr, t, 1H), 5.09 (s, 2H), 4.59-4.54 (m, 1H), 4.13-4.06 (m, 1H), 3.72 (s, 
3H), 3.20-3.14 (m, 2H), 1.93-1.83 (m, 1H), 1.78-1.68 (m, 1H), 1.57-1.48 (m, 
2H), 1.45 (d, 3H, J=7.1 Hz), 1.40-1.36 (m, 11H); 13C NMR, (100 MHz, CDCl3) δ 
172.7, 172.6, 156.9, 136.7, 128.6, 128.2, 66.7, 60.3, 54.0, 52.6, 52.2, 40.5, 
31.5, 29.3, 24.3, 22.2, 20.3; [α]D +24.8 (c 1.0, CHCl3); ESI/MS for 
C22H35N3O7S calculated (M+H+) 486, found 486. 
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  N-Bus-D-Ala-N6-Boc-L-Lys-OMe (1.39a) : The general procedure was 
followed using N6-tert-butyloxycarbonyl-L-lysine methyl ester hydrochloride 
34 (297 mg, 1.0 mmol), tert-butylsulfonyl-D-alanine 1.38a (209 mg, 1.0 
mmol),  EDC (288 mg, 1.5 mmol), 2,6-lutidine (0.35 mL, 3.0 mmol), HOBt 
(202 mg, 1.5 mmol), DCM (16 mL) and DMF (4 mL). The crude product was 
purified by flash column chromatography (EtOAc/hexane 1:1) to afford 
tert-butylsulfonyl-D-alanine-N6-tert-butyloxycarbonyl-L-lysine methyl ester 
1.39b (415 mg, 92%), as a colorless solid, m.p. 92-94 oC: 1H NMR, (400 MHz, 
CDCl3) δ 7.31 (s, 1H), 5.83 (d, 1H, J=8.5 Hz), 5.03 (s, 1H), 4.39 (br, d, 1H), 
3.98 (br, t, 1H), 3.56 (s, 3H), 2.92 (br, m, 2H), 1.71 (br, m, 1H), 1.58 (br, m, 
1H), 1.31 (br, m, 3H), 1.30 (br, m, 3H), 1.27 (s, 9H), 1.23 (s, 9H); 13C NMR, 
(100 MHz, CDCl3) δ 172.8, 172.4, 156.0, 78.6, 59.7, 53.6, 52.1, 51.9, 39.8, 
31.2, 29.0, 28.2, 23.9, 22.2, 20.2; [α]D +24.6 (c 1.0, CHCl3); ESI/MS for 
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C19H37N3O7S calculated (M+H+) 452, found 452. 
 
 
Cleavage Boc of N-Bus-D-Ala-N6-Boc-L-Lys-OMe (1.46d): To a solution 
of tert-butylsulfonyl-D-alanine-N6-tert-butyloxycarbonyl-L-lysine methyl ester 
1.39a (45 mg, 0.1 mmol) in DCM (5 mL), trifluoroacetic acid (0.5 mL, 6.7 
mmol) was added dropwise and stirred at R.T. for 2 h (TLC monitoring, 
EtOAc/hexane 1:1). Solvent was evaporated to afford tert-butylsulfonyl- 
D-alanine-L-lysine methyl ester trifluoroacetic acid salt 1.46d (42 mg, 89%), 
as a colorless oil: 1H NMR, (400 MHz, MeOH-d4) δ 4.44 (dd, 1H, J=4.8 Hz, J=9.2 
Hz), 4.05 (dd, 1H, J=7.2 Hz, J=14.4 Hz), 3.73 (s, 3H), 2.95-2.91 (t, 2H, J=7.5 
Hz), 1.97-1.89 (m, 1H), 1.82-1.60 (m, 3H), 1.53-1.44 (m, 2H), 1.42 (d, 3H, 
J=7.2 Hz), 1.38 (s, 9H); 13C NMR, (100 MHz, MeOH-d4) δ 175.8, 174.8, 173.6, 
61.1, 55.4, 53.3, 52.9, 40.6, 32.0, 28.0, 24.6, 23.6, 20.1; [α]D +23.4 (c 1.0, 
MeOH); ESI/MS for C16H30F3N3O7S calculated (M-TFA+H+) 352, found 352.  
  
 
  N-Bus-L-Ala-N6-Boc-L-Lys-OMe (1.37a): The general procedure was 
followed using N6-tert-butyloxycarbonyl-L-lysine methyl ester hydrochloride 
1.34 (30 mg, 0.1 mmol), tert-butylsulfonyl-L-alanine 1.36a (21 mg, 0.1 
mmol),  EDC (29 mg, 0.15 mmol), HOBt (20 mg, 0.15 mmol), 2,6-lutidine (35 
μL, 0.3 mmol), DCM (1.6 mL) and DMF (0.4 mL). The crude product (56 mg) 
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was checked directly by HPLC, and then purified by flash column 
chromatography (EtOAc/hexane 1:1) to afford tert-butylsulfonyl-L-alanine- 
N6-tert-butyloxycarbonyl-L-lysine methyl ester 1.37a (41 mg, 90%), as a 
colorless soft solid . 1H NMR, (400 MHz, CDCl3) δ 6.99 (d, 1H, J=9.4 Hz), 5.40 
(d, 1H, J=9.4 Hz), 4.91 (br, t, 1H), 4.60-4.57 (br, m, 1H), 4.09-4.06 (br, t, 1H), 
3.73 (s, 3H), 3.09-3.07 (br, m, 2H), 1.92-1.84 (br, m, 1H), 1.77-1.67 (br, m, 
1H), 1.44 (br, d, 14H), 1.40 (br, s, 11H); 13C NMR, (100 MHz, CDCl3) δ 172.7, 
172.5, 156.4, 79.3, 60.2, 53.8, 52.6, 52.2, 40.1, 31.6, 29.4, 28.6, 24.3, 22.4, 
20.0; [α]D -18.0 (c 1.0, CHCl3); HRMS for C19H37N3O7S calculated (M+Na+) 
474.22444, found 474.22551. 
 
 
N-Bus-O-Bn-L-Ser-L-Pro-OMe (1.33a): The general procedure was 
followed using tert-butylsulfonyl-O-benzyl-L-serine 1.31a (158 mg, 0.5 mmol), 
EDC (144 mg, 0.75 mmol), L-proline methyl ester hydrochloride 1.23b (83 mg, 
0.5 mmol), HOBt (101 mg, 0.75 mmol), 2,6-lutidine (0.17 mL, 1.5 mmol), DCM 
(8 mL), DMF (2 mL). The crude product was purified by flash column 
chromatography (EtOAc/hexane 3:7) to afford tert-butylsulfonyl-O-benzyl- 
L-serine-L-proline methyl ester 1.33a (184 mg, 86%), as a colorless liquid: 1H 
NMR, (400 MHz, CDCl3) δ 7.31-7.21 (m, 5H), 5.49-5.45 (m, 1H), 4.58-4.39 (m, 
4H), 3.68-3.55 (m, 6H), 2.32 (s, 1H), 2.20-2.04 (m, 1H), 1.99-1.86 (m, 
3H),1.81-1.71 (m, 1H), 1.33 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 172.1, 
169.5, 137.7, 128.3, 127.6, 127.5, 73.5, 71.1, 60.0, 59.0, 55.4, 52.2, 46.9, 
29.0, 24.8, 24.1; [α]D -43.3 (c 1.0, CHCl3); HRMS for C20H30N2O6S calculated 
(M+H+) 427.18973, found 427.19101.  
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Cleavage Bn of N-Bus-O-Bn-L-Ser-L-Pro-OMe (1.46e): To a solution of 
tert-butylsulfonyl-O-benzyl-L-serine-L-proline methyl ester 1.33a (43 mg, 0.1 
mmol) in MeOH (5 mL), 20 wt.% Pd(OH)2 over activated carbon (3 mg, cat.) 
was added and hydrogenated at 1 atm at R.T. for 3 h (TLC monitoring, EtOAc/ 
hexane 1:1). The reaction mixture was filtered over celite, and the filtrate was 
concentrated under reduced pressure to afford tert-butylsulfonyl-L-serine- 
L-proline methyl ester 1.46e (30 mg, 89%), as a colorless liquid: 1H NMR, (400 
MHz, CDCl3) δ 5.45 (d, 1H, J=9.4 Hz), 4.62-4.59 (m, 1H), 4.42-4.36 (m, 1H), 
3.86-3.365 (m, 7H), 2.28-2.19 (m, 1H), 2.05-1.94 (m, 3H), 1.37 (s, 9H); 13C 
NMR, (100 MHz, CDCl3) δ 173.2, 170.5, 64.5, 60.2, 59.2, 56.7, 52.9, 47.3, 
29.0, 24.9, 24.2; [α]D -67.0 (c 1.0, CHCl3); ESI/MS for C13H24N2O6S calculated 
(M+H+) 337, found 337. 
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N-Bus-O-Bn-L-Tyr-L-Pro-OMe (1.33b): The general procedure was 
followed using tert-butylsulfonyl-O-benzyl-L-tyrosine 1.31b (196 mg, 0.5 
mmol), EDC (144 mg, 0.75 mmol), L-proline methyl ester hydrochloride 1.23b 
(83 mg, 0.5 mmol), HOBt (101 mg, 0.75 mmol), 2,6-lutidine (0.17 mL, 1.5 
mmol), DCM (8 mL) and DMF (2 mL). The crude product was purified by flash 
column chromatography (EtOAc/hexane 3:7) to afford tert-butylsulfonyl- 
O-benzyl-L-tyrosine-L-proline methyl ester 1.33b (223 mg, 89%), as a 
colorless solid, m.p. 45-47 oC: 1H NMR, (400 MHz, CDCl3) δ 7.39-7.27 (m, 5H), 
7.22-7.10 (m, 2H), 6.90-6.88 (m, 2H), 5.63 (d, 1H, J=9.9 Hz), 5.02 (s, 2H), 
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3.66-3.64 (m, 4H), 3.33-3.30 (m, 1H), 3.06-3.01 (m, 1H), 2.89-2.83 (m, 1H), 
2.17-2.12 (m, 1H),1.93-1.92 (m, 1H), 1,27-1.19 (m, 2H), 1.13 (s, 9H); 13C 
NMR, (100 MHz, CDCl3) δ 172.2, 171.1, 157.6, 137.0, 131.0, 128.8, 128.4, 
127.8, 127.3, 114.8, 69.8, 59.7, 58.8, 57.6, 52.1, 46.6, 38.5, 28.9, 24.7, 23.6; 
[α]D -43.3 (c 1.0, CHCl3); HRMS for C26H34N2O6S calculated (M+H+) 503.22103, 
found 503.22170. 
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Cleavage Bn of N-Bus-O-Bn-L-Tyr-L-Pro-OMe (1.46f): To a solution of 
tert-butylsulfonyl-O-benzyl-L-tyrosine-L-proline methyl ester 1.33b (50 mg, 
0.1 mmol) in MeOH (5 mL), 20 wt.% Pd(OH)2 over activated carbon (3 mg, cat.) 
was added and hydrogenated at 1 atm at R.T. for 3 h (TLC monitoring, EtOAc/ 
hexane 1:1). The reaction mixture was filtered over celite, and the filtrate was 
concentrated under reduced pressure to afford tert-butylsulfonyl-L-tyrosine- 
L-proline methyl ester 1.46f (37 mg, 89%) as a colorless solid, m.p. 70-72 oC: 
1H NMR, (400MHz, CDCl3) δ 7.09 (d, 2H, J=8.1 Hz), 6.75 (d, 2H, J=8.1 Hz), 
5.09 (d, 1H, J=9.8 Hz), 4.58-4.55 (m, 1H), 4.30-4.24 (m, 1H), 3.72-3.63 (m, 
4H), 3.40-3.37 (m, 1H), 3.01 (dd, 1H, J=5.8 Hz, J=13.8 Hz), 2.82 (dd, 1H, 
J=7.3 Hz, J=14.0 Hz), 2.39 (s, 1H), 2.21-1.95 (m, 2H), 1.33 (d, 2H, J=16.4 Hz), 
1.20 (s, 9H); 13C NMR, (100 MHz, CDCl3) δ 172.5, 171.4, 155.6, 131.2, 127.3, 
115.6, 60.1, 59.2, 57.5, 52.5, 46.9, 38.9, 29.1, 25.0, 24.1, 23.9; [α]D -38.9 (c 
1.0, CHCl3); ESI/MS for C19H28N2O6S calculated (M+H+) 413, found 413. 
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N-Bus-O-Bn-L-Ser-N6-Boc-L-Lys-OMe (1.32a): The general procedure 
was followed using tert-butylsulfonyl-O-benzyl-L-serine 1.31a (158 mg, 0.5 
mmol), N6-tert-butyloxycarbonyl-L-lysine methyl ester hydrochloride 1.34 
(148 mg, 0.5 mmol), EDC (144 mg, 0.75 mmol), HOBt (101 mg, 0.75 mmol), 
2,6-lutidine (0.17 mL, 1.5 mmol), DCM (8 mL) and DMF (2 mL). The product 
was purified by flash column chromatography (EtOAc/hexane 3:7) to afford 
tert-butylsulfonyl-O-benzyl-L-serine-N6-tert-butyloxycarbonyl-L-lysine methyl 
ester 1.32a (238 mg, 85%), as a colorless thick liquid: 1H NMR, (400 MHz, 
CDCl3) δ 7.30-7.21 (m, 5H), 5.44 (dd, 1H, J=8.2 Hz, J= 26.5 Hz), 4.76-4.74 (m, 
1H), 4.55-4.45 (m, 3H), 4.16-4.13 (m, 1H), 3.88-3.82 (m, 1H), 3.65-3.62 (m, 
3H), 2.97-2.95 (m, 2H), 1.80-1.76 (m, 1H), 1.62-1.59 (m, 1H), 1.37 (s, 11H), 
1.34 (s, 9H), 1.24-1.20 (m, 2H); 13C NMR, (100 MHz, CDCl3) δ 172.2, 169.7, 
156.0, 137.2, 128.4, 127.9, 127.7, 78.9, 73.5, 71.1, 70.8, 60.4, 52.3, 52.2, 
40.0, 31.8, 29.2, 28.4, 24.1, 22.3; [α]D +6.3 (c 1.0, CHCl3); HRMS for 
C26H43N3O8S calculated (M+Na+) 580.26631, found 580.26710. 
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Cleavage Bn of N-Bus-O-Bn-L-Ser-N6-Boc-L-Lys-OMe (1.46g): To a 
solution of tert-butylsulfonyl-O-benzyl-L-serine-N6-tert-butyloxycarbonyl-L- 
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lysine methyl ester 1.32a (56 mg, 0.1 mmol) in MeOH (5 mL), 20 wt.% 
Pd(OH)2 over activated carbon (3 mg, cat.) was added and hydrogenated at 1 
atm at R.T. for 1 h (TLC monitoring, EtOAc/hexane 1:1). The reaction mixture 
was filtered over celite, and filtrate was concentrated under reduced pressure 
to afford tert-butylsulfonyl-L-serine-N6-tert-butyloxycarbonyl-L-lysine methyl 
ester 1.46g (40 mg, 86%), as a colorless thick liquid: 1H NMR, (400 MHz, CDCl3) 
δ 7.36 (d, 1H, J=7.5 Hz), 5.84 (d, 1H, J=8.7 Hz), 5.74 (d, 1H, J=8.7 Hz), 4.89 
(br, m, 1H), 4.62-4.55 (br, m, 1H), 4,11 (br, m, 1H), 4.01 (br, m, 1H), 3.91 (br, 
m, 1H), 3.80 (br, m, 1H), 3.73 (s, 3H), 3.07 (d, 1H, J=5.3 Hz), 1.93-1.85 (br, 
m, 1H), 1.78-1.68 (br, m, 1H),1.57-1.34 (br, m, 20H); 13C NMR, (100 MHz, 
CDCl3) δ 172.9, 170.9, 156.4, 79.4, 64.1, 60.5, 59.4, 52.7, 52.5, 52.2, 40.2, 
31.4, 29.4, 28.6, 24.3, 22.5; [α]D -5.5 (c 1.0, CHCl3); ESI/MS for C19H37N3O8S 
calculated (M+H+) 468, found 468. 
 
 
Cleavage Boc of N-Bus-O-Bn-L-Tyr-N6-Boc-L-Lys-OMe (1.46h): To a 
solution of tert-butylsulfonyl-O-benzyl-L-serine-N6-tert-butyloxycarbonyl-L- 
lysine methyl ester 1.32a (56 mg, 0.1 mmol) in DCM (5 mL), trifluoroacetic 
acid (0.5 mL, 6.7 mmol) was added dropwise and stirred at R.T. for 2 h (TLC 
monitoring, EtOAc/hexane 1:1). Then the solvent was evaporated to afford 
tert-butylsulfonyl-O-benzyl-L-serine-L-lysine methyl ester trifluoroacetic acid 
salt 1.46h (53 mg, 92%), as a colorless solid, m.p. 37-39 oC: 1H NMR, (400 
MHz, MeOH-d4) δ 7.35-7.29 (m, 5H), 4.57 (s, 2H), 4.53-4.45 (m, 1H), 
4.24-4.23 (br, t, 1H), 3.73-3.69 (m, 4H), 2.90-2.79 (m, 2H), 1.95-1.86 (br, m, 
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1H), 1.76-1.59 (m, 3H),1.47-1.41 (m, 2H), 1.37 (s, 9H); 13C NMR, (100 MHz, 
MeOH-d4) δ 173.6, 172.9, 139.3, 129.5, 129.0, 189.9, 74.4, 71.9, 61.2, 59.3, 
53.2, 52.9, 40.6, 32.2, 27.9, 24.5, 23.5; [α]D -11.6 (c 1.0, MeOH); ESI/MS for 
C23H36F3N3O8S calculated (M-TFA+H+) 458, found 458. 
 
 
N-Bus-O-Bn-L-Tyr-N6-Boc-L-Lys-OMe (1.32b): The general procedure 
was followed using tert-butylsulfonyl-O-benzyl-L-tyrosine 1.31b (196 mg, 0.5 
mmol), N6-tert-butyloxycarbonyl-L-lysine methyl ester hydrochloride 1.34 
(148 mg, 0.5 mmol), EDC (144 mg, 0.75 mmol), HOBt (101 mg, 0.75 mmol), 
2,6-lutidine (0.17 mL, 1.5 mmol), DCM (8 mL) and DMF (2 mL). The product 
was purified by flash column chromatography (EtOAc/hexane 3:7) to afford 
tert-butylsulfonyl-O-benzyl-L-tyrosine-N6-tert-butyloxycarbonyl-L-lysine 
methyl ester 1.32b (295 mg, 93%), as a colorless solid, m.p. 160-161 oC: 1H 
NMR, (400 MHz, CDCl3) δ 7.42-7.31 (m, 5H), 7.16 (d, 2H, J=8.5 Hz), 6.90 (d, 
2H, J=8.6 Hz), 6.75 (d, 1H, J=8.2 Hz), 5.04 (s, 3H), 4.82 (m, 1H), 4.66-4.57 
(m, 1H), 4.07-4.03 (m, 1H), 3.70 (m, 3H), 3.16-2.87 (m, 4H), 1.84-1.81 (m, 
1H), 1.70-1.64 (m, 1H), 1.48-1.42 (m, 11H), 1.29-1.25 (m, 2H), 1.11 (s, 9H); 
13C NMR, (100 MHz, CDCl3) δ 172.4, 171.2, 158.0, 156.2, 137.0, 131.0, 128.7, 
128.5, 128.1, 127.5, 115.2, 79.1, 70.1, 60.3, 59.8, 52.5, 52.2, 40.2, 38.5, 
31.9, 29.4, 28.6, 23.9, 22.3; [α]D -7.0 (c 1.0, CHCl3); HRMS for C32H47N3O8S 
calculated (M+Na+) 656.29761, found 656.29837. 
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Cleavage Bn of N-Bus-O-Bn-L-Tyr-N6-Boc-L-Lys-OMe (1.46i): To a 
solution of tert-butylsulfonyl-O-benzyl-L-tyrosine-N6-tert-butyloxycarbonyl- 
L-lysine methyl ester 1.32b (63 mg, 0.1 mmol) in MeOH (5 mL), 20 wt.% 
Pd(OH)2 over activated carbon (3 mg, cat.) was added and hydrogenated at 1 
atm at R.T. for 1 h (TLC monitoring, EtOAc/hexane 1:1). The reaction mixture 
was filtered over celite, filtrate was concentrated under reduced pressure to 
afford tert-butylsulfonyl-L-tyrosine-N6-tert-butyloxycarbonyl-L-lysine methyl 
ester 1.46i (47 mg, 87%), as a white powder, m.p. 71-73 oC: 1H NMR, (400 
MHz, CDCl3) δ 8.14 (s, 1H), 7.07 (d, 2H, J=7.8 Hz), 6.93 (d, 1H, J=7.1 Hz), 
6.88 (d, 2H, J=7.8 Hz), 4.89 (br, r, 1H), 4.62 (br, d, 1H), 4.49 (d, 1H, J=10.2 
Hz), 4.25-4.24 (br, m, 1H), 3.73 (s, 3H), 3.50 (br, dd, 1H), 3.16-3.08 (m, 1H), 
1.92-1.85 (m, 1H), 1.73-1.62 (m, 1H), 1.49-1.42 (m, 11H), 1.42-1.30 (m, 9H), 
0.92-0.83 (m, 2H); 13C NMR, (100 MHz, CDCl3) δ 172.1, 170.2, 156.8, 156.7, 
131.1, 125.6, 116.1, 80.4, 60.6, 59.1, 52.8, 52.4, 40.8, 38.3, 31.7, 30.7, 28.6, 
24.2, 21.7; [α]D -9.9 (c 1.0, CHCl3); ESI/MS for C25H41N3O8S calculated (M+H+) 
544, found 544. 
 
 
Cleavage Boc of N-Bus-O-Bn-L-Tyr-N6-Boc-L-Lys-OMe (1.46j): To a 
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solution of tert-butylsulfonyl-O-benzyl-L-tyrosine-N6-tert-butyloxycarbonyl- 
L-lysine methyl ester 1.32b (63 mg, 0.1 mmol) in DCM (5 mL), trifluoroacetic 
acid (0.5 mL, 6.7 mmol) was added dropwise and stirred at R.T. for 2 h (TLC 
monitoring, EtOAc/hexane 1:1). Then the solvent was evaporated to afford 
tert-butylsulfonyl-O-benzyl-L-tyrosine-L-lysine methyl ester trifluoroacetic acid 
salt 1.46j (77 mg, 94%), as a colorless solid, m.p. 89-91 oC: 1H NMR, (400 MHz, 
MeOH-d4) δ 7.43-7.27 (m, 5H), 7.24 (d, 2H, J=8.6 Hz), 6.93 (d, 2H, J=8.6 Hz), 
6.75 (d, 1H, J=8.2 Hz), 5.07 (s, 2H), 4.53 (dd, 1H, J=4.5 Hz, J=10.0 Hz), 4.01 
(dd, 1H, J=4.6 Hz, J=10.4 Hz), 3.70 (m, 3H), 3.01 (dd, 1H, J=4.6 Hz, J=13.8 
Hz), 2.94-2.91 (m, 2H), 2.77-2.71 (m, 1H), 1.98-1.89 (m, 1H), 1.77-1.60 (m, 
3H), 1.54-1.46 (m,2H), 1.37-1.28 (m, 2H), 1.03 (s, 9H); 13C NMR, (100 MHz, 
MeOH-d4) δ 175.3, 173.7, 159.2, 138.9, 132.0, 130.9, 129.6, 128.9, 128.6, 
116.1,70.9, 61.7, 60.9, 52.9, 52.8, 40.6, 39.2, 32.1, 27.7, 24.1, 23.4; [α]D 
-28.4 (c 1.0, MeOH); ESI/MS for C29H40F3N3O8S calculated (M-TFA+H+) 534, 
found 534.  
 
 
N-Bus-L-Pro-N6-Cbz-L-Lys-OMe (1.41a): The general procedure was 
followed using N6-benzyloxycarbonyl-L-lysine methyl ester hydrochloride 1.35 
(332 mg, 1.0 mmol) with tert-butylsulfonyl-L-proline 1.40a (238 mg, 1.0 
mmol), EDC (288 mg, 1.5 mmol), HOBt (203 mg, 1.5 mmol), 2,6-lutidine (0.35 
mL, 3.0 mmol), DCM (8 mL) and DMF (2 mL). The crude product was purified by 
flash column chromatography (EtOAc/hexane 2:3) to afford tert-butylsulfonyl- 
L-proline-N6-benzyloxycarbonyl-L-lysine methyl ester 1.41a (469 mg, 92%), 
as a colorless oil. 1H NMR, (400 MHz, CDCl3) δ 7.38-7.31 (m, 5H), 6.80 (d, 1H, 
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J=7.2 Hz), 5.08 (m, 2H), 4.99 (br, t, 1H), 4.58-4.53 (m, 1H), 4.50 (dd, 1H, 
J=3.9Hz, J=7.9 Hz), 3.76-3.70 (m, 4H), 3.44-3.38 (m, 1H), 3.25-3.12 (m, 2H), 
2.23-2.08 (m, 2H), 2.05-1.85 (m, 3H), 1.78-1.69 (m, 1H), 1.58-1.51 (m, 2H), 
1.41-1.33 (m, 11H); 13C NMR, (100 MHz, CDCl3) δ 172.6, 171.9, 156.8, 136.8, 
128.7, 128.34, 128.28, 66.8, 62.9, 61.9, 52.7, 52.3, 50.8, 40.7, 32.0, 30.6, 
29.4, 25.6, 24.8, 22.4; [α]D -30.6 (c 1.0, CHCl3); HRMS for C24H37N3O7S 
calculated (M+H+) 512.24250, found 512.24303. 
 
1.40b
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DMF: DCM 1:4
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N-Bus-D-Pro-N6-Cbz-L-Lys-OMe (1.41b): The general procedure was 
followed using N6-benzyloxy-carbonyl-L-lysine methyl ester hydrochloride 
1.35 (166 mg, 0.5 mmol), EDC (144 mg, 0.75 mmol), 2,6-lutidine (0.17 mL, 
1.5 mmol), tert-butylsulfonyl-D-proline 1.40b (120 mg, 0.5 mmol),  HOBt 
(101 mg, 0.75 mmol), DCM (8 mL) and DMF (2 mL). The crude product was 
purified by flash column chromatography (EtOAc/hexane 3:2) to afford tert- 
butylsulfonyl-D-proline-N6-benzyloxycarbonyl-L-lysine methyl ester 1.41b 
(236 mg, 92%), as a colorless oil. 1H NMR, (400 MHz, CDCl3) δ 7.28-7.21 (m, 
5H), 6.96 (d, 1H, J=8.0 Hz), 5.36 (br, t, 1H), 5.01 (s, 2H), 4.52-4.44 (m, 2H), 
3.65-3.59 (m, 4H), 3.47-3.41 (m, 1H), 3.15-3.07 (m, 2H), 2.11-2.02 (m, 2H), 
1.98-1.82 (m, 3H), 1.69-1.61 (m, 1H), 1.51-1.41 (m, 2H), 1.32 (m, 11H); 13C 
NMR, (100 MHz, CDCl3) δ 172.4, 171.9, 156.6, 136.7, 128.4, 128.0, 127.9, 
66.4, 62.8, 62.0, 52.3, 51.8, 50.4, 40.3, 31.5, 30.8, 28.9, 25.0, 24.7, 22.1; 
[α]D +54.3 (c 1.0, CHCl3); ESI/MS for C24H37N3O7S calculated (M+H+) 512, 
found 512. 
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Hydrolyzation of N-Bus-L-Pro-N6-Cbz-L-Lys-OMe (1.42): The general 
procedure was followed using tert-butylsulfonyl-L-proline-N6-benzyloxy- 
carbonyl-L-lysine methyl ester 1.41a (409 mg, 0.8 mmol), LiOH×H2O (168 mg, 
4.0 mmol), MeOH (24 mL) and H2O (8 mL). The organic extract was combined, 
dried over Na2SO4, and concentrated under reduced pressure to afford tert- 
butylsulfonyl-L-proline-N6-benzyloxycarbonyl-L-lysine 1.42 (371 mg, 93%), as 
a colorless oil. 1H NMR, (400 MHz, CDCl3) δ 7.37-7.30 (m, 5H), 7.11 (d, 1H, 
J=7.2 Hz), 5.27-5.25 (br, t, 1H), 5.15-5.06 (m, 2H), 4.54-4.50 (m, 2H), 
3.73-3.66 (m, 1H), 3.45-3.39 (m, 1H), 3.24-3.15 (m, 2H), 2.16-2.11 (m, 2H), 
2.04-1.97 (m, 1H), 1.95-1.86 (m, 2H), 1.80-1.71 (m, 1H), 1.55-1.49 (m, 2H), 
1.37 (s, 11H); 13C NMR, (100 MHz, CDCl3) δ 174.9, 172.7, 157.0, 136.6, 128.7, 
128.3, 128.1, 66.9, 62.8, 61.9, 52.4, 50.9, 40.6, 31.5, 30.8, 29.4, 25.6, 24.7, 
22.3; [α]D -24.5 (c 1.0, CHCl3); HRMS for C23H35N3O7S calculated (M+H+) 
498.22685, found 498.22749. 
 
 
N-Bus-L-Pro-N6-Cbz-L-Lys-N6-Boc-L-Lys-OMe (1.43): The general 
procedure was followed using N6-tert-butyloxycarbonyl-L-lysine methyl ester 
hydrochloride 1.34 (148 mg, 0.5 mmol), EDC (144 mg, 0.75 mmol), 
2,6-lutidine (0.17 mL, 1.5 mmol), HOBt (101 mg, 0.75 mmol), tert-butyl- 
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sulfonyl-L-proline-N6-benzyloxycarbonyl-L-lysine 1.42 (249 mg, 0.5 mmol), 
DCM (8 mL) and DMF (2 mL). The product was purified by flash 
chromatography (EtOAc/hexane 7:3) to afford tert-butylsulfonyl-L-proline- 
N6-benzyloxycarbonyl-L-lysine-N6-tert- butyloxycarbonyl-L-lysine methyl ester 
1.43 (333 mg, 90%), as a colorless oil.1H NMR, (400 MHz, CDCl3) δ 7.33-7.28 
(m, 5H), 7.09 (br, s, 1H), 6.99 (br, s, 1H), 5.32 (br, s, 1H), 5.06 (s, 2H), 4.86 
(br, s, 1H), 4.49 (br, m, 3H), 3.72-3.65 (br, m, 4H), 3.52-3.46 (br, m, 1H), 3.17 
(br, d, 2H), 3.07 (br, d, 2H), 2.20-2.12 (m, 2H), 2.01-1.98 (m, 3H), 1.96-1.87 
(m, 1H), 1.82-1.63 (m, 2H), 1.60-1.24 (m, 22H); 13C NMR, (100 MHz, CDCl3) δ 
172.9, 172.3, 171.5, 156.8, 156,3, 136.8, 128.6, 128.2, 128.1, 79.2, 66.6, 
63.2, 62.2, 53.0, 52.5, 52.4, 52.2, 50.8, 40.5, 40.2, 31.9, 31.6, 31.3, 31.1, 
29.8, 29.5,29.3, 28.6, 25.4, 24.8, 22.8, 22.3; [α]D -31.3 (c 1.0, CHCl3); HRMS 
for C35H57N5O10S calculated (M+H+) 740.38989, found 740.39049. 
 
 
Cleavage Cbz of N-Bus-L-Pro-N6-Cbz-L-Lys-N6-Boc-L-Lys-OMe 
(1.47a): To a solution of tert-butylsulfonyl-L-proline-N6-benzyloxycarbonyl- 
L-lysine-N6-tert-butyloxycarbonyl-L-lysine methyl ester 43 (73.9 mg, 0.1 
mmol) in MeOH (5 mL), 20 wt.% Pd(OH)2 over activated carbon (5 mg, cat.) 
was added and hydrogenated at 1 atm at R.T. for 1 h (TLC monitoring, 
EtOAc/hexane 4:1). The reaction mixture was filtered over celite and acidified 
with 1 M HCl aqueous (10 mL) carefully to pH=6～7. The aqueous layer was 
frozen and lyophilized to afford tert-butylsulfonyl-L-proline-L-lysine-N6-tert- 
butyloxycarbonyl-L-lysine methyl ester hydrochloride salt 1.47a (63 mg, 98%), 
63 
 
as a colorless oil. 1H NMR, (400 MHz, MeOH-d4) δ 4.51 (dd, 1H, J=3.2 Hz, J=8.2 
Hz), 4.45-4.38 (m, 2H), 3.73 (s, 3H), 3.68-3.61 (m, 2H), 3.06-3.02 (t, 2H, 
J=7.5 Hz),  2.98-2.94 (t, 2H, J=7.5 Hz), 2.34-2.26 (m, 1H), 2.13-1.82 (m, 
5H), 1.79-1.68 (m, 4H), 1.56-1.47 (m, 4H), 1.45 (s, 10H), 1.41 (s, 10H); 13C 
NMR, (100 MHz, MeOH-d4) δ 175.7, 174.2, 156.4, 80.0, 64.0, 63.0, 54.0, 52.9, 
52.0, 41.2, 40.7, 32.6, 32.2, 30.6, 28.9, 28.1, 26.2, 25.0, 24.3, 23.5; [α]D 
-52.2 (c 1.0, MeOH);  ESI/MS for C27H52ClN5O8S calculated (M-HCl+H+) 606, 
found 606. 
 
 
Cleavage Boc of N-Bus-L-Pro-L-Lys-N6-Boc-L-Lys-OMe (1.47b): To a 
solution of tert-butylsulfonyl-L-proline-L-lysine-N6-tert-butyloxycarbonyl-L- 
lysine methyl ester hydrochloride 1.47a (58 mg, 0.09 mmol) in MeOH (1 mL), 
1.25 M HCl in MeOH solution 1 mL was added and stirred at R.T. for 4 h. Solvent 
was evaporated to afford tert-butylsulfonyl-L-proline-L-lysine-L-lysine methyl 
ester hydrochloride salt 1.47b (51 mg, 99%) as a colorless oil. 1H NMR, (400 
MHz, MeOH-d4) δ 4.53-4.50 (m, 1H), 4.44-4.36 (m, 2H), 3.74 (s, 3H), 
3.65-3.60 (m, 2H), 2.99-2.93 (m, 4H), 2.36-2.27 (m, 1H), 2.08-2.93 (m, 2H), 
1.90-1.89 (m, 3H), 1.81-1.72 (m, 6H), 1.57-1.48 (m, 4H), 1.41 (s, 9H); 13C 
NMR, (100 MHz, MeOH-d4) δ 175.7, 174.2, 173.9, 64.0, 63.1, 54.5, 53.6, 53.0, 
52.0, 40.7, 32.7, 32.3, 31.9, 28.1, 28.0, 26.2, 25.1, 23.9, 23.7; [α]D -45.6 (c 
1.0, MeOH); ESI/MS for C22H45Cl2N5O6S calculated (M-2HCl+H+) 506, found 
506. 
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Cleavage Boc of N-Bus-L-Pro-N6-Cbz-L-Lys-N6-Boc-L-Lys-OMe 
(1.47c): To a solution of tert-butylsulfonyl-L-proline-N6-benzyloxycarbonyl- 
L-lysine-N6-tert-butyloxycarbonyl-L-lysine methyl ester 1.43 (74 mg, 0.1 
mmol) in DCM (5 mL), trifluoroacetic acid (0.5 mL, 6.7 mmol) was added 
dropwise and stirred at R.T. for 4 h (TLC monitoring, 100% EtOAc). Solvent was 
evaporated to afford tert-butylsulfonyl-L-proline-N6-benzyloxycarbonyl-L- 
lysine-L-lysine methyl ester trifluoroacetic acid salt 1.47c (70 mg, 93%), as a 
colorless oil.1H NMR, (400 MHz, MeOH-d4) δ 7.36-7.30 (m, 5H), 5.07 (s, 2H), 
4.50 (dd, 1H, J=2.8 Hz, J=8.2 Hz), 4.47-4.39 (m, 1H), 4.30-4.24 (m, 1H), 
3.71(s, 3H), 3.68-3.62 (m, 1H), 3.59-3.53 (m, 1H), 3.16-3.12 (m, 2H), 
2.97-2.93 (t, 2H, J=7.5 Hz), 2.33-2.21 (m, 1H), 2.08-1.83 (m, 5H), 1.80-1.65 
(m, 4H), 1.62-1.42 (m, 6H), 1.39 (m, 9H); 13C NMR, (100 MHz, MeOH-d4) δ 
175.7, 175.1, 174.5, 159.0, 138.5, 129.6, 129.1, 128.9, 67.5, 63.9, 62.9, 55.1, 
53.3, 52.9, 52.0, 41.6, 40.6, 32.5, 32.4, 32.1, 30.5, 28.0, 26.3, 25.0, 24.2, 
23.9; [α]D -36.4 (c 1.0, MeOH); ESI/MS for C32H50F3N5O10S calculated (M-TFA 
+H+) 640, found 640.  
 
 
Cleavage the whole protecting groups of N-Bus-L-Pro-N6-Cbz-L- 
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Lys-N6-Boc-L-Lys-OMe (1.47d): To a solution of tert-butylsulfonyl- 
L-proline-N6-benzyloxycarbonyl-L-lysine-N6-tert-butyloxycarbonyl-L-lysine 
methyl ester 1.43 (74 mg, 0.1mmol) and anisole (0.11 mL, 1.0 mmol) in DCM 
(1.5 mL) was slowly added trifluoromethanesulfonic acid (0.2 N in DCM, 1.5 mL) 
at 0 oC. The solution was stirred at 0 oC for 48 h (TLC monitoring, 100% EtOAc), 
6 mL H2O and 4 mL DCM was added. The aqueous layer was neutralized with 
DOWEX anion exchange resin at 0 oC until pH=9.5. Then 6 mL MeOH was added 
and filtered. At last the solution was combined and acidified with 1 M HCl 
aqueous (3 mL). The acid layer was frozen and lyophilized to afford L-proline- 
L-lysine-L-lysine methyl ester hydrochloride salt 1.47d (41 mg, 82%), as a 
colorless oil.1H NMR, (400 MHz, MeOH-d4) δ  4.45-4.37 (m, 3H), 3.73 (s, 3H), 
3.45-3.33 (m, 2H), 3.01-2.94 (br, m, 4H), 2.57-2.47 (m, 1H), 2.17-2.01 (m, 
3H), 1.99-1.87 (m, 2H), 1.84-1.67 (m, 6H), 1.62-1.46 (m, 4H); ESI/MS for 
C18H38Cl3N5O4 calculated (M-3HCl+H+) 386, found 386. 
 
 
Elimination OBn of N-Bus-O-Bus-L-Ser-OMe (1.51): A solution of 
tert-butylsulfonyl-O-tert-butylsulfonyl-L-serine methyl ester 1.50 (54 mg, 
0.15 mmol) in 2 mL of THF was treated with Bu4N+ N3- (102 mg, 0.36 mmol) at 
R.T.. The solution was stirred at R.T. for 2 h (TLC monitoring, EtOAc/hexane 
1:4). Solvent was evaporated, and the residue was purified by flash column 
chromatography (EtOAc/hexane 1:4) to afford tert-butylsulfonyl-2-amino- 
acrylate methyl ester 1.51 (14 mg, 62%), as a colorless liquid: 1H NMR, (400 
MHz, CDCl3) δ 6.62 (s, 1H), 5.84 (s, 1H), 5.69 (s, 1H), 3.86 (s, 3H), 1.43 (s, 
9H); 13C NMR, (100 MHz, CDCl3) δ 164.3, 132.5, 106.8, 62.5, 53.5, 29.8, 24.6; 
HRMS for C8H15NO4S calculated (M+Na+) 244.06140, found 244.06116. 
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HPLC method of Mosher ester: 1) alanine Mosher ester: Column: AD-RH 
150*4.6 mm. Comment: 0.1% TFA and 25% MeCN in H2O solution. Flow: 0.5 
mL/min. 2) phenylalanine Mosher ester: Column: AD-RH 150*4.6 mm. 
Comment: 0.1% TFA and 45% MeCN in H2O solution. Flow: 0.5 mL/min. 
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Chapter Two 
Total Synthesis of a β-Methyl-D-leucinyl 
Unnatural Aeruginosin Hybrid 
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2-1 Introduction 
2-1-1 Aeruginosin family 
The aeruginosin family is a relatively new class of potent serine protease 
inhibitors.[1] In the last two decades, more than 20 aeruginosins have been 
isolated from blue-green algae or marine sponges originating from 
geographically distinct aquatic sources.[1-7] Their structures have been 
determined by chemical, spectroscopic, and X-ray crystallographic methods.[2] 
 The aeruginosins are a new class of linear peptides, that for the most part 
contain a characteristic central core (P2), which is a 6-mono- or 5,6-dihydroxy- 
2-carboxyoctahydroindole core unit (named as Choi or OH-Choi subunit 
respectively).[1,3] Almost all members are also composed of three subunits: an 
N-terminal hydroxy or acidic group (P4), a bulky hydrophobic amino acid (P3), 
and a C-terminal guanidine-containing group (P1)(Figure 3)[4-6].  
 
 
Figure 3. Generalized structure of the aeruginosins. 
 
The members of the aeruginosin family exhibit very different degrees of 
inhibitory activity against serine proteases, and the profile of their activity has 
been explained by a high degree of pharmacophoric and structural homology 
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within the family. This array of structural and functional features specifically, a 
basic P1 subunit with three hydrophobic P2, P3 and P4 main pharmacophoric 
subunits, is responsible for their affinity to the catalytic and optimal binding 
pockets of trypsin, thrombin, and other serine proteases, involved in the blood 
coagulation cascade. 
Due to the structural novelty and the biological activity of the aeruginosins, 
the family members have also garnered considerable attention from synthetic 
organic chemists. The 2-carboxyperhydroindole core has received the most 
attention with respect to conceptually diverse synthetic approaches. To date, 
the total syntheses of seven aeruginosins have been completed, and four of 
these involving revisions about their originally proposed structures.[2,4,7]  
 
2-1-2  Biological activity 
The biological activities associated with the aeruginosin family of natural 
products have mainly been in relation to inhibitors of serine proteases such as 
thrombin, Factor VIIa, and Factor Xa. [8-11] These proteases are implicated in 
either intrinsic or extrinsic pathways, and eventually leading to blood clots in 
humans. Some of the aeruginosins have also been evaluated against the 
cysteine protease papain or other enzymes. 
 
2-1-2-1 Inhibition of coagulation cascade factors 
Blood coagulation is a very complex process, but still an ordered event. The 
process involves two components. One is cellular such as blood platelets and 
leukocytes. The other one is called as proteinaceous, which includes the 
coagulation factors and cofactors. The basic events involve two steps: 1) 
primary hemostasis, which is the aggregation of platelet and formation of a 
primary platelet plug, 2) secondary hemostasis, where plasma coagulation 
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factors are activated and generate fibrin, then the fibrin intertwines and 
reinforces the aggregated platelets, to form a strong fibrin clot.[9-12] There are 
also two pathways, which are respectively defined as an intrinsic contact 
activation system and an extrinsic tissue factor system. Both pathways are 
responsible for the biochemical coagulation cascade, which leads to the 
generation of fibrin. The details are shown as Figure 4.[10] 
 
 
Figure 4. Schematic overview of the blood coagulation cascade.  
 
Both pathways involve a stepwise activation of proteases, including 
thrombin. Thrombin is a multifunctional serine protease,[13] and responsible for 
the final cleavage of fibrinogen and the formation of fibrin. Along both pathways, 
the coagulation process is accelerated by the positive- feedback mechanisms. 
In recent years, the extrinsic system has been considered to be the major 
pathway to thrombinogenesis, triggered by tissue factors.[10] 
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Several of the aeruginosins exhibit high inhibitory potency against blood 
coagulation factors, which has made them attractive small-molecule targets in 
the search for new anticoagulants, although they may not be suitable as such 
for direct use in humans. Overall, the aeruginosins exhibit in vitro inhibitory 
activities against thrombin with micromolar to nanomolar IC50 values. Until now 
two compounds, chlorodysinosin A[5,14] and oscillarin[4] (thrombin IC50=0.0057 
μM and 0.028 μM, respectively), are the most potent members of the 
aeruginosin family, which have been isolated to date. Their structures and data 
are depicted in Figure 5. Total synthesis and structure confirmation of the 
chlorodysinosin A[5,14] and oscillarin[4] have been reported by Hanessian and 
coworkers. A total synthesis of dysinosin A[15] was also reported by the 
Hanessian group. 
 
 
Figure 5. Structures and enzymatic activities of the natural aeruginosins 
dysinosin A, chlorodysinosin A, and oscillarin. 
 
2-1-2-2 Inhibition of trypsin 
Trypsin-like substrate specificity is responsible for the high inhibitory 
activities against serine proteases. These enzymes are involved in important 
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physiological processes, and their relevance in the complex blood coagulation 
cascade has been well established.[16,17] Trypsin-like proteases are known to 
cleave substrates, which contain positively charged amino acid residues in the 
P1 position. Due to the fact that the aeruginosins contain a basic C-terminal 
arginine mimetic in the active sites of these proteases, some members of the 
family bind well. Trypsin is a digestive enzyme, which is frequently employed as 
a marker for inhibition of trypsin-like serine proteases. Ingeneral inhibition of 
trypsin should be avoided and selectivity is a prime consideration. 
 
2-1-2-3 Other biological activities 
The aeruginosins have also been evaluated for activity against other of 
enzyme targets. Several of the naturally occurring aeruginosins have been 
considered as inhibitors of plasmin, which is a trypsin-like serine protease 
involved in the fibrinolytic system. Because plasmin has also been implicated in 
angiogenesis and metastasis during the progression of cancer,[18] the 
aeruginosin family has been regarded as the potential agents for development 
as anticancer agents.  
So far, no inhibitory activity of the aeruginosins has been found against the 
digestive serine proteases chymotrypsin and elastase. However, some of the 
aeruginosins have also been tested against the cysteine protease papain,[19] 
but only weak activity has been demonstrated. Only one aeruginosin has been 
evaluated against the metalloprotease neprolysine, but no inhibition was 
detected at 20.0 μgmL-1.[20] 
 
2-1-3  Effect of the chlorine substituent 
The most recently isolated chlorodysinosin A exhibits the highest in vitro 
inhibitory activities against thrombin (Factor IIA) and Factor VIIA (IC50= 
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0.0057 and 0.039 μM, respectively) among the 20 or so normally occurring 
aeruginosins.[5] Another member, dysinosin A (IC50 thrombin, 0.046 μM; Factor 
VIIA, 0.326 μM), lacks the chlorine in the (2S,3R)-3-chloroleucine subunit. The 
dramatically different activities of these two compounds is remarkable in view 
of the simple replacement of a hydrogen by a chlorine atom in the same amino 
acid unit.[15] Both the X-ray co-crystal structure data and molecular modeling 
studies[5] of chlorodysinosin A[5] and dysinosin A[3] have identified the possible 
reasons for this remarkable “chlorine effect”. The amino acid residues in the 
enzyme, do not undergo major positional or conformational changes in the 
presence of their inhibitors. Our laboratory has ascribed a more restricted χ1 
angle as the reason of this unexpected “chlorine effect”. Due to the possible 
position of the chlorine atom in a favorable orientation within the hydrophobic 
S3 pocket, an entropic gain associated with the loss of water molecules may 
present a distinct advantage (Figure 6).[5]  
 
 
Figure 6.  Contour diagram of the S3 pocket and the P3 side-chains from an 
overlay of the co-crystal structures of chlorodysinosin A[3] (pink) 
and dysinosin A[5] (green) with thrombin. 
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To map the structure-activity relationships of the P1, P2, P3, and the 
N-terminal subunits against thrombin, a series of unnatural aeruginosin hybrids 
were synthesized.[21] When incorporating a β-substituent on the D-leucinyl P3 
subunit instead of the chlorine, a pronounced increase in activity was found, 
which also established the previously acknowledged importance of a 
hydrophobic interaction originally observed with the (3R)-chloro-D-leucine unit 
in chlorodysinosin A. 
 
2-1-4 β-Methyl-D-leucinyl analog of aeruginosin 
According to the contour diagram in Figure 6,[3,5] it appears that the S3 
subsite can accommodate β-substituents of the D-leucinyl subunit, and even 
larger ones as potential aeruginosin hybrids.  
Due to the presence of the α-proton in D-(3R)-chloroleucine, in chloro- 
dysinosin A, there is a possibility of β-elimination under basic conditions. The 
methyl group is very similar to the chlorine atom in molecular size, and a 
D-(3R)-β-methylleucine analog would not be subject to elimination. To validate 
such this notion, the new unnatural amino acid was synthesized and 
incorporated in a hybrid type analog. 
Among a series of unnatural chloroaeruginosin hybrids, which have been 
previously synthesized, compound 2.1 (Figure 7) was found to be the most 
potent (thrombin IC50=0.0016 μM). [21] Thus, deleting the hydroxyl group from 
oscillarin bicyclic core was not detrimental to acitivity against thrombin. 
Compound 2.2, in which the β-substituent of the P3 D-leucinyl subunit is a 
methyl group, was the target compound (Figure 7). The regioisomer 2.3 was 
also prepared as a model compound for comparison of their thrombin inhibitory 
acitivities. 
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Figure 7. Structures of chloroaeruginosin 2.1 and target comounds. 
 
2-2 Synthesis of ”methyl-leucine” aeruginosin hybrids 
 
Figure 8. Retrosynthesis of the target compound. 
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Based on the method of synthesis of chloroaeruginosin 2.1,[21] we 
envisaged the disconnections shown in the Figure 8. The two hybrid molecules 
2.2 and 2.3 were formed by coupling four subunits. The C-terminal 
guanidine-containing group (P1) is 4-amidino-benzamide, the P2 subunit is the 
2-carboxyperhydroindole core, and the N-terminal subunit (P4) is 
D-phenyllactic acid. Aziridine 2.4 is the starting material, which could be 
opened by a methyl nucleophile, then followed by oxidation to carboxylic acid, 
to give β-methyl-D-leucine and its regioisomer (P3). 
 
2-2-1 Synthesis of (3R, 2R)-3-methyl-D-leucine (β-Me-Leu) 
and its 2-methyl regioisomer (P3 subunit) 
2-2-1-1 Aziridine opening  
The aziridine 2.4, was prepared as previously reported,[5] and was 
protected as N-Ts aziridine 2.5 and N-Bus aziridine 2.6. Trimethylaluminum 
(AlMe3) was the first reagent to be used as the source of the methyl nucleophile 
(Scheme 15). 
 
 
 
Initial attempts to open the corresponding TBS-protected N-Ts aziridine 2.5 
using AlMe3 led to a complex mixture and a poor yield of the desired 3-methyl 
regioisomer. Only cleavage of the Bus-group occurred in the case of the N-Bus 
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aziridine 2.6. 
Flame-dried copper(I) iodide (CuI) was treated with methyllithium and 
lithium bromide (MeLi.LiBr) complex to form LiMe2Cu. Reaction of 2.5 with 
LiMe2Cu led to a mixture of 2-methyl and 3-methyl regioisomers in good 
combined yield. In addition to the N-Ts aziridine and N-Bus aziridine, the free 
and protected hydroxyl groups of the N-Ts aziridine, were also reacted in order 
to obtain a better ratio of the desired 3-methyl regioisomer as shown in Table 5. 
 
Table 5 Reaction of N-sulfonylaziridines with lithium dimethylcopper(II) 
 
 
 
a) Determined by NMR on the crude reaction mixture after workup 
b) Yb(OTf)3 was added as catalyst (20 mol%) 
 
Using excess LiMe2Cu, the TIPS-protected N-Ts aziridine 2.10 led to a 1:1.2 
mixture of the two regioisomers 2.10a and 2.10b. The other protecting groups, 
such as TBS, TES, TBDPS and N-Bus all resulted in lower ratios, and the 
compound R1 R2 Temperature
Time 
(hr) 
Ratio(a) 
a : b 
Total 
Yield (%)
2.5 Ts TBS -10 oC - 0 oC 16 1.8 : 1 89 
2.7 Ts H -10 oC - 0 oC 16 1 : 0 96 
2.5 Ts TBS(b) -10 oC– r.t. 16 2.3 : 1 nd 
2.8 Ts TBDPS -10 oC – r.t. 24 3 : 1 nd 
2.9 Ts TES -10 oC – r.t. 24 1.6 : 1 nd 
2.10 Ts TIPS -10 oC – r.t. 24 1.2 : 1 84 
2.11 Bus TIPS -10 oC – r.t. 24 2 : 1 53 
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undesired 2-methyl regioisomer a was the predominant product. In the 
presence of the Lewis acid Yb(OTf)3, which was added as catalyst,[22] the ratio 
of the undesired 2-methyl regioisomer was also increased. 
 
2-2-1-2 N-Ts group cleavage 
Compound 2.5b was used as the model to test three different conditions, 
for cleavage the N-Ts group, including acidic, free radical and basic conditions. 
First, compound 2.5b was treated with 2 equivalents of phenol in 30% 
hydrogen bromide (HBr) in acetic acid solution and heated to 60 oC,[23] for 12 h. 
MS analysis showed the TBS-group was cleaved, and the Ts-group remained 
intact even after heating to reflux for 36 h. The result was the same with 3 
equivalents of phenol in 48% hydrogen bromide aqueous at 90 oC.[24,25] 
Compound 2.5b was heated to reflux with 20 equivalents of samarium (II) 
iodide (SmI2) and 120 equivalents of 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)- 
pyrimidinone (DMPU) in THF solution under argon atmosphere. [26] However all 
starting material remained unreacted after heating to reflux for 24 h. 
Compound 2.5b in THF with 6 equivalents of sodium in liquid ammonia at 
-78 oC for 1 h resulted in the cleavage of the Ts-group (Scheme 16). 
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In cases involving small scale reactions and short reaction times, the 
TBS-group was found to be stable during the reaction. When scaling up a 
reaction, the mixture of compounds 2.12 and 2.13 was obtained. Compound 
2.12 was totally transformed to 2.13 in longer reaction times. The TIPS-group 
was stable in the Birch reaction conditions, so the analog 2.10a and 2.10b was 
converted to free amines 2.14 and 2.15, respectively (Scheme 16). 
 
2-2-1-3 (3R, 2R)-β-Methyl-D-leucine  
As shown in Scheme 17, compound 2.5b was treated with an HF solution to 
form compound 2.16, which was oxidized to the β-methyl-N-Ts-D-leucine 
2.16a in the presence of H5IO6 and CrO3.[5] Unfortunately, the yield of the 
oxidation was low and the acid was difficult to purify. 
 
 
 
2-2-2 Synthesis of the intermediates 
2-2-2-1 Formation of the P1 and P2 subunit 
Methyl octahydroindole-2-carboxylate 2.17[21] was first protected as the 
Boc-group. After saponification with LiOH and acidification, the free acid 2.19 
was coupled with P1 subunit (benzamidine 2.20), in the presence of PyBOP and 
2.6-lutidine as coupling reagents, to afford the coupling product 2.21. Finally, 
the N-Boc was cleaved by trifluoroacetic acid (TFA) to give the free amine 2.22 
as the final segment of the P1 and P2 subunit. The conditions, reagents and 
yields are shown in Scheme 18. 
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2-2-2-2 Formation of the P3 and P4 subunit 
In the coupling reaction involving the free amine of P3 subunit with 
MOM-D-phenyllactic acid 2.23[21] (P4 subunit), using 2.6-lutidine as base, three 
different kinds of coupling reagents were tested: 1) EDC and HOBt, 2) DEPBT, 3) 
PyBOP. For the P3 subunit, compounds 2.12, 2.13 and 2.14 were used as the 
starting materials. The results are shown in Table 6. 
 
Table 6 Coupling reaction of P3 and P4 subunit 
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a) Yields of isolated pure product 
 
Coupling reagent PyBOP was not effective. However, when the R-group is 
small (as TBS in the compound 2.14), EDC and HOBt are suitable reagents for 
the coupling reaction. When the R-group is large (as TIPS in the compound 
2.15), DEBPT was satisfactory, although the reaction was slow. The 2-methyl 
regioisomer 2.16 of the P3 subunit was treated under the same conditions. 
2-Methyl-O-TIPS analog 2.16 was used as the starting material for 
coupling with the P4 acid 2.23 in the presence of DEPBT to afford the coupling 
product 2.25a, in an acceptable yield (Scheme 19).  
Hydrogen fluoride (HF) stock solution was used in wet acetonitrile (MeCN) 
solution to easily cleave the TBS- and TIPS- hydroxyl protecting groups to 
afford compounds 2.24 and 2.25 in excellent yields, respectively (Scheme 19). 
Oxidation of the primary alcohol was effected upon treatment with 0.4 M 
periodic acid (H5IO6)[5] in wet acetonitrile (MeCN) and a catalytic amount of 
chromium (VI) oxide (CrO3) at 0 oC to afford the carboxylic acid. Following the 
same method, compounds 2.24 and 2.25 were oxidized to afford the 
carboxylic acids 2.26 and 2.27 (Scheme 19), as the final segment of the P3 and 
P4 subunit. 
P3  subunit Coupling reagent 
condition A  
Time 
(h) 
Poduct 
Compound R Compound Yielda(%) 
2.13 H PyBOP 24 2.24 Not found 
2.13 H DEBPT 20 2.24 57 
2.14 TBS EDC and HOBt 16 2.24a 64 
2.15 TIPS EDC and HOBt 16 2.24b 56 
2.15 TIPS  DEBPT 40 2.24b 86 
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2-2-3 Synthesis of the β-methyl-D-leucinyl aeruginosin hybrid 
The carboxylic acids 2.26 and 2.27 were coupled with free amine 2.22, to 
form compounds 2.28 and 2.29, as shown in Scheme 20. 
The Cbz-group was cleaved using Pd over activated carbon (Pd/C) as a 
catalyst under hydrogen gas atmosphere, followed by cleavage of the MOM 
group using a solution of >99.9% trifluoroacetic acid (TFA) and dichloro- 
methane (DCM) (9:1). The final target compound methyl-aeruginosin hybrid 
2.2 and its isomer 2.3 were purified by RP-HPLC, (85 min. gradient of 20-80% 
CH3CN in 0.05% aqueous TFA) to afford products as the TFA salt, which was 
transformed to the hydrochloride salt (1.25 M hydrochloric acid in methanol 
solution), as shown in Scheme 20. 
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2-3 Biological results 
     Methyl-aeruginosin hybrid 2.2 and its isomer 2.3 were evaluated in 
enzymatic assays for their inhibitory activity against thrombin and trypsin. The 
results are presented as IC50 values as below. 
A. β-methyl-D-leucinyl aeruginosin hybrid 2.2 
Thrombin IC50=0.022 μM (n=2, 0.016 μM and 0.028 μM) 
Trypsin IC50=0.02 μM (n=1) 
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B. Isomer 2.3 
Thrombin IC50=17.6 μM (n=1) 
Trypsin IC50=2.89 μM (n=1) 
The β–methyl analog 2.2 is less active than the β–chloro one 2.1. As 
expected, the 2–methyl analog 2.3 is much less active than its isomer 2.2. 
 
2-4 Experimental 
General: Solvents were distilled under positive pressure of dry argon before 
use and dried by standard methods. THF, ether, DCM and toluene were dried by 
the SDS (Solvent Delivery System). All commercially available reagents were 
used without further purification. All reactions were performed under argon 
atmosphere and monitored by thin-layer chromatography. Visualization was 
performed by ultraviolet light and/or by staining with ceric ammonium 
molybdate, ninhydrine or potassium permanganate. IR, Perkin-Elmer FTIR 
Paragon 1000. Low- and high-resolution mass spectra were recorded using fast 
atom bombardement (FAB) or electrospray techniques. Optical rotations were 
recorded in a 1 dm cell at 20 oC (PerkinElmer 343). Flash column 
chromatography was performed using (40-60 μm) silica gel at increased 
pressure. NMR (1H, 13C) spectra were recorded on Bruker AV-300 and AV-400 
spectrometers. When necessary, assignments were aided by DEPT, COSY, 
NOESY, and HMBC and HMQC correlation experiments.  
 
 
Compound 2.5: To a solution of 2.4 (459 mg, 2.0 mmol) in DCM (10.0 mL) 
at 0 °C was added K2CO3 (1.38 g, 10.0 mmol) under argon atmosphere. After 
stirring for 5 min., TsCl was added to the reaction mixture at 0 °C, then warmed 
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to R.T.. After stirring at R.T. for 16 h, the reaction mixture was filtered and 
concentrated under reduced pressure. The crude residue was purified by flash 
column chromatography (toluene/hexane 1:1 to toluene/EtOAc 1:5) to give 
2.5 (679 mg, 89%), as a colorless solid, m.p. 46-48 °C: 1H NMR, (400 MHz, 
CDCl3) δ 7.79 (d, 2H, J=8.3 Hz), 7.23 (d, 2H, J=8.0 Hz), 4.02 (dd, 1H, J=5.0 Hz, 
J=11.0 Hz), 3.82 (dd, 1H, J=7.0 Hz, J=11.0 Hz),  2.77-2.73 (m, 1H), 2.52 (dd, 
1H, J=4.5 Hz, J=8.5 Hz), 2.35 (s, 3H), 1.64-1.56 (m, 1H), 0.88 (d, 3H, J=6.8 
Hz), 0.83-0.81 (m, 12H), -0.01 (s, 6H); 13C NMR, (100 MHz, CDCl3) δ 143.8, 
137.5, 129.4, 127.6, 61.1, 53.7, 49.0, 29.6, 25.8, 21.5 20.3, 19.8, 18.1, -5.3; 
[α]D -5.3 (c 1.0, CHCl3); ESI/MS for C19H33NO3SSi calculated (M+H+) 384, 
found 384. 
 
 
Compound 2.6: A solution of 2.4 (1.0 g, 4.4 mmol) in 40 mL of DCM was 
cooled to 0 °C and treated with Et3N (1.53 mL, 11.0 mmol), followed by 
dropwise addition of tert-butyl sulfinyl chloride 2.A (0.60 mL, 4.8 mmol) in 4.8 
mL of DCM. The reaction mixture was stirred at 0 oC until TLC showed 
consumption of the starting material (1 h). Upon completion, 40 mL of 
saturated aqueous NaHCO3 was added, and the layers separated (note: acidic 
washes should be avoided as tert-butyl sulfinamides are known to be unstable 
at low pH). The aqueous layer was extracted with DCM (3×50 mL). The organic 
layer was then dried over Na2SO4, and concentrated under reduced pressure. 
Flash column chromatography (EtOAc/hexane 1:9) afforded pure sulfinamide, 
which was directly taken up in 30 mL of DCM, and treated with m-CPBA (2.56 g, 
14.9 mmol). After the oxidation was complete by TLC (2 h), the reaction 
mixture was diluted with a mixture of saturated aqueous NaHCO3 (25 mL) and 
saturated aqueous Na2SO3 (25 mL). The aqueous layer was extracted with DCM 
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(3×50 mL). The organic extract was combined, dried over Na2SO4 and 
concentration under reduced pressure. The residue was purified by flash 
column chromatography (EtOAc/hexane 1:19) to afford 2.6 (1.36 g, 88% over 
2 steps), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 4.04 (m, 1H), 3.72 (dd, 
1H, J=7.1 Hz, J=10.9 Hz), 2.75 (m, 1H), 2.53 (m, 1H), 1.94-1.87 (m, 1H), 1.44 
(s, 9H), 1.16 (d, 3H, J=6.6 Hz), 0.96 (d, 3H, J=6.8 Hz), 0.88 (s, 9H), 0.08 (s, 
6H); 13C NMR, (100 MHz, CDCl3) δ 61.8, 59.8, 52.0, 46.6, 31.3, 28.3, 25.6, 
24.0, 23.5, 20.4, 18.0; [α]D +31.5 (c 1.0, CHCl3); HRMS for C16H35NO3SSi 
calculated (M+H+) 350.21797, found 350.21788. 
 
 
Compound 2.7: To a solution of 2.5 (58 mg, 0.15 mmol) in MeCN (1 mL) at 
0 °C was added HF stock solution (0.79 mL, prepared by mixing 43 mL MeCN, 
4.5 mL H2O, and 7.5 mL 48% aqueous HF solution), then warmed to R.T.. After 
stirring for 1 h, the reaction mixture was quenched by addition of saturated 
aqueous NaHCO3 (15 mL) and extracted with DCM (3×20 mL). The combined 
organic phases were dried over Na2SO4 and concentrated under reduced 
pressure. The product 2.7 (39 mg, 95%) is unstable in the silica gel which was 
sufficiently pure for use in the following step: 1H NMR, (400 MHz, CDCl3) δ 7.85 
(d, 2H, J=8.2 Hz), 7.33 (d, 2H, J=8.1 Hz), 4.15 (dd, 1H, J=2.9 Hz, J=13.3 Hz), 
4.00 (dd, 1H, J=8.7 Hz, J=13.5 Hz), 2.98-2.94 (m, 1H), 2.79 (dd, 1H, J=4.7 Hz, 
J=7.8 Hz), 2.45 (s, 3H), 1.54-1.46 (m, 1H), 1.27 (s, 1H), 0.89 (d, 3H, J=6.8 
Hz), 0.77 (d, 3H, J=6.7 Hz); 13C NMR, (100 MHz, CDCl3) δ 144.1, 137.7, 129.6, 
127.8, 61.7, 54.4, 49.3, 29.9, 21.8, 20.7, 20.0, 18.1, 12.1; ESI/MS for 
C13H19NO3S calculated (M+H+) 270, found 270. 
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  Compound 2.8: To a solution of 2.5 (77 mg, 0.2 mmol) in MeCN (3.6 mL) at 
0 °C was added HF stock solution (3.2 mL, prepared by mixing 43 mL MeCN, 4.5 
mL H2O, and 7.5 mL 48% aqueous HF solution), then warmed to R.T.. After 
stirring for 1 h, the reaction mixture was quenched by addition of saturated 
aqueous NaHCO3 (15 mL) and extracted with DCM (3×20 mL). The combined 
organic phases were dried over Na2SO4 and concentrated under reduced 
pressure and used directly. A solution of the crude 2.7 in DCM (8 mL) was 
cooled on ice to 0 °C and treated with NEt3 (366 μL, 0.9 mmol) and TBDPSCl 
(0.18 mL, 0.72 mmol), then warmed to R.T. After stirring for 10 h, the reaction 
mixture was diluted with DCM (10 mL) and washed with 1 M HCl aqueous (20 
mL). The aqueous phase extracted with DCM (2×20 mL). The organic phase 
was combined, dried over Na2SO4 and concentrated under reduced pressure. 
The crude residue was purified by flash column chromatography (hexane to 
EtOAc/hexane 1:19) to afford 2.8 (98 mg, 96%), as a colorless oil: 1H NMR, 
(400 MHz, CDCl3) δ 7.84 (d, 2H, J=8.3 Hz), 7.67 (d, 4H, J=6.6 Hz), 7.48-7.40 
(m, 6H), 7.27 (d, 2H, J=7.8 Hz), 4.09 (dd, 1H, J=5.2 Hz, J=11.2 Hz), 3.92 (dd, 
1H, J=6.6 Hz, J=11.2 Hz), 2.94-2.90 (m, 1H), 2.55 (dd, 1H, J=4.5 Hz, J=8.6 
Hz), 2.43 (s, 3H), 1.83-1.73 (m, 1H), 1.09 (s, 9H), 1.00-0.98 (t, 6H, J=6.8 Hz); 
13C NMR, (100 MHz, CDCl3) δ 144.0, 137.6, 134.0, 130.0, 129.6, 129.3, 127.8, 
61.7, 54.3, 49.3, 29.8, 21.8, 20.7, 20.0, 18.1, 17.9; ESI/MS for C29H37NO3SSi 
calculated (M+H+) 508, found 508. 
 
 
Compound 2.9: To a solution of compound 2.5 (77 mg, 0.2 mmol) in MeCN 
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(3.6 mL) at 0 °C was added HF stock solution (3.2 mL, prepared by mixing 43 
mL MeCN, 4.5 mL H2O, and 7.5 mL 48% aqueous HF solution), then warmed to 
R.T.. After stirring for 1 h, the reaction mixture was quenched by addition of 
saturated aqueous NaHCO3 (15 mL) and extracted with DCM (3×20 mL). The 
combined organic phases were dried over Na2SO4 and concentrated under 
reduced pressure and used directly. A solution of the crude 2.7 in DCM (8 mL) 
was cooled on ice to 0°C and treated with NEt3 (627 μL, 0.9 mmol) and TESCl 
(0.11 mL, 0.64 mmol), then warmed to R.T.. After stirring for 6 h, the reaction 
mixture was diluted with DCM (10 mL) and washed with 1 M HCl aqueous (20 
mL). The aqueous phase extracted with DCM (2×20 mL). The organic phase 
was combined, dried over Na2SO4 and concentrated under reduced pressure. 
The crude residue was purified by flash column chromatography (hexane to 
EtOAc/hexane 1:19) to give 2.9 (73 mg, 94%), as a colorless oil: 1H NMR, (300 
MHz, CDCl3) δ 7.82 (d, 2H, J=8.3 Hz), 7.27 (d, 2H, J=8.1 Hz), 4.03 (dd, 1H, 
J=5.0 Hz, J=11.0 Hz), 3.83 (dd, 1H, J=7.0 Hz, J=11.0 Hz), 2.81-2.75 (m, 1H), 
2.55 (dd, 1H, J=4.5 Hz, J=8.5 Hz), 2.40 (s, 3H), 1.74-1.58 (m, 1H), 0.93-0.84 
(m, 15H), 0.55 (dd, 6H, J=8.2 Hz, J=16.2 Hz); 13C NMR, (75 MHz, CDCl3) δ 
138.7, 132.8, 125.4, 123.8, 62.3, 56.0, 51.5, 33.5, 26.2, 25.0, 24.6, 12.4, 
10.2; ESI/MS for C19H33NO3SSi calculated (M+H+) 384, found 384. 
 
Et3N, DCM
OTBS
NTs
HF solution
MeCN
TIPSOTf OTIPS
NTs
2.5 2.10  
Compound 2.10: To a solution of 2.5 (575 mg, 1.50 mmol) in MeCN (9.0 mL) 
at 0 °C was added HF stock solution (7.9 mL, prepared by mixing 43 mL MeCN, 
4.5 mL H2O, and 7.5 mL 48% aqueous HF solution), then warmed to R.T.. After 
stirring for 1 h, the reaction mixture was quenched by addition of saturated 
aqueous NaHCO3 (40 mL) and extracted with DCM (3×50 mL). The combined 
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organic phases were dried over Na2SO4 and concentrated under reduced 
pressure and used directly. A solution of the crude 2.7 in DCM (20 mL) was 
cooled on ice to 0 °C and treated with NEt3 (627 μL, 4.5 mmol) and TIPSOTf (1.0 
mL, 3.75 mmol). After stirring at 0 °C for 4 h, the reaction mixture was diluted 
with DCM (30 mL) and washed with 1 M HCl aqueous (40 mL). The aqueous 
phase extracted with DCM (2×50 mL). The organic phase was combined, dried 
over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (hexane to EtOAc/hexane 1:19) to 
afford 2.10 (609 mg, 95%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 7.85 
(d, 2H, J=8.3 Hz), 7.30 (d, 2H, J=8.0 Hz), 4.14 (dd, 1H, J=4.7 Hz, J=10.7 Hz), 
3.92 (dd, 1H, J=7.3 Hz, J=10.7 Hz), 2.84-2.80 (m, 1H), 2.59 (dd, 1H, J=4.5 Hz, 
J=8.5 Hz), 2.43 (s, 3H), 1.71-1.62 (m, 1H), 1.04 (s, 18H), 1.03 (s, 3H), 0.95 (d, 
3H, J=6.8 Hz), 0.88 (d, 3H, J=6.6 Hz); 13C NMR, (100 MHz, CDCl3) δ 144.1, 
137.7, 129.6, 127.8, 61.7, 54.4, 49.3, 29.9, 21.8, 20.7, 20.0, 18.1, 12.1; [α]D 
-3.5 (c 1.0, CHCl3); HRMS for C22H39NO3SSi calculated (M+H+) 426.24927, 
found 426.25097. 
 
 
Compound 2.6a: To a solution of 2.6 (1.33 g, 3.8 mmol) in MeCN (18.0 mL) 
at 0 °C was added HF stock solution (15.8 mL, prepared by mixing 43 mL MeCN, 
4.5 mL H2O, and 7.5 mL 48% aqueous HF solution), then warmed to R.T.. After 
stirring for 1 h, the reaction mixture was quenched by addition of saturated 
aqueous NaHCO3 (60 mL) and extracted with DCM (3×80 mL). The combined 
organic phases were dried over Na2SO4 and concentrated under reduced 
pressure. The crude residue was purified by flash column chromatography 
(EtOAc/hexane 1:3) to afford 2.6a as a colorless oil (823 mg, 92%): 1H NMR, 
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(300 MHz, CDCl3) δ 4.10 (br, dd, 1H), 3.85 (dd, 1H, J=6.7 Hz, J=10.1 Hz), 3.23 
(s, 1H), 2.90-2.86 (m, 1H), 2.81-2.79 (t, 1H, J=3.8 Hz), 1.88-1.80 (m, 1H), 
1.50 (s, 9H), 1.03 (d, 3H, J=5.1 Hz), 0.91 (d, 3H, J=5.2 Hz); 13C NMR, (75 MHz, 
CDCl3) δ 63.1, 61.8, 49.7, 49.0, 28.7, 24.3, 19.7, 18.1, 12.5; [α]D -3.7 (c 1.0, 
CHCl3); HRMS for C10H21NO3S calculated (M+H+) 236.13149, found 236.13176. 
 
 
Compound 2.11: A solution of 2.6a (612 mg, 2.6 mmol) in DCM (20 mL) 
was cooled on ice to 0 °C and treated with NEt3 (1.09 mL, 7.8 mmol) and 
TIPSOTf (1.75 mL, 6.5 mmol). After stirring at 0 °C for 4 h, the reaction mixture 
was diluted with DCM (60 mL) and washed with 1 M HCl aqueous (80 mL). The 
aqueous phase extracted with DCM (2×80 mL). The combined organic phase 
was dried over Na2SO4 and concentrated under reduced pressure. The crude 
residue was purified by flash column chromatography (hexane to 
EtOAc/hexane 1:24) to afford compound 2.11 (916 mg, 90%), as a colorless 
oil: 1H NMR, (400 MHz, CDCl3) δ 4.13 (br, dd, 1H), 3.79 (dd, 1H, J=7.2 Hz, 
J=10.7 Hz), 2.77-2.73 (m, 1H), 2.55 (dd, 1H, J=4.6 Hz, J=6.8 Hz), 1.97-1.88 
(m, 1H), 1.46 (s, 9H), 1.03 (s, 3H), 1.13 (d, 3H, J=6.6 Hz), 1.05 (s, 14H), 1.04 
(s, 7H), 0.95 (d, 3H, J=6.8 Hz); 13C NMR, (100 MHz, CDCl3) δ 62.6, 60.2, 52.7, 
46.9, 28.7, 24.4, 20.8, 19.5, 18.1, 12.0; [α]D +31.5 (c 1.0, CHCl3); HRMS for 
C19H41NO3SSi calculated (M+H+) 392.26492, found 392.26553.  
 
 
Compounds 2.5a and 2.5b：Flame-dried CuI (1.91 g, 10 mmol) was 
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suspended in fresh dry THF (40 mL), and the solution was cooled to -10 °C. 
MeLi.LiBr (20 mmol) 1.5 M in Et2O (13.3 mL) was added dropwise and stirred at 
-10 °C until everything was transparent to colorless solution. Then a solution of 
2.5 (192 mg, 0.5 mmol) and activated 4Å molecular sieves in THF (5 mL) was 
added. Stirring was continued for 2.5 h, then the solution was warmed to R.T.. 
After stirring for 72 h, the reaction mixture was quenched with saturated 
aqueous NH4Cl (100 mL) and extracted with CHCl3 (4×100 mL). The combined 
organic phases were dried over Na2SO4 and concentrated under reduced 
pressure. The crude residue was purified by flash column chromatography 
(hexane to EtOAc/ hexane 1:49) to afford 2.5a (114 mg, 57%) as a colorless 
oil and 2.5b (63 mg, 32%) as a colorless oil. The ratio of 2.5a:2.5b is 1.8:1 
and total yield is 89%.  
Compound 2.5a：1H NMR, (400 MHz, CDCl3) δ 7.69 (d, 2H, J=8.3 Hz), 7.22 
(d, 2H, J=8.1 Hz), 5.68 (d, 1H, J=8.3 Hz), 3.64 (dd, 1H, J=3.8 Hz, J=10.5 Hz), 
3.33 (dd, 1H, J=4.5 Hz, J=10.3 Hz), 3.04-3.01 (m, 1H), 2.37 (s, 3H), 1.79- 
1.70 (m, 2H), 0.88 (s, 9H), 0.83(d, 6H, J=6.8 Hz), 0.76 (d, 3H, J=7.0 Hz), 0.01 
(d, 6H, J=1.7 Hz); 13C NMR, (100 MHz, CDCl3) δ 142.6, 139.7, 129.4, 126.9, 
65.6, 64.2, 35.6, 31.9, 26.0, 21.6, 20.3, 19.4, 18.1, 16.4, -5.5; [α]D -10.3 (c 
1.0, CHCl3); HRMS for C20H37NO3SSi calculated (M+H+) 400.23362, found 
400.23390. 
Compound 2.5b：1H NMR, (400 MHz, CDCl3) δ 7.75 (d, 2H, J=8.3 Hz), 7.29 
(d, 2H, J=8.4 Hz), 4.83 (d, 1H, J=8.9 Hz), 3.51 (dd, 1H, J=2.6 Hz, J=10.3 Hz), 
3.22 (dd, 1H, J=3.3 Hz, J=10.3 Hz), 3.12-3.07 (m, 1H), 2.43 (s, 3H), 
1.96-1.90 (m, 1H), 1.57-1.52 (m, 1H), 0.88 (d, 3H, J=6.9 Hz), 0.83 (s, 9H), 
0.73 (d, 3H, J=7.0 Hz), 0.68 (d, 3H, J=6.8 Hz), -0.06(d, 6H, J=14.5 Hz); 13C 
NMR, (100 MHz, CDCl3) δ 143.3, 138.5, 129.8, 127.2, 61.4, 57.4, 39.8, 27.3, 
25.9, 21.8, 21.7, 18.3, 16.4, 10.4, -5.5; [α]D +8.3 (c 1.0, CHCl3); HRMS for 
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C20H37NO3SSi calculated (M+H+) 400.23362, found 400.23389. 
 
 
Compound 2.7a： Flame-dried CuI (167 mg, 0.88 mmol) was suspended in 
fresh dry THF (28 mL), and the solution was cooled to -10 °C. MeLi.LiBr (1.76 
mmol) 1.5 M in Et2O (1.17 mL) was added dropwise and stirred at -10 °C, until 
everything was transparent to colorless solution. The reaction mixture was 
cooled to -10 °C, then a solution of 2.7 (17 mg, 0.044 mmol) and activated 4Å 
molecular sieves in THF (0.8 mL) was added at -10 °C. Stirring was continued 
for 1 h, then the solution was warmed to 0 °C. After stirring for 10 h, the 
reaction mixture was quenched with saturated aqueous NH4Cl (15 mL) and 
extracted with CHCl3 (3×20 mL), then the combined organic phases were dried 
over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (hexane to EtOAc/hexane 3:7) to give 
2.7a (12 mg, 97%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 7.75 (d, 2H, 
J=8.3 Hz),  7.28 (d, 2H, J=7.9 Hz), 4.87 (d, 1H, J=9.5 Hz), 3.97 (dd, 1H, 
J=3.0 Hz, J=11.6 Hz), 3.49 (dd, 1H, J=3.4 Hz, J=11.4 Hz), 3.17-3.11 (m, 1H), 
2.54 (s, 1H), 2.42 (s, 3H), 1.86-1.81 (m, 1H), 1.68-1.60 (m, 1H), 0.95 (d, 3H, 
J=7.0 Hz), 0.74 (d, 3H, J=6.9 Hz), 0.51(d, 3H, J=6.8 Hz); 13C NMR, (100 MHz, 
CDCl3) δ 143.4, 138.4, 129.8, 127.3, 62.3, 57.8, 39.9, 27.5, 21.9, 21.7, 18.1, 
16.7, 12.0, 10.7; HRMS for C14H23NO3S calculated (M+H+) 286.14714, found 
286.14719. 
 
 
Compounds 2.10a and 2.10b：Flame-dried CuI (1.33 g, 7.0mmol) was 
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suspended in fresh dry THF (28 mL), and the solution was cooled to -10 °C. 
MeLi.LiBr (14.0 mmol) 1.5 M in Et2O (9.3 mL) was added dropwise and stirred 
at -10 °C, until everything was transparent to colorless solution. The reaction 
mixture was cooled to -35 °C, then a solution of 2.10 (149 mg, 0.35 mmol) and 
activated 4Å molecular sieves in THF (5 mL) was added at -35 °C. Stirring was 
continued for 2.5 h, then the solution was warmed to R.T.. After stirring for 48 
h, the reaction mixture was quenched with saturated aqueous NH4Cl (80 mL) 
and extracted with CHCl3 (4×80 mL). The combined organic phases were dried 
over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (hexane to EtOAc/hexane 1:24) to 
afford 2.10a (71 mg, 46%) as a colorless oil and 2.10b (59 mg, 38%) as a 
colorless oil. The ratio of 2.10a:2.10b is 1.2:1 and total yield is 84%.  
Compound 2.10a：1H NMR, (400 MHz, CDCl3) δ 7.73 (d, 2H, J=8.3 Hz), 7.24 
(d, 2H, J=8.1 Hz), 5.77 (d, 1H, J=8.3 Hz), 3.51 (dd, 1H, J=2.6 Hz, J=10.3 Hz), 
3.22 (dd, 1H, J=3.3 Hz, J=10.3 Hz), 3.07-3.02 (m, 1H), 2.40 (s, 3H), 
1.86-1.76 (m, 2H), 1.06-1.05 (m, 21H), 0.87 (dd, 6H, J=2.0 Hz, J=6.8 Hz), 
0.81 (d, 3H, J=7.0 Hz); 13C NMR, (100 MHz, CDCl3) δ 142.6, 139.7, 129.4, 
127.0, 66.1, 64.3, 35.8, 31.9, 21.6, 20.4, 19.6, 18.1, 16.5, 11.9; [α]D -9.9 (c 
1.0, CHCl3); HRMS for C23H43NO3SSi calculated (M+H+) 442.28057, found 
442.28079. 
Compound 2.10b：1H NMR, (400 MHz, CDCl3) δ 7.75 (d, 2H, J=8.2 Hz), 7.27 
(d, 2H, J=8.3 Hz), 4.80 (d, 1H, J=8.5 Hz), 3.66 (dd, 1H, J=3.0 Hz, J=10.1 Hz), 
3.45 (dd, 1H, J=3.3 Hz, J=10.2 Hz), 3.15-3.09 (m, 1H), 2.41 (s, 3H), 
1.92-1.84 (m, 1H), 1.65-1.56 (m, 1H), 0.97 (s, 21H), 0.86 (d, 3H, J=6.9 Hz), 
0.76 (d, 3H, J=7.0 Hz), 0.66 (d, 3H, J=6.7 Hz); 13C NMR, (100 MHz, CDCl3) δ 
143.4, 138.4, 129.8, 127.3, 62.3, 57.8, 39.9, 27.5, 21.9, 21.7, 18.1, 16.7, 
12.0, 10.7; [α]D +14.9 (c 1.0, CHCl3); ESI/MS for C23H43NO3SSi calculated 
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(M+H+) 442, found 442. 
 
 
Compound 2.12：To 5 mL of liquid ammonia was added Na (8 mg, 0.36 
mmol) at -78 °C. After stirring, to the dark-blue solution 2.5b (24 mg, 0.6 
mmol) in fresh dry THF (2 mL) was added dropwise. The cooling bath was 
removed and stirring was continued for 30 min.. The reaction mixture was 
quenched by addition of solid NH4Cl carefully. After NH3 was evaporated, the 
residue was partitioned between water 5 mL and DCM 10 mL. The aqueous 
layer was extracted with DCM (2×10 mL), and the combined organic phases 
were dried over Na2SO4, then concentrated under reduced pressure. The 
residue was purified by flash column chromatography (MeOH/DCM 1:24) to 
give 2.12 (12 mg, 83%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 3.74 (d, 
1H, J=8.0 Hz), 3.36 (dd, 1H, J=8.0 Hz, J=9.7 Hz), 2.73 (s, 1H), 2.24 (s, 2H), 
1.99-1.91 (m, 1H), 1.35-1.20 (m, 1H), 0.92 (d, 3H, J=6.8 Hz), 0.90 (s, 9H), 
0.80 (d, 3H, J=6.8 Hz), 0.75 (d, 3H, J=6.9 Hz), 0.06 (d, 6H, J=3.0 Hz); 13C NMR, 
(100 MHz, CDCl3) δ 66.3, 55.4, 41.6, 27.9, 26.1, 21.8, 18.5, 16.6, 10.4, -5.1, 
-5.2; [α]D -10.0 (c 1.0, CHCl3); ESI/MS for C13H31NOS calculated (M+H+) 246, 
found 246. 
 
 
Compound 2.13：To 15 mL of liquid ammonia was added Na (58 mg, 2.5 
mmol) in small pieces at -78 °C. After stirring, to the dark-blue solution, 2.5b 
(100 mg, 0.25 mmol) in fresh dry THF (5 mL) was added dropwise. The cooling 
bath was removed and stirring was continued for 1 h. The reaction mixture was 
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quenched by addition of solid NH4Cl carefully. After NH3 was evaporated, the 
residue was partitioned between water 30 mL and DCM 35 mL. The aqueous 
layer was extracted with DCM (2×30 mL), and the combined organic phases 
were dried over Na2SO4, then concentrated under reduced pressure. The crude 
residue was purified by flash column chromatography (MeOH/DCM 1:1) to 
afford 2.13 (24 mg, 74%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 3.68 
(br, d, 1H), 3.26-3.21 (t, 1H, J=9.5 Hz), 2.69 (s, 1H), 2.17 (s, 3H), 1.96-1.85 
(m, 1H), 1.30-1.19 (m, 1H), 0.93 (d, 3H, J=6.8 Hz), 0.79 (d, 3H, J=6.8 Hz), 
0.74 (d, 3H, J=6.9 Hz); 13C NMR, (100 MHz, CDCl3) δ 64.6, 55.3, 28.0, 21.7, 
16.5, 10.2; [α]D -14.4 (c 1.0, CHCl3); ESI/MS for C7H17NO calculated (M+H+) 
132, found 132. 
 
 
Compound 2.14：To 15 mL of liquid ammonia was added Na (17 mg, 0.72 
mmol) at -78 °C. After stirring, to the dark-blue solution 2.10b (53 mg, 0.25 
mmol) in fresh dry THF (5 mL) was added dropwise. The cooling bath was 
removed and stirring was continued for 1 h. The reaction mixture was quenched 
by addition of solid NH4Cl carefully. After NH3 was evaporated, the residue was 
partitioned between water 20 mL and DCM 25 mL. The aqueous layer was 
extracted with DCM (2×20 mL), and the combined organic phases were dried 
over Na2SO4, then concentrated under reduced pressure. The crude residue 
was purified by flash column chromatography (MeOH/DCM 1:49) to afford 2.14 
(30 mg, 88%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 3.85 (dd, 1H, 
J=3.1 Hz, J=9.6 Hz), 3.46 (dd, 1H, J=8.2 Hz, J=9.5 Hz), 2.78 (br, t, 1H), 2.21 
(br, s, 2H), 2.03-1.95 (m, 1H), 1.36-1.23 (m, 1H), 1.11-1.07 (m, 21H), 0.94 (d, 
3H, J=6.8 Hz), 0.82 (d, 3H, J=6.8 Hz), 0.77 (d, 3H, J=6.9 Hz); 13C NMR, (100 
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MHz, CDCl3) δ 66.5, 55.8, 41.5, 27.9, 21.8, 18.2, 16.6, 12.1, 10.4; [α]D -5.7 (c 
1.0, CHCl3); ESI/MS for C16H37NOSi calculated (M+H+) 288, found 288. 
 
 
Compound 2.15：To 25 mL of liquid ammonia was added Na (31 mg, 1.32 
mmol) in small pieces at -78 °C. After stirring, to the dark-blue solution 2.10a 
(97 mg, 0.25 mmol) in fresh dry THF (7 mL) was added dropwise. The cooling 
bath was removed and stirring was continued for 1 h. The reaction mixture was 
quenched by addition of solid NH4Cl carefully. After NH3 was evaporated, and 
the residue was partitioned between water 30 mL and DCM 35 mL. The aqueous 
layer was extracted with DCM (2×30 mL), and the combined organic phases 
were dried over Na2SO4, then concentrated under reduced pressure. The crude 
residue was purified by flash column chromatography (MeOH/DCM 1:49 to 
MeOH/DCM 1:9) to give 2.15 (53 mg, 83%), as a colorless oil: 1H NMR, (400 
MHz, CDCl3) δ 3.80-3.71 (m, 2H), 2.47 (dd, 1H, J=4.5 Hz, J=6.8 Hz), 2.14 (s, 
2H), 1.88-1.80 (m, 1H), 1.71-1.63 (m, 1H), 1.13-1.04 (m, 21H), 0.96 (dd, 6H, 
J=5.3 Hz, J=5.1 Hz), 0.87 (d, 3H, J=6.8 Hz); 13C NMR, (100 MHz, CDCl3) δ 66.9, 
59.8, 38.9, 29.7, 20.9, 18.2, 16.0, 15.3, 12.2; [α]D +1.9 (c 1.0, CHCl3); 
ESI/MS for C16H37NOSi calculated (M+H+) 288, found 288. 
 
 
Compound 2.16：To a solution of 2.5b (20 mg, 0.05 mmol) in MeCN (0.9 mL) 
at 0 °C was added HF stock solution (0.79 mL, prepared by mixing 43 mL MeCN, 
4.5 mL H2O, and 7.5 mL 48% aqueous HF solution), then warmed to R.T.. After 
stirring for 1 h, the reaction mixture was quenched by addition of saturated 
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aqueous NaHCO3 (15 mL) and extracted with DCM (3×20 mL). The combined 
organic phases were dried over Na2SO4 and concentrated under reduced 
pressure. The crude residue was purified by flash column chromatography 
(EtOAc/hexane 2:3) to afford 2.16 (16 mg, 96%), as a colorless oil: 1H NMR, 
(400 MHz, CDCl3) δ 7.78 (d, 2H, J=8.3 Hz), 7.31 (d, 2H, J=7.9 Hz), 5.06 (d, 1H, 
J=8.2 Hz), 3.57 (d, 1H, J=3.3 Hz,), 3.20-3.13 (m, 1H), 2.43 (s, 3H), 2.02 (s, 
1H), 1.70-1.62 (m, 1H), 1.43-1.45 (m, 1H), 0.80 (d, 3H, J=6.8 Hz), 0.74 (d, 3H, 
J=7.0 Hz), 0.54 (d, 3H, J=6.7 Hz); 13C NMR, (100 MHz, CDCl3) δ 140.9, 135.0, 
127.1, 124.6, 59.6, 55.2, 37.8, 25.2, 18.9, 18.8, 14.2, 8.0; [α]D +11.7 (c 1.0, 
CHCl3); ESI/MS for C14H23NO3S calculated (M+H+) 286, found 286. 
 
 
Compound 2.18: To a solution of methyl octahydroindole-2-carboxylate 
2.17 (0.10 g, 0.46 mmol) in MeOH (2 mL) at 0 °C were added NEt3 (220 μL, 1.6 
mmol) and Boc2O (0.11 g, 0.50 mmol), then warmed to R.T.. After stirring for 
26 h, the reaction mixture was concentrated under reduced pressure. The 
crude residue was purified by flash column chromatography (EtOAc/hexane 
1:19 to EtOAc/ hexane 1:9) to afford 2.18 (124 mg, 95%), as a white powder: 
1H NMR, (300 MHz, CDCl3) δ (rotamers) 4.05 (br, m, 1H), 3.60 (br, m, 1H), 3.55 
(s, 3H), 2.10 (br, m, 1H), 2.08-0.79 (m, 19H); 13C NMR, (75 MHz, CDCl3) δ 
(rotamers) 59.0, 58.5, 56.8, 51.8, 51.6, 36.8, 36.2, 32.2, 31.4, 28.2, 28.0, 
27.6, 27.2, 25.6, 23.4, 20.3; [α]D -32.7 (c 1.0, CHCl3); ESI/MS for C15H25NO4 
calculated (M+H+) 284, found 284. 
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Compound 2.19: A solution of 2.18 (1.2 g, 4.3 mmol) in THF/H2O (5:3, 160 
mL) was treated with LiOH.H2O (0.72 g, 17.0 mmol). After stirring at R.T. for 18 
h, the reaction mixture was washed with Et2O. The aqueous phase was cooled 
on ice to 0 °C, acidified with 5% citric acid aqueous until pH=3-4 and extracted 
with DCM (3×100 mL). The combined organic phases were dried over Na2SO4 
and concentrated under reduced pressure to afford carboxylic acid 2.19 (0.98 
g, 85%) as a colorless solid, m.p. 130-132 °C, which was sufficiently pure for 
use in the following step: 1H NMR, (400 MHz, DMSO-d6) δ (rotamers) 12.49 (br, 
s, 1H), 4.03 (br, m, 1H), 3.63 (br, m, 1H), 2.24 (br, m, 1H), 2.06 (br, m, 1H), 
1.95-1.76 (m, 2H), 1.67-1.52 (m, 3H), 1.43-1.01 (m, 13H); 13C NMR, (100 
MHz, DMSO-d6) δ (rotamers) 174.6, 174.0, 153.0, 152.4, 78.4, 78.3, 58.8, 
58.5, 56.8, 56.4, 36.2, 35.7, 31.7, 31.0, 28.1, 27.9, 27.5, 27.0, 25.3, 23.3, 
23.2, 20.1, 20.0; [α]D -23.2 (c 1.0, MeOH); ESI/MS for C15H25NO4 calculated 
(M+H+) 270, found 270. 
 
 
Compound 2.21: To a solution of carboxylic acid 2.19 (71 mg, 0.26 mmol) 
in DMF (5 mL) at 0 °C was added PyBOP (0.21 g, 0.40 mmol) with stirring for 10 
min., then benzamidine 2.20 (0.11 g, 0.40 mmol) and 2,6-lutidine (92 μL, 0.79 
mmol) were added, and warmed to R.T.. After stirring for 18 h, the reaction 
mixture was diluted with DCM (50 mL), washed with 0.5 M HCl aqueous (50 mL), 
5% aqueous Na2CO3 (50 mL), brine (50 mL), and H2O (50 mL), dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by 
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flash column chromatography (EtOAc/hexane 1:1 to EtOAc/hexane 2:1) to give 
2.21 (126 mg, 91%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ (rotamers) 
9.50 (br, s, 1H), 7.85-7.70 (m, 2H), 7.47-7.24 (m, 8H), 5.3 (s, 0.3H), 5.2 (s, 
1.7H), 4.53-4.39 (m, 2H), 4.25 (m, 1H), 3.84 (m, 1H), 2.30-2.00 (m, 3H), 1.90 
(m, 1H), 1.75-1.55 (m, 3H), 1.51-1.10 (m, 13H); 13C NMR, (100 MHz CDCl3) δ 
(rotamers) 172.9, 167.8, 165.2, 164.3, 155.2, 151.2, 142.9, 136.5, 134.9, 
133.1, 128.59, 128.56, 128.3, 128.14, 128.18, 128.9, 127.7, 127.3, 80.3, 
67.8, 67.1, 60.3, 58.1, 42.7, 36.5, 28.5, 28.3, 25.8, 23.7, 20.4; [α]D –19.4 (c 
1.0, MeOH); ESI/MS for C30H38N4O5 calculated (M+H+) 535, found 535. 
 
 
Compound 2.22: Compound 2.21 (0.57 g, 1.1 mmol) was treated 
with >99.9% TFA/DCM (1:9, 10 mL). After stirring at R.T. for 1 h, the reaction 
mixture was diluted with EtOAc (50 mL) and concentrated under reduced 
pressure. The crude residue was suspended in 5% Na2CO3 aqueous (40 mL) 
and extracted with DCM (3×40 mL). The organic phases were combined, dried 
over Na2SO4, and concentrated under reduced pressure to afford 2.22 (473 mg, 
99%), as a colorless oil, which was sufficiently pure for use in the following step：
1H NMR, (400 MHz, CDCl3) δ (rotamers) 9.45 (br, s, 1H), 8.28 (t, 1H, J=6.2 Hz), 
7.84 (AA’ part of AA’XX’, 2H), 7.44-7.39 (m, 2H), 7.35-7.24 (m, 3H), 7.19 (XX’ 
part of AA’XX’, 2H), 5.17 (s, 2H), 4.46-4.30 (m, 2H), 3.67 (dd, 1H, J=5.1 Hz, 
J=10.6 Hz), 3.21 (br, m, 1H), 2.20 (br, m, 1H), 1.91 (br, m, 1H), 1.70 (br, m, 
1H), 1.55-1.35 (m, 5H), 1.30-1.13 (m, 3H); 13C NMR, (100 MHz, CDCl3) δ 
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(rotamers) 176.2, 176.1, 167.7, 164.3, 142.63, 142.61, 136.5, 133.2, 128.2, 
127.9, 127.71, 127.69, 127.1, 66.8, 58.6, 57.1, 42.3, 42.1, 37.8, 35.2, 29.0, 
27.3, 23.3, 21.5; [α]D +8.3 (c 1.0, CHCl3); ESI/MS for C25H30N4O3 calculated 
(M+H+) 435, found 435. 
 
 
Compound 2.24: To a solution of MOM-D-phenyllactic acid 2.23 (35 mg, 
0.17 mmol) in DCM (5 mL) at 0 °C were added DEPBT (75 mg, 0.25 mmol) with 
stirring at 0 °C for 10 min., then a solution of 2,6-lutidine (58 μL, 0.50 mmol) 
and 2.13 (18 mg, 0.14 mmol) in DCM (1.5 mL) was added, and then slowly 
warmed to R.T.. After stirring for 20 h, the reaction mixture was diluted with 
DCM (15 mL), washed with saturated aqueous NaHCO3 (20 mL), 1 M HCl 
aqueous (20 mL) and brine (20 mL), dried over Na2SO4 and concentrated under 
reduced pressure. The crude residue was purified by flash column 
chromatography (100% EtOAc) to afford 2.24 (26 mg, 57%), as a colorless 
solid, m.p. 62-64 °C: 1H NMR, (400 MHz, CDCl3) δ 7.30-7.20 (m, 5H), 6.59 (d, 
1H, J=8.4 Hz), 4.66 (d, 1H, J=6.4 Hz), 4.52 (d, 1H, J=6.4 Hz), 4.31 (dd, 1H, 
J=3.8 Hz, J=7.4 Hz), 3.79-3.72 (m, 1H), 3.71 (dd, 1H, J=3.0 Hz, J=11.4 Hz), 
3.60 (dd, 1H, J=5.2 Hz, J=11.2 Hz), 3.22 (s, 3H), 3.19 (dd, 1H, J=3.8 Hz, 
J=14.2 Hz), 2.98 (dd, 1H, J=7.2 Hz, J=14.0 Hz), 2.55 (s, 1H), 1.53-1.42 (m, 
2H), 0.86 (d, 3H, J=6.8 Hz), 0.76 (d, 3H, J=6.8 Hz), 0.73 (d, 3H, J=6.8 Hz); 13C 
NMR, (100 MHz, CDCl3) δ 172.2, 137.2, 130.0, 128.4, 126.8, 96.8, 79.3, 63.7, 
56.2, 54.2, 39.0, 27.9, 21.7, 16.5, 10.7; [α]D +80.3 (c 1.0, CHCl3); ESI/MS for 
C18H29NO4 calculated (M+H+) 324, found 324.  
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Compound 2.24a: To a solution of MOM-D-phenyllactic acid 2.23 (18 mg, 
0.084 mmol) in DCM (3 mL) at 0 °C were added EDC (20 mg, 0.11 mmol) and 
HOBt (14 mg, 0.11 mmol) with stirring at 0 °C for 10 min., then a solution of 
2.14 (17 mg, 0.07 mmol) and 2,6-lutidine (16 μL, 0.14 mmol) in DCM (2 mL) 
was added, and then slowly warmed to R.T.. After stirring for 72 h, the reaction 
mixture was diluted with DCM (15 mL), washed with saturated aqueous 
NaHCO3 (20 mL), 1 M HCl aqueous (20 mL) and brine (20 mL), dried over 
Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (EtOAc/hexane 1:9) to give 2.24a 
(20 mg, 64%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 7.29-7.24 (m, 
4H), 7.23-7.19 (m, 1H), 6.72 (d, 1H, J=9.7 Hz), 4.57 (d, 1H, J=6.6 Hz), 4.52 
(d, 1H, J=6.6 Hz), 4.36 (dd, 1H, J=3.7 Hz, J=7.6 Hz), 3.85-3.78 (m, 1H), 3.73 
(dd, 1H, J=2.6 Hz, J=10.3 Hz), 3.57 (dd, 1H, J=2.8 Hz, J=10.3 Hz), 3.20 (dd, 
1H, J=3.6 Hz, J=10.5 Hz), 3.11 (s, 3H), 2.97 (dd, 1H, J=7.5 Hz, J=14.1 Hz), 
1.57-1.49 (m, 1H), 1.48-1.40 (m, 1H), 0.87 (s, 9H), 0.83 (d, 3H, J=6.8 Hz), 
0.73 (dd, 6H, J=3.3 Hz, J=6.8 Hz), 0.01 (d, 6H, J=11.0 Hz); 13C NMR, (100 MHz, 
CDCl3) δ 170.7, 137.5, 130.0, 128.4, 126.7, 95.8, 87.2, 63.3, 56.0, 52.5, 39.0, 
38.5, 27.4, 26.0, 21.9, 16.2, 14.3, 10.3, -5.3, -5.4; [α]D +103.6 (c 1.0, CHCl3); 
ESI/MS for C24H43NO4Si calculated (M+H+) 438, found 438.  
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Compound 2.24：To a solution of 2.24a (19 mg, 0.044 mmol) in MeCN (0.9 
mL) at 0 °C was added HF stock solution (0.79 mL, prepared by mixing 43 mL 
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MeCN, 4.5 mL H2O, and 7.5 mL 48% aqueous HF solution), then warmed to R.T.. 
After stirring for 1 h, the reaction mixture was quenched by addition of 
saturated aqueous NaHCO3 (15 mL) and extracted with DCM (3×20 mL), and 
the combined organic phases were dried over Na2SO4, then concentrated under 
reduced pressure. The crude residue was purified by flash column 
chromatography (100% EtOAc) to give 2.24 (14 mg, 99%), as a colorless solid. 
 
 
Compound 2.24b: To a solution of MOM-D-phenyllactic acid 2.23 (23 mg, 
0.11 mmol) in DCM (3 mL) at 0°C were added DEPBT (48 mg, 0.16 mmol) with 
stirring at 0°C for 10 min., a solution of 2.15 (26 mg, 0.09 mmol) and 
2,6-lutidine (38 μL, 0.32 mmol) in DCM (2 mL) was added, then slowly warmed 
to R.T.. After stirring for 40 h, the reaction mixture was diluted with DCM (15 
mL), washed with saturated aqueous NaHCO3 (20 mL), 1 M HCl aqueous (20 mL) 
and brine (20 mL), dried over Na2SO4 and concentrated under reduced pressure. 
The crude residue was purified by flash column chromatography (EtOAc/ 
hexane 1:9) to afford 2.24b (37 mg, 86%), as a colorless oil: 1H NMR, (400 
MHz, CDCl3) δ 7.28-7.25 (m, 4H), 7.23-7.21 (m, 1H), 6.72 (d, 1H, J=9.3 Hz), 
4.56 (dd, 1H, J=6.6 Hz, J=20.4 Hz), 4.36 (dd, 1H, J=3.6 Hz, J=7.3 Hz), 
3.91-3.77 (m, 2H), 3.73-3.71 (m, 1H), 3.21 (dd, 1H, J=3.6 Hz, J=14.1 Hz), 
3.09 (s, 9H),  2.99 (dd, 1H, J=7.4 Hz, J=14.1 Hz), 1.62-1.54 (m, 1H), 
1.48-1.40 (m, 1H), 1.12-0.98 (m, 21H), 0.84 (d, 3H, J=6.9 Hz), 0.76 (d, 3H, 
J=6.9 Hz), 0.72 (d, 3H, J=6.7 Hz); 13C NMR, (100 MHz, CDCl3) δ 170.8, 137.5, 
130.0, 128.4, 126.7, 96.1, 78.5, 63.7, 56.0, 52.9, 39.2, 38.6, 27.6, 22.0, 18.2, 
16.3, 12.1, 10.6; [α]D +89.9 (c 1.0, CHCl3); ESI/MS for C27H49NO4Si calculated 
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(M+H+) 480, found 480.  
 
 
Compound 2.24：To a solution of 2.24b (36 mg, 0.075 mmol) in MeCN (0.9 
mL) at 0 °C was added HF stock solution (0.79 mL, prepared by mixing 43 mL 
MeCN, 4.5 mL H2O, and 7.5 mL 48% aqueous HF solution), then warmed to R.T.. 
After stirring for 6 h, the reaction mixture was quenched by addition of 
saturated aqueous NaHCO3 (20 mL) and extracted with DCM (3×25 mL), and 
the combined organic phases were dried over Na2SO4, then concentrated under 
reduced pressure. The crude residue was purified by flash column 
chromatography (100% EtOAc) to give 2.24 (24 mg, 98%) as a colorless solid. 
 
 
Compound 2.25a: To a solution of MOM-D-phenyllactic acid 2.23 (45 mg, 
0.22 mmol) in DCM (6 mL) at 0 °C were added DEPBT (97 mg, 0.32 mmol) with 
stirring at 0 °C for 10 min., a solution of 2,6-lutidine (75 μL, 0.65 mmol) and 
2.16 (52 mg, 0.18 mmol) in DCM (4 mL) was added, and then slowly warmed 
to R.T.. After stirring for 48 h, the reaction mixture was diluted with DCM (25 
mL), washed with saturated aqueous NaHCO3 (30 mL), 1 M HCl aqueous (30 mL) 
and brine (30 mL), dried over Na2SO4 and concentrated under reduced pressure. 
The crude residue was purified by flash column chromatography (EtOAc/ 
hexane 1:9) to afford 2.25a (45 mg, 52%), as a colorless oil: 1H NMR, (400 
MHz, CDCl3) δ 7.30-7.26 (m 4H), 7.24-7.18 (m, 1H), 6.98 (d, 1H, J=10.1 Hz), 
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4.52 (d, 1H, J=6.6 Hz), 4.39 (d, 1H, J=6.6 Hz), 4.33 (dd, 1H, J=3.1 Hz, J=9.4 
Hz), 3.79 (dd, 1H, J=4.6 Hz, J=10.1 Hz), 3.72-3.65 (m, 1H), 3.56 (dd, 1H, 
J=4.1 Hz, J=10.1 Hz), 3.25 (dd, 1H, J=3.1 Hz, J=14.0 Hz), 2.98 (s, 3H), 2.86 
(dd, 1H, J=9.5 Hz, J=14.0 Hz), 1.96-1.82 (m, 2H), 1.16-1.09 (m, 21H), 0.95 
(dd, 6H, J=2.5 Hz, J=6.8 Hz), 0.90 (d, 3H, J=6.7Hz); 13C NMR, (100 MHz, CDCl3) 
δ 171.9, 138.1, 129.8, 128.4, 126.6, 95.9, 78.9, 65.6, 57.5, 55.7, 40.0, 35.9, 
31.0, 20.3, 19.1, 18.3, 18.2, 15.7, 12.1; [α]D +36.9 (c 1.0, CHCl3); ESI/MS for 
C27H49NO4Si calculated (M+H+) 480, found 480.  
 
 
Compound 2.25：To a solution of 2.25a (43 mg, 0.09 mmol) in MeCN (0.9 
mL) at 0 °C was added HF stock solution (0.79 mL, prepared by mixing 43 mL 
MeCN, 4.5 mL H2O, and 7.5 mL 48% aqueous HF solution), then warmed to R.T.. 
After stirring for 4 h, the reaction mixture was quenched by addition of 
saturated aqueous NaHCO3 (25 mL) and extracted with DCM (3×30 mL). The 
combined organic phases were dried over Na2SO4 and concentrated under 
reduced pressure. The crude residue was purified by flash column 
chromatography (EtOAc/hexane 1:1) to afford 2.25 (25 mg, 86%), as a 
colorless solid, m.p. 59-60 °C: 1H NMR, (400 MHz, CDCl3) δ 7.33-7.27 (m, 4H), 
7.26-7.21 (m, 1H), 6.69 (d, 1H, J=9.8 Hz), 4.62 (d, 1H, J=6.5 Hz), 4.52 (d, 1H, 
J=6.5 Hz), 4.39 (dd, 1H, J=3.4 Hz, J=8.3 Hz), 3.75-3.69 (m, 1H), 3.37 (dd, 1H, 
J=3.0 Hz, J=11.8 Hz), 3.32-3.25 (m, 2H), 3.14 (s, 3H), 2.95 (dd, 1H, J=8.3 Hz, 
J=14.1 Hz), 2.89 (s, 1H), 2.08-1.99 (m, 1H), 1.52-1.43 (m, 1H), 1.01 (d, 3H, 
J=6.9 Hz), 0.92 (d, 3H, J=6.8 Hz), 0.85 (d, 3H, J=6.9 Hz); 13C NMR, (100 MHz, 
CDCl3) δ 173.0, 137.4, 129.9, 128.5, 126.9, 96.3, 78.8, 64.8, 56.1, 55.1, 39.2, 
37.4, 27.8, 20.8, 15.5, 15.2; [α]D +78.6 (c 1.0, CHCl3); ESI/MS for C18H29NO4 
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calculated (M+H+) 324, found 324. 
 
 
Compound .26: A solution of 2.24 (23 mg, 0.07 mmol) in MeCN (2.5 mL) 
was cooled to 0 °C and a solution of 1.0 mg CrO3 dissolved in 420 μL of 0.4 M 
H5IO6 in wet MeCN (MeCN/H2O 99.3:0.7) was added. After stirring at 0 °C for 30 
min., the reaction mixture was quenched at same temperature by adding 2.4 
mL saturated aqueous NaHCO3. After MeCN was evaporated, the aqueous 
mixture was treated with 1 mL of 0.5 M aqueous NaOH, and washed with DCM 
(15 mL). The aqueous layer was acidified with 0.5 M HCl aqueous (10 mL) and 
extracted with DCM (3×20 mL). The combined organic phases were dried over 
Na2SO4 and concentrated under reduced pressure to give carboxylic acid 2.26 
(19 mg, 82%), as a colorless oil, which was sufficiently pure for use in the 
following step. 1H NMR, (400 MHz, CDCl3) δ 10.4 (s, 1H), 7.31-7.22 (m, 5H), 
7.03 (d, 1H, J=8.8 Hz), 4.65-4.58 (m, 3H), 4.40 (dd, 1H, J=3.6 Hz, J=6.9 Hz), 
3.22-3.14 (m, 4H), 2.99 (dd, 1H, J=6.9 Hz, J=14.0 Hz), 1.62-1.50 (m, 2H), 
0.95 (d, 3H, J=6.6 Hz), 0.78 (dd, 6H, J=6.6 Hz, J=11.4 Hz); 13C NMR, (100 MHz, 
CDCl3) δ 176.2, 171.8, 136.9, 130.0, 128.4, 126.9, 96.1, 77.9, 56.2, 55.0, 
42.1, 38.9, 28.6, 21.5, 18.2, 11.8; [α]D +45.5 (c 1.0, CHCl3); ESI/MS for 
C18H27NO5 calculated (M+H+) 338, found 338. 
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Compound 2.27: A solution of alcohol 2.25 (24 mg, 0.075 mmol) in MeCN 
(2.5 mL) was cooled to 0 °C and a solution of 1.0 mg CrO3 dissolved in 450 μL 
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of 0.4 M H5IO6 in wet MeCN (MeCN/H2O, 99.3:0.7) was added. After stirring at 
0 °C for 30 min., the reaction mixture was quenched by adding 2.4 mL saturated 
aqueous NaHCO3. After MeCN was evaporated, the aqueous mixture was 
treated with 1 mL 0.5 M aqueous NaOH, and washed with DCM (15 mL). The 
aqueous layer was acidified with 0.5 M HCl aqueous (10 mL) and extracted with 
DCM (3×20 mL). The combined organic phases were dried over Na2SO4 and 
concentrated under reduced pressure to give carboxylic acid 2.27 (21 mg, 
82%), as a colorless oil, which was sufficiently pure for use in the following step. 
1H NMR, (400 MHz, CDCl3) δ 10.6 (s, 1H), 7.44 (d, 1H, J=10.2 Hz), 7.35-7.25 
(m, 4H), 7.23-7.18 (m, 1H), 4.59 (d, 1H, J=6.7 Hz), 4.48 (d, 1H, J=6.7 Hz), 
4.39 (dd, 1H, J=3.1 Hz, J=8.7 Hz), 3.82-3.76 (m, 1H), 3.26 (dd, 1H, J=3.1 Hz, 
J=14.0 Hz), 3.12 (s, 3H), 2.93-2.83 (m, 2H), 1.85-1.76 (m, 1H), 1.07 (d, 3H, 
J=7.1 Hz), 0.98 (d, 3H, J=6.6 Hz), 0.91 (d, 3H, J=6.7 Hz); 13C NMR, (100 MHz, 
CDCl3) δ 180.4, 172.5, 137.6, 129.9, 128.5, 126.8, 96.4, 78.9, 56.6, 56.1, 
40.1, 39.5, 31.6, 20.0, 19.5, 15.6; [α]D +20.7 (c 1.0, CHCl3); ESI/MS for 
C18H27NO5 calculated (M+H+) 338, found 338.  
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Compound 2.28: To a solution of 2.22 (29 mg, 0.085 mmol) and carboxylic 
acid 2.26 (44 mg, 0.10 mmol) in DCM (2 mL) at 0 °C were added fresh 
recrystallized DEPBT (45 mg, 0.15 mmol), and 2,6-lutidine (35 μL, 0.30 mmol), 
and then warmed to R.T.. After stirring for 20 h, the reaction mixture was 
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diluted with DCM (20 mL), washed with 0.5 M HCl aqueous (20 mL), 5% Na2CO3 
aqueous (20 mL) and brine (20 mL), dried over Na2SO4, and concentrated 
under reduced pressure. The crude residue was purified by flash column 
chromatography (EtOAc/toluene 1:3 to EtOAc/hexane 3:1 to 100% EtOAc to 
MeOH/CHCl3 1:49) to afford 2.28 as a colorless oil (47 mg, 74%). 1H NMR, (400 
MHz, CDCl3) δ 9.43 (s, 1H), 7.81 (d, 2H, J=8.0 Hz), 7.56-7.52 (m, 1H), 7.46 (d, 
2H, J=6.8 Hz), 7.38-7.14 (m, 9H), 7.07 (d, 2H, J=6.8 Hz), 6.79 (d, 1H, J=6.8 
Hz), 5.23 (s, 2H), 4.76 (dd, 1H, J=7.6 Hz, J=16.0 Hz), 4.62-4.56 (m, 1H), 4.38 
(d, 1H, J=6.8 Hz), 4.32 (d, 1H, J=6.8 Hz), 4.29 (d, 1H, J=4.4 Hz), 4.25 (d, 1H, 
J=4.4 Hz), 3.92-3.89 (br, t, 1H), 3.68 (dd, 1H, J=3.4 Hz, J=7.8 Hz), 3.04 (s, 
3H), 2.98 (dd, 1H, J=3.2 Hz, J=14.2 Hz), 2.74 (dd, 1H, J=7.9 Hz, J=14.1 Hz), 
2.32-2.23 (m, 4H), 1.84-1.15 (m, 9H), 0.88 (d, 3H, J=6.9 Hz), 0.77 (dd, 6H, 
J=1.9 Hz, J=6.9 Hz); 13C NMR, (100 MHz, MeOH-d4) δ 174.2, 173.7, 172.3, 
170.5, 165.2, 144.9, 138.5, 138.4, 134.3, 131.0, 129.6, 129.3, 129.21, 
129.17, 129.16, 128.9, 128.5, 127.8, 97.0, 78.6, 68.2, 61.8, 60.5, 56.6, 54.4, 
43.7, 42.7, 39.7, 38.8, 32.0, 28.9, 27.8, 26.7, 25.0, 21.9, 21.2, 16.1, 9.6; [α]D 
+9.6 (c 1.0, CHCl3); ESI/MS for C43H55N5O7 calculated (M+H+) 754, found 754.  
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Compound 2.29: To a solution of 2.22 (20 mg, 0.06 mmol) and carboxylic 
acid 2.27 (31 mg, 0.072 mmol) in DCM (2 mL) at 0 °C were added fresh 
recrystallized DEPBT (31 mg, 0.11 mmol), and 2,6-lutidine (24 μL, 0.21 mmol), 
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and then warmed to R.T.. After stirring for 20 h, the reaction mixture was 
diluted with DCM (20 mL), washed with 0.5 M HCl aqueous (20 mL), 5% Na2CO3 
aqueous (20 mL) and brine (20 mL), dried over Na2SO4, and concentrated 
under reduced pressure. The crude residue was purified by flash column 
chromatography (EtOAc/toluene 1:3 to EtOAc/hexane 3:1 to 100% EtOAc to 
MeOH/CHCl3 1:99) to afford 2.29 as a colorless oil (31 mg, 69%). 1H NMR, (400 
MHz, CDCl3) δ 9.56 (s, 1H),  8.32 (d, 1H, J=9.9 Hz), 7.83 (d, 2H, J=8.2 Hz), 
7.53-7.17 (m, 14H), 5.22 (s, 2H), 4.61-4.34 (m, 5H), 3.76-3.66 (m, 2H), 3.22 
(dd, 1H, J=3.1 Hz, J=14.0 Hz), 3.02 (s, 3H), 2.90 (dd, 1H, J=8.8 Hz, J=14.0 
Hz), 2.79 (dd, 1H, J=3.4 Hz, J=7.1 Hz), 2.67-2.58 (m, 1H), 2.32-2.19 (m, 1H), 
2.03-1.95 (m, 1H), 1.85-1.18 (m, 10H), 0.97 (d, 3H, J=7.1 Hz), 0.82 (dd, 6H, 
J=6.7 Hz, J=12.3 Hz); 13C NMR, (100 MHz, MeOH-d4) δ 176.3, 174.43, 174.37, 
170.4, 154.3, 144.9, 138.9, 138.4, 134.6, 131.0, 129.6, 129.4, 129.2, 129.1, 
128.7, 127.7, 97.3, 79.8, 68.1, 61.8, 59.80, 59.76, 56.5, 43.8, 40.4, 39.0, 
38.7, 33.2, 32.0, 29.5, 26.8, 25.0, 21.15, 21.10, 20.3, 16.9,; [α]D -12.0 (c 1.0, 
CHCl3); ESI/MS for C43H55N5O7 calculated (M+H+) 754, found 754.  
 
 
Compound 2.2: To a solution of 2.28 (34 mg, 0.045 mmol) in MeOH (2 mL) 
was added Pd/C 10 wt.% (6 mg) and the reaction mixture was stirred under H2 
(1 atm) at R.T. for 10 h. The Pd/C catalyst was removed by filtration and the 
filtrate was concentrated under reduced pressure to afford benzamidine (18 mg) 
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as a colorless oil, which was used directly. The crude benzamidine was treated 
with >99.9% TFA/DCM (9:1, 2 mL) and 1 drop of H2O. After stirring at R.T. for 
3 h, the reaction mixture was diluted with EtOAc (15 mL) and concentrated 
under reduced pressure. The crude residue was purified by RP-LC-MS (85 min. 
gradient of 20-80% CH3CN in 0.05% aqueous TFA) to afford final 2.2 (18 mg, 
57%, over two steps) as the TFA salt. The TFA salt of the product was 
transformed to the hydrochloride salt (16 mg) and analyzed. 1H NMR, (400 MHz, 
MeOH-d4) δ 8.61 (s, 1H), 7.74 (d, 2H, J=6.8 Hz), 7.56 (d, 2H, J=6.9 Hz), 7.37 
(br, d, 1H), 7.21 (br, m, 5H), 4.57 (d, 2H, J=12.5 Hz), 4.43-4.36 (br, m, 2H), 
4.15 (br, m, 1H), 3.96 (br, m, 1H), 3.01 (d, 1H, J=13.6 Hz), 2.82 (br, dd, 1H), 
2.38 (br, m, 1H), 2,15 (br, m, 2H), 2.04 (br, dd, 1H), 1.80-1.58 (br, m, 5H), 
1.50 (br, d, 1H), 1.41 (br, m, 1H), 1.29 (d, 2H, J=15.0 Hz), 0.80 (d, 3H, J=5.9 
Hz), 0.73 (t, 6H, J=7.1 Hz); 13C NMR, (100 MHz, MeOH-d4) δ 175.4, 174.6, 
172.4, 168.2, 147.2, 138.7, 131.0, 129.15, 129.12, 129.0, 128.0, 127.6, 73.8, 
61.8, 60.4, 54.1, 43.6, 42.9, 41.3, 38.7, 32.1, 28.9, 27.6, 26.6, 24.9, 21.8, 
21.2, 16.0, 9.5; [α]D +70.7 (c 0.10, MeOH); HRMS (Not salt, Free amine) for 
C33H45N5O4 calculated (M+H+) 576.35443, found 576.35492. 
 
 
Compound 2.3: To a solution of 2.29 (30 mg, 0.04 mmol) in MeOH (2 mL) 
was added Pd/C 10 wt.% (6 mg) and the reaction mixture was stirred under H2 
(1 atm) at R.T. for 10 h. The Pd/C catalyst was removed by filtration and the 
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filtrate was concentrated under reduced pressure to afford the benzamidine (19 
mg) as a colorless oil, which was used directly. The crude benzamidine was 
treated with >99.9% TFA/DCM (9:1, 2 mL) and 1 drop of H2O. After stirring at 
R.T. for 3 h, the reaction mixture was diluted with EtOAc (15 mL) and 
concentrated under reduced pressure. The crude residue was purified by 
RP-LC-MS (85 min. gradient of 20-80% CH3CN in 0.05% aqueous TFA) to afford 
final 2.3 (16 mg, 59%, over two steps) as the TFA salt. The TFA salt of the 
product was transformed to the hydrochloride salt (15 mg) and analyzed. 1H 
NMR, (400 MHz, MeOH-d4) δ 9.22 (s, 1H), 8.72 (s, 1H), 7.76 (d, 2H, J=7.9 Hz), 
7.61 (d, 2H, J=7.9 Hz), 7.26-7.22 (br, m, 4H), 7.19-7.15 (br, m, 1H), 4.66 (d, 
1H, J=16.2 Hz), 4.39-4.35 (m, 2H), 4.26 (d, 1H, J=7.5 Hz), 3.95-3.89 (br, m, 
1H), 3.75 (br, m, 1H), 3.05 (d, 1H, J=14.2 Hz), 2.90-1.96 (br, m, 1H), 2.76 (d, 
1H, J=8.4 Hz, J=14.0 Hz), 2.41 (br, m, 1H), 2.11 (t, 2H, J=9.2 Hz), 2.00-1.95 
(br, m, 1H), 1.85-1.73 (m, 4H), 1.54-1.50 (m, 1H), 1.43-1.23 (m, 3H), 1.00 (d, 
3H, J=6.4 Hz), 0.95 (d, 3H, J=6.6 Hz), 0.85 (d, 3H, J=6.6 Hz); 13C NMR, (100 
MHz, MeOH-d4) δ 176.3, 176.1, 174.8, 168.5, 147.4, 139.7, 130.8, 129.3, 
129.24, 129.19, 128.1, 127.5, 74.4, 62.0, 59.7, 59.0, 43.7, 41.5, 39.4, 39.1, 
32.6, 32.1, 29.8, 26.9, 25.0, 21.2, 19.2, 16.6; [α]D +24.7 (c 0.10, MeOH); 
HRMS (Not salt, Free amine) for C33H45N5O4 calculated (M+H+) 576.35443, 
found 562.35369. 
 
General Procedure for Recrystallization of DEPBT: DEPBT (5 g) was 
dissolved in DCM (50 mL), and then filtered out the undissolved solid, which is 
probably the acid. The solution was washed with saturated aqueous Na2CO3 
(3×30 mL), dried over Na2SO4, and concentrated under reduced pressure. The 
crude residue was redissolved in very small amount of hot EtOAc (reflux, a few 
drops), and then petroleum ether (20 mL) was added. The solution was stand 
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at R.T. for 1 h, then removed the solution, and washed with petroleum ether (2 
mL) to afford recrystallized DEPBT (4 g), as a colorless crystalline solid. The 
recrystallized DEPBT was stored in the 0 oC under the argon atmosphere. 
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Chapter Three 
Total Synthesis and Structural Revision of the 
Presumed Aeruginosin 205B 
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3-1 Introduction 
3-1-1 Revision of proposed and misassigned structures of 
aeruginosins through total synthesis 
The aeruginosins are classified as natural products produced by the 
cyanobacterium Microcystis aeruginosa that incorporate a new azabicyclic 
amino acid, 2-carboxy-6-hydroxyoctahydroindole (Choi). To date, the total 
syntheses of seven aeruginosins have been completed, four of these involving 
revisions to the originally proposed structures.[1-14] 
 
3-1-1-1 Revision of aeruginosin 298A 
In 1994, aeruginosin 298A was isolation from from Microcystis aeruginosa 
by Murakami and coworkers.[1] The structure of aeruginosin 298A (3.1a in 
Figure 9)[1,2] was initially elucidated through 2D NMR studies. In Murakami’s 
initial report,[1] a linear peptide containing four subunits was proposed: a 
reduced arginine (L-Argol), a 2-carboxy-6-octahydroindole (L-Choi) core, a 
L-leucine, and an hydroxyphenyllactic acid (D-Hpla), based on degradation and 
derivatization of the acid hydrolyzate. 
In 1998, Tulinsky and coworkers[2] published an X-ray crystallographic 
structure of a ternary complex of 3.1a bound to a hirugen–thrombin complex, 
thus providing an absolute stereochemical configuration. The crystal structure 
of the ternary complex revealed some unexpected interactions between 3.1a 
and the binding pocket of thrombin. L-Leu was found to occupy the hydrophobic 
D-enantiomorphic S3 subsite. In addition, the Hpla subunit was also found to 
interact with the S3 subsite, which was expected to accommodate the L-Leu 
subunit. These key observations cast some doubt on the stereochemical 
assignments initially made for aeruginosin 298A, and would not be resolved 
until the proposed structure (3.1a) was revised through total synthesis by the 
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groups of Bonjoch[3,4] and Wipf[5] independently in 2000 (see revised structure 
3.1b in Figure 9). 
 
 
Figure 9. Originally proposed and revised structures of aeruginosin 298A. 
 
3-1-1-2 Revision of oscillarin 
In 1997, researchers at Boehringer Mannheim GmbH (now Roche 
Diagnostics) in Germany disclosed the isolation and characterization of a new 
compound 3.2a (Figure 10) called oscillarin, from algal cultures of Oscillatoria 
agardhii, and originally isolated from Lake Kasumigaura in Japan.[6]  
The structure and absolute configuration were proposed on the basis of 
NMR data and a partially resolved co-crystal complex with trypsin. Oscillarin 
was proposed to comprise a D-phenyllactic acid (D-Pla), a D-Phe subunit, a 
L-Choi subunit and a cyclic guanidine containing P1 subunit. The structure was 
later revised to be 3.2b (Figure 10) without any change in the original data.[7] 
The revised structure of oscillarin 3.2b was confirmed by total synthesis, and 
by high-resolution X-ray crystallography of a thrombin–oscillarin complex by 
Hanessian and coworkers.[8] Oscillarin comprises a D-phenyllactic acid (D-Pla), 
a D-phenylalanine, a L-Choi coin, and an unique heterocyclic motif, described 
as 1-(N-amidino-Δ3-pyrrolino)ethyl subunit (Adc).  
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Figure 10. Originally proposed and revised structures of oscillarin. 
 
3-1-1-3 Total synthesis of dysinosin A and chlorodysinosin A 
The unique Adc heterocyclic motif is also present in dysinosin A 3.3a 
(Figure 11),[9,10] whose isolation and characterization were reported by Quinn 
and coworkers in 2002.[10] Dysinosin A, isolated from the extracts of sponge 
belonging to the family Dysideidae, is a functionally novel aeruginosin. Its 
structural elucidation was achieved through a combination of NMR and 
degradation studies, while the stereochemical assignments were confirmed by 
the X-ray structure of a ternary complex of dysinosin A, thrombin, and 
hirugen.[10] The familiar perhydroindole core structure of Dysinosin A harbors 
an additional hydroxy group at C5, resulting in a trans-diaxial orientation. The 
N-terminal residues are D-Leu and a sulfated glyceric acid derivative not 
previously found in the other aeruginosins. A total synthesis of dysinosin A was 
reported by Hanessian and coworkers.[11]  
In 2003, the Pharmacia Corporation[12] disclosed the isolation and 
characterization of a chlorinated dysinosin A derivative 3.3b (Figure 11) later, 
named as chlorodysinosin A following its total synthesis by Hanessian and 
coworkers.[13] It contains 3-chloroleucine (Cleu), an amino acid unknown in the 
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natural-product literature. The basic structure of 3.3b was first deduced by 
NMR spectroscopy and degradation studies, and its structure and absolute 
configuration have recently been confirmed by total synthesis and a high 
resolution X-ray structure with thrombin.[13]  
 
 
Figure 11. Structure of dysinosin A and chlorodysinosin A. 
 
3-1-2 Original structure of aeruginosins 205A and B 
In 1997, Murakami and coworkers[15] isolated new aeruginosins from the 
genus Microcystis, designed as 205A and 205B. Two compounds were isolated 
from the cyanobacterium Oscillatoria agardhii, which was collected from Lake 
Kasumigaura in Japan. These glycopeptides are potent inhibitors of trypsin 
(IC50=0.07 μg/mL) and thrombin (IC50=1.5 μg/mL 205A, IC50=0.17 μg/mL 
205B).[15] A characteristic isotopic and fragmentation pattern in positive-ion 
FAB mass spectrum indicated that there is a chlorine atom and a sulfate group 
in the molecules. 
Extensive spectroscopic studies based on previous reports that related to 
aeruginosins,[1,14,16] suggested the presence of five subunits: 1) P1 subunit is 
Plas (phenyllactic acid 2-O-sulfate), 2) P2 subunit is Hleu (3-hydroxyleucine), 3) 
P3 subunit is Ccoi (2-carboxy-6-chloro octahydroindole), 4) P4 subunit is Agma 
(agmatine), and 5) P5 subunit is Xyl (xylopyranose), assembled as a linear 
peptide array, and shown in expressions 3.4a and 3.4b (Figure 12).  
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Figure 12. Originally proposed structures of aeruginosins 205A and B. 
 
The absolute stereochemistry of these aeruginosins was determined by 
acid hydrolysis and HPLC analysis of appropriate derivatives.[15]  
Hydrolysis of the peptides and derivatization of the Plas residues as their 
methyl esters showed an L- and D-Plas configuration for aeruginosins 205A and 
205B, respectively.  
Although the relative stereochemistry of the Ccoi residue was determined 
from the NMR coupling constants and by NOE analysis, however the absolute 
stereochemistry of the Ccoi subunit remained undisclosed.  
The (2R,3S)- and (2S,3R)-stereochemistry of Hleu, respectively, were 
assigned after derivatization with Marfey's reagent and comparison of HPLC 
retention times with the authentic three of the four possible diastereomers of 
the same compound. Since the retention time did not match, the 
stereochemistry was assigned by exclusion.   
An assignment of D-xylose arose from GC analysis of the degradation 
fragment on a chiral column.  
121 
 
205A and 205B were the only known glycopeptidic aeruginosins at the time 
of their discovery, and they are among a very small group of sugar-containing 
natural products isolated from cyanobacteria.[9,17-22] The elucidation of their 
structures also resulted in the identification of two new structural units named 
Ccoi and Plas, respectively. The third residue, Hleu, is also quite rare among 
natural products.  
 
3-1-3 Revised structure of aeruginosins 205A and 205B 
There has been an ongoing debate over the definitive structures of 
aeruginosins. In spite of a seemingly definitive evidence for the original and 
revised structures of 3.4a and 3.4b, recent developments in the total synthesis 
of other members of this family of glycopeptides have cast some doubt on the 
structural and stereochemical assignments. 
 
3-1-3-1 The first revision of aeruginosins 205A and 205B 
In 2003, Toyooka, Nemoto and coworkers[23] synthesized glycopeptides 
model compounds 3.7a and 3.7b (α and β isomers)(Scheme 21).  
 
 
 
Based on the comparison of NMR data and the composition of other 
members of aeruginosin family, the authors revised the position of the sulfate 
group, which was originally thought to be on the Plas residue, to the 3- or 
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4-position of the xyl residue, while maintaining the Ccoi subunit intact. The 
proposed revised structures of aeruginosins 205A and B are showed as 3.8a 
and 3.8b in the Figure 13. 
 
23
8a: Aeruginosins 205A
R1=SO3H, R2=H, L-Plas, (2R, 3S)-Hleu;
8b: Aeruginosins 205B
R1=H, R2=SO3H, D-Plas, (2S, 3R)-Hleu;
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Figure 13. First revision of aeruginosins 205A and B by Toyooka/Nemoto.[23] 
 
3-1-3-2 The synthesis of the supposed Ccoi core  
The position of the chlorine atom on aeruginosins 205A and 205B has been 
called into question by definitive synthesis of the Ccoi subunit,[24] which was the 
original proposed structure by Murakami, Toyooka and their respective 
coworkers. Recently, Valls, Bonjoch and coworkers[24] reported the synthesis of 
the supposed Ccoi core (Scheme 22).  
 
 
 
When the NMR data of the synthetic Ccoi subunit was compared with the 
data of isolated natural products, some significant differences in the chemical 
shifts of the protons and carbons close to the 6-chlorine atom were found. For 
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example, in the 1H NMR spectrum the H-6 methine proton of synthetic Ccoi 
shows a signal peak at δ=4.60, while in the spectrum of the natural products 
the resonance for this proton is recorded at δ=3.83. There are also a number of 
differences in the 13C NMR spectrum, such as the C-6 methine carbon of 
synthetic Ccoi shows a peak at δ=59.1, while in the spectrum of the natural 
products the resonance for this carbon is recorded at δ=68.7. These results 
seemed to indicate that the chlorine atom of aeruginosins 205A and 205B is not 
on the 2-carboxyperhydroindole (Choi) core. 
 
3-1-3-3 The second revision of aeruginosins 205A and 205B 
In 2006, Valls and Bonjoch reported the synthesis of β-chloroleucine 
derivatives 3.13 and 3.15, which consisted of the chlorine promoted ring 
opening of hydroxyleucine β-lactones 3.12 and 3.14 (Scheme 23).  
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3.14 3.14a
c
Cl
CO2H
NHCbz
S
S
Cl
CO2H
NH2
S
Sd
3.14b 3.15
Scheme 23: Reagents and conditions: a) Cbz-Suc, 3.12 92%, 3.14 92%; b) O-benzotriazole-
N,N,N',N'-tetramethyluronium-hexafluorophosphate (HBTU), 3.12 83%; c) LiCl, THF,
reflux, 90 h, 3.12 46%, 3.14 35%;d) H2, Pd/C, EtOH, 3.12 96%, 3.14 85%; e) benzo-
triazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), 3.14 95%;
a, e
 
The reported occurrence of a 3-chloroleucine in chlorodysinosin A[25] and a 
Choi subunit (as above discussion in B)[24] prompted Valls and Bonjoch to 
suspect that the same subunits might also be present in aeruginosin 205A and 
205B. Thus, not only the originally proposed structures of aeruginosins 205 A 
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and B (3.4a and 3.4b), but also the first revised structures 3.8a and 3.8b were 
incorrect. Furthermore, the authors proposed the structures of aeruginosins 
205A and 205B to be as 3.16a and 3.16b (shown in Figure 14),[25] in which the 
sulfated xylose residue (O-sulfated D-xylopyranosyl ring) must be residing on 
the C-6 methine carbon of a 2-carboxy-6-hydroxyocta-hydroindole (Choi) 
subunit instead of the originally assumed Ccoi; and the chlorine atom was 
assumed to be part of a 3-chloroleucine (Cleu) residue as in chlorodysinosin 
A[13] instead of Hleu as originally proposed. 
 
 
Figure 14. Second revision of aeruginosins 205A and B by Valls/Bonjoch.[25] 
  
3-2 Synthesis of the presumed aeruginosin 205B 
Based on the above information it seemed most likely that the structure of 
aeruginosin 205A and 205B should be revised as shown 3.16a and 3.16b. We 
therefore undertook the total synthesis of 3.16b to validate this conclusion. 
Based on the previous synthesis of compounds in aeruginosins’ family, we 
envisaged the disconnections to the 5 subunits (Figure 15). These are 1) Agma 
subunit, an agmatine; 2) Choi subunit, a 2-carboxy-6-hydroxyoctahydroindole; 
3) Xyl subunit, a D-xylose; 4) Cleu subunit, 3-chloroleucine; and 5) Pla subunit, 
a D-phenyllactic acid. 
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Figure 15. Retrosynthesis of the target compound. 
 
3-2-1 Synthesis plan for aeruginosin 205B 
3-2-1-1 Original attempt 
Initially, the previously published method to synthesize the aeruginosin 
family[14,26] was used to obtain the protected aglycone subunit 3.17 of 
aeruginosin 205B (Scheme 24) by postdoctoral associates Dr. Karolina Ersmark 
and Dr. Juan R. Del Valle.  
First the Choi subunit 3.17a was coupled with the Agma subunit 3.18 to 
afford compound 3.17c. Next, the Cleu subunit 3.19 was coupled with Pla 
subunit 3.20, followed by deprotection and oxidation to give free acid 3.21. 
Finally, compound 3.17c was coupled with free acid 3.21 to afford the 
protected aeruginosin 205B aglycone 3.17d. Because of steric hindrance, the 
yield of the coupling reaction was low. Cleavage of the TBS ether group led to 
intermediate 3.17 ready to be coupled with the Xyl subunit to get our target. At 
the same time, the sequential deprotected of the O-MOM and N-Boc groups 
with TFA afforded the intended glycone 3.16c, which inhibited the enzyme 
thrombin at IC50=0.31 μM.  
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Two coupling methods[27, 28] between compound 3.17 and Xyl subunit were 
studied to afford the product 3.22 (scheme 25). 
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Due to the hindrance, the coupling reaction is too hard to finish. However, 
the ratios of α– and β–regioisomers and the yields of glycoside synthesis were 
unsatisfactory, so this route was abandoned. 
 
3-2-1-2 Coupling of Xyl subunit and Choi subunit 
To solve the glycoside problem, as a second option, the coupling between 
the Xyl subunit and the Choi subunit was studied as a model. 
Firstly, two different solvent systems were tested in the glycosylation of 
cyclohexanol 3.23 with the trichloroacetimidate derivative of 2,3,4-tri-O- 
benzyl-D-xylopyranose 3.24 (Scheme 26). The results showed that the 
presence of Et2O can increase the ratio of the desired α-regioisomer 3.24a. 
 
 
 
Secondly, two glycosylation methods, using anomeric trichloroacet- 
imidate[27] and 2-pyridyl thiocarbonate derivatives[28], were also attempted by 
using the 3-acetate derivatives 3.36 and 3.38 as models (Scheme 27). 
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Excellent yields of the α– and β–anomers (3.25a and 3.25b) were 
obtained, favoring the α-anomer (3.25b), especially when 3.38 was used as 
the glycosyl donor. Glycosylation reactions were done between the Xyl donors 
3.36 and 3.38, and the Choi subunit led to excellent yields with the acceptable 
ratios, as shown in Table 7. 
 
Table 7 Coupling reaction between the Xyl subunit and the Choi subunit 
 
 
 
Xyl Reagents and Conditions Et2O/DCM 
α/β 
(3.34b/3.34a) 
Yielda(%) 
31 cat. TfOH, MS 4A, r.t., 0.5 h 6:1 1:1.4 91 
31 cat. TfOH, MS 4A, r.t., 0.5 h 8:1 1:1.2 90 
31 cat. TfOH, MS 4A, r.t., 0.5 h 10:1 1:1.1 82 
33 
1) 1.4 eq. TMU, MS 4A, 12 h,
2) 9 eq. AgOTf, 36 h, 
10:1 1:1.2 95 
a) Yields of isolated pure product 
 
    Due to the hindrance of the Choi subunit, the α-anomer (3.34b), which is 
the desired intermediate, is not favoring. Increasing the α/β ratio to 1:1.2, we 
therefore decided to adopt the 2-pyridyl thiocarbonate method[28] and use 
Et2O/DCM 10:1 as the solvent system in view of the excellent yield and 
acceptable α/β–ratio. 
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3-2-1-3 Final plan 
Due to the successful result of coupling between the Xyl subunit and the Choi 
subunit, the synthesis plan was changed to another sequence of coupling 
(Figure 16). Firstly, the Choi subunit was coupled with the Xyl subunit, followed 
by the Agma subunit to get the subunit B. Secondly, the Cleu subunit was 
coupled with Pla subunit, followed by deprotection and oxidation to afford 
subunit C. Finally the subunit B was coupling with the subunit C. After sulfation 
and deprotection, the intended target aeruginosin 205B was obtained.  
 
 
Figure 16. Final plan of retrosynthesis of the target compound. 
 
3-2-1-4 Sulfation  
Methyl α-D-xylopyranoside 3.26[29] was used as a model in search of a 
method for selective 3-O-sulfation.  
Sulfur trioxide pyridine complex, is a common sulfation reagent for the 
secondary alcohols of the sugars.[30, 31] In the case of 3.26, NMR studies result 
showed that a mixture of 2-monosulfated (3.26c) 4-monosulfated (3.26b) and 
2,4-disulfated (3.26d) products was obtained. 3-Monosulfated as in 3.26a was 
not observed (Scheme 28).  
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The use of bis(tributyltin) oxide reagent[32, 33] to activate hydroxyl groups 
through stannylene acetals such as 3.26e was expected to give the single 
product 3.26a. Unfortunately, a complex mixture was obtainedunpo sulfation 
(Scheme 28). 
To get the single 3-monosulfation product 3.26a, the 2,4-hydroxy groups of 
3.26 were first protected by Bn-groups to get the major di-benzyl product 
3.27[34], which was sulfated, followed by deprotection to form the single sulfate 
ester 3.26a. The reagents and conditions are shown in Scheme 29. 
 
 
 
3-2-1-5 Choice of protecting group 
From the analysis of the structure and previous experience in the synthesis 
of the aeruginosin family, the stability of the final compound was considered in 
the choice of orthogonally compatible protecting groups. 
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Firstly in basic conditions: Due to the presence of the α-proton and the 
β-chlorine atom on the Cleu subunit, the elimination of the β-chlorine atom was 
a possibility under the basic conditions. Hence, strong bases should be avoided 
in the final deprotection.  
Secondly in acidic conditions: The final product is a monosulfate, and most 
sulfates are reported to be unstable to mineral acids.[35, 36] The compound 
3.26a, which is the 3-O-sulfated product of methyl α-D-xylopyranoside 3.26, 
was used as the model, and the results showed that the sulfates can be purified 
via the silica gel chromatography with 5% methanol in DCM, but not stable 
under pH<3 conditions.  
According to these results, hydrogenation was considered as a safe 
deprotection process, and new protecting groups, which should remain intact 
until the last step, were considered (Figure 17). For example: 1) The Cbz- 
groups on the guanidine on the Agma subunit was used in place of Boc-groups. 
2) The Bn-group on the alcohol on the Pla subunit was to be used instead of 
MOM-group. 3) The two final free alcohols on the Xyl subunit were also to be 
protected with Bn-groups. 
 
 
Figure 17. Protecting groups in the total synthesis. 
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3-2-2 Synthesis of the A-C subunits 
3-2-2-1 The Choi subunit 
Following our previous studies,[8] N-Cbz-L-glutamic acid dimethyl ester 
3.28 was converted to intermediate 3.29. Azonia-Prins reaction led to 
compound 3.30 in greater yield than previously reported.[8] During this 
reaction, dry DCM as solvent, 2 equivalents of tin(IV) bromide (SnBr4) and 
extending the reaction time to 30min led to a higher yield (90%). The bromine 
atom was substituted in an SN2 reaction with Bu4NOAc to form 3.31, which was 
followed by Cbz-group deprotection, Boc-group protection and Ac-group 
cleavage to give the N-Boc Choi derivative 3.33. The structure and 
stereochemistry of 3.33 was ascertained by X-ray crystallography. The details 
are shown as Scheme 30. 
 
 
 
3-2-2-2 The Xyl subunit 
The 2,4-hydroxyl groups of methyl α-D-xylopyranoside 3.26[29] were 
selectively protected as Bn-ethers[34] to give 3.27, which was hydrolyzed under 
acidic conditions and acetylated to afford 3.34. After selective deacetylation, 
3-O-acetyl-2,4-di-O-benzyl-α,β-D-xylopyranose 3.35 was obtained. The 
reagents and conditions are shown in Scheme 31. 
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Scheme 31: Reagents and conditions: a) BnCl, NaH, 100 oC, 4 h, 62%; b) 1,4-dioxane/AcOH
1:1, 1 M H2SO4, 60 oC , 72 h; c) Ac2O, DMAP, Et3N, DCM, r.t., 3 h, 98% over 2
steps; d) benzylamine, THF, r.t., 48 h, 83%;
O
HO
HO
OH
OMe
O
BnO
HO
OBn
OMe
a b, c O
BnO
AcO
OBn
OAc
d O
BnO
AcO
OBn
OH
3.26 3.27 3.34 3.35
 
 
3-2-2-3 Subunit A 
As the discussed in section 3-2-1-2, N-Boc Choi 3.33 was glycosylated 
with 3.38 to form compound 3.39, which is a 1.2:1 mixture of β- and α- 
anomers (3.39a and 3.39b). These were separated by flash column 
chromatography and their structures determined by NMR data of 3.40a and 
3.40b (Scheme 32). The ratio of the desired α-anomer was lower compared to 
cyclohexanol possibly due to the axial disposition of the hydroxyl group in 3.33. 
 
 
 
3-2-2-4 The Agma subunit  
Following the literature[37], guanidine hydrochloride 3.41 was transformed 
into the Goodman’s reagent 3.42, which was reacted with 10 equivalents of 
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1,4-diaminobutane 3.43 to form the Agma subunit 3.44. Protection as N-Boc 
gave an easily purifiable product 3.45, as shown in Scheme 33.  
 
H2N NH2
NH
HCl
3.41
CbzHN NHCbz
NTf
3.42
RHN
H
N NCbz
NHCbz
3.44, R=H
3.45, R=Boc
a,b c
d e
Scheme 33: Reagents and conditions: a) 5 eq. NaOH, 3 eq. CbzCl, H2O/DCM 1:2, 20 h, 0 oC,
86%; b) 2 eq. NaH, 0 oC, 1 eq. Tf2O, chlorobenzene, r.t., 9 h, 67%; c) CHCl3,
10 eq. 1,4-diaminobutane 3.43, r.t., 2 h, 94%; d) 1.4 eq. Boc2O, 2 eq. NEt3, DCM,
0 oC to r.t., 10 h, 92%; e) 4 M HCl, 1,4-dioxane, 99%;
 
 
3-2-2-5 Subunit B 
Compounds 3.46a and 3.46b, which were obtained by saponification of 
the compounds 3.39a and 3.39b respectively, were coupled with the Agma 
subunit 3.44 to afford compounds 3.47a and 3.47b, in the good yield 
(Scheme 34). The structure and stereochemistry of compound 3.46b was also 
established by X-ray crystallography. 
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3-2-2-6 The Cleu subunit  
    The Cleu subunit was prepared as previously described[13] from aziridine 
3.48. First the reaction with tert-butylsulfinyl chloride 3.49, followed by 
oxidation with m-CPBA gave 3.50. Then regioselectivie opening with CeCl3 as 
the chloride source afforded the major isomer 3.51, which was oxidized with 
H5IO6 in the presence of CrO3 catalyst[13] to afford N-Bus-3-chloroleucine 3.51a. 
The detailed reagents and conditions are shown in Scheme 35. 
 
 
 
3-2-2-7 The Pla subunit 
D-(+)-3-Phenyllactic acid 3.52 was treated with NaH and BnBr to obtain 
O-Bn-D-(+)-3-phenyllactic acid 3.53 as the major product in addition to the 
ester 3.53a. After saponification, the transesterification by-product 3.53a was 
transformed back to 3.53 (Scheme 36).  
 
 
 
3-2-2-8 Subunit C 
The Cleu intermediate 3.51 was treated with TfOH to cleave the N-Bus 
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group, then the free amine salt was coupled in presence of DEPBT and 
2,6-lutidine with O-Bn-D-(+)-3-phenyllactic acid 3.53 to afford 3.54. The 
carboxylic acid 3.55 was obtained by oxidation of intermediate 3.54 with H5IO6 
and CrO3 catalyst. The details are shown in Scheme 37. 
 
 
 
3-2-3 Synthesis of aeruginosin 205B 
As shown in Scheme 38, free amines 3.57a and 3.57b, obtained from 
3.42a and 3.42b respectively, were coupled with the subunit C carboxylic acid 
55 to form corresponding 3.57a and 3.57b in presence of 2,6-lutidine and 
DEPBT. The compounds 3.57a and 3.57b were sulfated with 50 equivalents 
sulfur trioxide (SO3) pyridine complex at 50 oC for 2 days. The O-Bn and N-Cbz 
groups in 3.58a and 3.58b were cleaved in presence of excess palladium 
hydroxide (Pd(OH)2, 20 wt.% Pd on carbon) and hydrogen in methanol to form 
target compounds 3.59 and 3.16b respectively. The progress of the 
deprotection was checked by MS each hour to avoid the over-reduction of the 
D-Pla subunit.  
Finally, HPLC was used to purify the compounds 3.59 and 3.16b. Due to 
the stability of the sulfates on these two compounds, the whole HPLC system 
was treated in the neutral condition, and no acidic buffer (0.5% Formate Acid) 
was presence in the flow. 
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3-3 Comparison of NMR data 
3-3-1 Comparison of NMR data of aeruginosin 205B aglycone，
synthetic aeruginosin 205B and natural aeruginosin 205B 
To confirm the presumed structure of aeruginosin 205B 3.16b, comparison 
of 1H and 13C NMR of synthetic aeruginosin 205B aglycone 3.16c, synthetic 
aeruginosin 205B 3.16b, desulfated synthetic aeruginosin 205B 3.16d and 
natural aeruginosin 205B 3.16e[15] has been done. The chemical shift values for 
the Cleu, Pla, Agma, Choi and Xyl subunit of each compound were listed group 
by group in Table 8.  
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Table 8 1H and 13C NMR data for each subunit of synthetic aeruginosin 205B aglycone 3.16c (500 Hz), synthetic 
presumed aeruginosin 205B 3.16b (700 Hz) and desulfated presumed aeruginosin 205B 3.16d (700 Hz) with 
reported data[15] for natural aeruginosin 205B 3.16e in DMSO-d6a 
 
 
  3.16c 3.16d 3.16b 3.16e 3.16c 3.16d 3.16b 3.16e 
Subunit  1H 1H 1H 1H 13C 13Cb 13C 13C 
Cleu 1 -- -- -- -- 169.1  167.5 167.3 
 2 4.88 4.91 4.93 4.90 51.0 51.4 51.1 51.1 
 3 3.92 3.99 3.97 3.98 69.5 69.3 69.0 68.9 
 4 1.62 1.67 1.66 1.69 27.3 30.0 27.5 27.5 
 5,5’ 0.83,0.84 0.85,0.86 0.84,0.86 0.85,0.88 20.3,14.7 21.2,15.9 20.9,15.4 20.8,15.4
 NH 7.52  7.67 7.62 -- -- -- -- 
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  3.16c 3.16d 3.16b 3.16e 3.16c 3.16d 3.16b 3.16e 
Subunit  1H 1H 1H 1H 13C 13Cb 13C 13C 
Pla 1 -- -- -- -- 173.8  172.4 172.4 
 2 4.19 4.19 4.19 4.19 72.0 72.1 71.8 71.9 
 3a,3b 2.82,2.93 2.79,2.96 2.78,2.94 2.78, 2.93 39.8 40.4 40.0 40.0 
 4 -- -- -- -- 139.1  138.1 137.9 
 5,9 7.22 7.23 7.22 7.23 130.9 130.0 129.8 129.6 
 6,8 7.25 7.26 7.24 7.25 129.0 128.3 127.9 127.9 
 7 7.18 7.19 7.17 7.18 127.2 126.4 126.1 126.0 
 2-OH 5.92  3.16 -- -- -- -- -- 
Choi 1 -- -- -- -- 172.8  171.2 171.2 
 2 4.17 4.19 4.19 4.19 60.0 60.2 59.8 59.8 
 3,3’ 1.80,1.97 1.82,2.01 1.85,2.01 1.84,2.02 30.6 31.1 30.8 30.8 
 3a 2.18 2.23 2.26 2.24 35.7 36.3 35.9 35.8 
 4,4’ 1.41,2.01 1.47,2.14 1.49,2.13 1.48,2.13 18.5 19.9 19.5 19.4 
 5 1.42 1.53 1.54 1.54 25.9 25.2 24.9 24.7 
 6 3.89 3.84 3.86 3.83 64.1 68.8 67.3 68.7 
 7,7’ 1.62,2.02 1.58,2.22 1.58,2.32 1.59,2.23 33.2 29.0 28.8 28.7 
 7a 4.26 4.31 4.35 4.23 54.7 54.6 54.0 54.2 
Table 8 (contd.) 
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  3.16c 3.16d 3.16b 3.16e 3.16c 3.16d 3.16b 3.16e 
Subunit  1H 1H 1H 1H 13C 13Cb 13C 13C 
Agma 1 2.99,3.09 2.98,3.08 3.00,3.07 2.97,3.11 37.9 38.3 38.0 37.9 
 2 1.38 1.44 1.41 1.40 26.0 26.4 26.3 26.2 
 3 1.42 1.45 1.44 1.44 26.0 25.5 25.9 25.8 
 4 3.06 3.09 3.03 3.09 40.3 40.8 40.3 40.4 
 1-NH 7.96  8.83 7.92  -- -- -- 
 4-NH 7.63  8.05 7.44  -- -- -- 
 C=N   -- -- 158.5  157.5 156.6 
a. Recorded at MHZ (1H) and MHZ (13C);   b. Recorded from HMQC  
 
Part of Xyl subunit of synthetic 3.16b, desulfated 3.16d and natural 3.16e in DMSO-d6a 
  3.16d 3.16b 3.16e 3.16d 3.16b 3.16e 
Subunit  1H 1H 1H 13Cb 13C 13C 
Xyl 1 4.96 5.09 4.93 95.8 94.2 95.2 
 2 3.24 3.39 3.28 72.5 70.7 72.1 
 3 3.27 4.14 3.58 70.5 80.5 71.7 
 4 3.42 3.45 3.93 73.9 68.6 74.9 
 5 3.30,3.39 3.35,3.45 3.37,3.67 62.4 61.4 59.6 
a. Recorded at MHZ (1H) and MHZ (13C);   b. Recorded from HMQC  
Table 8 (contd.) 
Table 8 (contd.) 
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Thus similarity of chemical shift values for the Cleu, Pla, Agma and Choi 
subunit listed in Table 8, indicate that the structure of the natural product 
should be revised to include a Cleu , Pla and Choi subunit, rather than a Hleu, 
Plas and Ccoi subunit as originally proposed by Murakami.[15]  
Comparison of 1H and 13C NMR shows virtual identity with allowance made 
for the absence of the Xyl subunit in the synthetic aeruginosin 205B aglycone 
3.16c. The 1H and 13C spectra characteristics matched those published for 
aeruginosin 205B 3.16e except for the absence of resonances due to the 
sulfated D-xylopyranosyl moiety. Thus, the reported values for the Pla and Cleu 
subunits were agree to those in the synthetic sample of 205B aglycone 3.16c.  
The same was also true for the Choi subunit with allowance made for C-6, which 
carries a glycosidic moiety in the natural product. The agreement also extends 
to the synthetic aeruginosin 205B 3.16b, and desulfated synthetic aeruginosin 
205B 3.16d, according to the 1H and 13C chemical shift at C-6 of the Choi 
sununit.  
Comparison of 1H and 13C NMR data of the Xyl subunit of synthetic 
aeruginosin 205B 3.16b, desulfated synthetic aeruginosin 205B 3.16d and 
natural aeruginosin 205B 3.16e, indicates that the 1H and 13C chemical shifts 
do not match at the C-3 position. Therefore the sulfate group cannot be on C-3 
of the Xyl subunit (Table 8, the part of Xyl subunit). To validate this conclusion, 
we prepared methyl α-D-xylopyranosides with sulfate group on each hydroxyl 
group individually.  
 
3-3-2 NMR Comparison of model sulfate esters 
Model compounds with and without the O-sulfated group were synthesized. 
Firstly, Methyl α-D-xylopyranoside 3.26, 2-O-sulfate 3.26c, 3-O-sulfate 3.26a, 
4-O-sulfate 3.26d and 2,4-O-disulfate 3.26d were prepared (Scheme 39).  
 
142 
 
O
AcO
BnO
OBn
OMe
3.60a 3.61a
O
BnO
BnO
OAc
OMe
3.60
3.60a
O
HO
BnO
OBn
OMe
3.26b3.60bO
HO3SO
BnO
OBn
OMe
O
HO3SO
HO
OH
OMe
3.613.61a
O
BnO
BnO
OH
OMe
3.26c3.61bO
BnO
BnO
OSO3H
OMe
O
HO
HO
OSO3H
OMe
O
HO
HO
OH
OMe
3.26
3.62O
MOMO
HO
OMOM
OMe
3.63O
MOMO
BnO
OMOM
OMe
3.64O
HO
BnO
OH
OMe
3.65O
HO3SO
BnO
OSO3H
OMe
3.26dO
HO3SO
HO
OSO3H
OMe
a
b c
d
e
f
g
i d e
i d e
O
BnO
HO
OBn
OMe
3.27
O
BnO
BnO
OH
OMe
3.60 3.61
O
HO
BnO
OBn
OMe
O
BnO
HO3SO
OBn
OMe
O
HO
HO3SO
OH
OMe
3.27a
h
3.26a
e
Scheme 39: Reagents and conditions: a) 1) 2.2 eq. Bu2SnO, MS, toluene/MeOH, 70 oC, 10 h,
2) 2.2 eq. MOMCl, 1 eq. Bu4NI, toluene, r.t., 10 h, 47%; b) 1.5 eq. NaH, 1.5 eq.
BnBr, 1 eq. Bu4NI, r.t., 10 h, 89%; c) TFA/DCM 1:2, r.t., 3 h, 82%; d) pyridine,
25 eq. SO3/pyridine, 50 oC, 10 h, 3.65 87%, 3.60b 92%, 3.61b 91%; e) 20 wt.%
Pd(OH)2/C, H2, r.t., 3h, 3.26a 96%, 3.26b 96%, 3.26c 97%, 3.26d 96%; f) BnCl,
2 eq. NaH, 100 oC, 3 h, 3.27 62%, 3.60+3.61 12%; g) 1.5 eq. Ac2O, cat. DMAP,
2 eq. Et3N, r.t., 3 h, 3.60a 35%, 3.61a 48%; h) 50 eq. SO3/pyridine, pyridine, 24 h,
50 oC, 87%; i) 2 eq. NaOMe, MeOH, r.t., 2 h, 3.60 96%, 3.61 96%
 
 
Compound 3.26 was protected as Bn-ethers to give 3.27, 3.60 and 3.61, 
which were sulfated and cleaved O-Bn groups to afford 3.26a-c respectively. 
Compound 3.26 was also selectively protected as MOM-ethers to give 3.62, 
which subjected Bn-protection, MOM-cleavage and sulfation, followed by O-Bn 
group cleavage to afford 3.26d. 1H and 13C NMR data are shown in Table 9. 
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Table 9 1H and 13C NMR data for compounds 3.26, 3.26a-d (Xyl subunit), aeruginosin 205A and B in DMSO-d6  
 
 
 
 3.26 3.26a 3.26b 3.26c 3.26d 205B 205A 3.26 3.26a 3.26b 3.26c 3.26d 205B 205A
 1H 1H 1H 1H 1H 1H 1H 13C 13C 13C 13C 13C 13C 13C 
1 4.47 4.52 4.48 4.72 4.79 4.93 4.95 100.2 99.8 99.8 98.3 97.9 95.2 95.1 
2 3.17 3.35 3.25 3.81 3.83 3.28 3.28 72.0 70.4 71.7 76.2 76.0 72.1 72.1 
3 3.29 4.11 3.46 3.46 3.53 3.58 3.58 73.5 79.8 71.9 71.8 69.4 71.7 71.8 
4 3.24 3.46 3.90 3.32 3.93 3.93 3.93 70.0 68.6 74.8 70.3 74.9 74.9 75.0 
5 
3.25 
3.39 
3.25 
3.48 
3.30 
3.66 
3.22 
3.43 
3.26  
3.76 
3.37 
3.67 
3.37 
3.67 
61.7 61.5 59.3 61.2 59.0 59.6 59.5 
OMe 3.24 3.26 3.25 3.23 3.24   54.6 54.7 54.7 54.7 54.8   
a. Recorded at MHZ (1H) and MHZ (13C);  
 
Conclusion: The similarity in the chemical shifts of the protons and carbons reported for aeruginosin 205B and 
205A with those recorded for 3.26b shows that sulfate unit is not on C-3, but on C-4 of the Xyl subunit. 
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Secondly, compound 3.47 subjected esterification to afford D-Phenyllactic 
acid methyl ester 3.52a, and followed by sulfation to give O-sulfated product 
3.52b. The reagents and conditions are shown in Scheme 40. Both 3.52a and 
3.52b were used as the Pla subunit models. 1H and 13C NMR data are shown in 
Table 10. 
 
 
 
Table 10 1H and 13C NMR data for compounds 3.52a and 3.52b (Pla subunit) 
in DMSO-d6 (400 MHz) 
 3.52a 3.52b 205B 3.52a 3.52b 205B 
 1H 1H 1H 13C 13C 13C 
1 -- -- -- 174.0 171.3 172.4 
2 4.25 4.68 4.19 71.3 74.9 71.9 
3 2.83,2.96 2.95,3.002.78,2.93 40.1 38.3 40.0 
Ph 
7.18-7.23 
7.26-7.29 
7.16-7.22 
7.24-7.28 
7.18,7.23 
7.25 
126.3,128.1
129.4,137.7
126.6,128.2,
129.3, 36.3,
126.0,127.9
129.6,137.9
OMe 3.61 3.50  51.5 51.3  
a. Recorded at MHZ (1H) and MHZ (13C); 
 
Conclusion: The similarity in the chemical shifts of the protons and 
carbons on 3-position of 3.52a and aeruginosin 205B shows that sulfate group 
is not on the D-Pla subunit. 
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3-3-3 Conclusion 
     According to the 1H and 13C NMR data reported[15] for natural 205B and 
synthetic 3.16b, the O-sulfated group must be present on the 4-OH of Xyl 
subunit, but not on the D-Pla subunit or on the 3-OH of the D-Xyl subunit as 
originally proposed by Toyooka[23]. Furthermore, the chlorine atom is not 
situated at C-6 of the Choi subunit as originally proposed. The third revised 
structure and stereochemistry of aeruginosin 205B based on the work 
described in this thesis is shown in the Figure 18. The structure of aeruginosin 
205A is the same as 205B except for the presence of (2R, 3S)-Cleu and L-Plas 
instead of (2S, 3R)-Cleu and D-Plas. The revision should also be valid for 205A. 
 
 
Figure 18. Third revision of aeruginosin 205B. 
 
3-4 Experimental 
General: Solvents were distilled under positive pressure of dry argon before 
use and dried by standard methods. THF, ether, DCM, and toluene were dried 
by the SDS (Solvent Delivery System). All commercially available reagents 
were used without further purification. All reactions were performed under 
argon atmosphere and monitored by thin-layer chromatography. Visualization 
was performed by ultraviolet light and/or by staining with ceric ammonium 
molybdate, ninhydrine or potassium permanganate. IR, Perkin-Elmer FTIR 
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Paragon 1000. Low- and high-resolution mass spectra were recorded using fast 
atom bombardement (FAB) or electrospray techniques. Optical rotations were 
recorded in a 1 dm cell at 20 oC (PerkinElmer 343). Flash column chromate- 
graphy was performed using (40-60 μm) silica gel at increased pressure. NMR 
(1H, 13C) spectra were recorded on Bruker AV-300, AV-400, AV-500 and AV-700 
spectrometers. When necessary, assignments were aided by DEPT, COSY, 
NOESY, and HMBC and HMQC correlation experiments.  
 
 
Compound 3.29: To a solution of 3.28a (500 mg, 1.5 mmol) in dry THF (15 
mL) under argon atmosphere was added dropwise LiBEt3H (1.7 mmol) 1 M in 
THF (1.7 mL) at -78 °C. After stirring at -78 °C for 2 h, the reaction mixture was 
quenched with saturated aqueous NaHCO3 (7.5 mL) carefully, then warmed to 
R.T., and 30% H2O2 aqueous (7.5 mL) was added. After stirring for 30 min., the 
reaction mixture was extracted with EtOAc (4×50 mL), then the organic phases 
were combined, dried over Na2SO4 and concentrated under reduced pressure. 
The crude residue was redissolved in DCM (20 mL), washed with brine (20 mL), 
dried over Na2SO4 and concentrated under reduced pressure. The crude residue 
was redissolved in dry DCM (5 mL) and cooled at 0 °C. To the solution was 
added Ac2O (430 μL, 4.5 mmol), DMAP (15 mg, 0.15 mmol) and Et3N (421 μL, 
3.0 mmol), and warmed to R.T.. After stirring for 4 h, the reaction mixture was 
diluted with DCM (20mL), washed with 0.5 M HCl aqueous (20 mL), dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by 
flash column chromatography (hexane to EtOAc/hexane 1:9) to afford 3.29 
(454 mg, 80%)(two products mixture as 1:1.5), as a colorless oil: 1H NMR, 
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(400 MHz, CDCl3) δ 7.35-7.17 (m, 5H), 6.73 (d, 0.4H, J=4.5 Hz), 6.7 (d, 0.6H, 
J=4.6 Hz), 5.78-5.67 (m, 1H),  5.21-4.95 (m, 4H), 4.30 (dd, 1H, J=10.5 Hz, 
J=18.4 Hz), 3.76 (s, 2H), 3.57 (s, 1H), 2.46-2.39 (m, 1H), 2.28-2.15 (m, 1H), 
2.10-2.01 (m, 4H), 1.83-1.70 (m, 1H), 1.62-1.52 (m, 1H), 1.40-1.31 (m, 1H); 
13C NMR, (100 MHz, CDCl3) δ 172.3, 172.0, 169.9, 153.6, 153.4, 137.6, 136.0, 
128.5, 128.23, 128.19, 128.1, 127.8, 115.5, 83.1, 82.5, 67.6, 67.5, 59.1, 59.1, 
52.4, 52.2, 43.0, 42.4, 33.7, 32.7, 31.7, 27.3, 27.2, 21.11, 21.06; ESI/MS for 
C20H25NO6 calculated (M-OAc+H+) 316, found 316.  
 
 
Compound 3.30: To a solution of 3.29 (319 mg, 0.85 mmol) in dry DCM (5 
mL) under argon atmosphere was added dropwise SnBr4 (223 μL, 1.7 mmol) in 
fresh dry DCM (6 mL) at -78 °C. After stirring for 30 min., the reaction mixture 
was quenched with aqueous 10% Na2CO3 (30 mL), then warmed to R.T., and 
extracted with DCM (3×30 mL). The combined organic phases were dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by 
flash column chromatography (EtOAc/hexane 1:4) to give 3.30 (300 mg, 89%), 
as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ (rotamers) 7.42-7.24 (m, 5H), 
5.21-4.97 (m, 2H), 4.38-4.23 (m, 1H), 4.07-4.00 (m, 0.5H), 3.98-3.70 (m, 
3H), 3.56 (s, 1.5H), 2.85-2.75 (m, 0.5H), 2.70-2.60 (m, 0.5H), 2.40-2.30 (m, 
1H), 2.28-1.92 (m, 4H), 1.90-1.65 (m, 3H); 13C NMR, (100 MHz, CDCl3) δ 
(rotamers) 173.0, 172.8, 154.0, 153.4, 136.3, 136.1, 128.4, 128.3, 128.0, 
127.9, 127.7, 67.1, 67.0, 59.1, 59.0, 57.8, 57.4, 52.3, 52.0, 46.8, 38.9, 38.3, 
35.4, 34.7, 32.2, 31.9, 31.7, 31.1, 25.4, 25.3; [α]D +5.2 (c 1.0, CHCl3);  
ESI/MS for C16H23BrNO4 calculated (M+H+) 396, found 396. 
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Compound 3.31: To a solution of 3.30 (320 mg, 0.8 mmol) in dry toluene (9 
mL) at 40 °C was added Bu4NOAc (3.65 g, 12 mmol). After stirring at 40 °C for 
2.5 h, the reaction mixture was diluted by addition hexane (40 mL) and cooled 
to R.T.. The reaction mixture was washed with H2O (40 mL) and brine (40 mL), 
dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (EtOAc/hexane 3:17) to afford 3.31 
(245 mg, 82%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ  (rotamers) 
7.36-7.28 (m, 5H), 5.23-4.99 (m, 3H), 4.39-4.31 (m, 1H), 4.27-4.21 (m, 
0.5H), 4.17-4.11 (m, 0.5H), 3.77 (s, 1.5H), 3.57 (s, 1.5H), 2.46-2.30 (m, 2H), 
2.25-2.18 (m, 1H), 2.06 (s, 1.5H), 2.05 (s, 1.5H), 2.03-1.88 (m, 2H), 
1.78-1.69 (m, 2H), 1.64-1.54 (m, 2H); 13C NMR, (100 MHz, CDCl3) δ (rotamers) 
173.8, 173.6, 170.5, 170.4, 154.6, 153.9, 136.9, 136.6, 128.6, 128.5, 128.1, 
128.05, 127.98, 127.6, 69.4, 69.2, 67.2, 67.0, 59.4, 59.3, 54.5, 54.1, 52.5, 
52.3, 36.8, 36.5, 35.8, 32.7, 31.7, 31.2, 30.7, 23.8, 21.4; ESI/MS for 
C20H25NO6 calculated (M+H+) 376, found 376.  
 
 
  Compound 3.31a: To a solution of 3.31 (99 mg, 0.25 mmol) in dry MeOH (5 
mL) was added Pd/C 10 w.t.% (20 mg) and the suspension was stirred under H2 
(1 atm) at R.T. for 5 h. The Pd/C catalyst was removed by filtration and the 
filtrate was concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (MeOH/DCM 1:39) to give 3.31a (57 
mg, 95%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 5.03-4.95 (m, 1H), 
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3.79 (dd, 1H, J=5.7 Hz, J=10.3 Hz), 3.72 (s, 3H), 3.66 (s, 1H), 3.31 (dd, 1H, 
J=4.9 Hz, J=9.9 Hz), 2.36 (br, m, 1H), 2.22-2.15 (m, 1H), 2.05-1.89 (m, 5H), 
1.85-1.78 (m, 1H), 1.74-1.56 (m, 4H); 13C NMR, (100 MHz, CDCl3) δ 175.8, 
170.6, 69.7, 58.4, 52.3, 37.2, 35.2, 32.9, 29.3, 24.9, 21.5; ESI/MS for 
C12H19NO4 calculated (M+H+) 242, found 242. 
 
 
Compound 3.32: To a solution of 3.31a (145 mg, 0.6 mmol) in dry DCM (15 
mL) at 0 °C was added NEt3 (167 μL, 1.20 mmol) and Boc2O (196 mg, 0.9 
mmol), then warmed to R.T.. After stirring for 26 h, the reaction mixture was 
diluted with DCM (30 mL) and washed with brine (30 mL). The aqueous phase 
extracted with DCM (2×30 mL). The organic phases were combined, dried over 
Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (EtOAc/hexane 3:17) to afford 3.32 
(180 mg, 88%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 5.07 (br, m, 1H), 
4.24-4.18 (m, 1H), 4.16-4.10 (m, 0.65H), 3.97 (br, m, 0.35H), 3.71 (s, 3H), 
2.36-2.29 (br, m, 2H), 2.18-2.11 (m, 1H), 2.02 (s, 3H), 1.99-1.88 (m, 2H), 
1.73-1.62 (m, 2H), 1.56-1.47 (m, 2H), 1.37 (s, 9H); 13C NMR, (100 MHz, CDCl3) 
δ 174.1, 170.4, 153.3, 80.1, 69.3, 59.5, 53.6, 52.1, 35.8, 32.5, 30.8, 28.4, 
23.8, 21.3, 20.1; [α]D -47.5 (c 1.0, CHCl3); ESI/MS for C17H28NO6 calculated 
(M+H+) 342, found 342. 
 
 
Compound 3.33: A solution of 3.32 (51 mg, 0.15 mmol) in 1.8 mL of MeOH 
was treated with 0.5 M NaOMe (1.1 mmol) in MeOH 2.1 mL. After stirring at R.T. 
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for 6 h, the reaction mixture was diluted with saturated aqueous NH4Cl (1 mL), 
and concentrated under reduced pressure. The residue was redissolved in 
EtOAc (20 mL), filtered and concentration under reduced pressure. The crude 
residue was purified by flash column chromatography (EtOAc/hexane 2:3) to 
afford 3.33 (40 mg, 90%), the solid was recrystallized from DCM, to give a 
colorless crystalline solid, m.p. 153-155 °C: 1H NMR, (400 MHz, CDCl3) δ 
4.20-4.11 (br, m, 3H), 3.72 (s, 3H), 2.32 (br, m, 2.5H), 2.16-2.09 (m, 2.5H), 
1.98-1.38 (m, 12H); 13C NMR, (100 MHz, CDCl3) δ 174.2, 153.4, 80.0, 66.0, 
59.6, 53.7, 52.1, 36.0, 33.8, 32.6, 28.4, 26.5, 19.7; [α]D -31.8 (c 1.0, CHCl3); 
ESI/MS for C15H25NO5 calculated (M+H+) 300, found 300. 
 
 
Methyl D-xylopyranoside 3.B：SOCl2 (0.25 ml, 3.45 mmol) was added 
carefully at 0 °C into dry MeOH, then the reaction mixture was allowed to warm 
up to R.T. slowly. After stirring for 30 min., D-xylose 3.A (1.2 g, 8.0 mmol) was 
added, and the reaction mixture was heated to reflux. After refluxing for 15 h, 
the reaction mixture was cooled to R.T., and neutralized by solid NaHCO3 
carefully. After MeOH was evaporated, the crude residue was purified by flash 
column chromatography (MeOH/DCM 3:17) to afford 3.B (1.28 g, 98%, a 
colorless oil), as a α/β=7:3 mixture: 1H NMR, (400 MHz, MeOH-d4)(α and β 
mixture) δ 4.63 (d, 0.7H, J=3.6 Hz), 4.12 (d, 0.3H, J=7.6 Hz), 3.88 (dd, 0.3H, 
J=5.3 Hz, J=11.4 Hz), 3.59-3.53 (m, 1H), 3.51-3.45 (m, 2H), 3.43-3.30 (m, 
4H), 3.23-3.14 (m, 0.7H); 13C NMR, (100 MHz, MeOH-d4)(α and β mixture) δ 
106.1, 101.5, 77.8, 75.2, 74.9, 73.6, 71.5, 71.2, 67.0, 62.8, 57.4, 55.7; 
Chemical Formula: C6H12O5.  
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Methyl 2,3,4-tri-O-acetyl-D-xylopyranosides 3.C (β) and 3.D (α) : 
Methyl D-xylopyranoside 3.B (0.98 g, 6.0 mmol) was dissolved in dry DCM (50 
mL), and cooled at 0 °C, then Ac2O (2.8 mL, 30.0 mmol), DMAP (73 mg, 0.6 
mmol), and Et3N (5.0 mL, 36 mmol) were added. After stirring at 0 °C for 6 h, 
the reaction mixture was washed with 1 M HCl aqueous (50 mL), dried over 
Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (hexane to EtOAc/hexane 3:17) to 
give the β-isomer 3.C (507 mg, 29%), as a colorless solid, m.p. 100-105 °C, 
and the α-isomer 3.D (1.18 g, 68%), as a colorless solid, m.p. 76-81 °C. 
Methyl 2,3,4-tri-O-acetyl-β-D-xylopyranoside 3.C: 1H NMR, (400VMHz, 
CDCl3) δ 5.05 (t, 1H, J=8.6 Hz), 4.87-4.76 (m, 2H), 4.30 (d, 1H, J=6.9 Hz), 
4.01 (dd, 1H, J=5.1 Hz, J=11.8 Hz), 3.35 (s, 3H), 3.28 (dd, 1H, J=5.1 Hz, 
J=6.7 Hz), 1.94 (s, 3H), 1.93 (s, 3H), 1.92 (s, 3H); 13C NMR, (100 MHz, CDCl3) 
δ 169.9, 169.7, 169.3, 101.5, 71.4, 70.7, 68.8, 61.9, 56.5, 20.6; [α]D -56.3 (c 
1.0, CHCl3); ESI/MS for C12H18O8 calculated (M-OAc+H+) 259, found 259.  
Methyl 2,3,4-tri-O-acetyl-α-D-xylopyranoside 3.D: 1H NMR, (400 MHz, 
CDCl3) δ 5.42 (t, 1H, J=9.7 Hz), 4.92 (ddd, 1H, J=6.0 Hz, J=9.6 Hz, J=10.5 Hz), 
4.83 (d, 1H, J=3.6 Hz), 4.79 (dd, 1H, J=3.6 Hz, J=10.0 Hz), 3.75 (dd, 1H, 
J=6.0 Hz, J=10.9 Hz), 3.54 (t, 1H, J=10.8 Hz), 3.35 (s, 3H), 2.03 (s, 3H), 1.99 
(s, 6H); 13C NMR, (100 MHz, CDCl3) δ 170.3, 170.1, 170.0, 96.9, 71.1, 69.6, 
69.4, 58.2, 55.4, 20.8; [α]D +117.9 (c 1.0, CHCl3); ESI/MS for C12H18O8 
calculated (M-OAc+H+) 259, found 259. 
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Methyl α-D-xylopyranoside 3.26: A solution of methyl 2,3,4-tri-O-acetyl- 
α-D-xylopyranoside 3.D (3.5 g, 12.0 mmol) in dry fresh MeOH (40 mL) was 
treated with small pieces of Na (414 mg, 18.0 mmol) carefully. After stirring at 
R.T. for 1 h, the reaction mixture was diluted with solid NH4Cl, filtered and 
concentrated under reduced pressure. The crude residue was redissolved in 
DCM (40 mL), filtered and concentration under reduced pressure. The residue 
was purified by flash column chromatography (MeOH/DCM 3:17) to afford 3.26 
(1.9 g, 97%), as a colorless solid, m.p. 81-82 °C: 1H NMR, (300 MHz, MeOH-d4) 
δ 5.54 (s, 1H), 5.38 (d, 1H, J=6.2 Hz), 4.62 (d, 1H, J=3.7 Hz), 3.60–3.49 (m, 
2H), 3.49–3.41 (m, 2H), 3.41–3.35 (m, 4H); 13C NMR, (75 MHz, MeOH-d4) δ 
101.5, 75.2, 73.6, 71.5, 62.8, 55.7; [α]D +153.4 (c 1.0, MeOH); Chemical 
Formula: C6H12O5. 
 
 
Compounds 3.27, 3.60+3.61: To a solution of methyl α-D-xylopyranoside 
3.26 (879 mg, 5.35 mmol) in dry BnCl (20 mL) at 0 °C was added NaH (428 mg, 
10.7 mmol) carefully, and then heated to 100 °C. After stirring at 100 °C for 10 
h, the reaction mixture was cooled to R.T., and quenched with AcOH (0.06 mL). 
Then solvent was evaporated at 90 °C to afford yellow oil, which was purified by 
flash column chromatography (EtOAc/hexane 1:4) to give the major product 
3.27 (1.14 g, 62%), as a colorless solid, m.p. 77-78 °C. Then the mixture of 
products 3.60 and 3.61 (221 mg, 12%), as a colorless oil, was obtained by 
flash column chromatography (EtOAc/hexane 1:4). 
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Methyl 2,4-di-O-benzyl-α-D-xylopyranoside 3.27: 1H NMR, (400 MHz, 
CDCl3) δ 7.43-7.29 (m, 10H), 4.79 (dd, 2H, J=5.5 Hz, J=12.1 Hz), 4.69 (t, 2H, 
J=11.7 Hz), 4.60 (d, 1H, J=3.5 Hz), 4.09 (t, 1H, J=8.1 Hz), 3.66-3.63 (m, 1H), 
3.53-3.51 (m, 2H), 3.39 (dd, 1H, J=3.6 Hz, J=9.6 Hz), 3.37 (s, 3H), 3.09 (s, 
1H); 13C NMR, (100 MHz, CDCl3) δ 138.4, 138.2, 128.43, 128.39, 127.98, 
127.87, 127.71, 97.8, 79.4, 77.7, 73.1, 73.0, 72.8, 59.5, 55.1; [α]D +63.0 (c 
1.0, CHCl3); ESI/MS for C20H24O5 calculated (M+H+) 345, found 345.  
 
 
2,4-Di-O-benzyl-α,β-D-xylopyranose 3.34a: To a solution of methyl 
2,4-di-O-benzyl-α-D-xylopyranoside 3.27 (2.15 g, 6.25 mmol) in 1,4-dioxane 
(18 mL) was added 3 M H2SO4 aqueous (18 mL) and AcOH (18 mL), then the 
reaction mixture was heated to 60 °C. After refluxing for 72 h, the reaction 
mixture was cooled to R.T., diluted with H2O (200 mL), and extracted with 
EtOAc (3×200 mL). The organic phases were combined, dried over Na2SO4 and 
concentrated under reduced pressure. The oil was purified by flash column 
chromatography (EtOAc/hexane 3:7) to afford 3.34a (2.04 g, 99%, a colorless 
oil), as a α/β=1:1 mixture: 1H NMR, (400 MHz, CDCl3)(α and β mixture) δ 
7.40-7.29 (m, 10H), 5.18 (d, 0.5H, J=3.6 Hz), 4.97 (d, 0.5H, J=11.5 Hz), 
4.79-4.56 (m, 4H), 4.01 (t, 0.5H, J=9.1 Hz), 3.97 (dd, 0.5H, J=5.2 Hz, J=11.5 
Hz), 3.79-3.66 (m, 1H), 3.57-3.44 (m, 1.5H), 3.41 (dd, 0.5H, J=3.6 Hz, J=9.3 
Hz), 3.27 (dd, 0.5H, J=10.1 Hz, J=11.6 Hz), 3.21 (dd, 0.5H, J=7.5 Hz, J=9.1 
Hz); 13C NMR, (100 MHz, CDCl3)(α and β mixture) δ 138.5, 138.4, 137.9, 
128.82, 128.74, 128.34, 128.30, 128.24, 128.15, 128.13, 128.10, 128.03, 
128.00, 97.9, 91.2, 79.7, 77.7, 74.6, 73.9, 73.4, 73.3,73.03, 72.98, 72.94, 
64.2, 61.7; ESI/MS for C19H22O5 calculated (M+H2O) 348, found 348.  
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1,3-Di-O-acetyl-2,4-di-O-benzyl-α,β-D-xylopyranose 3.34: 2,4-di-O- 
benzyl-α,β-D-xylopyranose 3.34a (1.31 g, 3.95 mmol) was dissolved in dry 
DCM (50 mL), and cooled at 0 °C, then Ac2O (1.12 mL, 11.85 mmol), DMAP (48 
mg, 0.4 mmol), and Et3N (2.2 mL, 15.8 mmol) were added, then warmed to 
R.T.. After stirring for 3 h, the reaction mixture was washed with 1 M HCl 
aqueous (50 mL), dried over Na2SO4 and concentrated under reduced pressure. 
The crude residue was purified by flash column chromatography (hexane to 
EtOAc/ hexane 1:4) to afford 3.34 (1.61 g, 98%, a colorless oil), as a α/β=1:1 
mixture: 1H NMR, (400 MHz, CDCl3)(α and β mixture) δ 7.38-7.32 (m, 10H), 
7.32-7.27 (m, 10H), 6.26 (d, 1H, J=3.6 Hz), 5.63 (d, 1H, J=7.6 Hz), 5.43 (t, 1H, 
J=9.6 Hz), 5.25 (t, 1H, J=8.9 Hz), 4.73-4.50 (m, 8H), 3.99 (dd, 1H, J=5.0 Hz, 
J=11.6 Hz), 3.80 (dd, 1H, J=5.8 Hz, J=11.2 Hz), 3.70 (t, 1H, J=10.9 Hz), 
3.61-3.44 (m, 5H), 2.17 (s, 3H), 2.09 (s, 3H), 2.04 (s, 3H), 1.98 (s, 3H); 13C 
NMR, (100 MHz, CDCl3)(α and β mixture) δ 170.2, 169.9, 169.8, 169.1, 137.99, 
137.97, 137.93, 137.63, 128.66, 128.63, 128.59, 128.16, 128.14, 128.00, 
127.96, 127.92, 127.88, 127.83, 94.7, 89.7, 78.2, 76.1, 75.4, 75.2, 74.5, 74.4, 
73.2, 72.91, 72.88, 64.5, 62.0; ESI/MS for C23H26O7 calculated (M+H2O) 432, 
found 432. 
 
 
3-O-Acetyl-2,4-di-O-benzyl-α,β-D-xylopyranose 3.35: 1,3-di-O-acetyl- 
2,4-di-O-benzyl-α,β-D-xylopyranose 3.34 (2.3 g, 5.55 mmol) was dissolved in 
dry THF (30 mL), and benzylamine (2.42 mL, 22.2 mmol) was added at R.T.. 
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After stirring for 48 h, the reaction mixture was concentrated under reduced 
pressure. The crude residue was redissolved in DCM (30 mL), and washed with 
1 M HCl aqueous (30 mL). The aqueous phase was extracted with DCM (2×30 
mL). The organic phases were combined, dried over Na2SO4 and concentrated 
under reduced pressure. The crude residue was purified by flash column 
chromatography (hexane to EtOAc/hexane 1:3) to give 3.35 (1.72 g, 83%, a 
colorless oil), as a α/β=1:1 mixture: 1H NMR, (400 MHz, CDCl3)(α and β mixture) 
δ 7.38-7.27 (m, 20H), 5.44 (t, 1H, J=8.9 Hz), 5.19 (t, 2H, J=9.3 Hz), 4.88 (d, 
1H, J=11.9 Hz), 4.71 (d, 1H, J=7.5 Hz), 4.68-4.52 (m, 7H), 4.19 (s, 1H), 3.97 
(dd, 1H, J=5.3 Hz, J=11.6 Hz), 3.90 (dd, 1H, J=10.5 Hz, J=10.9 Hz), 3.72 (dd, 
1H, J=5.2 Hz, J=11.4 Hz), 3.61 (s, 1H), 3.60-3.48 (m, 2H), 3.46 (dd, 1H, J=3.4 
Hz, J=9.1 Hz), 3.34-3.25 (m, 2H), 2.04 (s, 3H), 1.97 (s, 3H); 13C NMR, (100 
MHz, CDCl3)(α and β mixture)  δ 170.3, 138.4, 138.1, 138.0, 137.6, 128.7, 
128.58, 128.57, 128.47, 128.2, 128.02, 127.98, 127.8, 98.0, 91.1, 80.2, 77.4, 
75.6, 75.3, 74.9, 74.1, 72.9, 72.8, 72.6, 72.4, 63.9, 60.3, 21.2, 21.1; ESI/MS 
for C21H24O6 calculated (M+H2O) 390, found 390. 
 
 
Compound 3.36: 3-O-acetyl-2,4-di-O-benzyl-α,β-D-xylopyranose 3.35 
(104 mg, 0.28 mmol) was dissolved in dry DCM (10 mL), then CCl3CN (93 μL, 
0.93 mmol) and DBU (13 μL, 0.08 mmol) were added at R.T.. After stirring for 
2.5 h, the solvent was evaporated. The residue was purified by flash column 
chromatography (hexane to EtOAc/hexane 1:4) to give 3.36 (131 mg, 91%, a 
light yellow oil), as a α/β=3.5:1 mixture, which is not stable by keeping and 
used directly after made: 1H NMR, (400 MHz, CDCl3)(α and β mixture) δ 8.74 (s, 
0.3H), 8.61 (s, 1H), 7.39-7.28 (m, 13H), 6.41 (d, 1H, J=3.5 Hz), 5.93 (d, 0.3H, 
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J=6.5 Hz), 5.54 (t, 1H, J=9.6 Hz), 5.29 (t, 0.3H, J=7.9 Hz), 4.86 (d, 0.3H, J= 
11.8 Hz), 4.70-4.55 (m, 4.9H), 4.15 (q, 0.3H, J=7.1 Hz), 4.11-4.07 (m, 0.3H), 
3.86 (d, 1H, J=2.4 Hz), 3.84 (d, 1H, J=5.3 Hz), 3.68-3.58 (m, 2.6H), 2.04 (s, 
3H), 1.98 (s, 0.9H); 13C NMR, (100 MHz, CDCl3)(α and β mixture)  δ 170.0, 
161.6, 160.9, 137.93, 137.88, 137.81, 137.78, 128.7, 128.57, 128.56, 128.15, 
128.12, 128.08, 128.0, 127.95, 127.91, 127.7, 98.4, 93.9, 91.2, 91.0, 77.1, 
76.6, 75.3, 74.5, 74.2, 73.14, 73.11, 72.75, 72.73, 72.66, 64.0, 62.3, 21.2, 
21.1; ESI/MS for C23H24Cl3NO6 calculated (M-O(C=NH)CCl3) 355, found 355.  
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Compounds 3.39a and 3.39b: To a solution of 3.33 (129 mg, 0.4 mmol) 
and 4Å molecular sieves (400 mg, powdered, activated) in DCM (1 mL) was 
added a solution of 3.36 (289 mg, 0.6 mmol) in Et2O (10 mL) under argon 
atmosphere. After stirring at R.T. for 30 min., TfOH (4 μL, 0.04 mmol) was 
added dropwise. After addition was completed, the solution was stirring for 30 
min., then neutralized with solid NaHCO3, filtered and concentrated under 
reduced pressure. The residue was purified by flash column chromatography 
(EtOAc/hexane 3:17) to obtain the β-isomer 3.39a (126 mg, 44%), as a 
colorless oil, and the α-isomer 3.39b (114 mg, 40%), as a colorless oil. 
Compound 3.39a: 1H NMR, (400 MHz, CDCl3) δ (rotamers)  7.35-7.25 (m, 
10H), 5.13 (t, 1H, J=9.3 Hz), 4.83 (d, 1H, J=11.8 Hz), 4.63-4.51 (m, 3H), 4.44 
(br, m, 1H), 4.31-4.21 (br, m, 1.5H), 4.11 (br, m, 1.5H), 4.00-3.87 (br, m, 
1.5H), 3.73 (s, 3H), 3.55-3.48 (br, m, 1H), 3.30-3.23 (m, 2H), 2.53-2.44 (br, m, 
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0.5H), 2.41-2.25 (br, m, 1.5H), 2.19-2.10 (br, m, 1H), 2.08-1.87 (m, 5H), 
1.88-1.76 (br, d, 1H), 1.71-1.60 (br, m, 1H), 1.50-1.36 (br, m, 11H); 13C NMR, 
(100 MHz, CDCl3) δ (rotamers) 174.2, 174.0, 170.1, 154.0, 153.1, 138.33, 
138.26, 138.15, 138.01, 128.5, 128.4, 128.0, 127.97, 127.94, 127.92, 127.7, 
101.5, 101.2, 79.7, 79.4, 79.0, 75.6, 75.5, 74.9, 74.6, 74.2, 72.8, 72.1, 63.8, 
63.7, 59.5, 58.9, 54.1, 53.8, 52.2, 52.0, 36.4, 35.8, 32.6, 32.4, 32.3, 31.8, 
28.5, 28.4, 22.9, 22.7, 21.1, 19.8; [α]D -30.9 (c 1.0, CHCl3); HRMS for 
C36H47NO10 calculated (M+H+) 654.32727, found 654.32596.  
Compound 3.39b: 1H NMR, (400 MHz, CDCl3) δ (rotamers) 7.34-7.27 (m, 
10H), 5.47-5.42 (br, t, 1H), 5.14-5.18 (br, m, 1H), 4.89-4.82 (br, m, 1H), 4.56 
(q, 3H, J=12.0 Hz), 4.28-4.11 (br, m, 2H), 3.99 (br, m, 1H), 3.74 (s, 3H), 3.64 
(d, 2H, J=8.9 Hz), 3.53 (t, 1H, J=8.4 Hz), 3.47 (dd, 1H, J=3.1 Hz, J=9.9 Hz), 
2.58-2.53 (br, m, 0.6H), 2.45-2.40 (br, m, 0.4H), 2.36-2.10 (br, m, 3H), 
2.03-1.92 (br, m, 5H), 1.70-1.67 (br, m, 1H), 1.59-1.41 (br, m, 11H); 13C NMR, 
(100 MHz, CDCl3) δ (rotamers) 174.4, 174.1, 170.2, 154.0, 153.0, 138.5, 
138.1, 128.52, 128.48, 128.44, 128.29, 128.14, 127.94, 127.79, 127.57, 
127.45, 93.9, 93.1, 79.9, 79.5, 76.3, 75.0, 73.15, 73.04, 72.95, 72.89, 72.3, 
72.0, 70.3, 69.3, 60.0, 59.8, 59.5, 59.1, 53.8, 53.5, 52.2, 52.0, 36.4, 35.7, 
32.7, 31.8, 29.8, 29.4, 28.5, 28.4, 25.7, 25.6, 21.2, 21.1, 20.2, 20.1; [α]D 
+21.4 (c 1.0, CHCl3); HRMS for C36H47NO10 calculated (M+H+) 654.32727, 
found 654.32635. 
 
 
Di(S-2-pyridyl) Thiocarbonate (3.37): To a solution of triphosgene (505 
mg, 1.7 mmol) and 2-mercaptopyridine 3.E (1.1 g, 10 mmol) in DCM (50 mL) 
at 0 °C was added dropwise Et3N (1.5 mL, 10.8 mmol). The reaction mixture 
was stirred for 1 h, then warmed to R.T. and stirred for 2 h. The reaction 
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mixture was concentrated, treated with cold saturated aqueous NaHCO3 (50 mL) 
at 0 °C, and extracted with EtOAc (2×50 mL). The organic layer was washed 
with H2O (50 mL) and brine (50 mL), dried over NaSO4, filtered and 
concentrated under reduced pressure to obtain the crude product as a yellow 
solid. The crude residue was purified by flash column chromatography (EtOAc/ 
hexane 3:7) to afford 3.37 (1.04 g, 84%), as a pale yellow needle-shaped 
crystals, m.p. 42-44 °C: 1H NMR (400 MHz, CDCl3) δ 8.57 (ddd, 2H, J=0.8 Hz, 
J=1.9 Hz, J=4.8 Hz), 7.69 (td, 2H, J=1.9 Hz, J=7.9 Hz), 7.63 (dt, 2H, J=1.1 Hz, 
J=7.9 Hz), 7.26 (ddd, 2H, J=1.3 Hz, J=4.8 Hz, J=7.3 Hz); 13C NMR (CDCl3, 100 
MHz) δ 185.6, 150.6, 150.5, 137.5, 130.5, 124.2; ESI/MS for C11H9ON2S2 
calculated (M+H+) 250, found 250. 
 
 
3-O-Acetyl-2,4-di-O-benzyl-α,β-D-xylopyranose 2-Thiopyridyl 
Carbonate 3.38: A mixture of di(S-2-pyridyl) thiocarbonate 3.37 (201 mg, 
0.81 mmol), 3-O-acetyl-2,4-di-O-benzyl-α,β-D-xylopyranose 3.35 (101 mg, 
0.27 mmol), and Et3N (113 μL, 0.81 mmol) in DCM (10 mL) was stirred at R.T. 
for 24 h. Concentration and purification by flash column chromatography 
(EtOAc/hexane 1:3) gave 3.38 (119 mg, 86%, a light yellow oil), as a 
α/β=1:3.2 mixture: 1H NMR, (400 MHz, CDCl3)(α and β mixture) δ 8.63-8.59 
(m, 4H), 8.49-8.48 (m, 1H), 7.76-7.70 (m, 9H), 7.66-7.59 (m, 2H), 7.38-7.27 
(m, 52H), 7.12 (ddd, 1H, J=1.7Hz, J=4.8 Hz, J=6.7 Hz), 6.28 (d, 1H, J=3.5 Hz), 
5.79 (d, 3H, J=6.8 Hz), 5.32 (t, 1H, J=9.6 Hz), 5.24 (t, 3H, J=8.2 Hz), 4.77 (d, 
4H, J= 11.8 Hz), 4.67-4.51 (m, 12H), 4.03 (dd, 3H, J=4.3 Hz, J=11.4 Hz), 3.80 
(dd, 1H, J=5.6 Hz, J=11.2 Hz), 3.67-3.48 (m, 12H), 2.03 (s, 3H), 1.99 (s, 9H); 
13C NMR, (100 MHz, CDCl3)(α and β mixture)  δ 169.93, 169.88, 167.9, 167.6, 
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151.0, 150.33, 150.28, 149.6, 137.8, 137.7, 137.58, 137.54, 137.51, 137.49, 
137.43, 129.9, 129.4, 128.56, 128.53, 128.09, 128.06, 128.01, 127.84, 
127.81, 127.7, 123.87, 123.85, 121.2, 119.7, 97.0, 92.8, 76.8, 75.9, 74.9, 
74.4, 74.2, 73.1, 72.9, 72.8, 72.6, 72.4, 64.0, 62.2, 21.1, 21.0; HRMS for 
C23H24Cl3NO6 calculated (M+H+) 510.1581, found 510.15856.  
 
 
Compounds 3.39a and 3.39b: A mixture of 3-O-acetyl-2,4-di-O-benzyl- 
α,β-D-xylopyranose 2-thiopyridyl carbonate 3.38 (120 mg, 0.24 mmol), 3.33 
(50 mg, 0.17 mmol), 1,1,3,3-tetramethylurea (30 μL, 0.24 mmol) and 4Å 
activated molecular sieves in Et2O (20 mL) and DCM (2 mL) was stirred at R.T. 
for 10 h, and then cooled at 0 °C. Silver triflate (400 mg, 1.53 mmol) was added 
to the reaction mixture, and the stirring was continued 24 h at R.T. in the dark. 
The suspension was treated with a few drops of pyridine, filtered over celite and 
concentrated under reduced pressure. The crude residue was purified by flash 
column chromatography (EtOAc/hexane 2:3) to give 3.39a (58 mg, 53%), as 
a colorless oil, and 3.39b (47 mg, 43%), as a colorless oil. 
 
 
Compound 3.40a: Compound 3.39a (39 mg, 0.06 mmol) was treated 
with >99.9% TFA/DCM (1:9, 3 mL). After stirring at R.T. for 3 h, the reaction 
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mixture was diluted with EtOAc (20 mL) and concentrated under reduced 
pressure. The crude residue was suspended in saturated aqueous Na2CO3 (10 
mL) and extracted with DCM (3×10 mL). The organic phases were combined, 
dried over Na2SO4 and concentrated under reduced pressure. The crude residue 
was purified by flash column chromatography (DCM to MeOH/DCM 1:24) to 
afford 3.40a (32 mg, 95%), as a light yellow oil: 1H NMR, (400 MHz, CDCl3) δ 
7.35-7.26 (m, 10H), 5.13 (t, 1H, J=9.4 Hz), 4.82 (d, 1H, J=11.9 Hz), 4.60-4.48 
(m, 4H), 4.03-3.89 (m, 3H), 3.77 (s, 3H), 3.52 (dt, 1H, J=5.4 Hz, J=9.9 Hz, 
J=9.7 Hz), 3.46 (dd, 1H, J=5.0 Hz, J=10.0 Hz), 3.29-3.24 (m, 2H), 2.30-2.23 
(m, 1H), 2.11-2.03 (m, 3H), 1.97-1.93 (m, 3H), 1.86-1.66 (m, 3H), 1.45-1.31 
(m, 2H); 13C NMR, (100 MHz, CDCl3) δ176.1, 170.2, 138.5, 138.1, 128.61, 
128.47, 128.11. 128.05, 127.88, 127.84, 127.77, 102.4, 79.2, 75.6, 75.1, 
74.4, 74.1, 72.9, 72.4, 63.9, 58.43, 58.38, 52.4, 37.3, 35.4, 34.8, 29.9, 29.4, 
25.0, 21.2; [α]D -9.3 (c 1.0, CHCl3); ESI/MS for C31H39NO8 calculated (M+H+) 
554, found 554.  
 
 
Compound 3.40b: Compound 3.39b (27 mg, 0.042 mmol) was treated 
with >99.9% TFA/DCM (1:9, 3 mL). After stirring at R.T. for 3 h, the mixture 
was diluted with EtOAc (20 mL) and concentrated under reduced pressure. The 
crude residue was suspended in saturated aqueous Na2CO3 (10 mL) and 
extracted with DCM (3×10 mL). The organic phases were combined, dried over 
Na2SO4, and concentrated under reduced pressure. The residue was purified by 
flash column chromatography (DCM to MeOH/DCM 1:24) to give 3.40b (22 mg, 
92%), as a light yellow oil: 1H NMR, (400 MHz, CDCl3) δ 7.38-7.28 (m, 10H), 
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5.42 (t, 1H, J=9.6 Hz), 4.88 (d, 1H, J=3.6 Hz), 4.61-4.52 (m, 4H), 3.93 (dd, 1H, 
J=5.6 Hz, J=10.5 Hz), 3.84-3.76 (m, 4H), 3.70-3.61 (m, 2H), 3.54-3.43 (m, 
2H), 3.40 (dd, 1H, J=3.6 Hz, J=10.0 Hz), 1.79-1.70 (m, 2H), 1.52-1.43 (m, 
1H), 1.36-1.30 (m, 2H); 13C NMR, (100 MHz, CDCl3) δ176.1, 170.2, 138.26, 
138.24, 128.6, 128.0, 127.93, 127.86, 95.2, 77.3, 76.3, 73.2, 73.0, 72.5, 72.4, 
59.9, 58.54, 58.45, 52.4, 37.4, 35.7, 32.6, 31.2, 25.5, 21.3; [α]D +37.2 (c 1.0, 
CHCl3); ESI/MS for C31H39NO8 calculated (M+H+) 554, found 554.  
 
 
Compound 3.41a: To a solution of guanidine hydrochloride 3.41 (960 mg, 
10 mmol) and NaOH (2.0 g, 50 mmol) in H2O (10 mL) was added DCM (20 mL), 
then the reaction mixture was cooled to 0 °C. CbzCl (4.3 mL, 30 mmol) was 
added dropwise with stirring over a period of 45 min.. After addition was 
completed, the reaction mixture was stirring at 0 °C for 20 h, and diluted with 
DCM (10 mL). The layers were separated, and the aqueous layer was extracted 
with DCM (25 mL). The combined organic phases were washed with H2O (2×50 
mL), dried over Na2SO4 and concentrated under reduced pressure. The crude 
residue was recrystallized from MeOH to give 3.41a (2.8 g, 86%), as a 
colorless crystals, m.p. 148-150 °C: 1H NMR, (400 MHz, DMSO-d6) δ 10.88 (br, 
s, 1H), 8.67 (br, s, 2H), 7.40-7.25 (m, 10H), 5.10 (s, 4H); ESI/MS for 
C17H17N3O4 calculated (M+H+) 328, found 328.  
 
 
Compound 3.42: A solution of crystals 3.41a (1.65 g, 5.0 mmol) in 
chlorobenzene (50 mL) was cooled on ice to 0 °C, and treated with NaH (400 mg, 
60 dispersion in mineral oil) under argon atmosphere. After stirring at 0 °C for 
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2 h, the reaction mixture was cooled to -45 °C, and Tf2O (0.82 mL, 5 mmol) was 
added, then allowed to warm up to R.T. and stirred for 10 h. After solvent was 
evaporated, the residue was redissolved in a mixture of EtOAc (100 mL) and 2 
M NaHSO4 aqueous (50 mL), then the phases were separated. The organic 
phase was washed with H2O (50 mL) and brine (50 mL), dried over Na2SO4 and 
concentrated under reduced pressure. The crude residue was purified by flash 
column chromatography (DCM/Et2O 19:1) to afford Goodman’s reagent 3.42 
(1.56 g, 67%), as a pale oil that was crystallized under reduced pressure, m.p. 
73-75 °C: 1H NMR, (400 MHz, CDCl3) δ 10.35 (br, s, 2H), 7.46-7.42 (m, 10H), 
5.29 (s, 4H); ESI/MS for C18H16F3N3O6S calculated (M+H+) 460, found 460.  
 
 
Compound 3.44：A solution of Goodman’s reagent 3.42 (1.17 g, 2.55 mmol) 
in CHCl3 (40 mL) was added dropwise to a vigorously stirred solution of 
1,4-diaminobutane 43 (2.25 g, 25.5 mmol) in CHCl3 (30 mL) at R.T. over 2 h. 
After addition, the reaction mixture was stirred for 30 min.. then diluted with 
CHCl3 (30 mL) and washed with 10% NaHCO3 aqueous (2×100 mL), dried over 
Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (MeOH/CHCl3 1:9) to give 3.44 (0.96 
g, 94%), as a colorless wax: 1H NMR, (400 MHz, CDCl3) δ 8.34 (s, 1H), 
7.40-7.23 (m, 10H), 5.24 (s, 1H), 5.15 (s, 2H), 5.12 (s, 2H), 3.40 (t, 2H, J=6.1 
Hz), 2.67 (t, 2H, J=6.1 Hz), 1.61-1.54 (m, 2H), 1.49-1.42 (m, 2H); 13C NMR, 
(100 MHz, CDCl3) δ 163.6, 155.9, 153.7, 136.7, 134.6, 128.7, 128.6, 128.4, 
128.3, 128.0, 127.8, 68.0, 67.0, 41.4, 40.8, 30.3, 26.2; ESI/MS for C21H26N4O4 
calculated (M+H+) 399, found 399. 
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Compound 3.45: To a solution of 3.44 (300 mg, 0.75 mmol) in dry DCM (15 
mL) at 0 °C was added NEt3 (209 μL, 1.50 mmol) and Boc2O (231 mg, 1.06 
mmol), then warmed to R.T.. After stirring for 10 h, the reaction mixture was 
diluted with DCM (15 mL) and washed with brine (30 mL). The aqueous phase 
was extracted with DCM (3×30 mL). The organic phase was combined, dried 
over Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (EtOAc/hexane 1:4) to afford 3.45 
(344 mg, 92%), as a colorless solid, m.p. 63-65 °C: 1H NMR, (400 MHz, CDCl3) 
δ 11.75 (s, 1H), 8.32 (t, 1H, J=5.2 Hz), 7.39-7.24 (m, 10H), 5.15 (s, 2H), 5.12 
(s, 2H), 4.87 (br, t, 1H), 3.40 (dd, 2H, J=6.7 Hz, J=12.6 Hz), 3.11 (br, dd, 2H), 
1.59-1.53 (m, 2H), 1.52-1.46 (m, 2H), 1.43 (s, 9H); 13C NMR, (100 MHz, CDCl3) 
δ 163.6, 155.95, 155.88, 153.7, 136.7, 134.6, 128.7, 128.6, 128.34, 128.28, 
128.0, 127.8, 78.9, 68.0, 67.0, 40.6, 39.9, 28.3, 27.2, 26.2; ESI/MS for 
C26H34N4O6 calculated (M+H+) 499, found 499.  
 
 
Compound 3.44：A solution of 3.45 (136 mg, 0.27 mmol) was treated with 
4 M HCl in 1,4-dioxane (2 mL) at R.T. for 6 h. Then the reaction mixture was 
diluted with CHCl3 (10 mL) and washed with 10% NaHCO3 aqueous (15 mL) 
carefully, dried over Na2SO4 and concentrated under reduced pressure to obtain 
Cbz-protected agmatine 3.44, as a colorless wax (108 mg, 99%), which was 
sufficiently pure for use in the following step. 
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Compound 3.46a: A solution of 3.39a (85 mg, 0.13 mmol) in THF/H2O (5:3, 
3.2 mL) was treated with LiOH×H2O (16 mg, 0.39 mmol). After stirring at R.T. 
for 24 h, the reaction mixture was cooled on ice to 0 °C and acidified with 5% 
citric acid aqueous to pH=3-4. The organic phase was separated and the 
aqueous phase was extracted with DCM (3×20 mL). The combined organic 
phases were dried over Na2SO4 and concentrated under reduced pressure to 
afford carboxylic acid 3.46a (77 mg, 99%), as a colorless oil, which was 
sufficiently pure for use in the following step. 1H NMR, (400 MHz, CDCl3) δ 
(rotamers) 7.38-7.30 (m, 10H), 4.94 (d, 1H, J=11.4Hz), 4.77 (d, 1H, J=11.9 
Hz), 4.72 (d, 1H, J=11.4 Hz), 4.65 (d, 1H, J=11.8 Hz), 4.41 (d, 1H, J=7.4 Hz), 
4.32 (s, 1H), 4.17 (s, 1H), 4.08 (s, 1H), 3.91 (s, 1H), 3.70 (t, 1H, J=8.9 Hz), 
3.55-3.49 (m, 1H), 3.28-3.19 (m, 2H), 2.38-2.28 (br, m, 1.5H), 2.20-2.13 (br, 
m, 1.5H), 2.08-1.99 (br, m, 1H), 1.79-1.76 (br, dd, 1H), 1.56-1.53 (br, dd, 2H), 
1.46 (br, s, 9H), 1.28 (br, s, 2H); 13C NMR, (100 MHz, CDCl3) δ (major rotamer) 
138.43, 138.36, 128.71, 128.67, 128.09, 128.02, 101.6, 81.3, 77.4, 75.8, 
74.7, 73.3, 73.0, 64.0, 59.3, 54.7, 36.0, 32.6, 29.9, 28.6, 23.4, 20.1; [α]D 
-43.5 (c 1.0, CHCl3); HRMS for C33H43NO9 calculated (M+Na+) 620.283, found 
620.28556. 
 
 
Compound 3.46b: A solution of 3.39b (118 mg, 0.18 mmol) in THF/H2O 
(5:3, 4.8 mL) was treated with LiOH×H2O (23 mg, 0.54 mmol). After stirring at 
R.T. for 24 h, the reaction mixture was cooled on ice to 0 °C and acidified with 
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5% citric acid aqueous to pH=3-4. The organic phase was separated and the 
aqueous phase was extracted with DCM (3×20 mL). The combined organic 
phases were dried over Na2SO4 and concentrated under reduced pressure to 
afford 3.46b (107 mg, 99%). The crude solid was recrystallized from MeCN to 
give as a colorless crystalline solid, m.p. 143-145 °C, which was sufficiently 
pure for use in the following step. 1H NMR, (700 MHz, CDCl3, 50 °C) δ (rotamers) 
7.37-7.35 (m, 7.5H), 7.32-7.28 (m, 2.5H), 5.03 (s, 1H), 4.84 (s, 1H), 4.80 (d, 
1H, J=11.7 Hz), 4.68 (dd, 3H, J=6.5 Hz, J=11.8 Hz), 4.30 (s, 1H), 4.16 (s, 1H), 
4.07 (t, 1H, J=9.0 Hz), 3.93 (s, 1H), 3.63 (dd, 1H, J=5.1 Hz, J=10.3 Hz), 
3.56-3.49 (m, 2H), 3.40(dd, 1H, J=3.5 Hz, J=9.6 Hz), 2.37-2.31 (m, 1H), 
2.19-2.13 (m, 2H), 1.72-1.67 (m, 1H), 1.65-1.59 (m, 2H), 1.57-1.48 (m, 1H), 
1.44 (s, 9H), 1.35-1.30 (m, 2H); 13C NMR, (175 MHz, CDCl3, 50 °C) δ (major 
rotamer) 138.6, 138.4, 130.3, 129.9, 128.7, 128.1, 94.3, 79.8, 78.0, 73.6, 
73.1, 72.7, 70.8, 60.3, 59.5, 54.5, 36.1, 32.1, 29.99, 29.92, 29.91, 29.73, 
29.55, 29.51, 29.43, 29.39, 29.33, 28.6, 27.5, 27.4, 25.9, 25.7, 22.9, 20.5, 
14.3; [α]D +15.5 (c 1.0, CHCl3); HRME for C33H43NO9 calculated (M+NH4+) 
615.32761, found 615.32741. 
 
 
Compound 3.47a: To a solution of 3.46a (60 mg, 0.1 mmol) in DCM (2 mL) 
at 0 °C was added PyBOP (78 mg, 0.15 mmol) with stirring for 10 min., and then 
a solution of Cbz-protected agmatine 3.44 (60 mg, 0.15 mmol) in DCM (3 mL) 
and 2,6-lutidine (58 μL, 0.5 mmol) were added, then allowed to warm to R.T. 
slowly. After stirring for 10 h, the reaction mixture was diluted with DCM (20 
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mL), washed with 0.5 M HCl aqueous (15 mL) quickly, saturated aqueous 
NaHCO3 (25 mL) and brine (25 mL), dried over Na2SO4 and concentrated under 
reduced pressure. The crude residue was purified by flash column 
chromatography (DCM/EtOAc/hexane 1:8:11 to DCM/EtOAc/hexane 1:12:7) 
to afford 3.47a (82 mg, 84%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 
(major rotamer) 11.76 (br, s, 1H), 8.34 (t, 1H, J=5.1 Hz), 7.42-7.28 (m, 20H), 
5.17 (d, 4H, J=17.2 Hz), 4.95(d, 1H, J=11.4 Hz), 4.74 (dd, 2H, J=11.7 Hz, 
J=17.4 Hz), 4.63 (d, 1H, J=11.9 Hz), 4.41 (d, 1H, J=7.4 Hz), 4.20 (t, 1H, J=8.0 
Hz), 4.08 (br, s, 1H), 3.91 (dd, 1H, J=5.1 Hz, J=11.6 Hz), 3.69 (t, 1H, J=8.9 
Hz), 3.53-3.43 (m, 3H), 3.33-3.19 (m, 4H), 2.61 (br, s, 1H), 2.26-2.15 (br, m, 
3H), 2.08-1.96 (br, m, 3H), 1.76-1.72 (br, d, 1H), 1.66-1.49 (br, m, 5H), 1.43 
(br, s, 9H); 13C NMR, (100 MHz, CDCl3) δ (major rotamer) 172.7, 163.8, 156.2, 
155.4, 154.0, 138.5, 138.4, 136.9, 134.8, 128.9, 128.8, 128.7, 128.64, 
128.61, 128.55, 128.3, 128.07, 128.04, 127.98, 101.3, 81.3, 80.3, 77.3, 75.8, 
74.6, 73.2, 72.9, 68.3, 67.3, 64.0, 60.4, 55.2, 40.8, 39.1, 36.0, 33.0, 29.9, 
28.6, 27.0, 26.5, 23.3, 20.3; [α]D -27.8 (c 1.0, CHCl3); HRMS for C54H67N5O12 
calculated (M+H+) 978.4859, found 978.48615. 
 
 
Compound 3.47b: To a solution of 3.46b (107 mg, 0.18 mmol) in DCM (6 
mL) at 0 °C, was added PyBOP (141 mg, 0.27 mmol) with stirring for 10 min., 
and then a solution of Cbz-protected agmatine 3.44 (108 mg, 0.27 mmol) in 
DCM (8 mL) and 2,6-lutidine (105 μL, 0.9 mmol) were added, then allowed to 
warm to R.T. slowly. After stirring for 10 h, the reaction mixture was diluted 
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with DCM (20 mL), washed with 0.5 M HCl aqueous (15 mL) quickly, saturated 
aqueous NaHCO3 (25 mL) and brine (25 mL), dried over Na2SO4 and 
concentrated under reduced pressure. The crude residue was purified by flash 
column chromatography (EtOAc/DCM 1:4 to EtOAc/DCM 2:3) to afford 3.47b 
(148 mg, 84%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ (major rotamer) 
11.77 (br, s, 1H), 8.36 (t, 1H, J=5.2 Hz), 7.45-7.28 (m, 20H), 5.16 (d, 4H, 
J=13.5 Hz), 5.03 (d, 1H, J=3.4 Hz), 4.84 (d, 0.8H, J=11.6 Hz), 4.79 (d, 1.2H, 
J=11.7 Hz), 4.66 (dd, 2H, J=6.6 Hz, J=11.7 Hz), 4.20-4.14 (br, m, 2H), 4.07 (t, 
1H, J=8.8 Hz), 3.92 (br, s, 1H), 3.64-3.60 (br, m, 1H), 3.57-3.43 (m, 4H), 3.39 
(dd, 1H, J=3.4 Hz, J=9.6 Hz), 3.36-3.19 (m, 2H), 2.34-2.20 (br, m, 2H), 
2.15-2.01 (br, m, 2H), 1.66-1.50 (br, d, 9H), 1.40 (br, s, 9H); 13C NMR, (100 
MHz, CDCl3) δ (major rotamer) 172.8, 163.8, 156.1, 154.8, 153.9, 138.4, 
138.2, 136.8, 134.7, 128.9, 128.8, 128.57, 128.56, 128.52, 128.50, 128.2, 
128.08, 128.03, 128.00, 127.95, 127.91, 93.9, 80.2, 79.4, 77.7, 73.4, 72.8, 
72.3, 70.7, 68.2, 67.2, 60.9, 60.0, 54.8, 40.7, 39.1, 36.0, 30.2, 29.8, 28.5, 
26.9, 26.5, 25.8, 20.5; [α]D +10.9 (c 1.0, CHCl3); HRMS for C54H67N5O12 
calculated (M+H+) 978.4859, found 978.48704.    
 
 
Compound 3.50: A solution of 3.48 (460 mg, 2 mmol) in 40 mL of DCM was 
cooled to 0 oC and treated with Et3N (0.7 mL, 5 mmol), followed by dropwise 
addition of tert-butylsulfinyl chloride 3.49 (0.3 mL, 2.4 mmol) in 2.4 mL of DCM. 
The reaction mixture was stirred at 0 oC until TLC showed consumption of the 
starting material (1 h). Upon completion, 40 mL of saturated aqueous NaHCO3 
was added, and the layers separated (note: acidic washes should be avoided as 
tert-butylsulfinamides are known to be unstable at low pH). The aqueous layer 
was extracted with DCM (3×50 mL). The organic layer was combined, dried 
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over Na2SO4 and concentrated under reduced pressure. Flash column 
chromatography (EtOAc/hexane 1:9) gave pure sulfinamide, which was taken 
up directly in 30 mL of DCM, and treated with m-CPBA (466 mg, 2.7 mmol). 
After oxidation was complete by TLC (2 h), the reaction mixture was diluted 
with a mixture of saturated aqueous NaHCO3 (25 mL) and saturated aqueous 
Na2SO3 (25 mL). The aqueous layer was extracted with DCM (3×50 mL). The 
organic extract was combined, dried over Na2SO4 and concentration under 
reduced pressure. The crude residue was purified by flash column 
chromatography (EtOAc/hexane 1:19) to afford 3.50 (594 mg, 85% over 2 
steps), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 4.04 (m, 1H), 3.72 (dd, 
1H, J=7.1 Hz, J=10.9 Hz), 2.75 (m, 1H), 2.53 (m, 1H), 1.94-1.87 (m, 1H), 1.44 
(s, 9H), 1.16 (d, 3H, J=6.6 Hz), 0.96 (d, 3H, J=6.8 Hz), 0.88 (s, 9H), 0.08 (s, 
6H); 13C NMR, (100 MHz, CDCl3) δ 61.8, 59.8, 52.0, 46.6, 31.3, 28.3, 25.6, 
24.0, 23.5, 20.4, 18.0; [α]D +31.5 (c 1.0, CHCl3); ESI/MS for C16H35NO3SSi 
calculated (M+H+) 350, found 350.  
 
 
Compounds 3.50a and 3.51：A solution of 50 (700 mg, 2.0 mmol) in 30 mL 
MeCN was heated to reflux and treated with CeCl3.7H2O (3.35 g, 6.0 mmol) in 
portions over 36 h (best results were obtained, when 1 equiv. was added every 
12 h). The reaction mixture was then refluxed for an additional 36 h, cooled to 
R.T. and filtered over Celite pad with EtOAc rinsing. After concentration of the 
filtrate under reduced pressure, the crude residue could be readily crystallized 
from DCM/hexane to give pure by-product 3.50a. Alternatively, the crude 
material was purified by flash column chromatography (EtOAc/hexane 3:7) to 
afford 3.51 as a white solid (428 mg, 79%).  
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Compound 3.50a：1H NMR, (300 MHz, CDCl3) δ 4.10 (br, dd, 1H), 3.85 (dd, 
1H, J=6.7 Hz, J=10.1 Hz), 3.23 (s, 1H), 2.90-2.86 (m, 1H), 2.81-2.79 (t, 1H, 
J=3.8 Hz), 1.88-1.80 (m, 1H), 1.50 (s, 9H), 1.03 (d, 3H, J=5.1 Hz), 0.91 (d, 3H, 
J=5.2 Hz); 13C NMR, (75 MHz, CDCl3) δ 63.1, 61.8, 49.7, 49.0, 28.7, 24.3, 19.7, 
18.1, 12.5; [α]D -3.7 (c 1.0, CHCl3); ESI/MS for C10H21NO3S calculated (M+H+) 
236, found 236. 
Compound 3.51：1H NMR, (400 MHz, CDCl3) δ 4.48 (d, 1H, J=10.0 Hz), 
4.00- 3.76 (m, 4H), 2.14 (sept, 1H, J= 6.8 Hz), 2.01 (br, s, 1H), 1.42 (s, 9H), 
1.07 (2d, 6H, J= 6.4 Hz, J= 6.4 Hz); 13C NMR, (100MHz, CDCl3) δ 71.7, 61.8, 
60.7, 60.6, 60.5, 60.0, 57.4, 31.3, 29.7, 24.3, 24.1, 20.2, 19.0 ; [α]D -4.6 (c 
1.0, CHCl3); ESI/MS for C10H22ClNO3S calculated (M+H+) 272, found 272. 
 
 
Compound 3.51a:  A solution of 3.51 (49 mg, 0.18 mmol) in MeCN (1 mL) 
was cooled to 0 °C and a solution of 1 mg CrO3 dissolved in 1.1 mL of 0.4 M 
H5IO6 in wet MeCN (MeCN/H2O 99.3:0.7) was added. After stirring for 1 h, the 
reaction mixture was quenched with 1.2 mL saturated aqueous NaHCO3. The 
solvent was evaporated, and the aqueous mixture was treated with 400 μL 0.5 
M NaOH aqueous, and washed with Et2O (5 mL). The aqueous layer was 
acidified with 1 M HCl aqueous (5 mL) and extracted with DCM (3×10 mL). The 
combined organic phases were dried over Na2SO4 and concentrated under 
reduced pressure. The residue was purified by flash column chromatography 
(CHCl3/MeOH 10:1) to afford carboxylic acid 3.51a, as a colorless oil (30 mg, 
57%). 1H NMR, (400 MHz, MeOH-d4) δ 3.02 (d, 1H, J=4.1 Hz), 2.74 (dd, 1H, 
J=3.0 Hz, J=7.6 Hz), 2.02 (td, 1H, J=6.5 Hz, J=13.5 Hz), 1.45 (s, 9H), 1.21 (d, 
3H, J=6.5 Hz), 1.04 (d, 3H, J=6.7 Hz); 13C NMR, (100 MHz, MeOH-d4) δ 174.4, 
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61.9, 55.2, 47.4, 29.8, 24.5, 21.7, 21.0; [α]D +42.3 (c 1.0, MeOH). HRMS for 
C10H20ClNO4S calculated (M-H)- 284.07288, found 284.07270. 
 
 
Compounds 3.53 and 3.53a： A solution of D-(+)-3-phenyllactic acid 3.52 
(400 mg, 2.4 mmol) in THF (25 mL) was cooled on ice under argon atmosphere 
to 0°C, and treated with NaH (240 mg, 60 dispersion in mineral oil), then 
allowed to warm up to R.T.. After stirring for 2 h, BnBr (0.43 mL, 3.6 mmol) and 
Bu4NI (369 mg, 1.0 mmol) were added, then stirring was continued for 10 h. 
The reaction mixture was quenched by H2O (2 mL) carefully and concentrated 
under reduced pressure. Then the residue was redissolved in a mixture of DCM 
(35 mL) and H2O (25 mL). The phases were separated and the organic phase 
was washed with H2O (25 mL) and brine (25 mL). The organic phase was dried 
over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (hexane to EtOAc/hexane 1:19) to 
give 3.53a (271 mg, 33%), as a colorless oil. The aqueous layer was acidified 
carefully by concentrated aqueous HCl to pH=1 and then extracted with DCM 
(3×50 mL). The organic phases were combined, dried over Na2SO4 and 
concentration under reduced pressure. The residue was purified by flash 
column chromatography (MeOH/DCM 1:19) to afford carboxylic acid 3.53 (379 
mg, 62%), as a colorless solid, m.p. 47-49 °C. 
Compound 3.53：1H NMR, (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.37-7.28 (m, 
8H), 7.22-7.20 (m, 2H), 4.74 (d, 1H, J=11.8 Hz), 4.46(d, 1H, J=11.8 Hz), 4.24 
(dd, 1H, J=4.1 Hz, J=8.5 Hz), 3.22 (dd, 1H, J=4.0 Hz, J=14.0 Hz), 3.11 (dd, 1H, 
J=8.6 Hz, J=14.0 Hz); 13C NMR, (100 MHz, CDCl3) δ 177.3, 137.0, 136.9, 129.7, 
128.5, 128.1, 127.0, 78.8, 72.9, 39.2; [α]D +59.0 (c 1.0, CHCl3); ESI/MS for 
C16H16O3 calculated (M+H2O) 274, found 274.  
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Compound 3.53a: 1H NMR, (400 MHz, CDCl3) δ 7.45-7.40 (m, 3H), 
7.39-7.35 (m, 2H), 7.34-7.30 (m, 6H), 7.29-7.26 (m, 2H), 7.24-7.21 (m, 2H), 
5.19 (s, 2H), 4.74 (d, 1H, J=11.8 Hz), 4.45 (d, 1H, J=11.8 Hz), 4.26 (dd, 1H, 
J=5.4 Hz, J=8.0 Hz), 3.21-3.11 (m, 2H),; 13C NMR, (100 MHz, CDCl3) δ 172.1, 
137.4, 127.0, 135.6, 129.6, 128.7, 128.5, 128.43, 128.42, 128.0, 127.9, 
126.8, 79.4, 72.6, 66.8, 39.4; [α]D +43.7 (c 1.0, CHCl3); ESI/MS for C23H22O3 
calculated (M+H2O) 364, found 364.  
 
 
Compound 3.53: To a solution of 3.53a (118 mg, 0.34 mmol) in THF (3.5 
mL) and H2O (1.5 mL) was added LiOH×H2O (43 mg, 1.0 mmol) at R.T., and 
then stirred for 4 h (TLC monitoring, EtOAc/hexanes 1:9). After solvent was 
evaporated, 15 mL H2O was added and extracted with DCM (20 mL), then 
acidified dropwise with concentrated HCl aqueous to pH=1. The aqueous layer 
was extracted with DCM (3×20 mL). The organic phases were combined, dried 
over Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (MeOH/DCM 1:19) to give 3.53 (75 
mg, 86%), as a colorless solid, m.p. 47-49 °C. 
 
 
Compound 3.54: A solution of 3.51 (340 mg, 1.25 mmol) in DCM (63 mL) 
was cooled to 0 °C and treated with anisole (2.7 mL, 25 mmol) and TfOH (0.56 
mL, 6.25 mmol). The solution was stirred at R.T. for 12 h, after which the 
volatiles were removed under reduced pressure. The residue was taken up in 
water (15 mL), washed with Et2O (2×15 mL), frozen and lyophilized to afford 
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triflate salt of amine, which was used directly. A solution of crude amine salt in 
DCM (10 mL) was cooled to 0 °C. 2,6-Lutidine (0.73 ml, 6.25 mmol), carboxylic 
acid 53 (352 mg, 1.38 mmol), and DEPBT (598 mg, 2.0 mmol) were added, 
then allowed to warm up to R.T. slowly. After stirring for 27 h, the reaction 
mixture was diluted with DCM (30 mL), washed with 0.5 M HCl aqueous (30 mL), 
saturated aqueous NaHCO3 (30 mL) and brine (30 mL), dried over Na2SO4 and 
concentrated under reduced pressure. The crude residue was purified by flash 
column chromatography (EtOAc/Hexane/DCM 4:15:1) to afford 3.54 (422 mg, 
87% over 2 steps), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 7.38-7.27 (m, 
10H), 7.14 (d, 1H, J=9.5 Hz), 4.54 (dd, 2H, J=11.6 Hz, J=28.3 Hz), 4.26-4.20 
(m, 1H), 4.17 (dd, 1H, J=3.6 Hz, J=7.0 Hz), 3.98 (dd, 1H, J=4.5 Hz, J=11.3 
Hz), 3.78-3.72 (m, 2H), 3.23 (dd, 1H, J=3.6 Hz, J=14.1 Hz), 3.01 (dd, 1H, 
J=7.1 Hz, J=14.1 Hz), 1.76-1.68 (m, 1H), 0.99 (dd, 6H, J=3.6 Hz, J=6.6 Hz); 
13C NMR, (100 MHz, CDCl3) δ 171.9, 137.0, 136.9, 129.9, 128.6, 128.25, 
128.17, 128.13, 126.7, 80.6, 73.0, 68.5, 62.2, 52.6, 38.6, 30.2, 20.8, 17.1; 
[α]D +60.3 (c 1.0, CHCl3); HRMS for C22H28ClNO3 calculated (M+H+) 390.18305, 
found 390.18235.  
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Compound 3.55: A solution of 3.54 (300 mg, 0.77 mmol) in MeCN (5 mL) 
was cooled to 0 °C and a solution of 8 mg CrO3, which was dissolved in 4.6 mL 
of 0.4 M H5IO6 in wet MeCN (MeCN/H2O 99.3:0.7), was added. After stirring at 
0 °C for 45 min., the reaction mixture was quenched by adding 5mL saturated 
aqueous NaHCO3. After MeCN was evaporated, the aqueous mixture was 
treated with 2 mL 0.5 M NaOH aqueous and washed with Et2O (15 mL). The 
aqueous layer was acidified with concentrated HCl aqueous carefully at 0 °C, 
173 
 
and extracted with DCM (3×30 mL). The organic phases were combined, dried 
over Na2SO4 and concentrated under reduced pressure to give 3.55 (271 mg, 
87%), as a colorless oil, which was sufficiently pure for use in the following step, 
and was purified by RP-LC-MS (C4 column, 25 min., gradient of 73-80% CH3CN 
in 0.1% aqueous FA) to afford pure 3.55 (217 mg, 70%): 1H NMR, (400 MHz, 
CDCl3) δ 11.03 (s, 1H), 7.48 (d, 1H, J=9.0 Hz), 7.33-7.27 (m, 8H), 7.25-7.22 
(m, 2H), 5.07 (dd, 1H, J=4.3 Hz, J=9.0 Hz), 4.60 (d, 1H, J=11.4 Hz), 4.45 (d, 
1H, J=11.4 Hz), 4.22 (dd, 1H, J=3.4 Hz, J=7.4 Hz), 3.51 (dd, 1H, J=4.4 Hz, 
J=8.4 Hz), 3.21 (dd, 1H, J=3.4 Hz, J=14.1 Hz), 2.99 (dd, 1H, J=7.4 Hz, J=14.1 
Hz), 2.16-2.04 (m, 1H), 1.12 (d, 3H, J=6.6 Hz), 1.06 (d, 3H, J=6.5 Hz); 13C 
NMR, (100 MHz, CDCl3) δ 172.7, 172.4, 136.9, 136.8, 130.0, 128.7, 128.5, 
128.4, 128.3, 127.0, 80.4, 73.3, 69.6, 54.3, 39.0, 31.9, 20.4, 20.0; [α]D +37.7 
(c 1.0, CHCl3); HRMS for C22H26ClNO4 calculated (M+H+) 404.16231, found 
404.16164. 
 
 
Compound 3.56a: Compound 3.47a (103 mg, 0.11 mmol) was treated 
with >99.9% TFA/DCM (1:9, 3 mL) at R.T.. After stirring for 2 h, the reaction 
mixture was diluted with EtOAc (20 mL) and concentrated under reduced 
pressure. The crude residue was suspended in saturated aqueous Na2CO3 (20 
mL) and extracted with DCM (3×30 mL). The organic phases were combined, 
dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (DCM to MeOH/DCM 1:49 to MeOH/ 
DCM 1:19) to give 3.56a (89 mg, 96%), as a colorless oil: 1H NMR, (400 MHz, 
CDCl3) δ 11.77 (s, 1H), 8.35 (t, 1H, J=5.2 Hz), 7.65 (t, 1H, J=6.0 Hz), 
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7.42-7.28 (m, 20H), 5.16 (d, 4H, J=14.6 Hz), 4.95(d, 1H, J=11.4 Hz), 4.77 (d, 
1H, J=11.9 Hz), 4.69 (d, 1H, J=11.4 Hz), 4.64 (d, 1H, J=11.9 Hz), 4.49 (d, 1H, 
J=7.5 Hz), 4.02-3.97 (m, 1H), 3.93 (dd, 1H, J=5.1 Hz, J=11.6 Hz), 3.71 (t, 1H, 
J=5.6 Hz), 3.67 (d, 1H, J=8.9 Hz), 3.55-3.43 (m, 4H), 3.32-3.22 (m, 4H), 
2.37-2.26 (m, 1H), 1.98-1.88 (br, m, 3H), 1.77-1.67 (m, 3H), 1.64-1.53 (br, m, 
4H), 1.42-1.26 (m, 2H); 13C NMR, (100 MHz, CDCl3) δ 175.7, 163.8, 156.1, 
154.0, 138.5, 138.3, 136.8, 134.7, 128.9, 128.8, 128.58, 128.57, 128.53, 
128.50, 128.2, 128.07, 128.02, 127.96, 127.93, 101.8, 81.2, 77.2, 75.7, 74.5, 
74.2, 73.2, 68.3, 67.2, 63.9, 58.8, 57.7, 40.8, 38.5, 37.1, 35.9, 35.2, 29.4, 
27.2, 26.5, 25.6; [α]D -12.9 (c 1.0, CHCl3); HRMS for C49H59N5O10 calculated 
(M+H+) 878.43347, found 878.43666.  
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  Compound 3.56b: Compound 3.47b (104 mg, 0.11 mmol) was treated 
with >99.9% TFA/DCM (1:9, 3 mL) at R.T.. After stirring for 2 h, the reaction 
mixture was diluted with EtOAc (20 mL) and concentrated under reduced 
pressure. The crude residue was suspended in saturated aqueous Na2CO3 (20 
mL) and extracted with DCM (3×30 mL). The organic phases were combined, 
dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (DCM to MeOH/DCM 1:49 to MeOH/ 
DCM 1:19) to give 3.56b (84 mg, 91%), as a colorless oil: 1H NMR, (400 MHz, 
CDCl3) δ 11.77 (s, 1H), 8.35 (t, 1H, J=5.2 Hz), 7.66 (t, 1H, J=5.5 Hz), 
7.41-7.28 (m, 20H), 5.15 (d, 4H, J=10.4 Hz), 4.89 (d, 1H, J=3.4 Hz), 4.77 (d, 
1H, J=11.8 Hz), 4.70 (d, 2H, J=5.3 Hz), 4.66 (d, 1H, J=11.8 Hz), 4.04 (t, 1H, 
J=9.2 Hz), 3.82-3.76 (br, m, 1H), 3.72 (dd, 1H, J=4.1 Hz, J=11.0 Hz), 3.61 (d, 
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2H, J=8.2 Hz), 3.51-3.43 (m, 4H), 3.35 (dd, 1H, J=3.4 Hz, J=9.6 Hz), 
3.32-3.26 (m, 2H), 2.61 (s, 1H), 2.35-2.28 (m, 1H), 1.99-1.90 (br, m, 1H), 
1.87-1.68 (br, m, 3H), 1.67-1.52 (br, m, 5H), 1.48-1.39 (br, m, 1H), 1.35-1.25 
(br, m, 1H); 13C NMR, (100 MHz, CDCl3) δ 175.5, 163.8, 156.1, 154.0, 138.4, 
138.3, 136.8, 134.7, 128.9, 128.8, 128.64, 128.60, 128.55, 128.53, 128.3, 
128.10, 128.06, 127.97, 127.95, 95.1, 79.6, 77.8, 73.3, 72.9, 72.8, 68.3, 67.2, 
60.0, 58.9, 57.7, 40.8, 38.5, 37.1, 35.2, 34.0, 30.9, 29.8, 27.1, 26.6, 25.8; 
[α]D +26.1 (c 1.0, CHCl3); HRMS for C49H59N5O10 calculated (M+H+) 878.43347, 
found 878.43746. 
 
 
Compound 3.57a: To a solution of 3.55 (11 mg, 0.026 mmol) and 3.56a 
(21 mg, 0.024 mmol) in DCM (2 mL) at 0 °C were added fresh recrystallized 
DEPBT (11 mg, 0.036 mmol) and 2,6-lutidine (8 μL, 0.072 mmol). After 
addition, the reaction mixture was allowed to warm to R.T. slowly, and stirred 
for 20 h, then cooled to 0 °C. To the mixture, 3.55 (6 mg, 0.013 mmol) in DCM 
(0.3 mL), fresh recrystallized DEPBT (11 mg, 0.036 mmol) and 2,6-lutidine (8 
μL, 0.072 mmol) were added at 0 °C. After addition, the reaction mixture was 
allowed to warm to R.T. slowly, and stirred for 24 h, then diluted with DCM (10 
mL), washed with 0.5 M HCl aqueous (15 mL) and brine (15 mL), dried over 
Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (EtOAc/DCM 7:13) to give crude 
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product, which was purified by RP-LC-MS (C4 column, 26 min., isocratic of 80% 
CH3CN in 0.1% aqueous FA) to afford pure 3.57a (21 mg, 69%), as a colorless 
oil. 1H NMR, (400 MHz, CDCl3) δ 11.73 (s, 1H), 8.30 (t, 1H, J=5.2Hz), 7.41-7.22 
(m, 30H), 7.12 (d, 1H, J=9.3 Hz), 6.83 (t, 1H, J=5.6 Hz), 5.15 (d, 4H, J=14.2 
Hz), 4.99 (dd, 2H, J=10.8 Hz, J=20.8 Hz), 4.77-4.69 (m, 3H), 4.54-4.47 (m, 
3H), 4.44-4.36 (m, 2H), 4.20 (dd, 1H, J=5.0 Hz, J=11.7 Hz), 4.11-4.08 (m, 
2H), 3.86 (d, 1H, J=10.4 Hz), 3.71 (t, 1H, J=9.0Hz), 3.49 (dt, 1H, J=5.1 Hz, 
J=9.4 Hz, J=9.1 Hz), 3.39-3.21 (m, 4H), 3.16 (dd, 1H, J=3.7 Hz, J=14.4 Hz), 
3.06 (dt, 1H, J=6.1 Hz, J=12.5 Hz, J=12.2 Hz), 2.96 (dd, 1H, J=6.9 Hz, J=14.1 
Hz), 2.54-2.46 (br, m, 2H), 2.35 (t, 2H, J=6.6Hz), 2.14-2.00 (m, 2H), 
1.79-1.68 (m, 2H), 1.60-1.39 (m, 7H), 1.31 (d, 1H, J=21.0 Hz), 0.89 (d, 6H, 
J=6.5 Hz); 13C NMR, (100 MHz, CDCl3) δ 171.3, 170.9, 169.8, 164.0, 156.2, 
154.0, 138.6, 138.5, 137.07, 137.00, 136.98, 134.8, 130.0, 129.0, 128.9, 
128.73, 128.72, 128.69, 128.64, 128.62, 128.35, 128.31, 128.29, 128.24, 
128.13, 128.06, 128.04, 128.00, 126.9, 102.7, 82.0, 80.6, 76.0, 74.9, 74.2, 
73.03, 72.99, 68.5, 68.3, 67.3, 63.8, 60.2, 55.9, 52.4, 40.7, 39.2, 38.6, 36.1, 
32.2, 29.8, 28.5, 26.6, 26.5, 24.0, 21.0, 20.0, 15.2; [α]D +1.5 (c 1.0, CHCl3); 
HRMS for C71H83ClN6O13 calculated (M+H+) 1263.57794, found 1263.57212.  
 
 
Compound 3.57b: To a solution of 3.55 (10 mg, 0.024 mmol) and 3.56b 
(20 mg, 0.022 mmol) in DCM (2 mL) at 0 °C were added fresh recrystallized 
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DEPBT (10 mg, 0.033 mmol) and 2,6-lutidine (8 μL, 0.066 mmol). After 
addition, the solution was allowed to warm to R.T. slowly, and stirred for 20 h, 
then cooled to 0 °C, and then 3.55 (4 mg, 0.011 mmol) in DCM (0.3 mL), fresh 
recrystallized DEPBT (10 mg, 0.033 mmol), and 2,6-lutidine (5 μL, 0.044 mmol) 
were added. After addition, the mixture was allowed to warm to R.T. slowly, and 
stirred for 24 h, then cooled to 0 °C, and then 3.55 (4 mg, 0.011 mmol) in DCM 
(0.3 mL), fresh recrystallized DEPBT (10 mg, 0.033 mmol) and 2,6-lutidine (5.2 
μL, 0.044 mmol) were added at 0 °C. After addition, the reaction mixture was 
allowed to warm to R.T. slowly, and stirred for 24 h, then diluted with DCM (10 
mL), washed with 0.5 M HCl aqueous (15 mL) and brine (15 mL), dried over 
Na2SO4 and concentrated under reduced pressure. The crude residue was 
purified by flash column chromatography (MeOH/DCM 1:49) to give crude 
product, which was purified by RP-LC-MS (C4 column, 26 min., isocratic of 80% 
CH3CN in 0.1% aqueous FA) to afford 3.57b (17 mg, 60%), as a colorless oil. 
1H NMR, (400 MHz, CDCl3) δ 11.74 (s, 1H), 8.33 (t, 1H, J=5.5 Hz), 7.47-7.22 
(m, 30H), 7.07 (d, 1H, J=9.9 Hz), 6.68 (t, 1H, J=5.0 Hz), 5.22 (d, 1H, J=2.5 
Hz), 5.16 (d, 4H, J=8.7 Hz), 5.02 (t, 1H, J=10.3 Hz), 4.93 (d, 1H, J=12.4 Hz), 
4.78 (dd, 2H, J=12.1 Hz, J=18.8 Hz), 4.65 (d, 1H, J=11.8 Hz), 4.55 (d, 1H, 
J=11.4 Hz), 4.44-4.34 (m, 3H), 4.11 (dd, 1H, J=3.2 Hz, J=6.5 Hz), 4.06 (d, 1H, 
J=8.1 Hz), 4.00-3.95 (m, 2H), 3.74-3.61 (m, 1H), 3.54-3.46 (m, 2H), 3.43- 
3.31 (m, 3H), 3.24 (dd, 1H, J=6.9 Hz, J=13.6 Hz), 3.19-3.09 (m, 2H), 2.94 (dd, 
1H, J=6.8 Hz, J=14.1 Hz), 2.57 (s, 1H), 2.48-2.44 (br, m, 1H), 2.42-2.34 (m, 
1H), 2.32-2.18 (m, 2H), 2.04-1.97 (m, 1H), 1.81-1.46 (m, 10H), 1.35-1.27 (m, 
1H), 0.89 (d, 1H, J=6.3 Hz), 0.82 (dd, 5H, J=6.5 Hz, J=14.4 Hz); 13C NMR, 
(100 MHz, CDCl3) δ 171.5, 171.0, 169.3, 163.8, 156.2, 154.0, 138.5, 138.4, 
137.04, 136.98, 136.93, 134.7, 130.0, 128.99, 128.89, 128.64, 128.61, 
128.33, 128.29, 128.22, 128.19, 128.13, 128.03, 128.00, 126.8, 94.2, 80.5, 
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78.5, 73.5, 72.9, 72.8, 71.8, 70.7, 68.3, 68.2, 67.3, 60.7, 60.3, 55.6, 52.5, 
40.7, 39.2, 38.7, 36.5, 30.0, 29.9, 28.3, 26.5, 26.4, 25.1, 20.8, 20.1, 15.5; 
[α]D +45.0 (c 1.0, CHCl3); HRMS for C71H83ClN6O13 calculated (M+H+) 
1263.57794, found 1263.58015. 
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Compound 3.58a: To a solution of 3.57a (10 mg, 0.008 mmol) in dry 
pyridine (3 mL) at R.T., was added sulfur trioxide pyridine complex (64 mg, 0.4 
mmol). After addition, the mixture was heated to 50 oC and stirred for 48 h, TLC 
(DCM/MeOH 19:1) showed the conversion of 3.57a into 3.58a, then cooled to 
R.T. and pyridine was evaporated. The crude residue was suspended in 15mL 
H2O and extracted with 15 mL×4 DCM. The organic phases were combined, 
dried over Na2SO4 and concentrated under reduced pressure. The residue was 
purified by flash column chromatography (DCM to MeOH/DCM 1:24 to MeOH/ 
DCM 2:23) to give 3.58a (10 mg, 88%), as a colorless film: 1H NMR, (700 MHz, 
MeOH-d4) δ (major rotamer) 8.01 (dd, 1H, J=4.8 Hz, J=6.5 Hz), 7.72 (d, 1H, 
J=9.5 Hz), 7.50 (d, 2H, J=7.1 Hz), 7.46 (d, 2H, J=7.0 Hz), 7.41-7.15 (m, 26H), 
5.11 (d, 2H, J=6.9 Hz), 5.10 (d, 2H, J=2.1 Hz), 5.00 (d, 1H, J=10.5 Hz), 4.76 
(d, 1H, J=10.5 Hz), 4.69 (d, 1H, J=11.9 Hz), 4.57 (dd, 2H, J= 8.6 Hz, J=9.9 Hz), 
4.51 (d, 2H, J=7.2 Hz), 4.41 (d, 1H, J=11.6 Hz), 4.32 (dd, 1H, J=8.0 Hz, 
J=10.0 Hz), 4.11 (dd, 1H, J=3.9 Hz, J=6.5 Hz), 4.05 (s, 1H), 4.03 (dd, 1H, 
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J=5.3 Hz, J=12.0 Hz), 4.00 (dd, 1H, J=1.7 Hz, J=10.8 Hz), 3.64-3.60 (m, 1H), 
3.39 (dd, 1H, J=7.3 Hz, J=8.7 Hz), 3.37 (d, 1H, J=4.8 Hz), 3.35-3.31 (m, 2H), 
3.13 (dd, 1H, J=3.8 Hz, J=14.1 Hz), 3.07 (qd, 1H, J=5.4 Hz, J=10.7 Hz), 2.96 
(dd, 1H, J=6.6 Hz, J=14.2 Hz), 2.62 (d, 1H, J=14.0 Hz), 2.31 (ddd, 1H, J=8.1 
Hz, J=14.7 Hz, J=23.0 Hz), 2.12–2.07 (m, 1H), 2.06–2.02 (m, 1H), 1.99 (td, 
1H, J=10.7 Hz, J=12.9 Hz), 1.81 (t, 1H, J=12.1 Hz), 1.71 (d, 1H, J=13.4 Hz), 
1.59- 1.44 (m, 8H), 1.34-1.30 (br, d, 2H), 0.86 (dd, 6H, J=6.6 Hz, J=11.5Hz); 
13C NMR, (175 MHz, MeOH-d4) δ (major rotamer) 172.40, 171.83, 168.82, 
163.4, 155.7, 153.2, 138.59, 138.56, 137.17, 136.90, 136.83, 134.9, 129.7, 
128.4, 128.37, 128.19, 128.11, 128.10, 128.03, 128.0, 127.9, 127.8, 127.7, 
127.69, 127.66, 127.5, 127.3, 127.2, 126.3, 101.64, 82.2, 80.6, 80.2, 76.0, 
74.7, 73.5, 72.9, 72.3, 67.9, 67.0, 63.3, 60.7, 55.5, 53.8, 52.1, 40.4, 38.2, 
37.8, 36.4, 31.8, 30.8, 28.1, 25.6, 23.0, 19.8, 19.2, 14.3; [α]D +4.2 (c 0.95, 
MeOH); HRMS for C71H83ClN6O16S calculated (M+Na+) 1365.5167, found 
1365.51264. 
 
 
Compound 3.58b: To a solution of 3.57b (9 mg, 0.007 mmol) in dry 
pyridine (2 mL) at R.T., was added sulfur trioxide pyridine complex (59 mg, 
0.37 mmol). After addition, the mixture was heated to 50 °C and stirred for 48 
h, TLC (DCM/MeOH 19:1) showed the conversion of 3.57b into 3.58b, then 
cooled to R.T. and pyridine was evaporated. The crude residue was suspended 
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in 15 mL H2O and extracted with 15 mL×4 DCM. The organic phases were 
combined, dried over Na2SO4 and concentrated under reduced pressure. The 
residue was purified by flash column chromatography (DCM to MeOH/DCM 1:24 
to MeOH/DCM 2:23) to give 3.53b (9 mg, 85%), as a colorless film: 1H NMR, 
(700 MHz, MeOH-d4) δ (major rotamer) 7.55 (d, 2H, J=7.1Hz), 7.42-7.29 (m, 
18H), 7.26-7.20 (m, 9H), 7.16-7.11 (m, 4H), 5.17 (d, 1H, J=2.8 Hz), 
5.14-5.09 (m, 3H), 5.04 (s, 2H), 4.89-4.87 (m, 2H), 4.67 (s, 1H), 4.60 (dd, 2H, 
J=11.6 Hz, J=20.0 Hz), 4.44 (dd, 1H, J=9.6 Hz, J=15.0 Hz), 4.42 (d, 1H, 
J=11.6 Hz), 4.32 (dd, 1H, J=8.1 Hz, J=10.1 Hz), 4,17 (dd, 1H, J=3.9 Hz, J=6.6 
Hz), 4.08 (dd, 1H, J=1.9 Hz, J=10.9 Hz), 4.03 (br, m, 1H), 3.68-3.63 (m, 3H), 
3.61-3.58 (m, 1H), 3.45-3.41 (1H, m), 3.35-3.33 (dr, m, 1H), 3.17 (dd, 1H, 
J=3.7 Hz, J=14.2 Hz), 3.06 (dt, 1H, J=5.2Hz, J=13.1Hz), 3.00 (dd, 1H, J=6.6 
Hz, J=14.1 Hz), 2.66-2.63 (br, m, 0.4H), 2.42-2.37 (m, 0.6H), 2.31-2.26 (m, 
1H), 2.14-2.10 (m, 1H), 2.05-1.99 (m, 1H), 1.86-1.83 (m, 1H), 1.76-1.74 (d, 
1H, J=14.3 Hz), 1.67-1.50 (m, 8H), 1.30 (br, m, 2H), 0.81 (dd, 6H, J=1.8 Hz, 
J=6.6 Hz); 13C NMR, (175 MHz, MeOH-d4) δ (major rotamer) 173.9, 173.2, 
170.2, 165.0, 157.3, 154.6, 140.2, 140.1, 138.8, 138.5, 138.4, 136.4, 131.2, 
129.91, 129.89, 129.63, 129.59, 129.51, 129.47, 129.36, 129.33, 129.31, 
129.24, 129.17, 129.14, 129.02, 128.7, 128.5, 127.8, 97.2, 81.8, 79.4, 77.8, 
76.9, 74.13, 74.01, 73.94, 72.0, 69.4, 69.3, 68.5, 63.3, 62.4, 56.9, 53.6, 41.9, 
49.5, 39.3, 38.2, 32.3, 31.0, 29.4, 27.0, 26.0, 21.2, 21.0, 16.3; [α]D +23.3 (c 
0.8, MeOH); HRMS for C71H83ClN6O16S calculated (M+H+) 1343.53476, found 
1343.53163. 
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Compound 3.59: To a solution of 3.58a (9 mg, 0.007 mmol) in MeOH (8 mL) 
was added Pd(OH)2/C (20 wt. %, max. 50% water)(65 mg) and the suspension 
was stirred under H2 at R.T. for 6 h. The catalyst was removed by filtration and 
the filtrate was concentrated under reduced pressure to obtain crude product, 
which was purified by RP-LC-MS (Column: Synergi Polar-RP, 12 min., gradient 
of 60-80% MeOH in H2O) to afford pure final 3.59 (5 mg, 85%), as a white 
powder. 1H NMR (700 MHz, DMSO-d6) δ (major rotamer) 8.43 (s, 1H), 7.97 (t, 
2H, J=5.5 Hz), 7.52 (d, 1H, J=9.5 Hz), 7.37 (s, 1H), 7.25 (dd, 2H, J=10.0 Hz, 
J=17.2 Hz), 7.22 (d, 2H, J=6.9 Hz), 7.20–7.17 (m, 1H), 6.69 (s, 1H), 5.97 (d, 
1H, J=5.8 Hz), 5.40 (d, 1H, J=3.0 Hz), 5.26 (d, 1H, J=3.4 Hz), 4.86 (t, 1H, 
J=10.0 Hz), 4.28–4.23 (m, 2H), 4.20–4.15 (m, 2H), 3.92 (t, 2H, J=8.9 Hz), 
3.87 (ddd, 2H, J=3.6 Hz, J=5.7 Hz, J=10.4 Hz), 3.45–3.39 (m, 1H), 3.34 (s, 
1H), 3.16 (t, 1H, J=11.0 Hz), 3.10 (dd, 1H, J=6.4 Hz, J=13.2 Hz), 3.08–3.03 
(m, 3H), 2.99 (dd, 1H, J=6.3 Hz, J=12.1 Hz), 2.96 (dd, 1H, J=3.7 Hz, J=13.9 
Hz), 2.82 (dd, 1H, J=7.0 Hz, J=13.8 Hz), 2.27 (d, 1H, J=13.3 Hz), 2.20 (td, 1H, 
J=6.1 Hz, J=12.6 Hz), 2.06–1.96 (m, 2H), 1.81 (dd, 1H, J=12.2 Hz, J=22.7 Hz), 
1.70–1.64 (m, 2H), 1.63 (dd, 1H, J=7.0 Hz, J=14.3 Hz), 1.49–1.36 (m, 6H), 
0.87 (d, 3H, J=6.5 Hz), 0.84 (d, 3H, J= 6.7 Hz); 13C NMR (175 MHz, DMSO-d6) 
δ (major rotamer) 172.11, 171.19, 167.60, 156.91, 137.86, 129.80, 127.90, 
126.14, 102.20, 82.98, 72.95, 72.32, 71.70, 69.28, 68.53, 65.32, 59.86, 
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54.66, 51.05, 40.38, 40.01, 37.97, 35.74, 31.71, 30.91, 27.79, 26.29, 25.86, 
23.12, 20.79, 19.16, 15.02; [α]D +13.0 (c 0.1, MeOH); HRMS for 
C34H53ClN6O12S calculated (M+H+) 805.32035, found 805.32158. 
 
 
Compound 3.16b: To a solution of 3.58b (10 mg, 0.008 mmol) in MeOH (10 
mL) was added Pd(OH)2/C (20 wt. %, max. 50% water)(70 mg) and the 
suspension was stirred under H2 at R.T. for 5.5 h. The catalyst was removed by 
filtration and the filtrate was concentrated under reduced pressure to obtain 
crude product, which was purified by RP-LC-MS (Column: Synergi Polar-RP, 12 
min., gradient of 60-80% MeOH in H2O) to afford pure final 3.16b (5 mg, 84%), 
as a white powder. 1H NMR (700 MHz, DMSO-d6) δ (major rotamer) 8.83 (s, 1H), 
8.05 (t, 1H, J=5.5 Hz), 7.83 (s, 2H), 7.67 (d, 1H, J=9.5 Hz), 7.24 (dd, 2H, 
J=8.0 Hz, J=15.0 Hz), 7.22 (d, 2H, J=6.7 Hz), 7.17 (t, 1H, J=7.7 Hz), 6.69 (s, 
1H), 6.01 (s, 1H), 5.32 (d, 1H, J=2.4 Hz), 5.09 (d, 1H, J=3.8 Hz), 4.93 (t, 1H, 
J=9.7 Hz), 4.82 (d, 1H, J=4.2 Hz), 4.35 (dt, 1H, J=6.1 Hz, J=12.0 Hz), 
4.22–4.13 (m, 3H), 3.97 (dd, 1H, J=1.6 Hz, J=10.7 Hz), 3.86 (s, 1H), 3.45 
(ddd, 2H, J=3.6 Hz, J=8.4 Hz, J=12.2 Hz), 3.39 (br, m, 1H), 3.35 (br, m, 1H), 
3.16 (s, 1H), 3.07 (dd, 1H, J=6.7 Hz, J=13.5 Hz), 3.03 (s, 2H), 3.00 (dd, 1H, 
J=6.4 Hz, J=13.9 Hz), 2.94 (dd, 1H, J=3.7 Hz, J=14.0 Hz), 2.78 (dd, 1H, J=7.5 
Hz, J=13.8 Hz), 2.32 (d, 1H, J=11.8 Hz), 2.26 (dt, 1H, J=6.9 Hz, J=13.1 Hz), 
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2.13 (ddd, 1H, J=6.4 Hz, J=11.2 Hz, J=19.8 Hz), 2.01 (dt, 1H, J=6.8 Hz, 
J=13.3 Hz), 1.85 (dd, 1H, J=13.1 Hz, J=23.5 Hz), 1.66 (dt, 1H, J=6.9 Hz, 
J=13.3 Hz), 1.58 (d, 1H, J=14.4 Hz), 1.54 (d, 2H, J=12.8 Hz), 1.49 (d, 1H, 
J=13.6 Hz), 1.46–1.43 (m, 2H), 1.43–1.38 (m, 2H), 0.85 (d, 3H, J=6.6 Hz), 
0.84 (d, 3H, J=6.6 Hz); 13C NMR (175 MHz, DMSO-d6) δ (major rotamer) 
172.37, 171.16, 167.45, 157.47, 138.05, 129.75, 127.91, 126.08, 94.20, 
80.45, 71.77, 70.71, 68.96, 68.58, 67.33, 61.43, 59.81, 54.03, 51.10, 40.25, 
40.03, 38.04, 35.92, 30.84, 28.78, 27.52, 26.25, 25.89, 24.89, 20.85, 19.51, 
15.37; [α]D +39.4 (c 0.5, MeOH); HRMS for C34H53ClN6O12S calculated (M-H+) 
803.30579, found 803.30339. 
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Methyl 3-O-sulfated-2,4-di-O-benzyl-α-D-xylopyranoside 3.27a: To a 
solution of methyl 2,4-di-O-benzyl-α-D-xylopyranoside 3.27 (172 mg, 0.5 
mmol) in dry pyridine (10 mL) at R.T. were added sulfur trioxide pyridine 
complex (3.98 g, 25 mmol). After addition, the reaction mixture was heated to 
50 oC slowly, and stirred for 24 h, when TLC (EtOAc/hexane 3:7) showed the 
conversion of 3.27 into 3.27a, then cooled to R.T. and pyridine was evaporated. 
The crude residue was suspended in 15 mL H2O and extracted with 15 mL×4 
DCM. The organic phases were combined, dried over Na2SO4 and concentrated 
under reduced pressure. The crude residue was purified by flash column 
chromatography (DCM to MeOH/DCM 2:23) to give 3.27a (220 mg, 87%), as a 
colorless oil: 1H NMR (400 MHz, CDCl3) δ 7.48–7.40 (m, 4H), 7.36–7.23 (m, 
6H), 4.91 (dd, 2H, J=2.0 Hz, J=11.9 Hz), 4.75 (td, 1H, J=3.8 Hz, J=8.4 Hz), 
4.65 (dd, 2H, J=11.9 Hz, J=17.5 Hz), 4.54 (d, 1H, J=3.3 Hz), 3.60 (dd, 1H, 
J=4.0 Hz, J=8.6 Hz), 3.57 (dd, 1H, J=3.3 Hz, J=7.9 Hz), 3.53 (dd, 1H, J=3.3 Hz, 
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J=5.9 Hz), 3.50 (td, 1H, J=3.5 Hz, J=9.2 Hz), 3.33 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 139.8, 139.7, 129.5, 129.42, 129.41, 129.35, 128.9, 128.8, 100.3, 
80.6, 79.0, 77.3, 74.9, 74.5, 61.8, 55.8; Chemical Formula: C20H24O8S. 
 
 
Methyl 3-O-sulfated-α-D-xylopyranoside 3.26a: To a solution of methyl 
3-O-sulfated-2,4-di-O-benzyl-α-D-xylopyranoside 3.27a (55 mg, 0.13 mmol) 
in dry MeOH (10 mL) was added Pd(OH)2/C 20 w.t.% (2 mg) and the 
suspension was stirred under H2 (1 atm) at R.T. for 4 h. The Pd(OH)2/C catalyst 
was removed by filtration and the filtrate was concentrated under reduced 
pressure to afford 3.26a (31 mg, 96%), as a colorless oil: 1H NMR (400 MHz, 
CDCl3) δ 4.68 (d, 1H, J=3.5 Hz), 4.40(t, 1H, J=8.8 Hz), 3.70 (ddd, 1H, J=5.5 Hz, 
J=8.3 Hz, J=9.9 Hz), 3.65 (dd, 1H, J=5.5 Hz, J=10.9 Hz), 3.60 (dd, 1H, J=3.5 
Hz, J=9.2 Hz), 3.52 (t, 1H, J=10.5 Hz), 3.42 (s, 3H), 3.35 (s, 2H); 13C NMR 
(100 MHz, CDCl3) δ 101.2, 82.8, 71.9, 70.2, 62.8, 55.8; HRMS for C6H12O8S 
calculated (M-H)- 243.01801, found 243.01846. 
 
 
Compounds 3.60a and 3.61a: The mixture of 3.60 and 3.61 (43 mg, 
0.125 mmol) was dissolved in dry DCM (5 mL), and cooled at 0 °C. To the 
solution at 0 °C, Ac2O (17 μL, 0.18 mmol), DMAP (1 mg, 0.01 mmol), and Et3N 
(35 μL, 0.25 mmol) were added, then warmed to R.T.. After stirring for 3 h, the 
reaction mixture was diluted with DCM (10 mL), washed with 1 M HCl aqueous 
(15 mL), dried over Na2SO4 and concentrated under reduced pressure. The 
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crude residue was purified by flash column chromatography (hexane to 
EtOAc/hexane 1:5) to afford the mixture of 3.60a and 3.61a (45mg, 93%), as 
a colorless oil, which was separated by RP-LC-MS (Column: Synergi Polar-RP, 
30 min., gradient of 70-73% MeOH in H2O with 0.1% FA) to give 3.60a (17 mg, 
35%), as a colorless oil and 3.61a (23 mg, 48%), as a colorless oil. 
Methyl 4-O-acetyl-2,3-di-O-benzyl-α-D-xylopyranoside 3.60a: 1H 
NMR (400 MHz, CDCl3) δ 7.38–7.24 (m, 10H), 4.86 (ddd, 2H, J=4.0 Hz, J=8.9 
Hz, J=15.2 Hz), 4.78 (d, 1H, J=12.1 Hz), 4.66 (dd, 2H, J=11.8 Hz, J=15.7 Hz), 
4.54 (d, 1H, J=3.5 Hz), 3.89 (t, 1H, J=9.4 Hz), 3.67 (dd, 1H, J=5.9 Hz, J=10.7 
Hz), 3.50 (dd, 1H, J=3.5 Hz, J=9.5 Hz), 3.42 (t, 1H, J=10.7 Hz), 3.36 (s, 3H), 
1.93 (s, 3H); 13C NMR, (100 MHz, CDCl3) δ 170.3, 138.8, 138.2, 128.7, 128.5, 
128.3, 128.2, 128.0, 127.8, 98.5, 79.6, 79.0, 75.6, 73.8, 71.4, 58.7, 55.6, 
21.1; ESI/MS for C22H26O6 calculated (M+Na+) 409, found 409. 
Methyl 2-O-acetyl-3,4-di-O-benzyl-α-D-xylopyranoside 3.61a: 1H 
NMR, (400 MHz, CDCl3) δ 7.37–7.24 (m, 10H), 4.85 (d, 1H, J=11.4 Hz), 4.80 (s, 
1H), 4.77 (d, 1H, J=3.6 Hz), 4.72 (dd, 2H, J=2.4 Hz, J=11.3 Hz), 4.62 (d, 1H, 
J=11.6 Hz), 3.89 (t, 1H, J=8.8 Hz), 3.65 (dd, 1H, J=3.9 Hz, J=7.5 Hz), 3.64 (dq, 
2H, J=5.4 Hz, J=8.6 Hz), 3.57–3.46 (m, 1H), 3.35 (s, 3H), 2.04 (s, 3H); 13C 
NMR, (100 MHz, CDCl3) δ 170.6 138.8, 138.3, 128.7, 128.6, 128.1, 128.0, 
127.8, 97.3, 79.5, 78.3, 75.6, 73.7, 73.3, 60.0, 55.3, 21.2; ESI/MS for 
C22H26O6 calculated (M+Na+) 409, found 409. 
 
 
Methyl 2,3-di-O-benzyl-α-D-xylopyranoside 3.60: A solution of methyl 
4-O-acetyl-2,3-di-O-benzyl-α-D-xylopyranoside 3.60a (15 mg, 0.04 mmol) in 
dry fresh MeOH (3 mL) was treated with 0.5 M MeONa in MeOH (0.16 mL, 0.08 
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mmol) carefully. After stirring at R.T. for 2 h, the reaction mixture was diluted 
with solid NH4Cl, filtered and concentrated under reduced pressure. The crude 
residue was redissolved in DCM (10 mL), filtered and concentration under 
reduced pressure. The residue was purified by flash column chromatography 
(EtOAc/hexane 1:4) to afford 3.60 (13 mg, 96%), as a colorless oil: 1H NMR, 
(400 MHz, CDCl3) δ 7.40–7.25 (m, 10H), 4.95 (d, 1H, J=11.4 Hz), 4.73 (d, 1H 
J=12.0 Hz), 4.68 (d, 1H, J=1.9 Hz), 4.66 (d, 1H, J=11.4 Hz), 4.56 (d, 1H, 
J=3.1 Hz), 3.71 (t, 1H, J=8.3 Hz), 3.68–3.57 (m, 2H), 3.54 (dd, 1H, J=7.0 Hz, 
J=10.6 Hz), 3.48 (dd, 1H, J=3.1 Hz, J=8.7 Hz), 3.38 (s, 3H); 13C NMR, (100 
MHz, CDCl3) δ 138.7, 138.1, 128.8, 128.7, 128.3, 128.2, 128.1, 98.8, 81.2, 
79.4, 75.3, 73.4, 69.7, 62.0, 55.6; ESI/MS for C20H25O5 calculated (M+H+) 345, 
found 345. 
 
 
Methyl 3,4-di-O-benzyl-α-D-xylopyranoside 3.61: A solution of methyl 
2-O-acetyl-3,4-di-O-benzyl-α-D-xylopyranoside 3.61a (19 mg, 0.05 mmol) in 
dry fresh MeOH (4 mL) was treated with 0.5 M MeONa in MeOH (0.2 mL, 0.1 
mmol) carefully. After stirring at R.T. for 2 h, the reaction mixture was diluted 
with solid NH4Cl, filtered and concentrated under reduced pressure. The crude 
residue was redissolved in DCM (10 mL), filtered and concentration under 
reduced pressure. The residue was purified by flash column chromatography 
(EtOAc/hexane 1:4) to afford 3.61 (17 mg, 96%), as a colorless oil: 1H NMR, 
(400 MHz, CDCl3) δ 7.38–7.24 (m, 10H), 4.88 (d, 1H, J=11.3 Hz), 4.81 (d, 1H, 
J=11.3 Hz), 4.70 (d, 1H, J=11.9 Hz), 4.68 (d, 1H, J=3.9 Hz), 4.61 (d, 1H, 
J=11.6 Hz), 3.68 (dd, 2H, J=7.2 Hz, J=16.0 Hz), 3.60 (ddd, 1H, J=3.3 Hz, 
J=6.6 Hz, J=9.8 Hz), 3.55 (d, 2H, J=6.4 Hz), 3.41 (s, 3H); 13C NMR, (100 MHz, 
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CDCl3) δ 138.8, 138.3, 128.7, 128.6, 128.12, 128.05, 127.96, 127.93, 99.6, 
81.7, 77.7, 75.3, 73.3, 72.3, 62.5, 55.5; ESI/MS for C20H25O5 calculated (M+H+) 
345, found 345. 
 
 
Methyl 4-O-sulfated-2,3-di-O-benzyl-α-D-xylopyranoside 3.60b: To a 
solution of methyl 2,3-di-O-benzyl-α-D-xylopyranoside 3.60 (13 mg, 0.036 
mmol) in dry pyridine (2 mL) at R.T. were added sulfur trioxide pyridine 
complex (143 mg, 0.9 mmol). After addition, the reaction mixture was heated 
to 50 oC slowly, and stirred for 10 h, when TLC (EtOAc/hexane 3:7) showed the 
conversion of 3.60 into 3.60b, then cooled to R.T. and pyridine was evaporated. 
The crude residue was suspended in 15 mL H2O and extracted with 15 mL×4 
DCM. The organic phases were combined, dried over Na2SO4 and concentrated 
under reduced pressure. The crude residue was purified by flash column 
chromatography (DCM to MeOH/DCM 2:23) to give 3.60b (14 mg, 92%), as a 
colorless oil: 1H NMR (400 MHz, MeOH-d4) δ 7.47–7.40 (m, 2H), 7.37–7.20 (m, 
8H), 5.01 (d, 1H, J=10.9 Hz), 4.72 (d, 1H, J=4.7 Hz), 4.69 (d, 1H, J=3.8 Hz), 
4.66 (d, 1H, J=3.6 Hz), 4.63 (d, 1H, J=11.8 Hz), 4.38 (ddd, 1H, J=5.9 Hz, 
J=9.0 Hz, J=10.7 Hz), 4.00 (dd, 1H, J=5.9 Hz, J=11.1 Hz), 3.78 (t, 1H, J=9.2 
Hz), 3.56 (t, 1H, J=11.0 Hz), 3.48 (dd, 1H, J=3.6 Hz, J=9.5 Hz), 3.36 (s, 3H); 
13C NMR (100 MHz, MeOH-d4) δ 140.3, 139.8, 129.6, 129.5, 129.31, 129.27, 
129.0, 128.6, 99.5, 80.6, 77.8, 76.3, 74.5, 60.7, 55.7; Chemical Formula: 
C20H24O8S. 
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Methyl 2-O-sulfated-3,4-di-O-benzyl-α-D-xylopyranoside 3.61b: To a 
solution of methyl 3,4-di-O-benzyl-α-D-xylopyranoside 3.61 (16 mg, 0.046 
mmol) in dry pyridine (2 mL) at R.T. were added sulfur trioxide pyridine 
complex (183 mg, 1.15 mmol). After addition, the reaction mixture was heated 
to 50 oC slowly, and stirred for 10 h, when TLC (EtOAc/hexane 3:7) showed the 
conversion of 3.61 into 3.61b, then cooled to R.T. and pyridine was evaporated. 
The crude residue was suspended in 15 mL H2O and extracted with 15 mL×4 
DCM. The organic phases were combined, dried over Na2SO4 and concentrated 
under reduced pressure. The crude residue was purified by flash column 
chromatography (DCM to MeOH/DCM 2:23) to give 3.61b (18 mg, 91%), as a 
colorless oil: 1H NMR (400 MHz, MeOH-d4) δ 7.45–7.40 (m, 2H), 7.34–7.20 (m, 
8H), 5.03 (d, 1H, J=3.5 Hz), 4.99 (d, 1H, J=10.9 Hz), 4.68 (dd, 2H, J=2.3 Hz, 
J=11.2 Hz), 4.62 (d, 1H, J=11.6 Hz), 4.27 (dd, 1H, J=3.6 Hz, J=9.7 Hz), 3.80 
(d, 1H, J=8.8 Hz), 3.82–3.75 (m, 1H), 3.78 (d, 1H, J=9.5 Hz), 3.66 (dd, 1H, 
J=5.4 Hz, J=10.2 Hz), 3.56 (ddd, 1H, J=5.4 Hz, J=8.6 Hz, J=10.4 Hz), 3.47 (t, 
1H, J=10.4 Hz), 3.39 (s, 3H); 13C NMR (100 MHz, MeOH-d4) δ 140.3, 140.0, 
129.6, 129.5, 129.3, 129.1, 128.8, 128.6, 99.7, 80.8, 79.3, 78.9, 76.3, 74.6, 
60.8, 55.9; Chemical Formula: C20H24O8S. 
 
 
Methyl 4-O-sulfated-α-D-xylopyranoside 3.26b: To a solution of methyl 
4-O-sulfated-2,3-di-O-benzyl-α-D-xylopyranoside 3.60b (14 mg, 0.033 mmol) 
in dry MeOH (5 mL) was added Pd(OH)2/C 20 w.t.% (2 mg) and the suspension 
was stirred under H2 (1 atm) at R.T. for 4 h. The Pd(OH)2/C catalyst was 
removed by filtration and the filtrate was concentrated under reduced pressure 
to afford 3.26b (8 mg, 96%), as a colorless oil: 1H NMR (400 MHz, DMSO-d6) 
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δ 5.01 (d, 1H, J=3.0 Hz), 4.88 (d, 1H, J=6.6 Hz), 4.48 (d, 1H, J=3.6 Hz), 3.90 
(ddd, 1H, J=5.8 Hz, J=8.9 Hz, J=10.7 Hz), 3.66 (dd, 1H, J=5.8 Hz, J=10.9 Hz), 
3.46 (td, 1H, J=3.0 Hz, J=9.2 Hz), 3.32–3.27 (m, 1H), 3.25 (s, 3H), 3.30–3.20 
(m, 1H); 13C NMR (100 MHz, DMSO-d6) δ 99.8, 74.8, 71.9, 71.7, 59.3, 54.7; 
HRMS for C6H12O8S calculated (M-H)- 243.01801, found 243.01851.  
 
 
Methyl 2-O-sulfated-α-D-xylopyranoside 3.26c: To a solution of methyl 
2-O-sulfated-3,4-di-O-benzyl-α-D-xylopyranoside 3.61b (17 mg, 0.13 mmol) 
in dry MeOH (10 mL) was added Pd(OH)2/C 20 w.t.% (2 mg) and the 
suspension was stirred under H2 (1 atm) at R.T. for 4 h. The Pd(OH)2/C catalyst 
was removed by filtration and the filtrate was concentrated under reduced 
pressure to afford 3.26c (9 mg, 97%), as a colorless oil: 1H NMR (400 MHz, 
DMSO-d6) δ 5.07 (d, 1H, J=4.9 Hz), 4.92 (d, 1H, J=2.2 Hz), 4.72 (d, 1H, J=3.3 
Hz), 3.81 (dd, 1H, J=3.2 Hz, J=9.4 Hz), 3.49–3.37 (m, 2H), 3.36–3.28 (m, 1H), 
3.23 (s, 3H), 3.22 (dd, 1H, J=5.5 Hz, J=13.3 Hz); 13C NMR (100 MHz, DMSO-d6) 
δ 98.3, 76.2, 71.8, 70.3, 61.2, 54.7; HRMS for C6H12O8S calculated (M-H)- 
243.01801, found 243.01820. 
 
 
Methyl 2,4-di-O-MOM-α-D-xylopyranoside 3.62: To a solution of Methyl 
α-D-xylopyranoside 3.26 (82 mg, 0.5 mmol) in dry toluene (12 mL) and dry 
MeOH (2 mL) at R.T. was added bis(tributyltin) oxide (274 mg, 1.1 mmol) and 
activated 4Å molecular sieves. After heating at 70 oC for 10 h, solvent was 
evaporated. The crude residue was redissolved in dry dry toluene (5 mL), then 
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treated with MOMCl (84 μL, 1.1 mmol) and Bu4NI (185 mg, 0.5mmol) at R.T. for 
10 h. The suspension was filtered over celite and concentrated under reduced 
pressure. The crude residue was purified by flash column chromatography 
(EtOAc/hexane 3:7) to afford major product 3.62 (59 mg, 47%), as a colorless 
oil: 1H NMR (300 MHz, CDCl3) δ 4.83 (d, 1H, J=6.9 Hz), 4.77 (d, 2H, J= 6.9 Hz), 
4.76 (dd, 2H, J=2.6 Hz, J=3.6 Hz), 4.71 (d, 1H, J=7.0 Hz), 3.87 (t, 1H, J=8.8 
Hz), 3.71 (d, 2H, J=4.9 Hz), 3.52 (d, 2H, J=6.4 Hz), 3.43 (s, 3H), 3.42 (s, 3H), 
3.41 (s, 3H),; 13C NMR (75 MHz, CDCl3) δ 98.9, 98.0, 97.5, 80.0, 78.7, 71.8, 
59.8, 55.86, 55.85, 55.4; [α]D +76.8 (c 1.0, CHCl3), ESI/MS for C10H20O7 
calculated (M+H+) 253, found 253. 
 
 
Methyl 3-O-benzyl-2,4-di-O-MOM-α-D-xylopyranoside 3.63 ：  A 
solution of methyl 2,4-di-O-MOM-α-D-xylopyranoside 3.62 (20 mg, 0.08 mmol) 
in THF (5 mL) was cooled to 0°C, and treated with NaH (5 mg, 60 dispersion in 
mineral oil) under argon atmosphere, and warmed up to R.T.. After stirring for 
1 h, BnBr (14 μL, 0.12 mmol) and Bu4NI (30 mg, 0.08 mmol) were added, and 
stirred for 10 h. The mixture was quenched by H2O (0.5 mL) carefully and 
concentrated under reduced pressure. Then the residue was redissolved in a 
mixture of DCM (15 mL) and H2O (15 mL). The phases were separated, and the 
organic phase was washed with H2O (15 mL) and brine (15 mL), then dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by 
flash column chromatography (hexane to EtOAc/hexane 3:17) to give 3.63 (25 
mg, 89%), as a colorless oil: 1H NMR, (400 MHz, CDCl3) δ 7.29 (d, 4H, J=4.4 
Hz), 7.28–7.21 (m, 1H), 4.79 (d, 1H, J=6.8 Hz),4.75 (dt, 3H, J=7.4 Hz, J=10.0 
Hz), 4.68 (d, 1H, J= 6.7 Hz), 4.60 (d, 1H, J=6.7 Hz), 3.76 (t, 1H, J= 9.3 Hz), 
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3.70 (dd, 1H, J=5.5 Hz, J=10.3 Hz), 3.61 (ddd, 1H, J=5.5 Hz, J=8.8 Hz, J=10.4 
Hz), 3.53 (dd, 1H, J=3.6 Hz, J=9.6 Hz), 3.50 (t, 1H, J=10.4 Hz),3.41 (s, 3H), 
3.35 (s, 3H), 3.31 (s, 3H); 13C NMR, (100 MHz, CDCl3) δ 138.9, 128.5, 127.9, 
127.8, 99.4, 97.9, 97.4, 80.7, 78.8, 77.0, 75.9, 60.5, 55.7, 55.6, 55.4; ESI/MS 
for C17H26O7 calculated (M+H+) 343, found 343.  
 
 
Methyl 3-O-benzyl-α-D-xylopyranoside 3.64: Methyl 3-O-benzyl-2,4-di- 
O-MOM-α-D-xylopyranoside 3.58 (24 mg, 0.07 mmol) was treated with >99.9% 
TFA/DCM (1:2, 3 mL) at R.T.. After stirring for 3 h, the reaction mixture was 
diluted with EtOAc (20 mL) and concentrated under reduced pressure. The 
crude residue was suspended in saturated aqueous Na2CO3 (20 mL) and 
extracted with DCM (3×30 mL). The organic phases were combined, dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by 
flash column chromatography (DCM to MeOH/DCM 1:49) to afford 3.64 (15 mg, 
82%), as a colorless oil: 1H NMR, (400 MHz, MeOH-d4) δ 7.43 (d, 2H, J=7.3 Hz), 
7.31 (t, 2H, J=7.4 Hz), 7.25 (t, 1H, J= 7.2 Hz), 4.86 (d, 2H, J=4.0 Hz), 4.61 (d, 
1H, J=3.3 Hz), 3.65–3.56 (m, 1H), 3.55 (dd, 1H, J=7.2 Hz, J=9.3 Hz), 
3.58–3.51 (m, 1H), 3.48 (dd, 2H, J=9.5 Hz, J=19.7 Hz), 3.40 (s, 3H); 13C NMR, 
(100 MHz, MeOH-d4) δ 140.6, 129.3, 129.2, 128.6, 101.9, 83.8, 76.3, 73.7, 71.5, 
63.1, 55.7; ESI/MS for C13H18O5 calculated (M+H+) 255, found 255. 
  
 
Methyl 3-O-benzyl-2,4-di-O-sulfated-α-D-xylopyranoside 3.65: To a 
solution of methyl 3-O-benzyl-α-D-xylopyranoside 3.64 (12 mg, 0.04 mmol) in 
192 
 
dry pyridine (2 mL) at R.T. were added sulfur trioxide pyridine complex (159 mg, 
1.0 mmol). After addition, the reaction mixture was heated to 50 oC slowly and 
stirred for 10 h, when TLC (MeOH/DCM 1:19) showed the conversion of 3.64 
into 3.65, then cooled to R.T.. The reaction mixture was filtered and pyridine 
was evaporated. The residue was purified by flash column chromatography 
(MeOH/DCM 1:9 to MeOH/DCM 1:4) to give 3.65 (14 mg, 87%), as a colorless 
oil: 1H NMR (400 MHz, MeOH-d4) δ 7.52 (d, 2H, J=7.2 Hz), 7.29 (t, 2H, J=7.3 
Hz), 7.24–7.18 (m, 1H), 5.05 (d, 1H, J=3.4 Hz), 4.88 (d, 2H, J=19.3 Hz), 4.40 
(ddd, 1H, J=6.1 Hz, J=8.9 Hz, J=10.6 Hz), 4.29 (dd, J=3.5 Hz, J=9.7 Hz), 4.02 
(dd, 1H, J=6.0 Hz, J=11.1 Hz), 3.77 (t, 1H, J=9.4 Hz), 3.60 (t, 1H, J=10.1 Hz), 
3.40 (s, 3H); 13C NMR (100 MHz, MeOH-d4) δ 139.9, 129.7, 129.2, 128.5, 99.6, 
78.5, 78.4, 77.1, 75.9, 60.7, 56.0; Chemical Formula: C13H18O11S2. 
 
 
Methyl 2,4-di-O-sulfated-α-D-xylopyranoside 3.26d: To a solution of 
methyl 3-O-benzyl-2,4-di-O-sulfated-α-D-xylopyranoside 3.65 (10 mg, 0.024 
mmol) in dry MeOH (5 mL) was added Pd(OH)2/C 20 w.t.% (2 mg) and the 
suspension was stirred under H2 (1 atm) at R.T. for 3 h. The Pd(OH)2/C catalyst 
was removed by filtration and filtrate was concentrated under reduced pressure 
to give 3.26d (7 mg, 96%), as a colorless oil: 1H NMR (400 MHz, DMSO-d6) δ 
4.97 (d, 1H, J=2.6 Hz), 4.79 (d, 1H, J=3.5 Hz), 3.93 (ddd, 1H, J=5.9 Hz, J=9.0 
Hz, J=10.8 Hz), 3.83 (dd, 1H, J=3.6 Hz, J=9.8 Hz), 3.76 (dd, J=5.9 Hz, J=11.0 
Hz), 3.53 (td, 1H, J=2.5 Hz, J=9.5 Hz), 3.26 (dd, 1H, J=12.6 Hz, J=23.7 Hz), 
3.24 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 97.9, 76.0, 74.9, 69.4, 59.0, 54.8; 
HRMS for C6H12O11S2 calculated (M-H)- 322.97483, found 322.97594.  
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Compound 3.52a: To a solution of D-(+)-3-phenyllactic acid 3.52 (50 mg, 
0.3 mmol) in MeOH (0.5 mL) and hexanes (1.0 mL) was added 2 M trimethyl- 
silyldiazomethane in hexanes (0.6 mmol, 0.3 mL) at R.T., and stirred for 1 h 
(TLC monitoring, EtOAc/hexanes 7:13), then solvents were evaporated. The 
crude residue was purified by flash column chromatography (EtOAc/hexanes 
1:4) to give 3.52a (51 mg, 94%), as a colorless needle: 1H NMR (400 MHz, 
Acetone-d6) δ 7.29–7.25 (m, 4H), 7.24–7.18 (m, 1H), 4.38 (dd, 1H, J=5.2 Hz, 
J=6.5 Hz), 4.29 (s, 1H), 3.67 (s, 3H), 3.06 (dd, 1H, J=4.6 Hz, J=13.8 Hz), 2.91 
(dd, 1H, J=7.6 Hz, J=13.8 Hz); 13C NMR (100 MHz, Acetone-d6) δ 174.9, 138.6, 
130.4, 129.0, 127.3, 72.6, 52.1, 41.4; ESI/MS for C10H12O3 calculated (M+H+) 
181, found 181. 
 
 
Compound 3.52b: To a solution of 3.52a (25 mg, 0.14 mmol) in dry toluene 
(10 mL) was added activated 4Å molecular sieves and bis(tributyltin) oxide (69 
mg, 0.28 mmol) at R.T.. After heating at 80 oC for 10 h, solvent was evaporated. 
The crude residue was redissolved in dry DMF (3 mL) and dry toluene (3 mL) at 
R.T., and treated with sulfur trioxide trimethylamine complex (38 mg, 0.28 
mmol) for 10 h. The suspension was filtered over celite and concentrated under 
reduced pressure. The residue was purified by flash column chromatography 
(DCM to MeOH/DCM 1:24 to MeOH/DCM 1:12) to afford 3.52b (23 mg, 65%), 
as a colorless oil: 1H NMR (400 MHz, Acetone-d6) δ 7.26–7.24 (m, 4H), 
7.23–7.16 (m, 1H), 5.07 (t, 1H, J=6.3 Hz), 3.59 (s, 3H), 3.17 (d, 1H, J=4.4 Hz), 
3.15 (d, 1H, J=5.1 Hz); 13C NMR (100 MHz, Acetone-d6) δ 172.3, 137.1, 130.6, 
129.1, 127.5, 77.2, 52.4, 39.2; HRMS for C10H12O6S calculated (M-H)- 
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259.02818, found 259.02827.  
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 Table 1.  Crystal data and structure refinement for C15 H25 N O5.  
        Identification code                benit94  
        Empirical formula                  C15 H25 N O5  
        Formula weight                      299.36  
        Temperature                          150K  
        Wavelength                           1.54178 Å  
        Crystal system                      Monoclinic  
        Space group                          P21  
        Unit cell dimensions                a = 8.8510(2) Å    α = 90°  
                                                b = 11.2574(3) Å    β = 115.248(1)°  
                                                c = 9.0523(2) Å    γ = 90°  
        Volume                                 815.80(3)Å3  
        Z                                       2  
        Density (calculated)                1.219  g/cm3  
        Absorption coefficient              0.750 mm-1  
        F(000)                                 324  
        Crystal size                          0.21 x 0.20 x 0.18 mm  
        Theta range for data collection   5.40 to 72.02°  
        Index ranges                          -10 ≤ h ≤ 10, -13 ≤ k ≤ 13, -11 ≤ l ≤ 10  
        Reflections collected               10191  
        Independent reflections             3035 [Rint = 0.034]  
        Absorption correction               Semi-empirical from equivalents  
        Max. and min. transmission         0.8737 and 0.8000  
        Refinement method                    Full-matrix least-squares on F2  
        Data / restraints / parameters     3035 / 1 / 196  
        Goodness-of-fit on F2                1.101  
        Final R indices [I>2sigma(I)]      R1 = 0.0403, wR2 = 0.0957  
        R indices (all data)                 R1 = 0.0406, wR2 = 0.0961  
        Absolute structure parameter        0.02(14)  
        Extinction coefficient               0.119(4)  
        Largest diff. peak and hole         0.433 and -0.304 e/Å3  
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Table 2.  Atomic coordinates (x 104) and equivalent isotropic  
         displacement parameters (Å2 x 103) for C15 H25 N O5.  
         Ueq is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          O(1)         2928(1)       3923(1)      10370(1)       42(1)  
          O(2)        -1309(2)       3994(1)       3001(2)       42(1)  
          O(3)        -1813(1)       2213(1)       1776(1)       38(1)  
          O(4)         2378(1)       3659(1)       3177(1)       30(1)  
          O(5)         3819(1)       4457(1)       5719(1)       32(1)  
          N(1)         1836(1)       3125(1)       5305(1)       25(1)  
          C(1)         2189(2)       3101(1)       7056(2)       24(1)  
          C(2)         1347(2)       4144(1)       7502(2)       30(1)  
          C(3)         1248(2)       3944(2)       9124(2)       36(1)  
          C(4)          337(2)       2786(2)       9092(2)       39(1)  
          C(5)         1184(2)       1718(2)       8723(2)       38(1)  
          C(6)         1479(2)       1882(1)       7184(2)       28(1)  
          C(7)          -79(2)       1787(1)       5562(2)       29(1)  
          C(8)          485(2)       2328(1)       4313(2)       24(1)  
          C(9)         -945(2)       2978(1)       2972(2)       26(1)  
          C(10)       -3306(2)       2675(2)        461(2)       55(1)  
          C(11)        2672(2)       3751(1)       4617(2)       23(1)  
          C(12)        5014(2)       5158(1)       5331(2)       29(1)  
          C(13)        4111(2)       6024(1)       3945(2)       38(1)  
          C(14)        6137(2)       4328(2)       4927(2)       39(1)  
          C(15)        5981(3)       5801(2)       6931(2)       51(1)  
         ________________________________________________________________  
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Table 3. Hydrogen coordinates (x 104) and isotropic displacement  
         parameters (Å2 x 103) for C15 H25 N O5.  
         ________________________________________________________________  
   
                         x             y             z           Ueq  
         ________________________________________________________________  
   
          H(1)         2917          3814         11283          63  
          H(1A)        3422          3119          7745          29  
          H(2A)        1984          4880          7570          35  
          H(2B)         205          4251          6629          35  
          H(3)          634          4621          9334          43  
          H(4A)        -830          2842          8249          47  
          H(4B)         307          2669         10163          47  
          H(5A)         482          1006          8586          46  
          H(5B)        2271          1577          9668          46  
          H(6)         2292          1261          7193          34  
          H(7A)       -1020          2242          5597          34  
          H(7B)        -423           948          5293          34  
          H(8)          922          1690          3831          28  
          H(10A)      -4079          2958           902          82  
          H(10B)      -3843          2045          -340          82  
          H(10C)      -3008          3335           -69          82  
          H(13A)       3497          5581          2931          57  
          H(13B)       4928          6548          3810          57  
          H(13C)       3327          6501          4199          57  
          H(14A)       6658          3755          5817          59  
          H(14B)       7007          4791          4791          59  
          H(14C)       5470          3902          3911          59  
          H(15A)       5223          6321          7167          77  
          H(15B)       6867          6279          6848          77  
          H(15C)       6478          5219          7813          77  
         ________________________________________________________________  
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Table 4.  Anisotropic parameters (Å2 x 103) for C15 H25 N O5.  
           The anisotropic displacement factor exponent takes the form:  
                   -2 π2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    O(1)     38(1)      68(1)      23(1)      -6(1)      14(1)     -12(1)  
    O(2)     41(1)      33(1)      49(1)       1(1)      16(1)       8(1)  
    O(3)     35(1)      41(1)      27(1)      -4(1)       4(1)      -3(1)  
    O(4)     35(1)      36(1)      23(1)      -3(1)      17(1)      -8(1)  
    O(5)     35(1)      40(1)      25(1)      -7(1)      17(1)     -17(1)  
    N(1)     26(1)      30(1)      20(1)      -4(1)      12(1)      -7(1)  
    C(1)     24(1)      30(1)      19(1)       1(1)      10(1)      -4(1)  
    C(2)     35(1)      32(1)      25(1)      -2(1)      16(1)      -3(1)  
    C(3)     36(1)      50(1)      26(1)      -8(1)      18(1)      -4(1)  
    C(4)     38(1)      61(1)      26(1)      -1(1)      21(1)     -10(1)  
    C(5)     43(1)      46(1)      27(1)       8(1)      15(1)     -10(1)  
    C(6)     33(1)      27(1)      25(1)       3(1)      14(1)      -3(1)  
    C(7)     32(1)      28(1)      28(1)      -1(1)      14(1)      -8(1)  
    C(8)     24(1)      25(1)      23(1)      -3(1)      11(1)      -3(1)  
    C(9)     25(1)      30(1)      26(1)       0(1)      14(1)      -2(1)  
    C(10)    36(1)      81(2)      32(1)       2(1)      -1(1)       3(1)  
    C(11)    23(1)      26(1)      23(1)      -1(1)      12(1)      -2(1)  
    C(12)    27(1)      30(1)      34(1)      -1(1)      18(1)      -8(1)  
    C(13)    36(1)      29(1)      53(1)       6(1)      22(1)       1(1)  
    C(14)    30(1)      34(1)      59(1)       2(1)      23(1)       1(1)  
    C(15)    55(1)      60(1)      43(1)     -17(1)      25(1)     -35(1)  
    _______________________________________________________________________  
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Table 5.  Bond lengths [Å] and angles [°] for C15 H25 N O5  
    ______________________________________________________________________  
  
 
    O(1)-C(3)              1.4325(19)  
    O(2)-C(9)              1.1919(19)  
    O(3)-C(9)              1.3398(17)  
    O(3)-C(10)             1.4459(19)  
    O(4)-C(11)             1.2194(17)  
    O(5)-C(11)             1.3395(16)  
    O(5)-C(12)             1.4766(16)  
    N(1)-C(11)             1.3512(16)  
    N(1)-C(8)              1.4580(16)  
    N(1)-C(1)              1.4791(16)  
    C(1)-C(2)              1.534(2)  
    C(1)-C(6)              1.5349(19)  
    C(2)-C(3)              1.5243(19)  
    C(3)-C(4)              1.527(2)  
    C(4)-C(5)              1.527(3)  
    C(5)-C(6)              1.534(2)  
    C(6)-C(7)              1.5306(19)  
    C(7)-C(8)              1.5419(18)  
    C(8)-C(9)              1.5171(17)  
    C(12)-C(15)            1.516(2)  
    C(12)-C(14)            1.518(2)  
    C(12)-C(13)            1.520(2)  
   
    C(9)-O(3)-C(10)        116.20(14)  
    C(11)-O(5)-C(12)       122.14(10)  
    C(11)-N(1)-C(8)        120.23(10)  
    C(11)-N(1)-C(1)        126.64(11)  
    C(8)-N(1)-C(1)         113.05(10)  
    N(1)-C(1)-C(2)         111.36(11)  
    N(1)-C(1)-C(6)         101.02(10)  
    C(2)-C(1)-C(6)         113.82(11)  
    C(3)-C(2)-C(1)         112.02(13)  
    O(1)-C(3)-C(2)         107.11(12)  
    O(1)-C(3)-C(4)         111.29(14)  
    C(2)-C(3)-C(4)         110.73(12)  
    C(3)-C(4)-C(5)         111.81(12)  
    C(4)-C(5)-C(6)         113.20(13)  
    C(7)-C(6)-C(5)         115.50(12)  
    C(7)-C(6)-C(1)         102.70(11)  
    C(5)-C(6)-C(1)         114.18(12)  
    C(6)-C(7)-C(8)         103.60(11)  
    N(1)-C(8)-C(9)         112.39(11)  
    N(1)-C(8)-C(7)         103.21(10)  
    C(9)-C(8)-C(7)         110.89(11)  
    O(2)-C(9)-O(3)         124.57(13)  
    O(2)-C(9)-C(8)         125.94(13)  
    O(3)-C(9)-C(8)         109.38(12)  
    O(4)-C(11)-O(5)        126.51(11)  
    O(4)-C(11)-N(1)        122.64(12)  
    O(5)-C(11)-N(1)        110.84(11)  
    O(5)-C(12)-C(15)       101.41(11)  
    O(5)-C(12)-C(14)       109.75(12)  
    C(15)-C(12)-C(14)      111.32(15)  
    O(5)-C(12)-C(13)       111.19(12)  
    C(15)-C(12)-C(13)      111.49(15)  
    C(14)-C(12)-C(13)      111.30(13)  
   
    
______________________________________________________________________  
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         Table 6.  Torsion angles [°] for C15 H25 N O5.  
  ______________________________________________________________________________  
  
 
  C(11)-N(1)-C(1)-C(2)      84.54(16)  
  C(8)-N(1)-C(1)-C(2)      -98.56(12)  
  C(11)-N(1)-C(1)-C(6)    -154.26(12)  
  C(8)-N(1)-C(1)-C(6)       22.64(13)  
  N(1)-C(1)-C(2)-C(3)      163.00(12)  
  C(6)-C(1)-C(2)-C(3)       49.60(15)  
  C(1)-C(2)-C(3)-O(1)       65.05(16)  
  C(1)-C(2)-C(3)-C(4)      -56.47(16)  
  O(1)-C(3)-C(4)-C(5)      -61.12(16)  
  C(2)-C(3)-C(4)-C(5)       57.91(17)  
  C(3)-C(4)-C(5)-C(6)      -52.09(17)  
  C(4)-C(5)-C(6)-C(7)      -73.87(17)  
  C(4)-C(5)-C(6)-C(1)       44.89(17)  
  N(1)-C(1)-C(6)-C(7)      -37.35(13)  
  C(2)-C(1)-C(6)-C(7)       82.09(14)  
  N(1)-C(1)-C(6)-C(5)     -163.15(12)  
  C(2)-C(1)-C(6)-C(5)      -43.71(16)  
  C(5)-C(6)-C(7)-C(8)      164.47(13)  
  C(1)-C(6)-C(7)-C(8)       39.53(14)  
  C(11)-N(1)-C(8)-C(9)     -61.76(15)  
  C(1)-N(1)-C(8)-C(9)      121.13(12)  
  C(11)-N(1)-C(8)-C(7)     178.71(12)  
  C(1)-N(1)-C(8)-C(7)        1.59(14)  
  C(6)-C(7)-C(8)-N(1)      -25.49(14)  
  C(6)-C(7)-C(8)-C(9)     -146.05(12)  
  C(10)-O(3)-C(9)-O(2)      -1.2(2)  
  C(10)-O(3)-C(9)-C(8)     175.12(14)  
  N(1)-C(8)-C(9)-O(2)      -26.55(19)  
  C(7)-C(8)-C(9)-O(2)       88.40(17)  
  N(1)-C(8)-C(9)-O(3)      157.19(11)  
  C(7)-C(8)-C(9)-O(3)      -87.85(14)  
  C(12)-O(5)-C(11)-O(4)     -5.9(2)  
  C(12)-O(5)-C(11)-N(1)    174.33(11)  
  C(8)-N(1)-C(11)-O(4)      -1.98(19)  
  C(1)-N(1)-C(11)-O(4)     174.71(13)  
  C(8)-N(1)-C(11)-O(5)     177.82(11)  
  C(1)-N(1)-C(11)-O(5)      -5.49(18)  
  C(11)-O(5)-C(12)-C(15)   178.98(15)  
  C(11)-O(5)-C(12)-C(14)   -63.22(17)  
  C(11)-O(5)-C(12)-C(13)    60.35(18)  
   
  
______________________________________________________________________________  
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   Table 7. Bond lengths [Å] and angles [°] related to the hydrogen  
   bonding for C15 H25 N O5.  
   ______________________________________________________________________  
   
        D-H         ..A       d(D-H)      d(H..A)     d(D..A)     <DHA  
   
     O(1)-H(1)      O(4)#1     0.84        1.97       2.7994(14)  167.6  
 
   ______________________________________________________________________  
   
    Symmetry transformations used to generate equivalent atoms:  
   
         #1 x,y,z+1      
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ORTEP view of the C15 H25 N O5 compound with the numbering scheme adopted. 
Ellipsoids drawn at 30% probability level. Hydrogen atoms are represented 
by sphere of arbitrary size.  
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      Table 1.  Crystal data and structure refinement for C33 H43 N O9.  
        Identification code                 bent112  
        Empirical formula                   C33 H43 N O9  
        Formula weight                       597.68  
        Temperature                           150K  
        Wavelength                            1.54178 Å  
        Crystal system                       Orthorhombic  
        Space group                           P212121  
        Unit cell dimensions                a = 10.4333(5) Å    α = 90°  
                                                b = 12.4407(5) Å    β = 90°  
                                                c = 23.9905(10) Å    γ = 90°  
        Volume                                 3113.9(2)Å3  
        Z                                       4  
        Density (calculated)                1.275  g/cm3  
        Absorption coefficient              0.758 mm-1  
        F(000)                                 1280  
        Crystal size                          0.22 x 0.15 x 0.14 mm  
        Theta range for data collection   3.68 to 72.64°  
        Index ranges                          -12 ≤ h ≤ 11, -15 ≤ k ≤ 15, -29 ≤ l ≤ 29  
        Reflections collected               40744  
        Independent reflections             6091 [Rint = 0.044]  
        Absorption correction               Semi-empirical from equivalents  
        Max. and min. transmission         0.87 and 0.85  
        Refinement method                    Full-matrix least-squares on F2  
        Data / restraints / parameters    6091 / 4 / 449  
        Goodness-of-fit on F2               0.967  
        Final R indices [I>2sigma(I)]     R1 = 0.0352, wR2 = 0.0868  
        R indices (all data)                R1 = 0.0404, wR2 = 0.0890  
        Absolute structure parameter      -0.10(12)  
        Extinction coefficient             0.00326(19)  
        Largest diff. peak and hole       0.136 and -0.186 e/Å3  
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          Table 2.  Atomic coordinates (x 104) and equivalent isotropic  
         displacement parameters (Å2 x 103) for C33 H43 N O9.  
         Ueq is defined as one third of the trace of the orthogonalized  
         Uij tensor.           
 
Occ.        x             y            z           Ueq           
          O(1)      1        4977(1)      -82(1)      566(1)      37(1)  
          O(2)      1        4361(1)    -5982(1)      210(1)      43(1)  
          O(3)      1        3168(1)    -4514(1)       54(1)      35(1)  
          O(4)      1        5309(1)    -2561(1)     -946(1)      48(1)  
          O(5)      1        5496(1)    -4379(1)     -822(1)      38(1)  
          O(6)      1        6259(1)      946(1)     -263(1)      36(1)  
          O(7)      1        7752(1)     2389(1)      412(1)      46(1)  
          O(9)      1        4052(1)     1522(1)      882(1)      50(1)  
          N(1)      1        5406(1)    -3312(1)      -84(1)      33(1)  
          C(1)      1        5414(2)    -2288(1)      222(1)      33(1)  
          C(2)      1        4093(2)    -1734(1)      206(1)      37(1)  
          C(3)      1        3978(2)     -876(1)      653(1)      39(1)  
          C(4)      1        4168(2)    -1370(1)     1223(1)      44(1)  
          C(5)      1        5504(2)    -1865(1)     1276(1)      43(1)  
          C(6)      1        5841(2)    -2646(1)      808(1)      37(1)  
          C(7)      1        5235(2)    -3771(1)      862(1)      38(1)  
          C(8)      1        5370(2)    -4258(1)      279(1)      34(1)  
          C(9)      1        4260(2)    -5015(1)      167(1)      33(1)  
          C(10)     1        5387(2)    -3347(1)     -648(1)      36(1)  
          C(11)     1        5086(2)    -4682(1)    -1391(1)      41(1)  
          C(12)     1        3677(2)    -4385(2)    -1454(1)      52(1)  
          C(13)     1        5259(2)    -5890(2)    -1384(1)      56(1)  
          C(14)     1        5901(2)    -4169(2)    -1836(1)      61(1)  
          C(15)     1        4562(2)      948(1)      419(1)      40(1)  
          C(16)     1        5709(2)     1556(1)      190(1)      37(1)  
          C(17)     1        6739(2)     1745(1)      631(1)      38(1)  
          C(20)     1        6369(2)     1546(1)     -772(1)      43(1)  
          C(21)     1        6816(2)      824(1)    -1238(1)      40(1)  
          C(22)     1        6604(2)     -275(1)    -1246(1)      40(1)  
          C(23)     1        6997(2)     -890(2)    -1696(1)      46(1)  
          C(24)     1        7604(2)     -423(2)    -2143(1)      55(1)  
          C(25)     1        7810(2)      681(2)    -2140(1)      65(1)  
          C(26)     1        7417(2)     1297(2)    -1693(1)      55(1)  
          O(8A)     0.807(4) 6993(5)     2280(4)     1596(3)      50(1)  
          C(18A)    0.807(4) 6131(9)     2298(11)    1131(3)      44(1)  
          C(19A)    0.807(4) 4972(13)    1664(17)    1319(5)      52(1)  
          C(27A)    0.807(4) 7977(2)     3074(2)     1625(1)      59(1)  
          C(28A)    0.807(4) 7533(2)     4171(1)     1812(1)      41(1)  
          C(29A)    0.807(4) 8306(2)     5051(2)     1691(1)      61(1)  
          C(30A)    0.807(4) 8005(3)     6057(2)     1907(2)      74(2)  
          C(31A)    0.807(4) 6931(4)     6183(2)     2243(2)      72(2)  
          C(32A)    0.807(4) 6158(3)     5303(2)     2364(1)      57(1)  
          C(33A)    0.807(4) 6459(2)     4298(2)     2148(1)      44(1)  
          O(8B)     0.193(4) 6850(20)    2249(18)    1669(11)     67(7)  
          C(18B)    0.193(4) 6180(40)    2290(50)    1146(10)     44(1)  
          C(19B)    0.193(4) 4990(50)    1680(70)    1310(20)     52(1)  
          C(27B)    0.193(4) 6446(13)    3039(8)     2032(5)      60(4)  
          C(28B)    0.193(4) 7000(9)     4160(6)     1925(5)      34(3)  
          C(29B)    0.193(4) 7897(8)     4325(7)     1505(5)      57(3)  
          C(30B)    0.193(4) 8438(9)     5335(9)     1430(5)      80(6)  
          C(31B)    0.193(4) 8082(14)    6182(6)     1775(7)     104(9)  
          C(32B)    0.193(4) 7186(16)    6018(7)     2195(6)      65(6)  
          C(33B)    0.193(4) 6645(12)    5007(9)     2270(4)      59(4)         
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         Table 3. Hydrogen coordinates (x 104) and isotropic displacement  
         parameters (Å2 x 103) for C33 H43 N O9.  
            
                    Occ.       x           y            z           Ueq          
          H(3)      1        2559       -4955          70         53  
          H(7)      1        8211        2014         201         68  
          H(1)      1        6075       -1799          58         39  
          H(2A)     1        3964       -1402        -165         44  
          H(2B)     1        3413       -2280         261         44  
          H(3A)     1        3116        -526         632         46  
          H(4A)     1        3512       -1932        1285         53  
          H(4B)     1        4056        -810        1512         53  
          H(5A)     1        6147       -1279        1282         52  
          H(5B)     1        5560       -2249        1637         52  
          H(6)      1        6793       -2735         803         44  
          H(7A)     1        5697       -4209        1142         46  
          H(7B)     1        4322       -3718         971         46  
          H(8)      1        6198       -4658         251         41  
          H(12A)    1        3189       -4684       -1142         78  
          H(12B)    1        3348       -4678       -1805         78  
          H(12C)    1        3589       -3601       -1456         78  
          H(13A)    1        6161       -6062       -1313         84  
          H(13B)    1        5003       -6188       -1746         84  
          H(13C)    1        4725       -6202       -1090         84  
          H(14A)    1        5789       -3387       -1824         91  
          H(14B)    1        5642       -4440       -2202         91  
          H(14C)    1        6804       -4346       -1770         91  
          H(15)     1        3891         890         123         48  
          H(16)     1        5413        2267          44         45  
          H(17)     1        7096        1036         752         46  
          H(20A)    1        6987        2141        -721         51  
          H(20B)    1        5527        1861        -870         51  
          H(22)     1        6186        -610        -940         48  
          H(23)     1        6845       -1643       -1696         55  
          H(24)     1        7880        -848       -2449         66  
          H(25)     1        8224        1014       -2448         77  
          H(26)     1        7557        2052       -1697         67  
          H(18A)    0.807(4) 5886        3053        1037         53  
          H(19A)    0.807(4) 5253         950        1453         63  
          H(19B)    0.807(4) 4559        2043        1634         63  
          H(27A)    0.807(4) 8375        3143        1252         70  
          H(27B)    0.807(4) 8647        2820        1885         70  
          H(29A)    0.807(4) 9041        4965        1461         73  
          H(30A)    0.807(4) 8534        6658        1824         89  
          H(31A)    0.807(4) 6725        6870        2390         87  
          H(32A)    0.807(4) 5423        5390        2593         68  
          H(33A)    0.807(4) 5930        3696        2230         52  
          H(18B)    0.193(4) 5956        3051        1056         53  
          H(19C)    0.193(4) 5246         968        1455         63  
          H(19D)    0.193(4) 4571        2072        1622         63  
          H(27C)    0.193(4) 6676        2818        2415         73  
          H(27D)    0.193(4) 5500        3084        2012         73  
          H(29B)    0.193(4) 8140        3746        1269         69  
          H(30B)    0.193(4) 9051        5448        1143         96  
          H(31B)    0.193(4) 8452        6873        1724        124  
          H(32B)    0.193(4) 6943        6596        2431         78  
          H(33B)    0.193(4) 6032        4895        2557         71  
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     Table 4.  Anisotropic parameters (Å2 x 103) for C33 H43 N O9.  
           The anisotropic displacement factor exponent takes the form:  
                   -2 π2 [ h2 a*2 U11 + ... + 2 h k a* b* U12 ]  
        
              U11         U22        U33         U23         U13        U12        
    O(1)     33(1)      27(1)      50(1)       0(1)       4(1)       2(1)  
    O(2)     44(1)      27(1)      58(1)       3(1)      -3(1)       2(1)  
    O(3)     32(1)      26(1)      47(1)       2(1)       1(1)      -2(1)  
    O(4)     71(1)      32(1)      40(1)       3(1)       8(1)      -7(1)  
    O(5)     42(1)      32(1)      40(1)      -5(1)       1(1)       2(1)  
    O(6)     40(1)      29(1)      39(1)       5(1)       0(1)       6(1)  
    O(7)     45(1)      33(1)      59(1)      -6(1)       3(1)      -5(1)  
    O(9)     43(1)      40(1)      67(1)      -8(1)      13(1)      10(1)  
    N(1)     38(1)      27(1)      35(1)       0(1)       5(1)      -4(1)  
    C(1)     33(1)      27(1)      38(1)      -2(1)       4(1)      -6(1)  
    C(2)     35(1)      31(1)      44(1)       0(1)      -2(1)      -2(1)  
    C(3)     33(1)      32(1)      51(1)      -4(1)       7(1)       0(1)  
    C(4)     50(1)      36(1)      46(1)      -7(1)      13(1)      -9(1)  
    C(5)     55(1)      36(1)      39(1)       0(1)      -3(1)     -10(1)  
    C(6)     35(1)      35(1)      41(1)       0(1)      -3(1)      -3(1)  
    C(7)     42(1)      35(1)      37(1)       3(1)      -3(1)      -2(1)  
    C(8)     31(1)      30(1)      42(1)       2(1)       0(1)       1(1)  
    C(9)     38(1)      28(1)      34(1)       1(1)       3(1)       2(1)  
    C(10)    35(1)      32(1)      41(1)      -2(1)       6(1)      -3(1)  
    C(11)    45(1)      37(1)      40(1)      -7(1)       3(1)      -5(1)  
    C(12)    52(1)      48(1)      56(1)       2(1)      -7(1)      -5(1)  
    C(13)    71(1)      41(1)      56(1)     -13(1)      -2(1)       4(1)  
    C(14)    70(1)      65(1)      47(1)     -14(1)      18(1)     -18(1)  
    C(15)    37(1)      32(1)      51(1)      -3(1)       2(1)       8(1)  
    C(16)    41(1)      24(1)      47(1)       1(1)       2(1)       8(1)  
    C(17)    41(1)      25(1)      48(1)      -2(1)      -1(1)       3(1)  
    C(20)    51(1)      33(1)      45(1)      10(1)      -5(1)      -1(1)  
    C(21)    39(1)      39(1)      41(1)       7(1)      -9(1)      -5(1)  
    C(22)    42(1)      38(1)      41(1)       8(1)      -6(1)      -3(1)  
    C(23)    51(1)      39(1)      47(1)       1(1)     -10(1)      -5(1)  
    C(24)    65(1)      56(1)      42(1)      -4(1)      -2(1)      -8(1)  
    C(25)    89(2)      59(1)      46(1)       2(1)      10(1)     -24(1)  
    C(26)    73(1)      43(1)      50(1)       5(1)      -1(1)     -20(1)  
    O(8A)    66(2)      38(2)      47(2)      -9(1)      -4(1)      16(2)  
    C(18A)   52(1)      28(1)      53(1)      -5(1)      -2(1)       9(1)  
    C(19A)   63(1)      43(1)      51(1)     -11(1)      11(1)       9(1)  
    C(27A)   47(2)      64(2)      65(2)     -29(1)      -4(1)       7(1)  
    C(28A)   40(2)      47(2)      35(2)      -4(1)      -3(1)      -4(1)  
    C(29A)   54(2)      67(2)      60(2)      13(2)     -13(2)     -10(2)  
    C(30A)   84(4)      45(2)      94(3)      16(2)     -46(2)     -21(2)  
    C(31A)  111(4)      39(2)      67(3)      -8(2)     -41(2)      15(2)  
    C(32A)   74(3)      50(2)      45(2)     -11(1)     -12(2)      19(2)  
    C(33A)   52(2)      40(1)      38(1)      -6(1)       1(1)       3(1)  
    O(8B)    93(12)     64(10)     43(8)      -5(6)     -14(8)     -43(8)  
    C(18B)   52(1)      28(1)      53(1)      -5(1)      -2(1)       9(1)  
    C(19B)   63(1)      43(1)      51(1)     -11(1)      11(1)       9(1)  
    C(27B)   87(9)      39(6)      56(7)       4(5)      17(6)     -21(5)  
    C(28B)   26(7)      29(5)      47(7)       1(4)       5(5)     -12(4)  
    C(29B)   32(6)      66(8)      75(9)      14(7)      -4(6)       3(5)  
    C(30B)   59(9)      61(9)     119(15)     31(10)    -51(9)      -3(6)  
    C(31B)  110(20)     71(14)    126(19)     29(14)    -57(14)     4(12)  
    C(32B)   68(10)     30(7)      97(15)      2(8)     -48(10)      1(8)  
    C(33B)   59(10)     83(13)     35(6)       7(7)      -3(6)       2(8)     
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      Table 5.  Bond lengths [Å] and angles [°] for C33 H43 N O9  
    ______________________________________________________________________  
  
 
    O(1)-C(15)             1.3973(18)  
    O(1)-C(3)              1.4517(19)  
    O(2)-C(9)              1.2116(18)  
    O(3)-C(9)              1.3279(19)  
    O(4)-C(10)             1.2139(19)  
    O(5)-C(10)             1.3559(18)  
    O(5)-C(11)             1.479(2)  
    O(6)-C(20)             1.4355(19)  
    O(6)-C(16)             1.4436(19)  
    O(7)-C(17)             1.426(2)  
    O(9)-C(15)             1.423(2)  
    O(9)-C(19a)            1.432(5)  
    O(9)-C(19b)            1.432(17)  
    N(1)-C(10)             1.353(2)  
    N(1)-C(8)              1.4639(18)  
    N(1)-C(1)              1.4692(18)  
    C(1)-C(6)              1.540(2)  
    C(1)-C(2)              1.542(2)  
    C(2)-C(3)              1.519(2)  
    C(3)-C(4)              1.511(2)  
    C(4)-C(5)              1.529(3)  
    C(5)-C(6)              1.526(2)  
    C(6)-C(7)              1.541(2)  
    C(7)-C(8)              1.531(2)  
    C(8)-C(9)              1.516(2)  
    C(11)-C(14)            1.506(3)  
    C(11)-C(13)            1.513(2)  
    C(11)-C(12)            1.523(3)  
    C(15)-C(16)            1.519(2)  
    C(16)-C(17)            1.528(2)  
    C(17)-C(18a)           1.521(5)  
    C(17)-C(18b)           1.524(16)  
    C(20)-C(21)            1.507(2)  
    C(21)-C(22)            1.385(2)  
    C(21)-C(26)            1.391(2)  
    C(22)-C(23)            1.385(3)  
    C(23)-C(24)            1.375(3)  
    C(24)-C(25)            1.390(3)  
    C(25)-C(26)            1.380(3)  
    O(8a)-C(27a)           1.426(6)  
    O(8a)-C(18a)           1.432(5)  
    C(18a)-C(19a)          1.512(5)  
    C(27a)-C(28a)          1.510(3)  
    C(28a)-C(29a)          1.39  
    C(28a)-C(33a)          1.39  
    C(29a)-C(30a)          1.39  
    C(30a)-C(31a)          1.39  
    C(31a)-C(32a)          1.39  
    C(32a)-C(33a)          1.39  
    O(8b)-C(27b)           1.38(3)  
    O(8b)-C(18b)           1.436(17)  
    C(18b)-C(19b)          1.512(17)  
    C(27b)-C(28b)          1.532(11)  
    C(28b)-C(29b)          1.39  
    C(28b)-C(33b)          1.39  
    C(29b)-C(30b)          1.39  
    C(30b)-C(31b)          1.39  
    C(31b)-C(32b)          1.39  
    C(32b)-C(33b)          1.39  
   
    C(15)-O(1)-C(3)        115.98(12)  
    C(10)-O(5)-C(11)       120.18(13)  
    C(20)-O(6)-C(16)       113.51(11)  
    C(15)-O(9)-C(19A)      112.5(9)  
    C(15)-O(9)-C(19B)      112(4)  
    C(19A)-O(9)-C(19B)       1(3)  
    C(10)-N(1)-C(8)        124.59(13)  
    C(10)-N(1)-C(1)        121.76(13)  
    C(8)-N(1)-C(1)         113.61(12)  
    N(1)-C(1)-C(6)         101.94(12)  
    N(1)-C(1)-C(2)         111.72(12)  
    C(6)-C(1)-C(2)         114.22(13)  
    C(3)-C(2)-C(1)         111.56(13)  
    O(1)-C(3)-C(4)         108.23(14)  
    O(1)-C(3)-C(2)         108.60(13)  
    C(4)-C(3)-C(2)         110.09(13)  
    C(3)-C(4)-C(5)         111.03(14)  
    C(6)-C(5)-C(4)         113.90(15)  
    C(5)-C(6)-C(1)         114.94(13)  
    C(5)-C(6)-C(7)         114.95(14)  
    C(1)-C(6)-C(7)         102.71(12)  
    C(8)-C(7)-C(6)         104.19(13)  
    N(1)-C(8)-C(9)         114.49(13)  
    N(1)-C(8)-C(7)         103.12(12)  
    C(9)-C(8)-C(7)         109.71(13)  
    O(2)-C(9)-O(3)         123.92(15)  
    O(2)-C(9)-C(8)         122.39(15)  
    O(3)-C(9)-C(8)         113.56(12)  
    O(4)-C(10)-N(1)        124.36(14)  
    O(4)-C(10)-O(5)        125.87(15)  
    N(1)-C(10)-O(5)        109.75(14)  
    O(5)-C(11)-C(14)       112.45(14)  
    O(5)-C(11)-C(13)       102.06(14)  
    C(14)-C(11)-C(13)      111.18(17)  
    O(5)-C(11)-C(12)       107.99(14)  
    C(14)-C(11)-C(12)      111.80(17)  
    C(13)-C(11)-C(12)      110.93(16)  
    O(1)-C(15)-O(9)        112.33(14)  
    O(1)-C(15)-C(16)       107.68(12)  
    O(9)-C(15)-C(16)       109.09(13)  
    O(6)-C(16)-C(15)       108.92(12)  
    O(6)-C(16)-C(17)       108.89(12)  
    C(15)-C(16)-C(17)      112.30(14)  
    O(7)-C(17)-C(18A)      110.2(6)  
    O(7)-C(17)-C(18B)      109(2)  
    C(18A)-C(17)-C(18B)      2.4(15)  
    O(7)-C(17)-C(16)       110.61(14)  
    C(18A)-C(17)-C(16)     108.9(3)  
    C(18B)-C(17)-C(16)     111.2(13)  
    O(6)-C(20)-C(21)       110.19(13)  
    C(22)-C(21)-C(26)      118.61(17)  
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    C(22)-C(21)-C(20)      123.32(16)  
    C(26)-C(21)-C(20)      118.00(16)  
    C(21)-C(22)-C(23)      120.61(17)  
    C(24)-C(23)-C(22)      120.68(18)  
    C(23)-C(24)-C(25)      119.05(19)  
 
    C(26)-C(25)-C(24)      120.43(19)  
    C(25)-C(26)-C(21)      120.61(18)  
    C(27A)-O(8A)-C(18A)    118.6(7)  
    O(8A)-C(18A)-C(19A)    105.3(6)  
    O(8A)-C(18A)-C(17)     110.2(5)  
    C(19A)-C(18A)-C(17)    109.4(11)  
    O(9)-C(19A)-C(18A)     112.5(9)  
    O(8A)-C(27A)-C(28A)    114.9(3)  
    C(29A)-C(28A)-C(33A)   120  
    C(29A)-C(28A)-C(27A)   118.2(2)  
    C(33A)-C(28A)-C(27A)   121.4(2)  
    C(30A)-C(29A)-C(28A)   120  
    C(29A)-C(30A)-C(31A)   120  
    C(32A)-C(31A)-C(30A)   120  
    C(31A)-C(32A)-C(33A)   120  
    C(32A)-C(33A)-C(28A)   120  
    C(27B)-O(8B)-C(18B)    112.2(19)  
    O(8B)-C(18B)-C(19B)     99(2)  
    O(8B)-C(18B)-C(17)     120(2)  
    C(19B)-C(18B)-C(17)    108(5)  
    O(9)-C(19B)-C(18B)     116(4)  
    O(8B)-C(27B)-C(28B)    115.4(14)  
    C(29B)-C(28B)-C(33B)   120  
    C(29B)-C(28B)-C(27B)   120.6(9)  
    C(33B)-C(28B)-C(27B)   119.3(9)  
    C(28B)-C(29B)-C(30B)   120  
    C(31B)-C(30B)-C(29B)   120  
    C(30B)-C(31B)-C(32B)   120  
    C(33B)-C(32B)-C(31B)   120  
    C(32B)-C(33B)-C(28B)   120  
   
    
______________________________________________________________________  
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          Table 6.  Torsion angles [°] for C33 H43 N O9.  
  ______________________________________________________________________________   
  C(10)-N(1)-C(1)-C(6)    -163.69(14)  
  C(8)-N(1)-C(1)-C(6)       18.60(16)  
  C(10)-N(1)-C(1)-C(2)      73.94(18)  
  C(8)-N(1)-C(1)-C(2)     -103.78(15)  
  N(1)-C(1)-C(2)-C(3)      162.80(12)  
  C(6)-C(1)-C(2)-C(3)       47.76(17)  
  C(15)-O(1)-C(3)-C(4)    -126.13(14)  
  C(15)-O(1)-C(3)-C(2)     114.36(14)  
  C(1)-C(2)-C(3)-O(1)       59.19(16)  
  C(1)-C(2)-C(3)-C(4)      -59.15(17)  
  O(1)-C(3)-C(4)-C(5)      -57.19(17)  
  C(2)-C(3)-C(4)-C(5)       61.38(17)  
  C(3)-C(4)-C(5)-C(6)      -52.25(18)  
  C(4)-C(5)-C(6)-C(1)       40.90(19)  
  C(4)-C(5)-C(6)-C(7)      -78.04(18)  
  N(1)-C(1)-C(6)-C(5)     -159.38(14)  
  C(2)-C(1)-C(6)-C(5)      -38.73(18)  
  N(1)-C(1)-C(6)-C(7)      -33.81(15)  
  C(2)-C(1)-C(6)-C(7)       86.84(15)  
  C(5)-C(6)-C(7)-C(8)      163.38(14)  
  C(1)-C(6)-C(7)-C(8)       37.82(16)  
  C(10)-N(1)-C(8)-C(9)     -53.7(2)  
  C(1)-N(1)-C(8)-C(9)      123.89(14)  
  C(10)-N(1)-C(8)-C(7)    -172.87(15)  
  C(1)-N(1)-C(8)-C(7)        4.77(17)  
  C(6)-C(7)-C(8)-N(1)      -26.33(16)  
  C(6)-C(7)-C(8)-C(9)     -148.72(13)  
  N(1)-C(8)-C(9)-O(2)      144.37(15)  
  C(7)-C(8)-C(9)-O(2)     -100.29(18)  
  N(1)-C(8)-C(9)-O(3)      -39.60(19)  
  C(7)-C(8)-C(9)-O(3)       75.74(16)  
  C(8)-N(1)-C(10)-O(4)     173.53(16)  
  C(1)-N(1)-C(10)-O(4)      -3.9(3)  
  C(8)-N(1)-C(10)-O(5)      -7.8(2)  
  C(1)-N(1)-C(10)-O(5)     174.75(13)  
  C(11)-O(5)-C(10)-O(4)    -21.3(2)  
  C(11)-O(5)-C(10)-N(1)    160.02(14)  
  C(10)-O(5)-C(11)-C(14)    65.8(2)  
  C(10)-O(5)-C(11)-C(13)  -174.99(15)  
  C(10)-O(5)-C(11)-C(12)   -58.03(18)  
  C(3)-O(1)-C(15)-O(9)      75.66(17)  
  C(3)-O(1)-C(15)-C(16)   -164.21(13)  
  C(19A)-O(9)-C(15)-O(1)    60.3(8)  
  C(19B)-O(9)-C(15)-O(1)    62(3)  
  C(19A)-O(9)-C(15)-C(16)  -59.0(8)  
  C(19B)-O(9)-C(15)-C(16)  -58(3)  
  C(20)-O(6)-C(16)-C(15)   125.27(14)  
  C(20)-O(6)-C(16)-C(17)  -111.96(15)  
  O(1)-C(15)-C(16)-O(6)     55.25(16)  
  O(9)-C(15)-C(16)-O(6)    177.41(13)  
  O(1)-C(15)-C(16)-C(17)   -65.45(16)  
  O(9)-C(15)-C(16)-C(17)    56.71(16)  
  O(6)-C(16)-C(17)-O(7)     63.83(16)  
  C(15)-C(16)-C(17)-O(7)  -175.46(12)  
  O(6)-C(16)-C(17)-C(18A) -174.9(6)  
  C(15)-C(16)-C(17)-C(18A) -54.2(6)  
  O(6)-C(16)-C(17)-C(18B) -174(3)  
  C(15)-C(16)-C(17)-C(18B) -54(3)  
  C(16)-O(6)-C(20)-C(21)  -173.99(13)  
  O(6)-C(20)-C(21)-C(22)    26.2(2)  
  O(6)-C(20)-C(21)-C(26)  -156.94(16)  
  C(26)-C(21)-C(22)-C(23)    0.7(3)  
  C(20)-C(21)-C(22)-C(23)  177.55(16)  
  C(21)-C(22)-C(23)-C(24)    0.1(3)  
  C(22)-C(23)-C(24)-C(25)   -0.6(3)  
  C(23)-C(24)-C(25)-C(26)    0.4(4)  
  C(24)-C(25)-C(26)-C(21)    0.4(4)  
  C(22)-C(21)-C(26)-C(25)   -0.9(3)  
  C(20)-C(21)-C(26)-C(25) -177.9(2)  
 C(27A)-O(8A)-C(18A)-C(19A) -160.1(1)  
  C(27A)-O(8A)-C(18A)-C(17) 82(1)  
  O(7)-C(17)-C(18A)-O(8A)  -70.9(1)  
  C(18B)-C(17)-C(18A)-O(8A) -1(71)  
  C(16)-C(17)-C(18A)-O(8A) 167.6(7)  
  O(7)-C(17)-C(18A)-C(19A) 173.9(6)  
  C(18B)-C(17)-C(18A)-C(19A) -116(72)  
  C(16)-C(17)-C(18A)-C(19A) 52.4(8)  
  C(15)-O(9)-C(19A)-C(18A)  60.9(15)  
  C(19B)-O(9)-C(19A)-C(18A)-13(10)  
  O(8A)-C(18A)-C(19A)-O(9)-174.9(12)  
  C(17)-C(18A)-C(19A)-O(9) -56.5(16)  
  C(18A)-O(8A)-C(27A)-C(28A)77.2(6)  
 O(8A)-C(27A)-C(28A)-C(29A) -160.6(3)  
  O(8A)-C(27A)-C(28A)-C(33A) 26.5(4)  
  C(33A)-C(28A)-C(29A)-C(30A)0  
C(27A)-C(28A)-C(29A)-C(30A) -173.1(2)  
  C(28A)-C(29A)-C(30A)-C(31A)0  
  C(29A)-C(30A)-C(31A)-C(32A)0  
  C(30A)-C(31A)-C(32A)-C(33A)0  
  C(31A)-C(32A)-C(33A)-C(28A)0  
  C(29A)-C(28A)-C(33A)-C(32A)0  
 C(27A)-C(28A)-C(33A)-C(32A) 172.8(2)  
  C(27B)-O(8B)-C(18B)-C(19B) -83(5)  
  C(27B)-O(8B)-C(18B)-C(17)161(4)  
  O(7)-C(17)-C(18B)-O(8B)  -77(5)  
  C(18A)-C(17)-C(18B)-O(8B)172(76)  
  C(16)-C(17)-C(18B)-O(8B) 161(4)  
  O(7)-C(17)-C(18B)-C(19B) 171(3)  
  C(18A)-C(17)-C(18B)-C(19B)60(71)  
  C(16)-C(17)-C(18B)-C(19B) 49(3)  
  C(15)-O(9)-C(19B)-C(18B)  59(7)  
  C(19A)-O(9)-C(19B)-C(18B) 166(10)  
  O(8B)-C(18B)-C(19B)-O(9)-179(6)  
  C(17)-C(18B)-C(19B)-O(9) -52(7)  
  C(18B)-O(8B)-C(27B)-C(28B-79(3)  
  O(8B)-C(27B)-C(28B)-C(29B)-3.2(17)  
 O(8B)-C(27B)-C(28B)-C(33B) 179.9(13) 
  C(33B)-C(28B)-C(29B)-C(30B)0  
C(27B)-C(28B)-C(29B)-C(30B) -176.9(1) 
  C(28B)-C(29B)-C(30B)-C(31B)0  
  C(29B)-C(30B)-C(31B)-C(32B)0  
  C(30B)-C(31B)-C(32B)-C(33B)0  
  C(31B)-C(32B)-C(33B)-C(28B)0  
  C(29B)-C(28B)-C(33B)-C(32B)0  
 C(27B)-C(28B)-C(33B)-C(32B) 176.9(1)  
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Table 7. Bond lengths [Å] and angles [°] related to the hydrogen  
   bonding for C33 H43 N O9.  
   
______________________________________________________________________  
   
        D-H         ..A       d(D-H)      d(H..A)     d(D..A)     <DHA  
   
     O(7)-H(7)      O(2)#1     0.84        2.01       2.8488(16)  171.8  
     O(3)-H(3)      O(6)#2     0.84        1.89       2.7195(15)  168.4  
   
   
______________________________________________________________________  
   
    Symmetry transformations used to generate equivalent atoms:  
   
         #1 x+1/2,-y-1/2,-z    #2 x-1/2,-y-1/2,-z      
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ORTEP view of the C33 H43 N O9 compound with the numbering scheme 
adopted. Ellipsoids drawn at 30% probability level. Hydrogen atoms 
are represented by sphere of arbitrary size.  
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